<!DOCTYPE html>
<html lang="en"><head>
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1">

    <!-- CSRF Token -->
    <meta name="csrf-token" content="fuRf4VGXyjLzEdZfUTB5JG01cS6WTRdvTQwS0FLR">

    <!-- Base URL -->
    <meta name="app-base-url" content="https://www.qeios.com">
    
    <!-- favicon -->
    <link rel="shortcut icon" href="https://www.qeios.com/images/favicon.png">

    <title>The association of smoking status with SARS-CoV-2 infection, 
hospitalisation and mortality from COVID-19: A living rapid evidence 
review (version 5) - Article (Preprint v6) | Qeios</title>

                            <meta name="description" content="Background: SARS-CoV-2 is the causative agent of COVID-19, an emergent zoonotic disease which has reached pandemic levels and is designated a public health emergency of international concern. It is plausible that former or current smoking status is a...">
                                <meta name="og:title" content="The association of smoking status with SARS-CoV-2 infection, hospitalisation and mortality from COVID-19: A living rapid evidence review (version 5)">
                                <meta name="og:description" content="Background: SARS-CoV-2 is the causative agent of COVID-19, an emergent zoonotic disease which has reached pandemic levels and is designated a public health emergency of international concern. It is plausible that former or current smoking status is a...">
                                <meta name="og:image" content="https://www.qeios.com/images/brand/Qeios_background_blue.png">
                                <meta name="twitter:card" content="summary_large_image">
                                <meta name="twitter:site" content="@qeios">
                                <meta name="citation_title" content="The association of smoking status with SARS-CoV-2 infection, hospitalisation and mortality from COVID-19: A living rapid evidence review (version 5)">
                                <meta name="citation_abstract" content="Background: SARS-CoV-2 is the causative agent of COVID-19, an emergent zoonotic disease which has reached pandemic levels and is designated a public health emergency of international concern. It is plausible that former or current smoking status is associated with infection, hospitalisation and/or mortality from COVID-19.

Objective: We aimed to estimate the association of smoking status with rates of i) infection, ii) hospitalisation, iii) disease severity, and iv) mortality from SARS-CoV-2/COVID-19 disease.

Methods: This is a living evidence review with frequent updates. We adopted recommended practice for rapid evidence reviews, which involved limiting the search to main databases and having one reviewer extract data and another verify. Published articles and pre-prints were identified via Ovid MEDLINE, medRxiv and expertise within the review team. We included observational or experimental studies with community-dwelling or hospitalised adults aged 16+ years who had received a test for SARS-CoV-2 infection or a diagnosis of COVID-19, providing that data on smoking status were reported. Studies were judged as ‘good’ quality if they: i) had low levels of missing data on smoking status (i.e. &lt;20%) and used a reliable self-report measure that distinguished between current, former and never smoking status; AND ii) used biochemical verification of smoking status and reported results from adjusted analyses; OR reported data from a representative/random sample. Studies were rated as ‘fair’ if they fulfilled criterion i) only and were otherwise rated as ‘poor’.

Results: Version 5 with searches up to 23 June 2020 included 148 studies, 43 of which were conducted in China, 37 in the US, 15 in the UK, nine in Mexico, nine in Spain, eight in France, six in Italy, five across multiple international sites, two in Israel, and one each from 14 further countries. Thirty-two (21.6%) studies reported current, former and never smoking status. Twenty-six studies (17.6%) explicitly reported the proportion missing data on smoking status, which ranged from 0.08% to 96.4%. Notwithstanding recording uncertainties, compared with adult national prevalence estimates, recorded current and former smoking rates were generally lower than expected. In 12 ‘fair’ quality studies, current smokers were at reduced risk of testing positive for SARS-CoV-2 compared with never smokers (RR = 0.70, 95% CI = 0.55-0.88, p = .003, I2 = 90%). No significant difference was observed between former and never smokers (RR = 1.02, 95% CI = 0.92-1.12, p = .76, I2 = 72%). In seven ‘fair’ quality studies, there was no significant difference between current and never (RR = 1.06, 95% CI = 0.79-1.44, p = .63, I2 = 79%) or former and never smokers (RR = 1.20, 95% CI = 0.95-1.51, p = .10, I2 = 79%) in the risk of requiring admission to hospital with COVID-19 among those testing positive in the community. In six ‘fair’ quality studies, no significant difference in disease severity was observed between current and never smokers (RR = 1.22, 95% CI = 0.98-1.53, p = .08, I2 = 22%). Former smokers were at increased risk of greater disease severity compared with never smokers (RR = 1.58, 95% CI = 1.07-2.32, p = .02, I2 = 68%). In five ‘fair’ quality studies, current (RR = 1.70, 95% CI = 1.14-2.55, p = .01, I2 = 29%) and former smokers (RR = 2.00, 95% CI = 1.57-2.55, p &lt; .0.001, I2 = 0%) were at increased risk of in-hospital death compared with never smokers.

Conclusions: Across 148 studies, there is substantial uncertainty about the associations of smoking with COVID-19 outcomes. The recorded smoking prevalence in the included studies was generally lower than overall adult national estimates. There was no evidence of reduced risk of admission to hospital for current compared with never smokers among those testing positive in the community. There was some evidence that current compared with never smoking is associated with reduced risk of testing positive in the community but also greater in-hospital mortality from COVID-19. There was some evidence that former compared with never smoking is associated with increased risk of greater disease severity and in-hospital mortality from COVID-19.

Implications: Unrelated to COVID-19, smokers are at a greater risk of a range of serious health problems. Given uncertainty around the association of smoking with COVID-19 outcomes, smoking cessation remains a public health priority and high-quality smoking cessation advice including recommendations to use alternative nicotine products should form part of public health efforts during this pandemic. High quality, smoking-specific research is needed to resolve these mixed findings.">
                                <meta name="citation_doi" content="10.32388/UJR2AW.6">
                                <meta name="citation_pdf_url" content="https://www.qeios.com/read/UJR2AW.6/pdf">
                                <meta name="citation_publication_date" content="2020-07-01">
                                <meta name="citation_issn" content="2632-3834">
                                <meta name="citation_journal_title" content="Qeios">
                                <meta name="citation_author" content="David Simons">
                                <meta name="citation_author_institution" content="Royal Veterinary College, RVC">
                                <meta name="citation_author" content="Lion Shahab">
                                <meta name="citation_author_institution" content="University College London, University of London">
                                <meta name="citation_author" content="Jamie Brown">
                                <meta name="citation_author_institution" content="University College London, University of London">
                                <meta name="citation_author" content="Olga Perski">
                                <meta name="citation_author_institution" content="University College London, University of London">
                                <meta name="citation_keywords" content="COVID-19; hospitalisation; infection; mortality; SARS-CoV-2; smoking; tobacco">
            
    <!-- Styles -->
    <link href="app.css" rel="stylesheet">
        <link href="article.css" rel="stylesheet">

            <!-- Global site tag (gtag.js) - Google Analytics -->
        <script type="text/javascript" async="" src="analytics.js"></script><script async="" src="js"></script>
        <script>
            window.dataLayer = window.dataLayer || [];
            function gtag(){dataLayer.push(arguments);}
            gtag('js', new Date());

            gtag('config', 'UA-116926471-1');
        </script>
    <style type="text/css">.resize-observer[data-v-b329ee4c]{position:absolute;top:0;left:0;z-index:-1;width:100%;height:100%;border:none;background-color:transparent;pointer-events:none;display:block;overflow:hidden;opacity:0}.resize-observer[data-v-b329ee4c] object{display:block;position:absolute;top:0;left:0;height:100%;width:100%;overflow:hidden;pointer-events:none;z-index:-1}</style><style>.cke{visibility:hidden;}</style><script id="altmetric-embed-js" src="altmetric_badges-75bc9437b4bcd96622a3f013e4e9519d1b65ea847ab6.js"></script><style type="text/css">a[data-v-152f5d80]{padding:.7em 1.08em;border-radius:.188rem;line-height:1rem;font-size:.88rem;font-weight:400}.base-orcid-signup-btn[data-v-152f5d80]{display:-webkit-inline-box;display:-ms-inline-flexbox;display:inline-flex;-webkit-box-align:center;-ms-flex-align:center;align-items:center;-webkit-box-pack:center;-ms-flex-pack:center;justify-content:center}.base-orcid-signup-btn img[data-v-152f5d80]{display:inline-block;width:17px;margin-right:8px}</style><style type="text/css">.modal-title-content[data-v-26f40cdb]{display:block;text-align:center}.modal-subtitle[data-v-26f40cdb]{margin-bottom:26px;padding:0 20px;text-align:center}form[data-v-26f40cdb]{padding:0 6.5% 22px}.submit-btn[data-v-26f40cdb]{width:100%;margin-top:32px}.no-account-cta[data-v-26f40cdb]{padding-bottom:24px;text-align:center;font-size:13px}.no-account-cta>a[data-v-26f40cdb]{cursor:pointer}</style><style type="text/css">._2sfQLp3e4EVxbl8n17w9Oz_0{-webkit-box-align:center;-ms-flex-align:center;align-items:center;-webkit-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between}._2sfQLp3e4EVxbl8n17w9Oz_0,.vQ9oh6hbHIFNvCuTkBMA9_0{display:-webkit-box;display:-ms-flexbox;display:flex}.vQ9oh6hbHIFNvCuTkBMA9_0{list-style-type:none;-webkit-box-orient:horizontal;-webkit-box-direction:reverse;-ms-flex-direction:row-reverse;flex-direction:row-reverse;margin-left:8px}.vQ9oh6hbHIFNvCuTkBMA9_0>li{margin-left:-8px}.QSV7rVelPoCzp998XLZGW_0{position:relative;display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-align:center;-ms-flex-align:center;align-items:center;-webkit-box-pack:center;-ms-flex-pack:center;justify-content:center;width:40px;height:40px;background:#fff;border:1px solid #e6eaf0;border-radius:50%;font-size:12px;font-weight:500;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none}._1reTLV_HW-MHSh0YHelgjn_0{cursor:pointer}._2HRxlpCKC7falf7tCfmzbN_0{border-color:#f46363}._2D9aP7k3d3EQeIbkU8kj96_0{width:14px}._2gMMR5amW24Qvr3pTlnThf_0{position:absolute;top:-4px;right:-61px;color:#f46363;padding:2px 3px;border-radius:5px;background:#fff;white-space:nowrap;font-size:12px}._2gMMR5amW24Qvr3pTlnThf_0:after{content:attr(data-pending-authoring-requests-count) " pending"}@media (max-width:1099px){._2gMMR5amW24Qvr3pTlnThf_0{top:-5px;right:-6px;display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-align:center;-ms-flex-align:center;align-items:center;-webkit-box-pack:center;-ms-flex-pack:center;justify-content:center;width:17px;height:17px;padding:0;border-radius:50%;background:#f46363;color:#fff;font-size:11px}._2gMMR5amW24Qvr3pTlnThf_0:after{content:attr(data-pending-authoring-requests-count)}}._2UFLs17Jhk-A10vHKrQre-_0{padding:34px}._2uYnTLn-63NXYvzfv_igQ2_0{display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-align:start;-ms-flex-align:start;align-items:flex-start;-webkit-box-pack:start;-ms-flex-pack:start;justify-content:flex-start}.a29nwBHfLpI09fHuuvCe5_0{-ms-flex-item-align:center;align-self:center;margin-left:16px}._3jD2xf81gz9G38sfMZBJ8F_0{color:#040e28;font-size:18px;font-weight:500}._3jD2xf81gz9G38sfMZBJ8F_0[href]:hover{text-decoration:underline}._29E4PGgVrvaUQvO9TQxisj_0{max-width:200px;margin-top:4px}.fxgSe6HcsBfEvUp-pbt1A_0{margin-top:4px;color:#a6b1c2;font-size:small}._1w6hiSPd4O76YasB6wBkOT_0{display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-align:center;-ms-flex-align:center;align-items:center;-webkit-box-pack:center;-ms-flex-pack:center;justify-content:center}._1w6hiSPd4O76YasB6wBkOT_0 button{margin-top:40px}._1w6hiSPd4O76YasB6wBkOT_0 button:not(:first-child){margin-left:16px}._2I-YihCwCwB7VeJHbw5O0z_0{list-style:none}._2I-YihCwCwB7VeJHbw5O0z_0>li{display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-align:center;-ms-flex-align:center;align-items:center;background:#fff}._2I-YihCwCwB7VeJHbw5O0z_0>li:not(:first-child){border-top:1px solid #e6eaf0}._2Hu6d_gTAtrSHj3I3gJAH9_0{display:inline-block;-webkit-box-sizing:content-box;box-sizing:content-box;width:14px;margin-left:8px;padding:8px 0 8px 4px;cursor:-webkit-grab;cursor:grab}@media (max-width:767px){._2Hu6d_gTAtrSHj3I3gJAH9_0{display:none}}._3eA3px6j-6ForgdnEHf6GR_0{display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-align:start;-ms-flex-align:start;align-items:flex-start;-webkit-box-pack:end;-ms-flex-pack:end;justify-content:flex-end}._3eA3px6j-6ForgdnEHf6GR_0>button:not(:first-child){margin-left:24px}@media (max-width:767px){._3eA3px6j-6ForgdnEHf6GR_0{-webkit-box-orient:vertical;-webkit-box-direction:normal;-ms-flex-direction:column;flex-direction:column;-webkit-box-align:end;-ms-flex-align:end;align-items:flex-end}._3eA3px6j-6ForgdnEHf6GR_0>button:not(:first-child){margin-left:0;margin-top:10px}}._2IHltC7yqESEhoUNo2mUFh_0{display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-align:center;-ms-flex-align:center;align-items:center;-webkit-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;color:#f46363}._2IHltC7yqESEhoUNo2mUFh_0>img{margin-right:10px}</style><style type="text/css">.avatar-placeholder[data-v-6fd402d6],.avatar[data-v-6fd402d6]{display:block;border-radius:50%}.avatar-placeholder[data-v-6fd402d6]{display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-pack:center;-ms-flex-pack:center;justify-content:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;max-width:100%;max-height:100%;background-size:cover;color:#fff;font-family:Roboto,sans-serif;text-decoration:none;-webkit-user-select:none;-ms-user-select:none;user-select:none;-moz-user-select:none}.avatar-wrapper[data-v-6fd402d6]{position:relative}.avatar-wrapper.clickable[data-v-6fd402d6]{cursor:pointer;text-align:center}.avatar-wrapper.clickable .avatar-placeholder[data-v-6fd402d6],.avatar-wrapper.clickable .avatar[data-v-6fd402d6]{opacity:.7}.update-icon-container[data-v-6fd402d6]{display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-align:center;-ms-flex-align:center;align-items:center;-webkit-box-pack:center;-ms-flex-pack:center;justify-content:center;position:absolute;top:0;width:100%;height:100%}.action-list[data-v-6fd402d6]{min-width:200px;margin:0;padding:0;list-style-type:none}.action-list>li[data-v-6fd402d6]{padding:3px 22px;text-align:center;font-size:14px;cursor:pointer}.action-list>li[data-v-6fd402d6]:hover{background:#40a9de;color:#fff}.account-badge-container[data-v-6fd402d6]{position:absolute;right:3%;bottom:-1%;display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-align:center;-ms-flex-align:center;align-items:center;-webkit-box-pack:center;-ms-flex-pack:center;justify-content:center;width:35%;pointer-events:none}.account-badge-container img[data-v-6fd402d6]{display:block;width:100%}</style><style type="text/css">.publication-stats-container .stat[data-v-1543fad5],.publication-stats-container[data-v-1543fad5]{display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-align:center;-ms-flex-align:center;align-items:center;-webkit-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between}.publication-stats-container .stat[data-v-1543fad5]:not(:first-child){margin-left:16px}.publication-stats-container .stat .icon[data-v-1543fad5]{height:15px;max-width:20px}.publication-stats-container .stat .amount[data-v-1543fad5]{margin-left:8px;font-size:12px}.stat.clickable[data-v-1543fad5]{cursor:pointer;-webkit-transition:opacity .1s;transition:opacity .1s}.stat.clickable[data-v-1543fad5]:hover{opacity:.7}.using-works-list[data-v-1543fad5]{padding:0 12px 12px;list-style:none}.using-works-list>li[data-v-1543fad5]:not(:first-child){margin-top:16px}.loading[data-v-1543fad5]{padding:16px;text-align:center}</style><style type="text/css">._3MlYAv5GFzRm3okMt8oNTx_0{color:#49abed}</style><style type="text/css">.bookmark-btn[data-v-34e61a6c]{display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-align:center;-ms-flex-align:center;align-items:center;cursor:pointer}.bookmark-btn>img[data-v-34e61a6c]{height:15px}.message[data-v-34e61a6c]{margin-left:8px;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none}</style><style type="text/css">._11z_6ul1Bpugy0zRSOWfKO_0>li{display:block;padding:1rem}._11z_6ul1Bpugy0zRSOWfKO_0>li:not(:first-child){border-top:1px solid #e6eaf0}._2x5HpdN0lWis62Ju499ecY_0{display:-webkit-box;display:-ms-flexbox;display:flex}._2x5HpdN0lWis62Ju499ecY_0>:not(:first-child){margin-left:.75rem}.V_cp6itHR2jm1Hbx5OlJA_0{-webkit-box-align:center;-ms-flex-align:center;align-items:center;margin-top:.75rem}._1nLIYFJzXAOW8zoRIy6g1__0,.V_cp6itHR2jm1Hbx5OlJA_0{display:-webkit-box;display:-ms-flexbox;display:flex}._1nLIYFJzXAOW8zoRIy6g1__0{-webkit-box-flex:1;-ms-flex:1;flex:1;-ms-flex-wrap:wrap;flex-wrap:wrap;-webkit-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;margin-left:.75rem;padding-left:.75rem;border-left:1px solid #e6eaf0}._1nLIYFJzXAOW8zoRIy6g1__0>:first-child{margin:8px 1rem 8px 0}._2SOcESCxKDKjbUE1k0W3n-_0{display:block;width:40px;margin:25px auto 40px}</style><style type="text/css">.confirmation-modal-primary-message[data-v-0fc97734],.confirmation-modal-secondary-message[data-v-0fc97734]{max-width:430px;margin:0 auto;line-height:1.5}.confirmation-modal-primary-message[data-v-0fc97734]{padding:24px 16px;text-align:center;font-weight:500}.confirmation-modal-secondary-message[data-v-0fc97734]{padding:0 16px;text-align:center;color:#a6b1c2;font-size:13px}.confirmation-modal-secondary-message[data-v-0fc97734]:empty{display:none}.confirmation-modal-buttons-container[data-v-0fc97734]{display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-align:center;-ms-flex-align:center;align-items:center;-webkit-box-pack:center;-ms-flex-pack:center;justify-content:center;padding:32px 26px}.confirmation-modal-buttons-container button[data-v-0fc97734]:not(:first-child){margin-left:16px}</style><style type="text/css">.DZ6LRsAQHQQmakTOGTi0Y_0{display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-align:center;-ms-flex-align:center;align-items:center;-webkit-box-pack:center;-ms-flex-pack:center;justify-content:center;min-height:80px;padding-bottom:24px}._39Nrafme_CbhdmkW83sHf6_0{display:inline-block;width:40px}.ApNQpz40BhSHgr3b8LXTP_0{list-style:none}.ApNQpz40BhSHgr3b8LXTP_0>li{display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-align:center;-ms-flex-align:center;align-items:center;-webkit-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;padding:16px;border-top:1px solid #e6eaf0}.ApNQpz40BhSHgr3b8LXTP_0>li>a{word-break:break-word}._1eFiS3ZedkCRgE6407g8y__0{padding:0 16px 16px;text-align:center;font-size:13px;color:#a6b1c2}.LFBX7Ca6nmcCcdZgLNf6a_0{cursor:pointer;font-size:13px;color:#646d82;white-space:nowrap}.LFBX7Ca6nmcCcdZgLNf6a_0:hover{text-decoration:underline}</style><style type="text/css">.report-form[data-v-da12ea46]{padding:16px}textarea.form-control[data-v-da12ea46]{resize:vertical}.report-submit-btn[data-v-da12ea46]{display:block;margin:20px auto 0}.success-tick[data-v-da12ea46]{display:block;width:40px;margin:24px auto}.success-message[data-v-da12ea46]{display:block;margin:0 24px 24px;text-align:center;line-height:1.5}</style><style type="text/css">._3t97eYwI04qDnoZJ5eKaT8_0{padding:0 16px 20px}._21gWVb5NN2CIaHxZEoAP-g_0{padding-left:20px}._21gWVb5NN2CIaHxZEoAP-g_0>li{line-height:1.7}._21gWVb5NN2CIaHxZEoAP-g_0>li:not(:first-child){margin-top:1rem}._21gWVb5NN2CIaHxZEoAP-g_0 ol>li{margin-top:.3rem}._21gWVb5NN2CIaHxZEoAP-g_0 button{min-height:0;margin-left:.3rem;padding:2px 4px;font-size:small}._1Fco7-ASxRtEU3rP3hWsHN_0{color:#a6b1c2}.n9OOd6-MRLX3oPlR7LHhV_0{margin-top:1rem;line-height:1.4}</style><style type="text/css">strong[data-v-050562bf]{font-weight:500}</style><style type="text/css">.wW9rE0_29Sha6Mk4uvmRU_0{color:#040e28;font-size:20px;font-weight:500;margin-bottom:8px}._1tykpbvLUDLpiPTfp-Lw7f_0{display:-webkit-box;display:-ms-flexbox;display:flex;-ms-flex-wrap:wrap;flex-wrap:wrap;list-style-type:none}._1tykpbvLUDLpiPTfp-Lw7f_0>li{margin:3px}._3BV8pJSyb3X3KaYr4CsQp1_0{color:#a6b1c2;font-size:13px}</style><style type="text/css">.search-container[data-v-37c0dfff]{display:-webkit-box;display:-ms-flexbox;display:flex;padding:0 16px 16px;border-bottom:1px solid #e2e2e2}.search-container .search[data-v-37c0dfff]{display:block;width:100%;padding:10px 12px;font-size:13px}.tag-list[data-v-37c0dfff]{display:block;margin:0;padding:0;list-style:none;overflow-y:auto}.tag-list>li[data-v-37c0dfff]{display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-ms-flex-align:center;align-items:center;margin:10px 0;padding:0;border-top:0}.add-icon[data-v-37c0dfff],.remove-icon[data-v-37c0dfff]{width:14px;cursor:pointer}</style><style type="text/css">._2JgbwNv_NSAvy1lPjhVC8H_0,._2oJKRb0zwZ5ez7p_4pc2Gu_0{display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-align:center;-ms-flex-align:center;align-items:center}._2JgbwNv_NSAvy1lPjhVC8H_0{font-size:small;margin-left:14px}._37LTnub7kUrMwQV17XO-Rg_0,._37LTnub7kUrMwQV17XO-Rg_0 ._2JgbwNv_NSAvy1lPjhVC8H_0{-webkit-box-orient:horizontal;-webkit-box-direction:reverse;-ms-flex-direction:row-reverse;flex-direction:row-reverse}._37LTnub7kUrMwQV17XO-Rg_0 ._2JgbwNv_NSAvy1lPjhVC8H_0{margin-right:10px;margin-left:0}</style><style type="text/css">._3xHVpiJsRdpfCVGMMfyQB_0{padding-bottom:4.5px}</style><style type="text/css">.vue-star-rating-star[data-v-34cbeed1]{display:inline-block}.vue-star-rating-pointer[data-v-34cbeed1]{cursor:pointer}.vue-star-rating[data-v-34cbeed1]{display:flex;align-items:center}.vue-star-rating-inline[data-v-34cbeed1]{display:inline-flex}.vue-star-rating-rating-text[data-v-34cbeed1]{margin-top:7px;margin-left:7px}.vue-star-rating-rtl[data-v-34cbeed1]{direction:rtl}.vue-star-rating-rtl .vue-star-rating-rating-text[data-v-34cbeed1]{margin-right:10px;direction:rtl}</style><style type="text/css">.vue-star-rating-star[data-v-21f5376e]{overflow:visible!important}</style><style type="text/css">._3YYcnWTLNfK4lxsi1fSIbf_0{padding:0 12px}._3YYcnWTLNfK4lxsi1fSIbf_0>div{display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-align:center;-ms-flex-align:center;align-items:center;-webkit-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;margin-bottom:12px}.HJdTfMDt66LwOmqHkECeh_0{margin-right:8px}._1kVsFbE-uvbTC544_8boUM_0{padding-bottom:3px;list-style:none}._1kVsFbE-uvbTC544_8boUM_0>li{border-top:1px solid #e6eaf0}a[href]._3KrC7b3wP6BrFAUg3VeBb__0{color:inherit;-webkit-transition:background-color .1s;transition:background-color .1s}a[href]._3KrC7b3wP6BrFAUg3VeBb__0:hover{background:#f5f5f5}._3KrC7b3wP6BrFAUg3VeBb__0{-webkit-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;padding:12px}._3cyJpPaarF0_XH5-rUUZKi_0,._3KrC7b3wP6BrFAUg3VeBb__0{display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-align:center;-ms-flex-align:center;align-items:center}._3UhspurJ3mCtH3a3RDF9Xa_0{margin:0 4px 0 8px;font-size:14px}._3UhspurJ3mCtH3a3RDF9Xa_0>a{color:inherit}._3UhspurJ3mCtH3a3RDF9Xa_0>a[href]{color:#040e28;font-weight:500}._3UhspurJ3mCtH3a3RDF9Xa_0>a[href]:hover,._22jC3VT5xVskGujCCoj73E_0[href]:hover+._3UhspurJ3mCtH3a3RDF9Xa_0>a[href]{text-decoration:underline}._3g2-ZYe5V79kH514QD4EoP_0{margin:0 10px 0 6px;color:#a6b1c2;font-size:small;font-weight:500;white-space:nowrap}._3bHJtwByYBiWdQwvqEqIHt_0{display:block;width:32px;margin:20px auto}._2ypLw40PGBM9BikWmH6AkM_0{padding:0 16px 20px;text-align:center;font-size:13px;color:#a6b1c2}</style><style type="text/css">._1Zw4_JBo5D9ZpI4oFQA4Wy_0{margin-bottom:2.5rem}._2ijTfW7RPI1ZIJw8WjCJja_0{line-height:1.5}._2ijTfW7RPI1ZIJw8WjCJja_0 a{color:#646d82}._2ijTfW7RPI1ZIJw8WjCJja_0 a[href]:hover{text-decoration:underline}._1pyOzZyVDhXVeSEaA1Iq0f_0{display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-align:center;-ms-flex-align:center;align-items:center;margin-bottom:.5rem}._1pyOzZyVDhXVeSEaA1Iq0f_0 :not(:first-child){margin-left:24px}._1pyOzZyVDhXVeSEaA1Iq0f_0 button{min-height:0;padding:2px 4px;font-size:small}._2Q28w-S5eEAnUGmSbwpngj_0{font-size:small;font-weight:500;color:#040e28;cursor:pointer;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none}._2Q28w-S5eEAnUGmSbwpngj_0:hover{opacity:.8}._2Q28w-S5eEAnUGmSbwpngj_0 img{width:.8em;margin-left:.25em;vertical-align:middle}.tY27lnZ6e5_Mz-8X_0o1g_0{margin-top:.3rem}.tY27lnZ6e5_Mz-8X_0o1g_0>li{color:#a6b1c2;font-size:small}.tY27lnZ6e5_Mz-8X_0o1g_0>li:not(:first-child){margin-top:4px}._3gSOAyfyTusN9ho3MMDFPG_0{-webkit-transform:rotate(180deg);transform:rotate(180deg)}</style><style type="text/css">._2YNtKNIXW0zZ5jHo8ATwOS_0{line-height:1.5}._2YNtKNIXW0zZ5jHo8ATwOS_0:not(:first-child){margin-top:28px}._1_PAwJ0EF2T4GxWFM4Yi35_0{display:block;margin-bottom:8px;font-size:medium;font-weight:500;color:#040e28}.Zqc_S_kuzuTKXY2msEiFN_0{white-space:pre-wrap;word-break:break-word}</style><style type="text/css">.xBL_RnPNHCChGTK3xf2tj_0{padding-top:32px;border-top:1px solid #e6eaf0}._38aJuJuFnnSi7syicbJR1Y_0{display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-align:center;-ms-flex-align:center;align-items:center;-webkit-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between}._38aJuJuFnnSi7syicbJR1Y_0>h2{color:#040e28;font-size:20px;font-weight:500}ul.F8cTAoYj-UoX0PTy1nkjM_0{margin:0;padding:0;list-style-type:none}ul.F8cTAoYj-UoX0PTy1nkjM_0:empty{display:none}ul.F8cTAoYj-UoX0PTy1nkjM_0>li{margin-top:32px}._1adS6QYnXSmhgIQ3VjYT2J_0{margin:40px 0;text-align:center}._2stjCAs9ND8AkVnqteokCZ_0{font-size:20px;font-weight:500}._3w1doBm5c0zCT0HZ0QmOHJ_0{margin-top:10px;font-size:12px;line-height:1.5}._3w1doBm5c0zCT0HZ0QmOHJ_0 a{cursor:pointer;font-weight:500}._2u0_C4IPqYTkW2Tf1EDQ34_0{display:block;width:40px;margin:40px auto}._17GP51wFxbnnjgchrThj-I_0{margin:40px 0;color:#f46363;text-align:center}._3bueFN-ilTjyaDkJQqsbVF_0{display:block;max-width:300px;margin:56px auto 0;padding:20px 4px 0;border-top:1px solid #e6eaf0;text-align:center;color:#040e28;font-weight:500}</style><style type="text/css">._1cHVZJqc2p3n80kMp8xwlb_0{color:#040e28;font-size:20px;font-weight:500;margin-bottom:8px}._3PVMo8Bg3S5acjMQ4C8MoR_0{list-style:none}._3PVMo8Bg3S5acjMQ4C8MoR_0>li{display:block;margin-top:.6rem;font-size:13px}._3PVMo8Bg3S5acjMQ4C8MoR_0>li>a{display:block;white-space:nowrap;overflow:hidden;text-overflow:ellipsis}._2-LSMw09_JqBcVXiPuVAS_0{display:inline-block;margin-top:.7rem;background:none;border:none;font-size:13px;color:#646d82;font-weight:500;cursor:pointer;outline:none}._2-LSMw09_JqBcVXiPuVAS_0:focus,._2-LSMw09_JqBcVXiPuVAS_0:hover{opacity:.8}._3bAPXsR6FYnl-DRm4qEoSx_0{color:#a6b1c2;font-size:13px}</style><style type="text/css">.section-title[data-v-31173c69]{color:#040e28;font-size:20px;font-weight:500}ul[data-v-31173c69]{padding:0;list-style-type:none}.definitions-used-section__title[data-v-31173c69]{margin:15px 0;color:#a6b1c2;font-size:13px;font-weight:500;line-height:19px}.definitions-used-list[data-v-31173c69]{margin:0;list-style-type:none}.definitions-used-list>li[data-v-31173c69]:not(:last-child){margin-bottom:10px}[data-v-31173c69] .definition-small-card{display:block;position:relative;max-width:300px;color:inherit;overflow:hidden;word-wrap:break-word;padding:16px;border-radius:2px 2px 7px 2px;-webkit-transition:-webkit-box-shadow .15s;transition:-webkit-box-shadow .15s;transition:box-shadow .15s;transition:box-shadow .15s,-webkit-box-shadow .15s;cursor:pointer}[data-v-31173c69] .definition-small-card.highlighted,[data-v-31173c69] .definition-small-card:hover{-webkit-box-shadow:0 0 1px 0 rgba(100,109,130,.1),0 2px 4px 0 rgba(100,109,130,.14);box-shadow:0 0 1px 0 rgba(100,109,130,.1),0 2px 4px 0 rgba(100,109,130,.14)}[data-v-31173c69] .definition-small-card__title{color:#49abed;font-size:16px}[data-v-31173c69] .definition-small-card__author{margin-top:10px;color:#a6b1c2;font-size:12px}[data-v-31173c69] .definition-small-card__highlight-toggle{position:absolute;right:5px;bottom:5px;padding:3px;cursor:pointer;border:none;outline:none;background:none}[data-v-31173c69] .definition-small-card__highlight-toggle>img{display:block;width:14px}</style><style type="text/css">._6hD2Lz5ysj_rssfmiGg05_0{background:#fafafa;font-size:small}._6hD2Lz5ysj_rssfmiGg05_0 a{color:#646d82;font-weight:500}._6hD2Lz5ysj_rssfmiGg05_0 a:hover{text-decoration:underline}._314Eb6zQf680xrNXVtUcRC_0{width:94vw;max-width:964px;margin:0 auto;padding:3.75rem 0}.iqAxatK_XnAn2tt5QYHck_0{display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-ms-flex-align:center;align-items:center}._18zgZn_SR0R4tUnqtjMng2_0{margin-top:26px;line-height:1.8;text-align:center}@media (max-width:899px){.iqAxatK_XnAn2tt5QYHck_0{-webkit-box-orient:vertical;-webkit-box-direction:normal;-ms-flex-direction:column;flex-direction:column}.iqAxatK_XnAn2tt5QYHck_0>:not(:first-child){margin-top:16px}}.vyEinM6KjO8O8hoxOZG7S_0{display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-pack:center;-ms-flex-pack:center;justify-content:center;-ms-flex-wrap:wrap;flex-wrap:wrap;list-style:none}.vyEinM6KjO8O8hoxOZG7S_0>li{margin:4px calc(6px + .1vw)}._3X2zHDsRrmCseC66623-JS_0{display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-align:center;-ms-flex-align:center;align-items:center;color:#49abed!important;white-space:nowrap}._3X2zHDsRrmCseC66623-JS_0:after{content:" ";display:inline-block;width:1.2rem;height:1.2rem;margin-left:8px;background:url("/images/icons/social/twitter_logo_blue.svg") no-repeat 50%;background-size:contain}._3Nd1-epD81ePEy78BqbNjD_0{display:inline-block;height:.9rem;vertical-align:middle}</style><style type="text/css">.MathJax_Hover_Frame {border-radius: .25em; -webkit-border-radius: .25em; -moz-border-radius: .25em; -khtml-border-radius: .25em; box-shadow: 0px 0px 15px #83A; -webkit-box-shadow: 0px 0px 15px #83A; -moz-box-shadow: 0px 0px 15px #83A; -khtml-box-shadow: 0px 0px 15px #83A; border: 1px solid #A6D ! important; display: inline-block; position: absolute}
.MathJax_Menu_Button .MathJax_Hover_Arrow {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 4px; -webkit-border-radius: 4px; -moz-border-radius: 4px; -khtml-border-radius: 4px; font-family: 'Courier New',Courier; font-size: 9px; color: #F0F0F0}
.MathJax_Menu_Button .MathJax_Hover_Arrow span {display: block; background-color: #AAA; border: 1px solid; border-radius: 3px; line-height: 0; padding: 4px}
.MathJax_Hover_Arrow:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_Hover_Arrow:hover span {background-color: #CCC!important}
</style><style type="text/css">#MathJax_About {position: fixed; left: 50%; width: auto; text-align: center; border: 3px outset; padding: 1em 2em; background-color: #DDDDDD; color: black; cursor: default; font-family: message-box; font-size: 120%; font-style: normal; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 15px; -webkit-border-radius: 15px; -moz-border-radius: 15px; -khtml-border-radius: 15px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_About.MathJax_MousePost {outline: none}
.MathJax_Menu {position: absolute; background-color: white; color: black; width: auto; padding: 2px; border: 1px solid #CCCCCC; margin: 0; cursor: default; font: menu; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
.MathJax_MenuItem {padding: 2px 2em; background: transparent}
.MathJax_MenuArrow {position: absolute; right: .5em; padding-top: .25em; color: #666666; font-size: .75em}
.MathJax_MenuActive .MathJax_MenuArrow {color: white}
.MathJax_MenuArrow.RTL {left: .5em; right: auto}
.MathJax_MenuCheck {position: absolute; left: .7em}
.MathJax_MenuCheck.RTL {right: .7em; left: auto}
.MathJax_MenuRadioCheck {position: absolute; left: 1em}
.MathJax_MenuRadioCheck.RTL {right: 1em; left: auto}
.MathJax_MenuLabel {padding: 2px 2em 4px 1.33em; font-style: italic}
.MathJax_MenuRule {border-top: 1px solid #CCCCCC; margin: 4px 1px 0px}
.MathJax_MenuDisabled {color: GrayText}
.MathJax_MenuActive {background-color: Highlight; color: HighlightText}
.MathJax_MenuDisabled:focus, .MathJax_MenuLabel:focus {background-color: #E8E8E8}
.MathJax_ContextMenu:focus {outline: none}
.MathJax_ContextMenu .MathJax_MenuItem:focus {outline: none}
#MathJax_AboutClose {top: .2em; right: .2em}
.MathJax_Menu .MathJax_MenuClose {top: -10px; left: -10px}
.MathJax_MenuClose {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; font-family: 'Courier New',Courier; font-size: 24px; color: #F0F0F0}
.MathJax_MenuClose span {display: block; background-color: #AAA; border: 1.5px solid; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; line-height: 0; padding: 8px 0 6px}
.MathJax_MenuClose:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_MenuClose:hover span {background-color: #CCC!important}
.MathJax_MenuClose:hover:focus {outline: none}
</style><style type="text/css">.MathJax_Preview .MJXf-math {color: inherit!important}
</style><style type="text/css">.MJX_Assistive_MathML {position: absolute!important; top: 0; left: 0; clip: rect(1px, 1px, 1px, 1px); padding: 1px 0 0 0!important; border: 0!important; height: 1px!important; width: 1px!important; overflow: hidden!important; display: block!important; -webkit-touch-callout: none; -webkit-user-select: none; -khtml-user-select: none; -moz-user-select: none; -ms-user-select: none; user-select: none}
.MJX_Assistive_MathML.MJX_Assistive_MathML_Block {width: 100%!important}
</style><style type="text/css">#MathJax_Zoom {position: absolute; background-color: #F0F0F0; overflow: auto; display: block; z-index: 301; padding: .5em; border: 1px solid black; margin: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; -webkit-box-sizing: content-box; -moz-box-sizing: content-box; box-sizing: content-box; box-shadow: 5px 5px 15px #AAAAAA; -webkit-box-shadow: 5px 5px 15px #AAAAAA; -moz-box-shadow: 5px 5px 15px #AAAAAA; -khtml-box-shadow: 5px 5px 15px #AAAAAA; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_ZoomOverlay {position: absolute; left: 0; top: 0; z-index: 300; display: inline-block; width: 100%; height: 100%; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
#MathJax_ZoomFrame {position: relative; display: inline-block; height: 0; width: 0}
#MathJax_ZoomEventTrap {position: absolute; left: 0; top: 0; z-index: 302; display: inline-block; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
</style><style type="text/css">.MathJax_Preview {color: #888}
#MathJax_Message {position: fixed; left: 1px; bottom: 2px; background-color: #E6E6E6; border: 1px solid #959595; margin: 0px; padding: 2px 8px; z-index: 102; color: black; font-size: 80%; width: auto; white-space: nowrap}
#MathJax_MSIE_Frame {position: absolute; top: 0; left: 0; width: 0px; z-index: 101; border: 0px; margin: 0px; padding: 0px}
.MathJax_Error {color: #CC0000; font-style: italic}
</style><style type="text/css">.MJXp-script {font-size: .8em}
.MJXp-right {-webkit-transform-origin: right; -moz-transform-origin: right; -ms-transform-origin: right; -o-transform-origin: right; transform-origin: right}
.MJXp-bold {font-weight: bold}
.MJXp-italic {font-style: italic}
.MJXp-scr {font-family: MathJax_Script,'Times New Roman',Times,STIXGeneral,serif}
.MJXp-frak {font-family: MathJax_Fraktur,'Times New Roman',Times,STIXGeneral,serif}
.MJXp-sf {font-family: MathJax_SansSerif,'Times New Roman',Times,STIXGeneral,serif}
.MJXp-cal {font-family: MathJax_Caligraphic,'Times New Roman',Times,STIXGeneral,serif}
.MJXp-mono {font-family: MathJax_Typewriter,'Times New Roman',Times,STIXGeneral,serif}
.MJXp-largeop {font-size: 150%}
.MJXp-largeop.MJXp-int {vertical-align: -.2em}
.MJXp-math {display: inline-block; line-height: 1.2; text-indent: 0; font-family: 'Times New Roman',Times,STIXGeneral,serif; white-space: nowrap; border-collapse: collapse}
.MJXp-display {display: block; text-align: center; margin: 1em 0}
.MJXp-math span {display: inline-block}
.MJXp-box {display: block!important; text-align: center}
.MJXp-box:after {content: " "}
.MJXp-rule {display: block!important; margin-top: .1em}
.MJXp-char {display: block!important}
.MJXp-mo {margin: 0 .15em}
.MJXp-mfrac {margin: 0 .125em; vertical-align: .25em}
.MJXp-denom {display: inline-table!important; width: 100%}
.MJXp-denom > * {display: table-row!important}
.MJXp-surd {vertical-align: top}
.MJXp-surd > * {display: block!important}
.MJXp-script-box > *  {display: table!important; height: 50%}
.MJXp-script-box > * > * {display: table-cell!important; vertical-align: top}
.MJXp-script-box > *:last-child > * {vertical-align: bottom}
.MJXp-script-box > * > * > * {display: block!important}
.MJXp-mphantom {visibility: hidden}
.MJXp-munderover {display: inline-table!important}
.MJXp-over {display: inline-block!important; text-align: center}
.MJXp-over > * {display: block!important}
.MJXp-munderover > * {display: table-row!important}
.MJXp-mtable {vertical-align: .25em; margin: 0 .125em}
.MJXp-mtable > * {display: inline-table!important; vertical-align: middle}
.MJXp-mtr {display: table-row!important}
.MJXp-mtd {display: table-cell!important; text-align: center; padding: .5em 0 0 .5em}
.MJXp-mtr > .MJXp-mtd:first-child {padding-left: 0}
.MJXp-mtr:first-child > .MJXp-mtd {padding-top: 0}
.MJXp-mlabeledtr {display: table-row!important}
.MJXp-mlabeledtr > .MJXp-mtd:first-child {padding-left: 0}
.MJXp-mlabeledtr:first-child > .MJXp-mtd {padding-top: 0}
.MJXp-merror {background-color: #FFFF88; color: #CC0000; border: 1px solid #CC0000; padding: 1px 3px; font-style: normal; font-size: 90%}
.MJXp-scale0 {-webkit-transform: scaleX(.0); -moz-transform: scaleX(.0); -ms-transform: scaleX(.0); -o-transform: scaleX(.0); transform: scaleX(.0)}
.MJXp-scale1 {-webkit-transform: scaleX(.1); -moz-transform: scaleX(.1); -ms-transform: scaleX(.1); -o-transform: scaleX(.1); transform: scaleX(.1)}
.MJXp-scale2 {-webkit-transform: scaleX(.2); -moz-transform: scaleX(.2); -ms-transform: scaleX(.2); -o-transform: scaleX(.2); transform: scaleX(.2)}
.MJXp-scale3 {-webkit-transform: scaleX(.3); -moz-transform: scaleX(.3); -ms-transform: scaleX(.3); -o-transform: scaleX(.3); transform: scaleX(.3)}
.MJXp-scale4 {-webkit-transform: scaleX(.4); -moz-transform: scaleX(.4); -ms-transform: scaleX(.4); -o-transform: scaleX(.4); transform: scaleX(.4)}
.MJXp-scale5 {-webkit-transform: scaleX(.5); -moz-transform: scaleX(.5); -ms-transform: scaleX(.5); -o-transform: scaleX(.5); transform: scaleX(.5)}
.MJXp-scale6 {-webkit-transform: scaleX(.6); -moz-transform: scaleX(.6); -ms-transform: scaleX(.6); -o-transform: scaleX(.6); transform: scaleX(.6)}
.MJXp-scale7 {-webkit-transform: scaleX(.7); -moz-transform: scaleX(.7); -ms-transform: scaleX(.7); -o-transform: scaleX(.7); transform: scaleX(.7)}
.MJXp-scale8 {-webkit-transform: scaleX(.8); -moz-transform: scaleX(.8); -ms-transform: scaleX(.8); -o-transform: scaleX(.8); transform: scaleX(.8)}
.MJXp-scale9 {-webkit-transform: scaleX(.9); -moz-transform: scaleX(.9); -ms-transform: scaleX(.9); -o-transform: scaleX(.9); transform: scaleX(.9)}
.MathJax_PHTML .noError {vertical-align: ; font-size: 90%; text-align: left; color: black; padding: 1px 3px; border: 1px solid}
</style><style type="text/css">._1_WunZCsvbkYjN37LLf03J_0{display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-align:center;-ms-flex-align:center;align-items:center;-webkit-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;margin-top:20px;color:#a6b1c2;font-size:small}._1_WunZCsvbkYjN37LLf03J_0 a{color:inherit}._1_WunZCsvbkYjN37LLf03J_0 a:hover{text-decoration:underline}._2OXTuAUzFQdX7t_9qL0vFq_0{display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-align:center;-ms-flex-align:center;align-items:center}@media (max-width:439px){._1_WunZCsvbkYjN37LLf03J_0{-webkit-box-orient:vertical;-webkit-box-direction:reverse;-ms-flex-direction:column-reverse;flex-direction:column-reverse;-webkit-box-align:start;-ms-flex-align:start;align-items:flex-start}._2OXTuAUzFQdX7t_9qL0vFq_0{margin-top:20px}}.lN8SYbshGK7NHsGeIPqvL_0{margin:0 6px 0 calc(10px + .6vw);color:#a6b1c2;font-weight:500}._1IrAplnFeWIqdU2Ut184y6_0{position:relative;margin-top:20px}._2R_X_G-Iyk4x5SQ4x9l-PE_0{position:absolute;right:0;left:0;bottom:0;display:block;padding:3px 8px;background:#f0f2f7;border-radius:4px 4px 0 0;text-align:center;font-size:14px;cursor:pointer;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;-webkit-transition:color .1s;transition:color .1s}._2R_X_G-Iyk4x5SQ4x9l-PE_0:hover{color:#040e28}._2nlIqXCXJn2qU-ZIE_NfvG_0{font-family:Roboto,sans-serif;font-size:16px;line-height:32px}._2nlIqXCXJn2qU-ZIE_NfvG_0 a[target=_blank]:not(.definition-use-case){color:inherit;text-decoration:underline}._2nlIqXCXJn2qU-ZIE_NfvG_0 h1,._2nlIqXCXJn2qU-ZIE_NfvG_0 h2,._2nlIqXCXJn2qU-ZIE_NfvG_0 h3{font-weight:500}._2nlIqXCXJn2qU-ZIE_NfvG_0 h1{font-size:21px}._2nlIqXCXJn2qU-ZIE_NfvG_0 h2{font-size:18px}._2nlIqXCXJn2qU-ZIE_NfvG_0 h3{font-size:16px}._2nlIqXCXJn2qU-ZIE_NfvG_0 p{word-wrap:break-word}._2nlIqXCXJn2qU-ZIE_NfvG_0 img{max-width:100%;-o-object-fit:contain;object-fit:contain}._2nlIqXCXJn2qU-ZIE_NfvG_0 sup{line-height:100%}._2nlIqXCXJn2qU-ZIE_NfvG_0 ul{padding-left:20px}._2nlIqXCXJn2qU-ZIE_NfvG_0 pre{padding:12px 18px;margin:0 0 12px;border:0;background:transparent;overflow-x:hidden;white-space:normal}._2nlIqXCXJn2qU-ZIE_NfvG_0 .definition-use-case{display:inline-block;color:#49abed;padding:0 1.4px;border-radius:2px;-webkit-transition:-webkit-box-shadow .1s;transition:-webkit-box-shadow .1s;transition:box-shadow .1s;transition:box-shadow .1s,-webkit-box-shadow .1s}._2nlIqXCXJn2qU-ZIE_NfvG_0 .definition-use-case:hover{-webkit-box-shadow:0 2px 4px 0 rgba(100,109,130,.14),0 0 1px 0 rgba(100,109,130,.1);box-shadow:0 2px 4px 0 rgba(100,109,130,.14),0 0 1px 0 rgba(100,109,130,.1)}._2nlIqXCXJn2qU-ZIE_NfvG_0 .image figcaption{padding:8px;word-wrap:break-word;font-size:13px;font-weight:500}._2nlIqXCXJn2qU-ZIE_NfvG_0 table{display:block;max-width:100%;border-collapse:collapse;font-size:13px}._2nlIqXCXJn2qU-ZIE_NfvG_0 table tbody{display:block;max-width:100%;overflow:auto;max-height:800px}._2nlIqXCXJn2qU-ZIE_NfvG_0 table td{padding:8px;border:1px solid #e6eaf0}._2nlIqXCXJn2qU-ZIE_NfvG_0 table caption{display:block;width:100%;caption-side:bottom;padding:8px;text-align:left;font-size:13px;font-weight:500;line-height:2}._2nlIqXCXJn2qU-ZIE_NfvG_0 .footnotes{margin-top:16px;padding:0;background-color:transparent;outline:none;word-wrap:break-word}._2nlIqXCXJn2qU-ZIE_NfvG_0 .footnotes header h2{margin:0;padding:10px 0;font-size:20px;outline:none}._2nlIqXCXJn2qU-ZIE_NfvG_0 .footnotes ol{margin:0;padding-bottom:10px}._2nlIqXCXJn2qU-ZIE_NfvG_0 .footnotes cite{outline:none}._2nlIqXCXJn2qU-ZIE_NfvG_0 [id^=footnote-marker-]:target{display:inline-block;margin-top:-56px;padding-top:56px}._10byB_HLpgkllZSaEm-RwP_0{overflow-y:hidden;max-height:260px}._2zkXP5q0wmeFiQiLh8T5r1_0{display:inline-block;margin-top:20px;font-size:.94em;cursor:pointer;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none}.kin6cMQVcVBc1wvFQkgh8_0{padding-top:20px;padding-left:28px}._1SpGw_Zj-vgJWHxoNCUNn9_0{display:block;width:32px;margin:24px auto}</style><style type="text/css">._14Rvbm0yZ3ys0Ku6srjUQy_0{display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-align:center;-ms-flex-align:center;align-items:center;-webkit-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;padding:16px 24px}@media (max-width:499px){._14Rvbm0yZ3ys0Ku6srjUQy_0{padding-right:12px;padding-left:12px}}._4B3sMsx6UQTJuv4kbAbCv_0{margin-left:8px;margin-right:auto;font-size:13px}._4B3sMsx6UQTJuv4kbAbCv_0 ._1PCWzjgVAD9So9IYYm-Rvl_0{color:inherit}._4B3sMsx6UQTJuv4kbAbCv_0 ._1PCWzjgVAD9So9IYYm-Rvl_0:hover{text-decoration:underline}._4B3sMsx6UQTJuv4kbAbCv_0 b{color:#040e28;font-weight:500}._1hWqjRdZGf2oU5m78bvT0O_0{display:block;margin-top:4px;color:#a6b1c2;font-size:12px}.I4q0qxXQ2tWXh0tktZQF5_0{display:inline-block;padding:10px;cursor:pointer}.I4q0qxXQ2tWXh0tktZQF5_0 img{display:block}</style><style type="text/css">._1WZuk8vh5YvBtI0uwqRho3_0{list-style-type:none}._1WZuk8vh5YvBtI0uwqRho3_0>li:not(:first-child){margin-top:16px;padding-top:16px;border-top:1px solid #e6eaf0}.TZtT5SDcqAf4egvNYn-We_0{display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-ms-flex-align:center;align-items:center;width:100%;margin-bottom:10px}.TZtT5SDcqAf4egvNYn-We_0>textarea{-webkit-box-flex:1;-ms-flex:1;flex:1;padding:8px 15px;border:1px solid #ededed;border-radius:2px;outline:none;resize:none;color:#646d82;font-size:13px;font-family:Roboto,sans-serif;line-height:1.7}.TZtT5SDcqAf4egvNYn-We_0>button{-ms-flex-item-align:end;align-self:flex-end;margin-left:15px}._2dI0s2EWTt9ywmZfun8C8t_0{display:block;margin-bottom:16px;font-size:14px}._3CNHyI_elyRVZ3Juon5WU__0{color:#040e28;font-weight:500}._3CNHyI_elyRVZ3Juon5WU__0>a{color:inherit}._3CNHyI_elyRVZ3Juon5WU__0>a:hover{text-decoration:underline}._3Ivb-z-5zSy5ttzxiVXTre_0{display:inline-block;margin-left:14px;font-size:13px;color:#a6b1c2}._3HWa8GSr1OJ3xVCO6mq7kA_0{line-height:1.7;white-space:pre-wrap;word-break:break-word}</style><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="embed-a458e1093bac38cf5adc51eff02159de22f9e260b3636d0ecefba2.css"></head>
<body><div id="MathJax_Message" style="display: none;"></div>
    <div class="preload-images" style="display: none"></div>
    <div id="app"><div class="app-header "><nav class="app-header-content"><div class="left-side"><a href="https://www.qeios.com/" class="app-logo-container"><img src="Qeios.svg" alt="Qeios" class="app-logo app-logo--large"> <img src="Q.svg" alt="Qeios" class="app-logo app-logo--small"></a> <div class="search-container  search-container--guest "><form action="https://www.qeios.com/search" method="get"><input name="q" placeholder="Search on Qeios" required="required" pattern=".*[^ ].*" class="form-control search-field" type="text"> <button type="submit" class="search-button"><img src="lens.svg" alt="Search" class="search-button__icon"></button></form></div> <a href="https://www.qeios.com/discover" class="app-header-navlink ">Discover</a></div> <ul class="right-side-navmenu"><li><a href="https://www.qeios.com/about" class="app-header-navlink ">About</a></li> <li><a href="https://www.qeios.com/how-it-works" class="app-header-navlink ">How It Works</a></li> <li><a href="https://www.qeios.com/membership" class="app-header-navlink ">Membership</a></li> <li><a data-v-152f5d80="" href="https://www.qeios.com/register" class="app-header-navlink app-header-navlink--signup full-btn">Sign Up Free</a></li> <li><a href="https://www.qeios.com/login" class="app-header-navlink app-header-navlink--login">Log In</a></li></ul></nav></div> <div><!----></div><div><!----></div> <div class="content-container"><div class="read-header"><section class="read-header__left-col"><section class="_2sfQLp3e4EVxbl8n17w9Oz_0"><ul class="vQ9oh6hbHIFNvCuTkBMA9_0"><!----> <li class="__sortable-ignore"><div class="QSV7rVelPoCzp998XLZGW_0 _1reTLV_HW-MHSh0YHelgjn_0">
                +1
            </div></li> <li><ul class="vQ9oh6hbHIFNvCuTkBMA9_0"><li data-reorder-data="{&quot;author_id&quot;:1767}"><div class="v-popover"><div aria-describedby="popover_p2p39z8tey" class="trigger" style="display: inline-block;"><div data-v-6fd402d6="" style="cursor: pointer;"><div data-v-6fd402d6="" class="v-popover"><div aria-describedby="popover_if0vxbmwgc" class="trigger" style="display: inline-block;"><div data-v-6fd402d6="" class="avatar-wrapper"><div data-v-6fd402d6="" style="display: inline-block;"><div data-v-6fd402d6="" class="avatar-placeholder" style="width: 40px; height: 40px; font-size: 14px; background-image: url(&quot;/images/avatar-placeholders/3.png&quot;);"><span data-v-6fd402d6="">JB</span></div></div> <div data-v-6fd402d6="" class="account-badge-container"><img data-v-6fd402d6="" src="member.svg"></div></div> </div> </div> <!----></div> </div> </div></li><li data-reorder-data="{&quot;author_id&quot;:1766}"><div class="v-popover"><div aria-describedby="popover_94lt4od0x1" class="trigger" style="display: inline-block;"><div data-v-6fd402d6="" style="cursor: pointer;"><div data-v-6fd402d6="" class="v-popover"><div aria-describedby="popover_hz9l2d1y6d" class="trigger" style="display: inline-block;"><div data-v-6fd402d6="" class="avatar-wrapper"><div data-v-6fd402d6="" style="display: inline-block;"><div data-v-6fd402d6="" class="avatar-placeholder" style="width: 40px; height: 40px; font-size: 14px; background-image: url(&quot;/images/avatar-placeholders/2.png&quot;);"><span data-v-6fd402d6="">LS</span></div></div> <div data-v-6fd402d6="" class="account-badge-container"><img data-v-6fd402d6="" src="member.svg"></div></div> </div> </div> <!----></div> </div> </div></li><li data-reorder-data="{&quot;author_id&quot;:2134}"><div class="v-popover"><div aria-describedby="popover_33t2wt1w0q" class="trigger" style="display: inline-block;"><div data-v-6fd402d6="" style="cursor: pointer;"><div data-v-6fd402d6="" class="v-popover"><div aria-describedby="popover_ovrc4z1a60" class="trigger" style="display: inline-block;"><div data-v-6fd402d6="" class="avatar-wrapper"><div data-v-6fd402d6="" style="display: inline-block;"><div data-v-6fd402d6="" class="avatar-placeholder" style="width: 40px; height: 40px; font-size: 14px; background-image: url(&quot;/images/avatar-placeholders/2.png&quot;);"><span data-v-6fd402d6="">DS</span></div></div> <div data-v-6fd402d6="" class="account-badge-container"><img data-v-6fd402d6="" src="member.svg"></div></div> </div> </div> <!----></div> </div> </div></li></ul></li></ul> <!----> <!----></section> <div data-v-1543fad5="" class="publication-stats-container publication-stats-container"><div data-v-1543fad5="" class="stat"><img data-v-1543fad5="" src="eye.svg" alt="Views" class="icon has-tooltip" data-original-title="null"> <p data-v-1543fad5="" class="amount">20,556</p></div> <!----> <div data-v-1543fad5="" class="stat clickable"><img data-v-1543fad5="" src="review_lightgrey.svg" alt="Peer Reviews" class="icon has-tooltip" data-original-title="null"> <p data-v-1543fad5="" class="amount">1</p></div> <div data-v-1543fad5="" class="stat"><img data-v-1543fad5="" src="download_lightgrey.svg" alt="Downloads" class="icon has-tooltip" data-original-title="null"> <p data-v-1543fad5="" class="amount">988</p></div> <!----></div></section> <div class="read-header__center-col"></div> <div class="read-header__right-col"><div><div class="v-popover"><div aria-describedby="popover_r70slujh6e" class="trigger" style="display: inline-block;"><a class="dot-menu-toggle"><img src="dot_menu.svg" alt="Make action"></a> </div> </div></div> <button class="hollow-btn white">Version History</button> <div class="v-popover"><div aria-describedby="popover_cgls84ptj4" class="trigger" style="display: inline-block;"><button class="hollow-btn white">Share&nbsp;&nbsp;<img src="arrow_down.svg" style="max-width: 10px;"></button> </div> </div> <div data-v-34e61a6c="" class="bookmark-btn read-header__bookmark-btn hollow-btn white has-tooltip" data-original-title="null"><img data-v-34e61a6c="" src="bookmark.svg"> <!----></div></div></div> <!----> <!----> <div><!----> <!----></div> <!----> <!----> <div class="publication-view-container"><div class="side-col-left"><section><h3 class="section-title">Altmetric Score</h3> <div class="altmetric-donut-container"><div data-badge-type="donut" data-badge-popover="right" class="altmetric-embed" data-uuid="530e6be9-0983-94e8-0d4b-d918441d34fd"><a target="_self" href="https://www.altmetric.com/details.php?domain=www.qeios.com&amp;citation_id=85037253" rel="popover" data-content="&lt;div&gt;    &lt;div style='padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;'&gt;
      &lt;a class='link-to-altmetric-details-tab' target='_self' href='https://www.altmetric.com/details.php?domain=www.qeios.com&amp;citation_id=85037253&amp;tab=twitter'&gt;
          Tweeted by &lt;b&gt;29&lt;/b&gt;
      &lt;/a&gt;
    &lt;/div&gt;

    &lt;div style='margin-top: 10px; text-align: center;'&gt;
        &lt;a class='altmetric_details' target='_self' href='https://www.altmetric.com/details.php?domain=www.qeios.com&amp;citation_id=85037253'&gt;
            See more details
        &lt;/a&gt;
    &lt;/div&gt;
&lt;/div&gt;" style="display:inline-block;" data-badge-popover="right">
        <img alt="Article has an altmetric score of 16" src="a.png" style="border:0; margin:0; max-width: none;" width="64px" height="64px">
</a></div></div></section> <section><h3 class="wW9rE0_29Sha6Mk4uvmRU_0">
        Tags
        <!----></h3> <ul class="_1tykpbvLUDLpiPTfp-Lw7f_0"><li><div><a href="https://www.qeios.com/topic/articles/COVID-19" class="article-tag clickable"><img src="article_tag.svg" class="tag-icon"> <span class="tag-name">COVID-19</span></a></div></li><li><div><a href="https://www.qeios.com/topic/articles/hospitalisation" class="article-tag clickable"><img src="article_tag.svg" class="tag-icon"> <span class="tag-name">hospitalisation</span></a></div></li><li><div><a href="https://www.qeios.com/topic/articles/infection" class="article-tag clickable"><img src="article_tag.svg" class="tag-icon"> <span class="tag-name">infection</span></a></div></li><li><div><a href="https://www.qeios.com/topic/articles/mortality" class="article-tag clickable"><img src="article_tag.svg" class="tag-icon"> <span class="tag-name">mortality</span></a></div></li><li><div><a href="https://www.qeios.com/topic/articles/SARS-CoV-2" class="article-tag clickable"><img src="article_tag.svg" class="tag-icon"> <span class="tag-name">SARS-CoV-2</span></a></div></li><li><div><a href="https://www.qeios.com/topic/articles/smoking" class="article-tag clickable"><img src="article_tag.svg" class="tag-icon"> <span class="tag-name">smoking</span></a></div></li><li><div><a href="https://www.qeios.com/topic/articles/tobacco" class="article-tag clickable"><img src="article_tag.svg" class="tag-icon"> <span class="tag-name">tobacco</span></a></div></li></ul> <!----></section></div> <div class="central-container"><section class="rating-section"><h3 class="rating-section__title">Article Rating</h3> <div class="rating-section__body"><div class="_2oJKRb0zwZ5ez7p_4pc2Gu_0" style="cursor: pointer;"><div><div class="_3xHVpiJsRdpfCVGMMfyQB_0"><div data-v-34cbeed1="" class="vue-star-rating vue-star-rating-inline"><div data-v-34cbeed1="" class="vue-star-rating"><span data-v-34cbeed1="" class="vue-star-rating-star" style="margin-right: 0px;"><svg data-v-21f5376e="" data-v-34cbeed1="" height="20" width="20" viewBox="0 0 29 29" class="vue-star-rating-star" step="1"><linearGradient data-v-21f5376e="" id="36pbfl" x1="0" x2="100%" y1="0" y2="0"><stop data-v-21f5376e="" offset="100%" stop-color="#3cbc87"></stop> <stop data-v-21f5376e="" offset="100%" stop-color="#e6eaf0"></stop></linearGradient> <filter data-v-21f5376e="" id="2ktjt" height="130%" width="130%" filterUnits="userSpaceOnUse"><feGaussianBlur data-v-21f5376e="" stdDeviation="0" result="coloredBlur"></feGaussianBlur> <feMerge data-v-21f5376e=""><feMergeNode data-v-21f5376e="" in="coloredBlur"></feMergeNode> <feMergeNode data-v-21f5376e="" in="SourceGraphic"></feMergeNode></feMerge></filter> <polygon data-v-21f5376e="" points="18.090909090909093,10.01010101010101,12.030303030303031,29,27.181818181818183,16.87878787878788,9,16.87878787878788,24.15151515151515,29" fill="url(#36pbfl)" stroke="#fff" filter="url(#2ktjt)"></polygon> <polygon data-v-21f5376e="" points="18.090909090909093,10.01010101010101,12.030303030303031,29,27.181818181818183,16.87878787878788,9,16.87878787878788,24.15151515151515,29" fill="url(#36pbfl)" stroke="#3cbc87" stroke-width="6" stroke-linejoin="round"></polygon> <polygon data-v-21f5376e="" points="18.090909090909093,10.01010101010101,12.030303030303031,29,27.181818181818183,16.87878787878788,9,16.87878787878788,24.15151515151515,29" fill="url(#36pbfl)"></polygon></svg></span><span data-v-34cbeed1="" class="vue-star-rating-star" style="margin-right: 0px;"><svg data-v-21f5376e="" data-v-34cbeed1="" height="20" width="20" viewBox="0 0 29 29" class="vue-star-rating-star" step="1"><linearGradient data-v-21f5376e="" id="6twls" x1="0" x2="100%" y1="0" y2="0"><stop data-v-21f5376e="" offset="100%" stop-color="#3cbc87"></stop> <stop data-v-21f5376e="" offset="100%" stop-color="#e6eaf0"></stop></linearGradient> <filter data-v-21f5376e="" id="un7w32" height="130%" width="130%" filterUnits="userSpaceOnUse"><feGaussianBlur data-v-21f5376e="" stdDeviation="0" result="coloredBlur"></feGaussianBlur> <feMerge data-v-21f5376e=""><feMergeNode data-v-21f5376e="" in="coloredBlur"></feMergeNode> <feMergeNode data-v-21f5376e="" in="SourceGraphic"></feMergeNode></feMerge></filter> <polygon data-v-21f5376e="" points="18.090909090909093,10.01010101010101,12.030303030303031,29,27.181818181818183,16.87878787878788,9,16.87878787878788,24.15151515151515,29" fill="url(#6twls)" stroke="#fff" filter="url(#un7w32)"></polygon> <polygon data-v-21f5376e="" points="18.090909090909093,10.01010101010101,12.030303030303031,29,27.181818181818183,16.87878787878788,9,16.87878787878788,24.15151515151515,29" fill="url(#6twls)" stroke="#3cbc87" stroke-width="6" stroke-linejoin="round"></polygon> <polygon data-v-21f5376e="" points="18.090909090909093,10.01010101010101,12.030303030303031,29,27.181818181818183,16.87878787878788,9,16.87878787878788,24.15151515151515,29" fill="url(#6twls)"></polygon></svg></span><span data-v-34cbeed1="" class="vue-star-rating-star" style="margin-right: 0px;"><svg data-v-21f5376e="" data-v-34cbeed1="" height="20" width="20" viewBox="0 0 29 29" class="vue-star-rating-star" step="1"><linearGradient data-v-21f5376e="" id="i84j6p" x1="0" x2="100%" y1="0" y2="0"><stop data-v-21f5376e="" offset="100%" stop-color="#3cbc87"></stop> <stop data-v-21f5376e="" offset="100%" stop-color="#e6eaf0"></stop></linearGradient> <filter data-v-21f5376e="" id="xr615tk" height="130%" width="130%" filterUnits="userSpaceOnUse"><feGaussianBlur data-v-21f5376e="" stdDeviation="0" result="coloredBlur"></feGaussianBlur> <feMerge data-v-21f5376e=""><feMergeNode data-v-21f5376e="" in="coloredBlur"></feMergeNode> <feMergeNode data-v-21f5376e="" in="SourceGraphic"></feMergeNode></feMerge></filter> <polygon data-v-21f5376e="" points="18.090909090909093,10.01010101010101,12.030303030303031,29,27.181818181818183,16.87878787878788,9,16.87878787878788,24.15151515151515,29" fill="url(#i84j6p)" stroke="#fff" filter="url(#xr615tk)"></polygon> <polygon data-v-21f5376e="" points="18.090909090909093,10.01010101010101,12.030303030303031,29,27.181818181818183,16.87878787878788,9,16.87878787878788,24.15151515151515,29" fill="url(#i84j6p)" stroke="#3cbc87" stroke-width="6" stroke-linejoin="round"></polygon> <polygon data-v-21f5376e="" points="18.090909090909093,10.01010101010101,12.030303030303031,29,27.181818181818183,16.87878787878788,9,16.87878787878788,24.15151515151515,29" fill="url(#i84j6p)"></polygon></svg></span><span data-v-34cbeed1="" class="vue-star-rating-star" style="margin-right: 0px;"><svg data-v-21f5376e="" data-v-34cbeed1="" height="20" width="20" viewBox="0 0 29 29" class="vue-star-rating-star" step="1"><linearGradient data-v-21f5376e="" id="he4n2o" x1="0" x2="100%" y1="0" y2="0"><stop data-v-21f5376e="" offset="100%" stop-color="#3cbc87"></stop> <stop data-v-21f5376e="" offset="100%" stop-color="#e6eaf0"></stop></linearGradient> <filter data-v-21f5376e="" id="g49174" height="130%" width="130%" filterUnits="userSpaceOnUse"><feGaussianBlur data-v-21f5376e="" stdDeviation="0" result="coloredBlur"></feGaussianBlur> <feMerge data-v-21f5376e=""><feMergeNode data-v-21f5376e="" in="coloredBlur"></feMergeNode> <feMergeNode data-v-21f5376e="" in="SourceGraphic"></feMergeNode></feMerge></filter> <polygon data-v-21f5376e="" points="18.090909090909093,10.01010101010101,12.030303030303031,29,27.181818181818183,16.87878787878788,9,16.87878787878788,24.15151515151515,29" fill="url(#he4n2o)" stroke="#fff" filter="url(#g49174)"></polygon> <polygon data-v-21f5376e="" points="18.090909090909093,10.01010101010101,12.030303030303031,29,27.181818181818183,16.87878787878788,9,16.87878787878788,24.15151515151515,29" fill="url(#he4n2o)" stroke="#3cbc87" stroke-width="6" stroke-linejoin="round"></polygon> <polygon data-v-21f5376e="" points="18.090909090909093,10.01010101010101,12.030303030303031,29,27.181818181818183,16.87878787878788,9,16.87878787878788,24.15151515151515,29" fill="url(#he4n2o)"></polygon></svg></span><span data-v-34cbeed1="" class="vue-star-rating-star" style="margin-right: 0px;"><svg data-v-21f5376e="" data-v-34cbeed1="" height="20" width="20" viewBox="0 0 29 29" class="vue-star-rating-star" step="1"><linearGradient data-v-21f5376e="" id="y0ssnx" x1="0" x2="100%" y1="0" y2="0"><stop data-v-21f5376e="" offset="0%" stop-color="#3cbc87"></stop> <stop data-v-21f5376e="" offset="0%" stop-color="#e6eaf0"></stop></linearGradient> <filter data-v-21f5376e="" id="alzvgd" height="130%" width="130%" filterUnits="userSpaceOnUse"><feGaussianBlur data-v-21f5376e="" stdDeviation="0" result="coloredBlur"></feGaussianBlur> <feMerge data-v-21f5376e=""><feMergeNode data-v-21f5376e="" in="coloredBlur"></feMergeNode> <feMergeNode data-v-21f5376e="" in="SourceGraphic"></feMergeNode></feMerge></filter> <polygon data-v-21f5376e="" points="18.090909090909093,10.01010101010101,12.030303030303031,29,27.181818181818183,16.87878787878788,9,16.87878787878788,24.15151515151515,29" fill="url(#y0ssnx)" stroke="#fff" filter="url(#alzvgd)" style="display: none;"></polygon> <polygon data-v-21f5376e="" points="18.090909090909093,10.01010101010101,12.030303030303031,29,27.181818181818183,16.87878787878788,9,16.87878787878788,24.15151515151515,29" fill="url(#y0ssnx)" stroke="#e6eaf0" stroke-width="6" stroke-linejoin="round"></polygon> <polygon data-v-21f5376e="" points="18.090909090909093,10.01010101010101,12.030303030303031,29,27.181818181818183,16.87878787878788,9,16.87878787878788,24.15151515151515,29" fill="url(#y0ssnx)"></polygon></svg></span> <!----></div></div></div></div> <p class="_2JgbwNv_NSAvy1lPjhVC8H_0"><strong>4.00</strong> <span style="margin: 0px 4px;">|</span> <span><strong>1</strong>&nbsp;Vote
        </span></p></div> <button type="button" class="full-btn blue">
    Review Article
</button></div> <!----></section> <div class="information-topbar"><div><div><div class="information-topbar__publication-type">Article</div> <time>Jul 1, 2020</time></div> <div>Qeios ID: UJR2AW.6</div></div> <div><div><span class="information-topbar__open-access-indication">Open Access</span> <div class="v-popover"><div aria-describedby="popover_68kn76c1fn" class="trigger" style="display: inline-block;"><span class="information-topbar__generic-btn">CC BY</span> </div> </div> <span role="button" class="information-topbar__generic-btn">Cite</span></div> <div><a href="https://doi.org/10.32388/UJR2AW.6">https://doi.org/10.32388/UJR2AW.6</a></div></div></div> <!----> <div><h1 data-version-label="Preprint v6" class="publication-title">The
 association of smoking status with SARS-CoV-2 infection, 
hospitalisation and mortality from COVID-19: A living rapid evidence 
review (version 5)</h1></div> <section class="_1Zw4_JBo5D9ZpI4oFQA4Wy_0"><p class="_2ijTfW7RPI1ZIJw8WjCJja_0"><span><a href="https://www.qeios.com/profile/2134" target="_self">David Simons</a><sup>1</sup>, </span><span><a href="https://www.qeios.com/profile/1766" target="_self">Lion Shahab</a><sup>2</sup>, </span><span><a href="https://www.qeios.com/profile/1767" target="_self">Jamie Brown</a><sup>2</sup>, </span><span><a href="https://www.qeios.com/profile/2135" target="_self">Olga Perski</a><sup>2</sup><!----></span></p> <section style="margin-top: 0.7rem;"><div class="_1pyOzZyVDhXVeSEaA1Iq0f_0"><h3 role="button" class="_2Q28w-S5eEAnUGmSbwpngj_0">
                Author(s) details
                <img src="arrow_down_002.svg" class=""></h3> <button type="button" class="hollow-btn white">Declarations</button> <!----></div> <ol class="tY27lnZ6e5_Mz-8X_0o1g_0" style="display: none;" type="1"><li>
                Royal Veterinary College, RVC, London, United Kingdom
            </li><li>
                University College London, University of London, United Kingdom
            </li></ol></section></section> <div><h3 class="publication-abstract-label">Abstract</h3> <p class="publication-abstract">Background: SARS-CoV-2 is the causative agent of COVID-19, an emergent zoonotic disease which has reached pandemic levels and is designated a public health emergency of international concern. It is plausible that former or current smoking status is associated with infection, hospitalisation and/or mortality from COVID-19.

Objective: We aimed to estimate the association of smoking status with rates of i) infection, ii) hospitalisation, iii) disease severity, and iv) mortality from SARS-CoV-2/COVID-19 disease.

Methods: This is a living evidence review with frequent updates. We adopted recommended practice for rapid evidence reviews, which involved limiting the search to main databases and having one reviewer extract data and another verify. Published articles and pre-prints were identified via Ovid MEDLINE, medRxiv and expertise within the review team. We included observational or experimental studies with community-dwelling or hospitalised adults aged 16+ years who had received a test for SARS-CoV-2 infection or a diagnosis of COVID-19, providing that data on smoking status were reported. Studies were judged as ‘good’ quality if they: i) had low levels of missing data on smoking status (i.e. &lt;20%) and used a reliable self-report measure that distinguished between current, former and never smoking status; AND ii) used biochemical verification of smoking status and reported results from adjusted analyses; OR reported data from a representative/random sample. Studies were rated as ‘fair’ if they fulfilled criterion i) only and were otherwise rated as ‘poor’.

Results: Version 5 with searches up to 23 June 2020 included 148 studies, 43 of which were conducted in China, 37 in the US, 15 in the UK, nine in Mexico, nine in Spain, eight in France, six in Italy, five across multiple international sites, two in Israel, and one each from 14 further countries. Thirty-two (21.6%) studies reported current, former and never smoking status. Twenty-six studies (17.6%) explicitly reported the proportion missing data on smoking status, which ranged from 0.08% to 96.4%. Notwithstanding recording uncertainties, compared with adult national prevalence estimates, recorded current and former smoking rates were generally lower than expected. In 12 ‘fair’ quality studies, current smokers were at reduced risk of testing positive for SARS-CoV-2 compared with never smokers (RR = 0.70, 95% CI = 0.55-0.88, p = .003, I2 = 90%). No significant difference was observed between former and never smokers (RR = 1.02, 95% CI = 0.92-1.12, p = .76, I2 = 72%). In seven ‘fair’ quality studies, there was no significant difference between current and never (RR = 1.06, 95% CI = 0.79-1.44, p = .63, I2 = 79%) or former and never smokers (RR = 1.20, 95% CI = 0.95-1.51, p = .10, I2 = 79%) in the risk of requiring admission to hospital with COVID-19 among those testing positive in the community. In six ‘fair’ quality studies, no significant difference in disease severity was observed between current and never smokers (RR = 1.22, 95% CI = 0.98-1.53, p = .08, I2 = 22%). Former smokers were at increased risk of greater disease severity compared with never smokers (RR = 1.58, 95% CI = 1.07-2.32, p = .02, I2 = 68%). In five ‘fair’ quality studies, current (RR = 1.70, 95% CI = 1.14-2.55, p = .01, I2 = 29%) and former smokers (RR = 2.00, 95% CI = 1.57-2.55, p &lt; .0.001, I2 = 0%) were at increased risk of in-hospital death compared with never smokers.

Conclusions: Across 148 studies, there is substantial uncertainty about the associations of smoking with COVID-19 outcomes. The recorded smoking prevalence in the included studies was generally lower than overall adult national estimates. There was no evidence of reduced risk of admission to hospital for current compared with never smokers among those testing positive in the community. There was some evidence that current compared with never smoking is associated with reduced risk of testing positive in the community but also greater in-hospital mortality from COVID-19. There was some evidence that former compared with never smoking is associated with increased risk of greater disease severity and in-hospital mortality from COVID-19.

Implications: Unrelated to COVID-19, smokers are at a greater risk of a range of serious health problems. Given uncertainty around the association of smoking with COVID-19 outcomes, smoking cessation remains a public health priority and high-quality smoking cessation advice including recommendations to use alternative nicotine products should form part of public health efforts during this pandemic. High quality, smoking-specific research is needed to resolve these mixed findings.</p></div> <!----> <div class="publication-body"><p><strong>Introduction</strong></p>

<p>&nbsp;</p>

<p>COVID-19 is a respiratory disease caused by the emerging SARS-CoV-2 
virus. Large age and gender differences in case severity and mortality 
have been observed in the ongoing COVID-19 pandemic<sup>1</sup>; however, these differences are currently unexplained. SARS-CoV-2 enters epithelial cells through the ACE-2 receptor<sup>2</sup>.
 Some evidence suggests that gene expression and subsequent receptor 
levels are elevated in the airway and oral epithelium of current smokers<sup>3,4</sup>,
 thus putting smokers at higher risk of contracting SARS-CoV-2. Other 
studies, however, suggest that nicotine downregulates the ACE-2 receptor<sup>5</sup>. These uncertainties notwithstanding, both former and current smoking is known to increase the risk of respiratory viral<sup>6,7</sup> and bacterial<sup>8,9</sup>
 infections and is associated with worse outcomes once infected. 
Cigarette smoke reduces the respiratory immune defence through 
peri-bronchiolar inflammation and fibrosis, impaired mucociliary 
clearance and disruption of the respiratory epithelium<sup>10</sup>. 
There is also reason to believe that behavioural factors (e.g. regular 
hand-to-mouth movements) involved in smoking may increase SARS-CoV-2 
infection and transmission in current smokers. However, early data from 
the COVID-19 pandemic have not provided clear evidence for a negative 
impact of current or former smoking on SARS-CoV-2 infection or COVID-19 
disease outcomes, such as hospitalisation or mortality<sup>11</sup>. It 
has also been hypothesised that nicotine might protect against a 
hyper-inflammatory response (or “cytokine storm”) to SARS-CoV-2 
infection, which may lead to adverse outcomes in patients with COVID-19 
disease<sup>12</sup>.</p>

<p>&nbsp;</p>

<p>There are several reviews that fall within the scope of smoking and COVID-19<sup>11,13–17</sup>.
 We aimed to produce a rapid synthesis of available evidence pertaining 
to the rates of infection, hospitalisation, disease severity and 
mortality from SARS-CoV-2/COVID-19 stratified by smoking status. Given 
the increasing availability of data on this topic, this is a living 
review with regular updates. As evidence accumulates, the review will be
 expanded to include studies reporting COVID-19 outcomes by alternative 
nicotine use (e.g., nicotine replacement therapy or e-cigarettes).</p>

<p>&nbsp;</p>

<p><strong>Methods</strong></p>

<p>&nbsp;</p>

<p><em>Study design</em></p>

<p>This is a living evidence review which is updated as new evidence becomes available<sup>18</sup>.
 We adopted recommended practice for rapid evidence reviews, which 
involved limiting the search to main databases and having one reviewer 
extract the data and another verify<sup>19</sup>.</p>

<p>Eligibility criteria</p>

<p>&nbsp;</p>

<p>Studies were included if they:</p>

<p>&nbsp;</p>

<p>1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Were primary research studies using 
experimental (e.g. randomised controlled trial), quasi-experimental 
(e.g. pre- and post-test) or observational (e.g. case-control, 
retrospective cohort, prospective cohort) study designs;</p>

<p>2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Included adults aged 16+ years;</p>

<p>3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recorded as outcome i) results of a 
SARS-CoV-2 diagnostic test (including antibody assays), ii) clinical 
diagnosis of COVID-19, iii) hospitalisation with COVID-19, iv) severity 
of COVID-19 disease in those hospitalised or v) mortality from COVID-19;</p>

<p>4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reported any of the outcomes of 
interest by self-reported or biochemically verified smoking status (e.g.
 current smoker, former smoker, never smoker);</p>

<p>5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Were available in English;</p>

<p>6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Were published in a peer-reviewed 
journal, as a pre-print or a public health report by reputable agents 
(e.g. governments, scientific societies).</p>

<p>&nbsp;</p>

<p><em>Search strategy</em></p>

<p>&nbsp;</p>

<p>The following terms were searched for in Ovid MEDLINE as free text or Medical Subject Headings:</p>

<p>&nbsp;</p>

<p>1. Tobacco Smoking/ or Smoking Cessation/ or Water Pipe Smoking/ or 
Smoking/ or Smoking Pipes/ or Cigar Smoking/ or Smoking Prevention/ or 
Cigarette Smoking/ or smoking.mp. or Pipe Smoking/ or Smoking, 
Non-Tobacco Products/ or Smoking Water Pipes/</p>

<p>2. Nicotine/ or nicotine.mp. or Electronic Nicotine Delivery Systems/ or Nicotine Chewing Gum/</p>

<p>3. vaping.mp. or Vaping/</p>

<p>4. 1 or 2 or 3</p>

<p>5. Coronavirus/ or Severe Acute Respiratory Syndrome/ or Coronavirus Infections/ or covid.mp.</p>

<p>6. 4 and 5</p>

<p>&nbsp;</p>

<p>The following terms were searched for in titles, abstracts and full texts in medRxiv:</p>

<p>&nbsp;</p>

<p>covid smoking</p>

<p>covid nicotine</p>

<p>covid vaping</p>

<p>&nbsp;</p>

<p>Additional articles/reports of interest were identified through 
mailing lists, Twitter, the International Severe Acute Respiratory and 
Emerging Infection Consortium (ISARIC), the Intensive Care National 
Audit &amp; Research Centre (ICNARC) and the US Centers for Disease 
Control and Prevention (CDC).</p>

<p>&nbsp;</p>

<p>Where updated versions of pre-prints or public health reports were available, old versions were superseded.</p>

<p>&nbsp;</p>

<p><em>Selection of studies</em></p>

<p>&nbsp;</p>

<p>One reviewer screened titles, abstracts and full texts against the inclusion criteria.</p>

<p>&nbsp;</p>

<p><em>Data extraction</em></p>

<p>&nbsp;</p>

<p>Data were extracted by one reviewer and verified by a second on i) 
author (year); ii) date published; iii) country; iv) study design; v) 
study setting; vi) sample size; vii) sex; viii) age; ix) smoking status 
(e.g. current, former, never, not stated, missing); x) SARS-CoV-2 
infection; xi) diagnosis of COVID-19; xii) hospitalisation with 
COVID-19; xiii) disease severity in those hospitalised with COVID-19; 
and xiv) mortality.</p>

<p>&nbsp;</p>

<p><em>Quality appraisal</em></p>

<p>&nbsp;</p>

<p>In previous review versions, we used the National Institutes of 
Health’s Quality Assessment Tool for Observational Cohort and 
Cross-Sectional Studies to determine the quality of included studies<sup>20</sup>.
 However, we decided against applying the entire tool in the current 
review version. The appraisal is challenging to apply when studying an 
emerging disease with unknown pathology. For example, it is not possible
 to determine what proportion of eligible participants/patients are 
included in the studied populations when the total number of infections 
in a given region/city is unknown. With a largely unknown disease 
process, it is also difficult to determine whether the time between the 
exposure and outcome is sufficient. We therefore focused on three of the
 14 criteria to determine whether studies were of sufficient quality to 
warrant inclusion in meta-analysis. Studies were judged as ‘good’ 
quality if they: i) had low levels of missing data on smoking status 
(i.e. &lt;20%) and used a reliable self-report measure that 
distinguished between current, former and never smoking status; AND ii) 
used biochemical verification of smoking status and reported results 
from adjusted analyses; OR reported data from a representative/random 
sample. Studies were rated as ‘fair’ if they fulfilled only criterion i)
 and were otherwise rated as ‘poor’. The quality appraisal was conducted
 by one reviewer and verified by a second.</p>

<p>&nbsp;</p>

<p><em>Evidence synthesis</em></p>

<p>&nbsp;</p>

<p>A narrative synthesis was conducted. Where possible, data were pooled in R v.3.6.3<sup>21</sup>
 with the Mantel-Haenszel or inverse variance method using random or 
fixed effects, depending on heterogeneity, and presented as risk ratios 
(RRs)<sup>22</sup>. Heterogeneity between study outcomes was assessed using the I2 statistic, suitable for smaller meta‐analyses<sup>23</sup>.</p>

<p>To aid in the visualisation of smoking prevalence in the included 
studies, 95% bootstrap percentile confidence intervals were calculated 
for each study estimate. We performed 1,000 bootstrap replications, with
 the 2.5th and 97.5th percentiles of the empirical distribution forming 
the 95% bootstrap percentile confidence intervals<sup>24</sup>. It 
should be noted that prevalence estimates in the included studies were 
not adjusted for age, sex, socioeconomic position, or region within 
countries.</p>

<p>&nbsp;</p>

<p><strong>Results</strong></p>

<p>&nbsp;</p>

<p>In the current review version (v5), a total of 636 new records were 
identified, with 148 studies included in a narrative synthesis and 23 
studies included in meta-analyses (see Figure 1).</p>

<p>&nbsp;</p>

<figure class="image"><img alt="" src="8vOhv67TaPUOGgK4Z9Tu1J7Gh9OMBmltUKeQCXW2.png">
<figcaption>
<p>Figure 1. PRISMA flow diagram of included studies.</p>
</figcaption>
</figure>

<p>&nbsp;</p>

<p><em>Study characteristics</em></p>

<p>&nbsp;</p>

<p>Characteristics of included studies are presented in Table 1. 
Forty-three studies were conducted in China, 37 in the US, 15 in the UK,
 nine in Mexico, nine in Spain, eight in France, six in Italy, five 
across multiple international sites, two in Israel, and one each from 
Brazil, Chile, Denmark, Finland, Germany, India, Iran, South Korea, 
Kuwait, Poland, Portugal, Saudi Arabia, Switzerland and Turkey (see 
Figure 2). One-hundred-and-five studies were conducted in hospital 
settings. Thirty-four studies included a community component in addition
 to hospitalised patients. Seven studies were conducted exclusively in 
the community, one in a quarantine centre and one did not state the 
study setting. Studies had a median of 326 (interquartile range = 
106-1,122) participants.</p>

<p>&nbsp;</p>

<figure class="image"><img alt="" src="YcDJoVHRdoAwAV3ZMtDeRsyobjIaa9hgc3fY3BVE.png" width="654" height="396">
<figcaption>
<p>Figure 2. Map of countries where included studies were conducted. 
Five studies were performed in multiple countries and are hence not 
included here.</p>
</figcaption>
</figure>

<p>&nbsp;</p>

<p><em>Smoking status</em></p>

<p>&nbsp;</p>

<p>Categorisation of smoking status was heterogeneous (see Table 1). 
Ninety-two studies collected data on smoking status through routine 
electronic health records, 35 studies used a bespoke case report form 
for COVID-19 and 21 studies did not state the source for information on 
smoking status. None of the studies verified smoking status 
biochemically. Notably, only 32 (21.6%) studies reported current, former
 and never smoking status, with a further 11 studies reporting 
current/former and never smoking status. The remaining 105 studies 
reported current, current/former or current and former smoking status 
but did not explicitly state whether remaining participants were never 
smokers or if data were missing on smoking status. Twenty-six studies 
explicitly reported the proportion with missing data on smoking status, 
which ranged from 0.08% to 96.4%.</p>

<p>&nbsp;</p>

<p><em>Use of alternative nicotine products</em></p>

<p>&nbsp;</p>

<p>Two studies recorded the use of alternative nicotine products in 
current and/or former smokers but did not report COVID-19 outcomes 
stratified by nicotine use<sup>25,26</sup>.</p>

<p>&nbsp;</p>

<p><em>Quality appraisal</em></p>

<p>&nbsp;</p>

<p>Twenty-eight studies were rated as ‘fair’ quality due to having low 
levels of missing data and distinguishing between current, former and 
never smoking status (see Table 1). The remaining 120 studies were rated
 as ‘poor’ quality.</p>

<p>&nbsp;</p>

<figure class="image"><img alt="" src="jLCZuDSyrlenhIUYA5OuZN6RUAb3784T6xuXxt77.png">
<figcaption>
<p>&nbsp;</p>
</figcaption>
</figure>

<figure class="image"><img alt="" src="qqydUW2B4Oar2xsLIysat1gDWFDqknClqChLK9Yt.png">
<figcaption>
<p>&nbsp;</p>
</figcaption>
</figure>

<figure class="image"><img alt="" src="x3gd2Hbvv0maA3E1wsR6PbFLtt9nspWMnOvVakfb.png">
<figcaption>
<p>&nbsp;</p>
</figcaption>
</figure>

<figure class="image"><img alt="" src="R7nKVgMAxfMTOqrI1AZEJQZFZEOvTLPdA38fpzHi.png">
<figcaption>
<p>&nbsp;</p>
</figcaption>
</figure>

<figure class="image"><img alt="" src="9Dk1ER8fcMI2cX17rJS7z6yabw9YBkUokh8DQty0.png">
<figcaption>
<p>&nbsp;</p>
</figcaption>
</figure>

<figure class="image"><img alt="" src="KP3RbfeLtvx1EK6yZtebHQLyF17DDYJUN8nyusTD.png">
<figcaption>
<p>&nbsp;</p>
</figcaption>
</figure>

<figure class="image"><img alt="" src="rCAYt9d9gSXKmNJ6TCJiTQHd9Vm2QxAeNcax6PTD.png">
<figcaption>
<p>&nbsp;</p>
</figcaption>
</figure>

<figure class="image"><img alt="" src="4jX7SQZthyeo5tgReT4RJflttwZ7lWodbBe1Qcve.png">
<figcaption>
<p>&nbsp;</p>
</figcaption>
</figure>

<figure class="image"><img alt="" src="B8Y9Yncd9qs42i4fpX8LJd44EFYKMOCmW1yrpEKF.png">
<figcaption>
<p>&nbsp;</p>
</figcaption>
</figure>

<p><em>Smoking prevalence by country</em></p>

<p>&nbsp;</p>

<p>Unadjusted smoking prevalence compared with overall estimates for 
national adult smoking prevalence split by country and study setting is 
presented in Figure 3a and 3b. Lower than expected current and former 
smoking prevalence was generally observed. Large variability in 
prevalence estimates was observed across studies conducted in the US.</p>

<p>&nbsp;</p>

<figure class="image"><img alt="" src="jR4PPcEyJyGc1x6p180xjJnzzRQv659yH6LsqwTq.png" width="653" height="380">
<figcaption>
<p>Figure 3a. Weighted mean prevalence of current smoking in included 
studies with 95% bootstrap confidence intervals compared with national 
current smoking prevalence (solid red lines), split by country. Shape 
corresponds to study setting (community, community and hospital, 
hospital) and shape size corresponds to relative study sample size.</p>
</figcaption>
</figure>

<p>&nbsp;</p>

<figure class="image"><img alt="" src="jzowbJRImaprGAfOMni2WWAqb7bfmZZS6b0TOMB6.png" width="647" height="379">
<figcaption>
<p>Figure 3b. Weighted mean prevalence of former smoking in included 
studies (where this was reported) with 95% bootstrap confidence 
intervals compared with national former smoking prevalence (solid red 
lines), split by country. Shape corresponds to study setting (community,
 community and hospital, hospital) and shape size corresponds to 
relative study sample size.</p>
</figcaption>
</figure>

<p>&nbsp;</p>

<p><em>SARS-CoV-2 infection by smoking status</em></p>

<p>&nbsp;</p>

<p>Twenty-five studies provided data on SARS-CoV-2 test results for 
people meeting local testing criteria by smoking status (see Table 2). 
Meta-analyses were performed for 12 ‘fair’ quality studies (see Figure 4
 and 5). Current smokers were at reduced risk of testing positive for 
SARS-CoV-2 compared with never smokers (RR = 0.70, 95% CI = 0.55-0.88, p
 = .003, I<sup>2</sup> = 90%). No significant difference was observed between former and never smokers (RR = 1.02, 95% CI = 0.92-1.12, p = .76, I<sup>2</sup> = 72%).</p>

<p>&nbsp;</p>

<p><em>Table 2</em>. SARS-CoV-2 infection by smoking status.</p>

<figure class="image"><img alt="" src="HuQMNbCMVtjA2VjM0Oq4SItZnCzcgNDnhH2VZ6uK.png">
<figcaption>
<p>&nbsp;</p>
</figcaption>
</figure>

<p><em>&nbsp;</em></p>

<figure class="image"><img alt="" src="K8TF9uuUUDAk2XPcbgwVXofYpAjJwIPEqt9KNW55.png">
<figcaption>
<p>&nbsp;</p>
</figcaption>
</figure>

<figure class="image"><img alt="" src="vXBXuDbiSImvRBFYiItlOixZAopxfWL4uDTnpaRd.png" width="655" height="349">
<figcaption>
<p>Figure 4. Forest plot for risk of testing positive for SARS-CoV-2 in current vs. never smokers.</p>
</figcaption>
</figure>

<p>&nbsp;</p>

<figure class="image"><img alt="" src="KNe8bbiGnAPWSQtLJub1dXssx78W7xHNNyq6pDuT.png" width="652" height="357">
<figcaption>
<p>Figure 5. Forest plot for risk of testing positive for SARS-CoV-2 in former vs. never smokers.</p>
</figcaption>
</figure>

<p>&nbsp;</p>

<p><em>Hospitalisation for COVID-19 by smoking status</em></p>

<p>&nbsp;</p>

<p>Twenty-one studies examined hospitalisation for COVID-19 disease 
stratified by smoking status (see Table 3). Meta-analyses were performed
 for seven ‘fair’ quality studies (see Figure 6 and 7). There was no 
significant difference between current and never (RR = 1.06, 95% CI = 
0.79-1.44, p = .63, I<sup>2</sup> = 79%) or former and never smokers (RR = 1.20, 95% CI = 0.95-1.51, p = .10, I<sup>2</sup> = 79%) in the risk of requiring admission to hospital with COVID-19.</p>

<p>&nbsp;</p>

<p><em>Table 3.</em> Hospitalisation for COVID-19 by smoking status.</p>

<figure class="image"><img alt="" src="qbcxovWb5A7GvK3yK7vvhD3ooAnuqQOZ5WZWl9QE.png">
<figcaption>
<p>&nbsp;</p>
</figcaption>
</figure>

<figure class="image"><img alt="" src="yaYyF8lvtFSPUDrwuEmpTjBsAhsxdXsxf08TjRoA.png">
<figcaption>
<p>&nbsp;</p>
</figcaption>
</figure>

<p>&nbsp;</p>

<figure class="image"><img alt="" src="VTSE0IcPE8FbpiKWKDI4CqJd4kQANkPH0NVSJ4ak.png" width="639" height="209">
<figcaption>
<p>Figure 6. Forest plot for risk of hospitalisation in current vs. never smokers.</p>
</figcaption>
</figure>

<figure class="image"><img alt="" src="WpGOy7JlScqcMPp9qthvgEtwxA0XwRrYTReUHuDl.png" width="655" height="212">
<figcaption>
<p>Figure 7. Forest plot for risk of hospitalisation in former vs. never smokers.</p>
</figcaption>
</figure>

<p>&nbsp;</p>

<p><em>Disease severity by smoking status</em></p>

<p>&nbsp;</p>

<p>Forty studies reported disease severity in hospitalised patients 
stratified by smoking status (see Table 4). Severe (as opposed to 
non-severe) disease was broadly defined as requiring ITU admission, 
requiring oxygen as a hospital inpatient or in-hospital death. 
Meta-analyses were performed for six ‘fair’ quality studies (see Figure 8
 and 9). No significant difference was observed between current and 
never smokers (RR = 1.22, 95% CI = 0.98-1.53, &nbsp;p = .08, I<sup>2</sup>
 = 22%). Former smokers were at increased risk of greater disease 
severity compared with never smokers (RR = 1.58, 95% CI = 1.07-2.32, p =
 .02, I<sup>2</sup> = 68%).</p>

<p>&nbsp;</p>

<p><em>Table 4.</em> Disease severity by smoking status.</p>

<figure class="image"><img alt="" src="62EMyGUuQ71sld86Yag3hpX9CPLvMoaHU39CqgKx.png">
<figcaption>
<p>&nbsp;</p>
</figcaption>
</figure>

<figure class="image"><img alt="" src="C42GQtmlZcUZWKZA5GoVasLNOvJLFDKV5Lb5lIJT.png">
<figcaption>
<p>&nbsp;</p>
</figcaption>
</figure>

<figure class="image"><img alt="" src="Ti2tZhi2FRXruMXCXChXEHbdDPS0AGcHmKcRVXk5.png">
<figcaption>
<p>&nbsp;</p>
</figcaption>
</figure>

<figure class="image"><img alt="" src="5aMUaBERffujL2950pxH0QIveK7sOvLEeJa6Mxvn.png" width="645" height="231">
<figcaption>
<p>Figure 8. Forest plot for the risk of severe disease in current vs. never smokers.</p>
</figcaption>
</figure>

<p>&nbsp;</p>

<figure class="image"><img alt="" src="kPkVGuUpxScmgiDMoI7YeSjPo8ZG7r1Vd6hdlPR8.png" width="642" height="212">
<figcaption>
<p>Figure 9. Forest plot for the risk of severe disease in former vs. never smokers.</p>
</figcaption>
</figure>

<p>&nbsp;</p>

<p><em>Mortality by smoking status</em></p>

<p>&nbsp;</p>

<p>Thirty studies reported mortality from COVID-19 by smoking status 
(see Table 5), with five ‘fair’ quality studies included in 
meta-analyses (see Figure 10 and 11). Current (RR = 1.70, 95% CI = 
1.14-2.55, p = .01, I<sup>2</sup> = 29%) and former (RR = 2.00, 95% CI = 1.57-2.55, p &lt; .0.001, I<sup>2</sup> = 0%) smokers were at increased risk of in-hospital mortality from COVID-19 compared with never smokers.</p>

<p>&nbsp;</p>

<p><em>Table 5</em>. Mortality by smoking status.</p>

<figure class="image"><img alt="" src="91E0nfxfs7eiAsFT9mQ476oA9RF2jqXB5bhz6dR8.png">
<figcaption>
<p>&nbsp;</p>
</figcaption>
</figure>

<figure class="image"><img alt="" src="UkbDtYuxD1nT1yh3fe4bxdH29VzrciEupRDZs7yj.png">
<figcaption>
<p>&nbsp;</p>
</figcaption>
</figure>

<p>&nbsp;</p>

<p>&nbsp;</p>

<figure class="image"><img alt="" src="ZEOZEbM2R9PGT6iNGoXeygPjtesnwDPvafyo7eRr.png" width="641" height="215">
<figcaption>
<p>Figure 10. Forest plot for the risk of mortality in current vs. never smokers.</p>
</figcaption>
</figure>

<p>&nbsp;</p>

<figure class="image"><img alt="" src="rJb7Qz5ooqFrEzGT2dNNI0hmjFsZq1EIzVXEXYgd.png" width="643" height="198">
<figcaption>
<p>Figure 11. Forest plot for the risk of mortality in former vs. never smokers.</p>
</figcaption>
</figure>

<p>&nbsp;</p>

<p><strong>Discussion</strong></p>

<p>&nbsp;</p>

<p>This rapid review of 148 studies found substantial uncertainty 
arising from the recording of smoking status. Notwithstanding these 
uncertainties, compared with overall adult national prevalence 
estimates, recorded current and former smoking rates in most countries 
were lower than expected. From available data, there was insufficient 
evidence to conclude that current and/or former smoking status is 
associated with hospitalisation. There was some evidence from ‘fair’ 
quality studies that the risk of SARS-CoV-2 infection is reduced in 
current compared with never smokers. Conversely, former compared with 
never smokers were at increased risk of greater disease severity in 
those hospitalised for COVID-19. Both current and former smokers had 
increased risk of in-hospital mortality from COVID-19 compared with 
never smokers.</p>

<p>&nbsp;</p>

<p><em>Infection by smoking status</em></p>

<p>&nbsp;</p>

<p>In 12 ‘fair’ quality studies, evidence suggests that current smokers 
in the community are less likely to test positive for SARS-CoV-2 
compared with never smokers. It should be noted that criteria for 
accessing testing will vary during the course of the epidemic. It is 
possible that current and former smokers are more likely to receive a 
test due to increased prevalence of cough or altered sense of smell or 
taste<sup>172</sup>, which are used as screening criteria. Infection 
positivity rates estimated among random samples will be more informative
 than currently available data. Smoking status is being collected in at 
least two large representative infection and antibody surveys in the UK<sup>173,174</sup>.</p>

<p>&nbsp;</p>

<p><em>Hospitalisation and disease severity by smoking status</em></p>

<p>&nbsp;</p>

<p>As reported elsewhere<sup>175</sup>, smoking prevalence among 
multiple hospital and community cohorts was consistently lower than 
national estimates. In a single study conducted in Korea and 15 studies 
of varying quality conducted in the UK, however, current and former 
smoking rates were more similar to expected national estimates.</p>

<p>&nbsp;</p>

<p>In seven ‘fair’ quality studies across four countries, there was no 
evidence that current or former smokers are at lower risk of 
hospitalisation for COVID-19 compared with never smokers among those 
testing positive in the community. There was some evidence from six 
‘fair’ quality studies that former (but insufficient evidence that 
current) smokers are at increased risk of greater disease severity 
compared with never smokers.</p>

<p>&nbsp;</p>

<p><em>Mortality by smoking status</em></p>

<p>&nbsp;</p>

<p>In five ‘fair’ quality studies, there was some evidence that current 
and former smokers are at increased risk of in-hospital mortality from 
COVID-19 compared with never smokers. It should, however, be noted that 
given lack of knowledge of the disease progression and long-term 
outcomes of COVID-19 disease, it is unclear whether studies conducted 
thus far in the pandemic have monitored patients for a sufficient time 
period to report complete survival outcomes or whether they are subject 
to early censoring.</p>

<p>&nbsp;</p>

<p><em>Issues complicating interpretation</em></p>

<p>&nbsp;</p>

<p>Interpretation of results from studies conducted during the first 
phase of the SARS-CoV-2 pandemic is complicated by several factors (see 
Figure 11). First, exposure to SARS-CoV-2 is heterogeneous with 
different subgroups at heightened risk of infection at different stages 
of the pandemic. This will likely introduce bias in studies assessing 
the rate of infection by smoking status conducted early on. Second, as 
mentioned above, current and former smokers may be more likely to meet 
local criteria for community testing due to increased prevalence of 
symptoms consistent with SARS-CoV-2 infection, such as cough, increased 
sputum production or altered sense of smell or taste<sup>172</sup>. 
Third, testing for acute infection requires swabbing of the mucosal 
epithelium, which may be disrupted in current smokers, potentially 
altering the sensitivity of assays<sup>88</sup>.</p>

<p>&nbsp;</p>

<p>Fourth, most included studies relied on electronic health records 
(EHRs) as the source of information on smoking status. Research shows 
large discrepancies between EHRs and actual behaviour<sup>176</sup>. 
Known failings of EHRs include implausible longitudinal changes, such as
 former smokers being recorded as never smokers at subsequent hospital 
visits<sup>176</sup>. Misreporting on the part of the patient (perhaps 
due to perceived stigmatisation) has also been observed, with 
biochemical measures showing higher rates of smoking compared with 
self-report in hospitalised patients in the US<sup>177</sup>. It is 
hence possible that under-reporting of current and former smoking status
 in hospitals occurred across the included studies. Fifth, individuals 
with severe COVID-19 symptoms may have stopped smoking immediately 
before admission to hospital and may therefore not have been recorded as
 current smokers (i.e. reverse causality).</p>

<p>&nbsp;</p>

<p>Sixth, smokers with COVID-19 may be less likely to receive a 
SARS-CoV-2 test or present to hospital due to lack of access to 
healthcare and may be more likely to die in the community from sudden 
complications (i.e. self-selection bias) and thus not be recorded. 
Seventh, if there is a protective effect of nicotine on COVID-19 disease
 outcomes, abrupt nicotine withdrawal upon hospitalisation may lead to 
worse outcomes<sup>12</sup>. Eight, during periods of heightened demand 
of limited healthcare resources, current and former smokers with 
extensive comorbidities may have reduced priority for intensive care 
admission, thus leading to higher in-hospital mortality.</p>

<p>&nbsp;</p>

<p>Another important issue is that the reason for hospitalisation varies
 by country and time in the pandemic. For example, early cases may have 
been hospitalised for isolation and quarantine reasons and not due to 
medical necessity. It is plausible that this may have skewed early data 
towards less severe cases. In addition, the observed association between
 former smoking and greater disease severity may be explained by 
collider bias<sup>178</sup>, where conditioning on a collider (e.g. 
testing or hospitalisation) by design or analysis may introduce a 
spurious association between current or former smoking (a potential 
cause of testing or hospitalisation) and SARS-CoV-2 infection/adverse 
outcomes from COVID-19 (potentially exacerbated by smoking)<sup>179</sup>.</p>

<p>&nbsp;</p>

<figure class="image"><img alt="" src="0DOMoKSZJgeS15o90DYAGRUmC50637Cr0MaLtC49.png" width="646" height="172">
<figcaption>
<p>Figure 11. A schematic of some of the interpretation issues for the 
association of smoking and SARS-CoV-2/COVID-19. * Indicates potential 
confounding with smoking status.</p>
</figcaption>
</figure>

<p>&nbsp;</p>

<p><em>Limitations</em></p>

<p>&nbsp;</p>

<p>This living rapid evidence review was limited by not having two 
independent reviewers extracting data, limiting the search to one 
electronic database and one pre-print server and by not including at 
least three large population surveys due to their reliance on 
self-reported suspected SARS-CoV-2 infection (which means they do not 
meet our eligibility criteria)<sup>172,180,181</sup>. Population surveys
 – particularly with linked health data – will be included in future 
review versions to help mitigate some of the limitations of healthcare 
based observational studies. . The comparisons of current and former 
smoking prevalence in the included studies with national prevalence 
estimates did not adjust observed prevalence for the demographic profile
 of those tested/admitted to hospital. Other reviews focused on this 
comparison have applied adjustment for sex, and continue to find lower 
than expected prevalence – notwithstanding the issues complicating 
interpretation described above<sup>16</sup>.&nbsp; Future versions of 
the review will take a Bayesian approach to the comparisons to mitigate 
the issue of repeating multiple meta-analyses across different versions 
of this living review.</p>

<p>&nbsp;</p>

<p><em>Implications for research, policy and practice</em></p>

<p>&nbsp;</p>

<p>Further scientific research is needed to resolve the mixed findings 
summarised in our review. First, clinical trials of the posited 
therapeutic effect of nicotine could have important implications both 
for smokers and for improved understanding of how the SARS-CoV-2 virus 
causes disease in humans. Such trials should focus on medicinal nicotine
 (as smoked tobacco is a dirty delivery mechanism that could mask 
beneficial effects) and potentially differentiate between different 
modes of delivery (i.e. inhaled vs. ingested) since this can affect 
pharmacokinetics<sup>182</sup> and potential therapeutic effects. A 
second research priority would be a large, representative (randomly 
sampled) population survey with a validated assessment of smoking status
 which distinguishes between recent and long-term ex-smokers – ideally 
biochemically verified – and assesses seroprevalence and links to health
 records.</p>

<p>&nbsp;</p>

<p>In the meantime, public-facing messages about the possible protective
 effect of smoking or nicotine are premature. In our view, until there 
is further research, the quality of the evidence does not justify the 
huge risk associated with a message likely to reach millions of people 
that a lethal activity, such as smoking, may protect against COVID-19. 
It continues to be appropriate to recommend smoking cessation and 
emphasise the role of alternative nicotine products to support smokers 
to stop as part of public health efforts during COVID-19. At the very 
least, smoking cessation reduces acute risks from cardiovascular disease
 and could reduce demands on the healthcare system<sup>183</sup>. GPs 
and other healthcare providers can play a crucial role – brief, 
high-quality and free online training is available at National Centre 
for Smoking Cessation and Training.</p>

<p>&nbsp;</p>

<p><strong>Conclusion</strong></p>

<p>&nbsp;</p>

<p>Across 148 studies, there is substantial uncertainty arising from the
 recording of smoking status on whether current and/or former smoking 
status is associated with SARS-CoV-2 infection, hospitalisation or 
mortality. There is some evidence that current smoking compared with 
never is associated with reduced risk of testing positive in the 
community but greater in-hospital mortality from COVID-19. There is some
 evidence that former compared with never smoking is associated with 
increased risk of greater disease severity and in-hospital mortality 
from COVID-19.</p>

<p>&nbsp;</p>

<p><strong>Acknowledgements</strong></p>

<p>&nbsp;</p>

<p>An original short review for the Royal College of Physicians was 
converted to an extended living review after a request by&nbsp;Martin 
Dockrell, Tobacco Control Lead,&nbsp;Public Health England. All 
scientific decisions were made by the authors independently of funders 
and external organisations. The authors would like to thank Rosemary 
Koper for her assistance in running the electronic searches and data 
extraction.</p>

<p>&nbsp;</p>

<p><strong>Declaration of conflicts of interest</strong></p>

<p>&nbsp;</p>

<p>DS and OP have no conflicts of interest to declare. LS has received a
 research grant and honoraria for a talk and travel expenses from 
manufacturers of smoking cessation medications (Pfizer and Johnson &amp;
 Johnson). JB has received unrestricted research funding to study 
smoking cessation from companies who manufacture smoking cessation 
medications. All authors declare no financial links with tobacco 
companies or e-cigarette manufacturers or their representatives.</p>

<p>&nbsp;</p>

<p><strong>Funding statement</strong></p>

<p>&nbsp;</p>

<p>DS is supported by a PhD studentship from the UK Biotechnology and 
Biological Sciences Research Council [BB/M009513/1]. OP receives salary 
support from Cancer Research UK (C1417/A22962). JB, LS, &amp; OP are 
members of SPECTRUM, a UK Prevention Research Partnership Consortium 
(MR/S037519/1). UKPRP is an initiative funded by the UK Research and 
Innovation Councils, the Department of Health and Social Care (England) 
and the UK devolved administrations, and leading health research 
charities.</p>

<p>&nbsp;</p>

<p><strong>Data availability</strong></p>

<p>&nbsp;</p>

<p>Extracted data from included studies is available from a maintained Google Sheet document here:&nbsp;<a href="https://docs.google.com/spreadsheets/d/1fuOcaN7K_f3msmt0aQAWwOWjgD4SsEt7iJ_0to1wotA/edit?usp=sharing" target="_blank">link</a></p>

<p>The code to reproduce&nbsp;the analysis and generate the plots and figures is available here:&nbsp;<a href="https://diddrog11.github.io/" target="_blank">link</a></p>

<p>&nbsp;</p>

<p><strong>References</strong></p>

<p>1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
Guan W, Ni Z, Hu YY, et al. Clinical Characteristics of Coronavirus 
Disease 2019 in China. N Engl J Med 2020; : NEJMoa2002032.</p>

<p>2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry 
Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven 
Protease Inhibitor. Cell 2020; published online March 5. 
DOI:10.1016/j.cell.2020.02.052.</p>

<p>3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
Brake SJ, Barnsley K, Lu W, McAlinden KD, Eapen MS, Sohal SS. Smoking 
Upregulates Angiotensin-Converting Enzyme-2 Receptor: A Potential 
Adhesion Site for Novel Coronavirus SARS-CoV-2 (Covid-19). J Clin Med 
2020, Vol 9, Page 841 2020; 9: 841.</p>

<p>4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
Cai G. Bulk and Single-Cell Transcriptomics Identify Tobacco-Use 
Disparity in Lung Gene Expression of ACE2, the Receptor of 2019-nCov. 
2020; published online March 2. DOI:10.20944/PREPRINTS202002.0051.V3.</p>

<p>5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
Oakes JM, Fuchs RM, Gardner JD, Lazartigues E, Yue X. Nicotine and the 
renin-angiotensin system. Am. J. Physiol. - Regul. Integr. Comp. 
Physiol. 2018; 315: R895–906.</p>

<p>6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
Denholm JT, Gordon CL, Johnson PD, et al. Hospitalised adult patients 
with pandemic (H1N1) 2009 influenza in Melbourne, Australia. Med J Aust 
2010; 192: 84–6.</p>

<p>7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
Abadom TR, Smith AD, Tempia S, Madhi SA, Cohen C, Cohen AL. Risk factors
 associated with hospitalisation for influenza-associated severe acute 
respiratory illness in South Africa: A case-population study. Vaccine 
2016; 34: 5649–55.</p>

<p>8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
Almirall J, González CA, Balanzó X, Bolíbar I. Proportion of 
community-acquired pneumonia cases attributable to tobacco smoking. 
Chest 1999; 116: 375–9.</p>

<p>9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
Feldman C, Anderson R. Cigarette smoking and mechanisms of 
susceptibility to infections of the respiratory tract and other organ 
systems. J. Infect. 2013; 67: 169–84.</p>

<p>10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dye JA, 
Adler KB. Occasional review Effects of cigarette smoke on epithelial 
cells of the respiratory tract. Thorax 1994; 49: 825–34.</p>

<p>11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vardavas CI,
 Nikitara K. COVID-19 and smoking: A systematic review of the evidence. 
Tob Induc Dis 2020; 18: 20.</p>

<p>12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Farsalinos 
K, Niaura R, Le Houezec J, et al. Editorial: Nicotine and SARS-CoV-2: 
COVID-19 may be a disease of the nicotinic cholinergic system. Toxicol 
Reports 2020; published online April. DOI:10.1016/j.toxrep.2020.04.012.</p>

<p>13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Emami A, 
Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of Underlying Diseases 
in Hospitalized Patients with COVID-19: a Systematic Review and 
Meta-Analysis. Arch Acad Emerg Med 2020; 8: e35.</p>

<p>14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alqahtani 
JS, Oyelade T, Aldhahir AM, et al. Prevalence, Severity and Mortality 
associated with COPD and Smoking in patients with COVID-19: A Rapid 
Systematic Review and Meta-Analysis. medRxiv 2020; : 
2020.03.25.20043745.</p>

<p>15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patanavanich
 R, Glantz SA. Smoking is Associated with COVID-19 Progression: A 
Meta-Analysis. medRxiv 2020. DOI:10.14171/j.2095-5944.sg.2014.02.004.</p>

<p>16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Farsalinos 
K, Barbouni A, Niaura R. Smoking, vaping and hospitalization for 
COVID-19. Qeios 2020; published online March 25. DOI:10.32388/Z69O8A.8.</p>

<p>17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Berlin I, 
Thomas D, Le Faou A-L, Cornuz J. COVID-19 and Smoking. Nicotine Tob Res 
DOI:10.1093/NTR/NTAA059.</p>

<p>18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elliott JH, 
Turner T, Clavisi O, et al. Living Systematic Reviews: An Emerging 
Opportunity to Narrow the Evidence-Practice Gap. PLoS Med 2014; 11. 
DOI:10.1371/journal.pmed.1001603.</p>

<p>19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tricco AC, 
Antony J, Zarin W, et al. A scoping review of rapid review methods. BMC 
Med 2015; 13: 224.</p>

<p>20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; National 
Heart Lung and Blood Institute. Study Quality Assessment Tools. Natonal 
Institutes Heal. 2018; : 1–35.</p>

<p>21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; R Core Team. The R Project for Statistical Computing. 2013; : 1–12.</p>

<p>22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Higgins JPT,
 Wells GA. Cochrane handbook for systematic reviews of interventions. 
2011.</p>

<p>23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Higgins JPT,
 Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in 
meta-analyses. Br. Med. J. 2003; 327: 557–60.</p>

<p>24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Efron B. 
Better bootstrap confidence intervals. J Am Stat Assoc 1987; 82: 171–85.</p>

<p>25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Miyara M, 
Tubach F, Martinez V, et al. Low rate of daily smokers in patients with 
symptomatic COVID-19. medrxiv 2020; : 2020.06.10.20127514.</p>

<p>26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rimland CA, 
Morgan CE, Bell GJ, et al. Clinical characteristics and early outcomes 
in patients with COVID-19 treated with tocilizumab at a United States 
academic center. medRxiv 2020; : 2020.05.13.20100404.</p>

<p>27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Guan W, 
Liang W, Zhao Y, et al. Comorbidity and its impact on 1590 patients with
 Covid-19 in China: A Nationwide Analysis. Eur Respir J 2020; : 2000547.</p>

<p>28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lian J, Jin 
X, Hao S, et al. Analysis of Epidemiological and Clinical Features in 
Older Patients With Coronavirus Disease 2019 (COVID-19) Outside Wuhan. 
Clin Infect Dis 2020; 2019: 1–8.</p>

<p>29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Jin X, Lian 
JS, Hu JH, et al. Epidemiological, clinical and virological 
characteristics of 74 cases of coronavirus-infected disease 2019 
(COVID-19) with gastrointestinal symptoms. Gut 2020; published online 
March 24. DOI:10.1136/gutjnl-2020-320926.</p>

<p>30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chen T, Wu 
D, Chen H, et al. Clinical characteristics of 113 deceased patients with
 coronavirus disease 2019: retrospective study. Bmj 2020; 368: m1295.</p>

<p>31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Zhou F, Yu 
T, Du R, et al. Clinical course and risk factors for mortality of adult 
inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. 
Lancet 2020; 0. DOI:10.1016/s0140-6736(20)30566-3.</p>

<p>32&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mo P, Xing 
Y, Xiao Y, et al. Clinical characteristics of refractory COVID-19 
pneumonia in Wuhan, China. Clin Infect Dis 2020; published online March 
16. DOI:10.1093/cid/ciaa270.</p>

<p>33&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Zhang J, 
Dong X, Cao Y, et al. Clinical characteristics of 140 patients infected 
with SARS‐CoV‐2 in Wuhan, China. Allergy 2020; : all.14238.</p>

<p>34&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wan S, Xiang
 Y, Fang W, et al. Clinical features and treatment of COVID-19 patients 
in northeast Chongqing. J Med Virol 2020; : 1–10.</p>

<p>35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liu W, Tao 
Z-W, Wang L, et al. Analysis of factors associated with disease outcomes
 in hospitalized patients with 2019 novel coronavirus disease. Chin Med J
 (Engl) 2020; 133: 1.</p>

<p>36&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Huang C, 
Wang Y, Li X, et al. Clinical features of patients infected with 2019 
novel coronavirus in Wuhan, China. Lancet 2020; 395: 497–506.</p>

<p>37&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Zhang X, Cai
 H, Hu J, et al. Epidemiological, clinical characteristics of cases of 
SARS-CoV-2 infection with abnormal imaging findings. Int J Infect Dis 
2020; 94: 81–7.</p>

<p>38&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Guo T, Fan 
Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of 
Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020; 
2019. DOI:10.1001/jamacardio.2020.1017.</p>

<p>39&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liu R, Ming 
X, Zhu H, et al. Association of Cardiovascular Manifestations with 
In-hospital Outcomes in Patients with COVID-19: A Hospital Staff Data. 
medRxiv 2020; : 2020.02.29.20029348.</p>

<p>40&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Xu HH, Hou 
K, Xu HH, et al. Acute Myocardial Injury of Patients with Coronavirus 
Disease 2019. medRxiv 2020; : 2020.03.05.20031591.</p>

<p>41&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Li J, Li S, 
Cai Y, et al. Epidemiological and Clinical Characteristics of 17 
Hospitalized Patients with 2019 Novel Coronavirus Infections Outside 
Wuhan, China. medRxiv 2020; : 2020.02.11.20022053.</p>

<p>42&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rentsch CT, 
Kidwai-Khan F, Tate JP, et al. Covid-19 Testing, Hospital Admission, and
 Intensive Care Among 2,026,227 United States Veterans Aged 54-75 Years.
 medRxiv 2020; : 2020.04.09.20059964.</p>

<p>43&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hu L, Chen 
S, Fu Y, et al. Risk Factors Associated with Clinical Outcomes in 323 
COVID-19 Patients in Wuhan, China. medRxiv 2020; : 2020.03.25.20037721.</p>

<p>44&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wang R, Pan 
M, Zhang X, et al. Epidemiological and clinical features of 125 
Hospitalized Patients with COVID-19 in Fuyang, Anhui, China. Int J 
Infect Dis 2020; : 127065.</p>

<p>45&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Petrilli CM,
 Jones SA, Yang J, et al. Factors associated with hospitalization and 
critical illness among 4,103 patients with COVID-19 disease in New York 
City. medRxiv 2020; : 2020.04.08.20057794.</p>

<p>46&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chow N, 
Fleming-Dutra K, Gierke R, et al. Preliminary Estimates of the 
Prevalence of Selected Underlying Health Conditions Among Patients with 
Coronavirus Disease 2019 — United States, February 12–March 28, 2020. 
Morb Mortal Wkly Rep 2020; 69: 382–6.</p>

<p>47&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dong X, Cao 
Y, Lu X, et al. Eleven Faces of Coronavirus Disease 2019. Allergy 2020; :
 1–11.</p>

<p>48&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kim ES, Chin
 BS, Kang CK, et al. Clinical Course and Outcomes of Patients with 
Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Preliminary
 Report of the First 28 Patients from the Korean Cohort Study on 
COVID-19. J Korean Med Sci 2020; 35: e142.</p>

<p>49&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shi Y, Yu X,
 Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19
 and establishment of a host risk score: Findings of 487 cases outside 
Wuhan. Crit Care 2020; 24: 2–5.</p>

<p>50&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yang X, Yu 
Y, Xu J, et al. Clinical course and outcomes of critically ill patients 
with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, 
retrospective, observational study. Lancet Respir Med 2020; 2600: 1–7.</p>

<p>51&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Argenziano 
MG, Bruce SL, Slater CL, et al. Characterization and Clinical Course of 
1000 Patients with COVID-19 in New York: retrospective case series. 
medRxiv 2020; : 2020.04.20.20072116.</p>

<p>52&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Solis P, 
Carreno H. COVID-19 Fatality and Comorbidity Risk Factors among 
Diagnosed Patients in Mexico. 2020. DOI:10.1101/2020.04.21.20074591.</p>

<p>53&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Richardson 
S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, 
Comorbidities, and Outcomes Among 5700 Patients Hospitalized With 
COVID-19 in the New York City Area. JAMA 2020; 10022: 1–8.</p>

<p>54&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fontanet A, 
Tondeur L, Madec Y, et al. Cluster of COVID-19 in northern France: A 
retrospective closed cohort study. medRxiv 2020; : 2020.04.18.20071134.</p>

<p>55&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Zheng KI, 
Gao F, Wang X-B, et al. Obesity as a risk factor for greater severity of
 COVID-19 in patients with metabolic associated fatty liver disease. 
Metabolism 2020; : 154244.</p>

<p>56&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liao Y, Feng
 Y, Wang B, et al. Clinical Characteristics and Risk factors for 
developed COVID-19 patients transferring to designated hospital from 
Jianghan Fangcang shelter Hospital : a retrospective , Summary : 2020; :
 1–16.</p>

<p>57&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
Rodriguez-Cola M, Jimenez-Velasco I, Gutierrez-Henares F, et al. 
Clinical features of coronavirus disease 2019 (COVID-19) in a cohort of 
patients with disability due to spinal cord injury. 2020. 
DOI:10.1101/2020.04.20.20072918.</p>

<p>58&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Magagnoli J,
 Narendran S, Pereira F, et al. Outcomes of hydroxychloroquine usage in 
United States veterans hospitalized with Covid-19. medRxiv 2020; : 
2020.04.16.20065920.</p>

<p>59&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shi P, Ren 
G, Yang J, et al. Clinical characteristics of imported and 
second-generation COVID-19 cases outside Wuhan, China: A multicenter 
retrospective study. 2020. DOI:10.1101/2020.04.19.20071472.</p>

<p>60&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hadjadj J, 
Yatim N, Barnabei L, et al. Impaired type I interferon activity and 
exacerbated inflammatory responses in severe Covid-19 patients. medRxiv 
2020; : 2020.04.19.20068015.</p>

<p>61&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Niedzweidz 
C, O’Donnell CA, Jani BD, et al. Ethnic and socioeconomic differences in
 SARS-CoV-2 infection: prospective cohort study using UK Biobank. 2020. 
DOI:10.1101/2020.04.22.20075663.</p>

<p>62&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gold JAW, 
Wong KK, Szablewski CM, Patel PR, Rossow J, Silva J. Characteristics and
 Clinical Outcomes of Adult Patients Hospitalized with COVID-19 — 
Georgia , March 2020. 2020; 69. 
https://www.cdc.gov/mmwr/volumes/69/wr/mm6918e1. htm?s_cid=mm6918e1_w.</p>

<p>63&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yu T, Cai S,
 Zheng Z, et al. Association between clinical manifestations and 
prognosis in patients with COVID-19. Clin Ther 2020; xxx: 1–9.</p>

<p>64&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Zheng Y, 
Xiong C, Liu Y, et al. Epidemiological and Clinical Characteristics 
Analysis of COVID-19 in the Surrounding Areas of Wuhan, Hubei Province 
in 2020. Pharmacol Res 2020; 157: 104821.</p>

<p>65&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rica R de 
la, Borges M, Aranda M, et al. Low albumin levels are associated with 
poorer outcomes in a case series of COVID-19 patients in Spain: a 
retrospective cohort study. medRxiv 2020; : 1–35.</p>

<p>66&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yin R, Yang 
Z, Wei Y, et al. Clinical characteristics of 106 patients with 
neurological diseases and co-morbid coronavirus disease 2019: a 
retrospective study. medRxiv 2020; : 2020.04.29.20085415.</p>

<p>67&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gaibazzi N, 
Tuttolomondo D, Guidorossi A, et al. Smoking Prevalence is Low in 
Symptomatic Patients Admitted for COVID-19. medRxiv 2020; : 
2020.05.05.20092015.</p>

<p>68&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shi H, Zuo 
Y, Yalavarthi S, et al. Neutrophil calprotectin identifies severe 
pulmonary disease in COVID-19 Hui. medRxiv 2020; : 1–15.</p>

<p>69&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cho ER, Jha 
P. Smoking and the risk of COVID-19 infection in the UK Biobank 
Prospective Study. 2020; : 10–3.</p>

<p>70&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allenbach Y,
 Saadoun D, Maalouf G, et al. Multivariable prediction model of 
intensive care unit transfer and death: a French prospective cohort 
study of COVID-19 patients. medRxiv 2020; : 2020.05.04.20090118.</p>

<p>71&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Robilotti E 
V, Babady NE, Ph D, et al. Determinants of Severity in Cancer Patients 
with COVID-19 Illness. medRxiv 2020; : 1–19.</p>

<p>72&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
Collaborative TO, Williamson E, Walker AJ, et al. OpenSAFELY: factors 
associated with COVID-19-related hospital death in the linked electronic
 health records of 17 million adult NHS patients. medRxiv 2020; : 
2020.05.06.20092999.</p>

<p>73&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Borobia AM, 
Carcas AJ, Arnalich F, Alvarez-Sala R, Montserrat J, Quintana M. A 
cohort of patients with COVID-19 in a major teaching hospital in Europe.
 medRxiv 2020. DOI:10.1101/2020.04.29.20080853.</p>

<p>74&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Giacomelli 
A, Ridolfo AL, Milazzo L, et al. 30-day mortality in patients 
hospitalized with COVID-19 during the first wave of the Italian 
epidemic: a prospective cohort study. medRxiv 2020; : 1–25.</p>

<p>75&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shah SJ, 
Barish PN, Prasad PA, et al. illness : a comparison of patients with and
 without COVID-19. 2020.</p>

<p>76&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
Bello-Chavolla OY, Bahena-Lopez JP, Antonio-Villa NE, et al. Predicting 
mortality attributable to SARS-CoV-2: A mechanistic score relating 
obesity and diabetes to COVID-19 outcomes in Mexico. medRxiv 2020; 52: 
2020.04.20.20072223.</p>

<p>77&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kolin DA, 
Kulm S, Elemento O. Clinical and Genetic Characteristics of Covid-19 
Patients from UK Biobank. medRxiv 2020; : 2020.05.05.20075507.</p>

<p>78&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lubetzky M, 
Aull M, Craig-Shapiro R, et al. Kidney Allograft Recipients Diagnosed 
with Coronavirus Disease-2019 : A Single Center Report. medRxiv 2020; : 
2020.04.30.20086462.</p>

<p>79&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Goyal P, 
Choi JJ, Pinheiro LC, et al. Clinical Characteristics of Covid-19 in New
 York City. N Engl J Med 2020; published online April 17. 
DOI:10.1056/nejmc2010419.</p>

<p>80&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feng Y, Ling
 Y, Bai T, et al. COVID-19 with Different Severity: A Multi-center Study
 of Clinical Features. Am J Respir Crit Care Med 2020; : 1–53.</p>

<p>81&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yao Q, Wang 
P, Wang X, et al. Retrospective study of risk factors for severe 
SARS-Cov-2 infections in hospitalized adult patients. Polish Arch Intern
 Med 2020. DOI:10.20452/pamw.15312.</p>

<p>82&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sami R, 
Soltaninejad F, Amra B, et al. A one-year hospital-based prospective 
CVOID-19 open-cohort in the Eastern Mediterranean region: The Khorshid 
COVID Cohort (KCC) study. medRxiv 2020; : 2020.05.11.20096727.</p>

<p>83&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Almazeedi S,
 Youha S Al, Jamal MH, et al. Clinical Characteristics, Risk Factors and
 Outcomes Among the First Consecutive 1,096 Patients Diagnosed with 
COVID-19: The Kuwait Experience. medRxiv 2020; : 2020.05.09.20096495.</p>

<p>84&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
Carrillo-Vega MF, Salinas-Escudero G, Garcia-Peña C, Gutierrez-Robledo 
LM, Parra-Rodriguez L, Fernanda M. Early estimation of the risk factors 
for hospitalisation and mortality by COVID-19 in Mexico. medRxiv 2020; :
 2020.05.11.20098145.</p>

<p>85&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yanover AC, 
Mizrahi B, Kalkstein N, Marcus K, Akiva P, Barer Y. What factors 
increase the risk of complications in SARS-CoV-2 positive patients ? A 
cohort study in a nationwide Israeli health organization. 2020.</p>

<p>86&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hamer M, 
Kivimäki M, Gale CR, Batty GD. Lifestyle Risk Factors for Cardiovascular
 Disease in Relation to COVID-19 Hospitalization : A Community-Based 
Cohort Study of 387 , 109 Adults in UK Division of Surgery and 
Interventional Sciences , Faculty Medical Sciences , University College 
London , L. 2020; : 1–11.</p>

<p>87&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Regina J, 
Papadimitriou-Olivgeris M, Burger R, et al. Epidemiology, risk factors 
and clinical course of SARS-CoV-2 infected patients in a Swiss 
university hospital: an observational retrospective study. medRxiv 2020;
 : 2020.05.11.20097741.</p>

<p>88&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; de Lusignan 
S, Dorward J, Correa A, et al. Risk factors for SARS-CoV-2 among 
patients in the Oxford Royal College of General Practitioners Research 
and Surveillance Centre primary care network: a cross-sectional study. 
Lancet Infect Dis 2020; 0. DOI:10.1016/S1473-3099(20)30371-6.</p>

<p>89&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Targher G, 
Mantovani A, Wang X-B, et al. Patients with diabetes are at higher risk 
for severe illness from COVID-19. Diabetes Metab 2020; published online 
May 13. DOI:10.1016/j.diabet.2020.05.001.</p>

<p>90&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Valenti L, 
Bergna A, Pelusi S, et al. SARS-CoV-2 seroprevalence trends in healthy 
blood donors during the COVID-19 Milan outbreak. medRxiv 2020; : 
2020.05.11.20098442.</p>

<p>91&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feuth T, 
Saaresranta T, Karlsson A, et al. Is sleep apnoea a risk factor for 
Covid-19? Findings from a retrospective cohort study. medRxiv 2020; : 
2020.05.14.20098319.</p>

<p>92&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ge H, Zhu M,
 Du J, et al. Cardiac Structural and Functional Characteristics in 
Patients with Coronavirus Disease 2019: A Serial Echocardiographic 
Study. medRxiv 2020; : 2020.05.12.20095885.</p>

<p>93&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Parrotta E, 
Kister I, Charvet L, et al. COVID-19 OUTCOMES IN MS EARLY EXPERIENCE 
FROM NYU MULTIPLE SCLEROSIS COMPREHENSIVE CARE CENTER. medrxiv 2020; : 
1–9.</p>

<p>94&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shekhar R, 
Upadhyay S, Sheikh A, Atencio J, Kapuria D. Early experience with 
COVD-19 patients at tertiary care teaching hospital in southwestern 
United states. medrxiv 2020; : 1–15.</p>

<p>95&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mejia-Vilet 
JM, Cordova-Sanchez BM, Fernandez-Camargo D, Mendez-Perez RA, 
Morales-Buenrostro LE, Hernandez-Gilsoul T. DERIVATION OF A SCORE TO 
PREDICT ADMISSION TO INTENSIVE CARE UNIT IN PATIENTS WITH COVID-19: THE 
ABC-GOALS SCORE. medRxiv 2020; : 2020.05.12.20099416.</p>

<p>96&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chen C, 
Jiang J, Xu X, Hu Y, Hu Y, Zhao Y. Dynamic liver function indexes 
monitoring and clinical characteristics in three types of COVID-19 
patients. medRxiv 2020; : 2020.05.13.20099614.</p>

<p>97&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Li J, Chen 
Y, Chen S, et al. Derivation and validation of a prognostic model for 
predicting in-hospital mortality in patients admitted with COVID-19 in 
Wuhan China the PLANS (Platelet Lymphocyte Age Neutrophil Sex) model. 
medrxiv 2020; : 2020.05.13.20100370.</p>

<p>98&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Palaiodimos 
L, Kokkinidis DG, Li W, et al. Severe obesity is associated with higher 
in-hospital mortality in a cohort of patients with COVID-19 in the 
Bronx, New York. Metabolism 2020; 108: 154262.</p>

<p>99&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ip A, Berry 
DA, Hansen E, et al. Hydroxychloroquine and Tocilizumab Therapy in 
COVID-19 Patients - An Observational Study. medRxiv 2020; : 
2020.05.21.20109207.</p>

<p>100&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heili-Frades S, Minguez P, 
Mahillo-Fernandez I, et al. COVID-19 Outcomes in 4712 consecutively 
confirmed SARS-CoV2 cases in the city of Madrid. medRxiv 2020; : 
2020.05.22.20109850.</p>

<p>101&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vaquero LM, Barrado MES, 
Escobar D, et al. C-Reactive protein and SOFA score as early predictors 
of critical care requirement in patients with COVID-19 pneumonia in 
Spain. medRxiv 2020; : 2020.05.22.20110429.</p>

<p>102&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kim L, Garg S, O’Halloran A, 
et al. Interim Analysis of Risk Factors for Severe Outcomes among a 
Cohort of Hospitalized Adults Identified through the U.S. Coronavirus 
Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network 
(COVID-NET). medRxiv 2020; : 2020.05.18.20103390.</p>

<p>103&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wu MA, Fossali T, Pandolfi L,
 et al. COVID-19 the key role of pulmonary capillary leakage. An 
observational cohort study. medrxiv 2020; : 2020.05.17.20104877.</p>

<p>104&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shi Q, Zhao K, Yu J, et al. 
Clinical characteristics of 101 COVID-19 nonsurvivors in Wuhan, China: a
 retrospective study. medRxiv 2020; : 2020.03.04.20031039.</p>

<p>105&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kimmig LM, Wu D, Gold M, et 
al. IL6 inhibition in critically ill COVID-19 patients is associated 
with increased secondary infections. medRxiv 2020; : 
2020.05.15.20103531.</p>

<p>106&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Al-Hindawi A, Sokhi J, 
Cuddihy J, et al. COVID-19 in London a Case Series Demonstrating Late 
Improvement in Survivors. medrxiv 2020; : 2020.05.16.20103853.</p>

<p>107&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Basse C, Diakite S, Servois 
V, et al. Characteristics and outcome of SARS-CoV-2 infection in cancer 
patients. medRxiv 2020; : 2020.05.14.20101576.</p>

<p>108&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Freites D, Leon L, Mucientes 
A, et al. Risk factors for hospital admission related to COVID-19 in 
inflammatory rheumatic diseases. medRxiv 2020; : 2020.05.14.20101584.</p>

<p>109&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alshami AA, Alattas RA, Anan 
HF, et al. Silent Disease and Loss of Taste and Smell are Common 
Manifestations of SARS-COV-2 Infection in a Quarantine Facility: First 
report from Saudi Arabia. medRxiv 2020; : 2020.05.13.20100222.</p>

<p>110&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Berumen J, Schmulson M, 
Alegre J, et al. Risk of infection and hospitalization by Covid-19 in 
Mexico: a case-control study. medRxiv 2020; : 2020.05.24.20104414.</p>

<p>111&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gianfrancesco M, Hyrich KL, 
Al-Adely S, et al. Characteristics associated with hospitalisation for 
COVID-19 in people with rheumatic disease: data from the COVID-19 Global
 Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2020; 
published online May 29. DOI:10.1136/annrheumdis-2020-217871.</p>

<p>112&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Li J, Long X, Zhu C, et al. 
Olfactory dysfunction in recovered COVID-19 patients. Mov Disord 2020; :
 mds.28172.</p>

<p>113&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Batty GD, Deary I, Luciano M,
 Altschul D, Kivimaki M, Gale C. Psychosocial factors and 
hospitalisations for COVID-19: Prospective cohort study of the general 
population. medRxiv 2020; : 2020.05.29.20100735.</p>

<p>114&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel A, Feldhamer I, Lahad 
A, Levin-Zamir D, Lavie G. Smoking and the risk of COVID-19 in a large 
observational population study. medRxiv 2020; : 2020.06.01.20118877.</p>

<p>115&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Valle DM Del, Kim-schulze S, 
Hsin-hui H, et al. An inflammatory cytokine signature helps predict 
COVID-19 severity and death. medRxiv 2020; : 2020.05.28.20115758.</p>

<p>116&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Zuo Y, Zuo M, Yalavarthi S, 
et al. Neutrophil extracellular traps and thrombosis in COVID-19. 
medRxiv 2020; : 2020.04.30.20086736.</p>

<p>117&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chaudhry F, Bulka H, Rathnam 
AS, et al. COVID-19 in Multiple Sclerosis Patients and Risk Factors for 
Severe Infection. medRxiv 2020; : 2020.05.27.20114827.</p>

<p>118&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Louis S, Dhawan A, Newey C, 
et al. Continuous Electroencephalography (cEEG) Characteristics and 
Acute Symptomatic Seizures in COVID-19 Patients. medRxiv 2020; : 
2020.05.26.20114033.</p>

<p>119&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Soto-Mota A, Garza BAM, 
Rodriguez EM, et al. THE LOW-HARM SCORE FOR PREDICTING MORTALITY IN 
PATIENTS DIAGNOSED WITH COVID-19: A MULTICENTRIC VALIDATION STUDY. 
medRxiv 2020; : 2020.05.26.20111120.</p>

<p>120&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patel M, Gangemi A, Marron R,
 et al. Use of High Flow Nasal Therapy to Treat Moderate to Severe 
Hypoxemic Respiratory Failure in COVID-19. medRxiv 2020; : 
2020.05.22.20109355.</p>

<p>121&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Garibaldi BT, Fiksel J, 
Muschelli J, et al. Patient trajectories and risk factors for severe 
outcomes among persons hospitalized for COVID-19 in the Maryland/DC 
region. medRxiv 2020; : 2020.05.24.20111864.</p>

<p>122&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Docherty AB, Harrison EM, 
Green CA, et al. Features of 20 133 UK patients in hospital with 
covid-19 using the ISARIC WHO Clinical Characterisation Protocol: 
prospective observational cohort study. BMJ 2020; 369: m1985.</p>

<p>123&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Boulware DR, Pullen MF, 
Bangdiwala AS, et al. A Randomized Trial of Hydroxychloroquine as 
Postexposure Prophylaxis for Covid-19. N Engl J Med 2020; : 
NEJMoa2016638.</p>

<p>124&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kuderer NM, Choueiri TK, Shah
 DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19):
 a cohort study. Lancet 2020; 395: 1907–18.</p>

<p>125&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Romão VC, Oliveira-Ramos F, 
Cruz-Machado AR, et al. A COVID-19 outbreak in a rheumatology department
 upon the early days of the pandemic. medRxiv 2020; : 
2020.06.05.20107011.</p>

<p>126&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Giannouchos T, Sussman R, 
Mier JM, Poulas K, Farsalinos K. Characteristics and risk factors for 
COVID-19 diagnosis and adverse outcomes in Mexico: an analysis of 89,756
 laboratory-confirmed COVID-19 cases. medRxiv 2020; : 
2020.06.04.20122481.</p>

<p>127&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ramlall V, Thangaraj P, 
Tatonetti NP, Shapira SD. Identification of Immune complement function 
as a determinant of adverse SARS-CoV-2 infection outcome. medRxiv 2020; :
 2020.05.05.20092452.</p>

<p>128&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wang B, Oekelen O Van, 
Mouhieddine T, et al. A tertiary center experience of multiple myeloma 
patients with COVID-19: lessons learned and the path forward. medRxiv 
2020; 1: 2020.06.04.20122846.</p>

<p>129&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Perrone F, Piccirillo MC, 
Ascierto PA, et al. Department of Mental Health and Preventive Medicine,
 Università degli Studi della Campania Luigi Vanvitelli 1. 2020.</p>

<p>130&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sharma AK, Ahmed A, Baig VN, 
et al. Characteristics and Outcomes of Hospitalized Young Adults with 
Mild to Moderate Covid-19 at a University Hospital in India. medRxiv 
2020; : 2020.06.02.20106310.</p>

<p>131&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; eugen-olsen&nbsp; jesper, 
Altintas I, Tingleff J, et al. Low levels of the prognostic biomarker 
suPAR are predictive of mild outcome in patients with symptoms of 
COVID-19 - a prospective cohort study. medRxiv 2020; : 
2020.05.27.20114678.</p>

<p>132&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Martinez-Portilla RJ, 
Sotiriadis A, Torres-Torres J, et al. Risk factors for mortality in 
pregnant women with SARS-CoV-2 infection. medRxiv 2020; : 
2020.05.31.20107276.</p>

<p>133&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Raisi-Estabragh Z, McCracken 
C, Bethell MS, et al. Greater risk of severe COVID-19 in non-White 
ethnicities is not explained by cardiometabolic, socioeconomic, or 
behavioural factors, or by 25(OH)-vitamin D status: study of 1,326 cases
 from the UK Biobank. medRxiv 2020; 25: 2020.06.01.20118943.</p>

<p>134&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Luo H, Liu S, Wang Y, et al. 
Age differences in clinical features and outcomes in patients with 
COVID-19 Jiangsu China a retrospective multi-center cohort study. 
medrxiv 2020; : 1–16.</p>

<p>135&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Houlihan C, Vora N, Byrne T, 
et al. SARS-CoV-2 virus and antibodies in front-line Health Care Workers
 in an acute hospital in London: preliminary results from a longitudinal
 study. medRxiv 2020; : 2020.06.08.20120584.</p>

<p>136&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cen Y, Chen X, Shen Y, et al.
 Risk factors for disease progression in patients with mild to moderate 
coronavirus disease 2019—a multi-centre observational study. Clin 
Microbiol Infect 2020; published online June. 
DOI:10.1016/j.cmi.2020.05.041.</p>

<p>137&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Klang E, Kassim G, Soffer S, 
Freeman R, Levin MA, Reich DL. Morbid Obesity as an Independent Risk 
Factor for COVID‐19 Mortality in Hospitalized Patients Younger than 50. 
Obesity 2020; : 0–3.</p>

<p>138&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Maraschini A, Corsi E, 
Salvatore MA, Donati S. Coronavirus and birth in Italy: results of a 
national population-based cohort study. medRxiv 2020; : 
2020.06.11.20128652.</p>

<p>139&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; WANG A-L, Zhong X, Hurd Y. 
Comorbidity and Sociodemographic determinants in COVID-19 Mortality in 
an US Urban Healthcare System. medRxiv 2020; : 2020.06.11.20128926.</p>

<p>140&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; McQueenie R, Foster H, Jani 
BD, et al. Multimorbidity, Polypharmacy, and COVID-19 infection within 
the UK Biobank cohort. medRxiv 2020; : 2020.06.10.20127563.</p>

<p>141&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Apea VJ, Wan YI, Dhairyawan 
R, et al. Ethnicity and outcomes in patients hospitalised with COVID-19 
infection in East London: an observational cohort study. medRxiv 2020; :
 2020.06.10.20127621.</p>

<p>142&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Woolford SJ, D’angelo S, 
Curtis EM, et al. COVID-19 and associations with frailty and 
multimorbidity: a prospective analysis of UK Biobank participants. 
medRxiv 2020; : 2020.06.09.20126292.</p>

<p>143&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hultcrantz M, Richter J, 
Rosenbaum C, et al. COVID-19 infections and outcomes in patients with 
multiple myeloma in New York City: a cohort study from five academic 
centers. medRxiv 2020; : 2020.06.09.20126516.</p>

<p>144&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rajter JC, Sherman M, Fatteh 
N, Vogel F, Sacks J, Rajter J-J. ICON (Ivermectin in COvid Nineteen) 
study: Use of Ivermectin is Associated with Lower Mortality in 
Hospitalized Patients with COVID19. medRxiv 2020; : 2020.06.06.20124461.</p>

<p>145&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lan F-Y, Suharlim C, Kales 
SN, Yang J. Association between SARS-CoV-2 infection, exposure risk and 
mental health among a cohort of essential retail workers in the United 
States. medRxiv 2020; : 2020.06.08.20125120.</p>

<p>146&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russell B, Moss C, Papa S, et
 al. Factors affecting COVID-19 outcomes in cancer patients − A first 
report from Guys Cancer Centre in London. medRxiv 2020; : 
2020.05.12.20094219.</p>

<p>147&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Zeng H, Zhang T, He X, et al.
 Impact of Chronic Comorbidities on Progression and Prognosis in 
Patients with COVID-19: A Retrospective Cohort Study in 1031 
Hospitalized Cases in Wuhan, China. medRxiv 2020; : 2020.06.14.20125997.</p>

<p>148&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Suleyman G, Fadel RA, Malette
 KM, et al. Clinical Characteristics and Morbidity Associated With 
Coronavirus Disease 2019 in a Series of Patients in Metropolitan 
Detroit. JAMA Netw open 2020; 3: e2012270.</p>

<p>149&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chen L, Yu J, He W, et al. 
Risk factors for death in 1859 subjects with COVID-19. Leukemia 2020; : 
1–11.</p>

<p>150&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chiara Garassino M, Whisenant
 JG, Huang L-C, et al. Articles COVID-19 in patients with thoracic 
malignancies (TERAVOLT): first results of an international, 
registry-based, cohort study. Lancet Oncol 2045. 
DOI:10.1016/S1470-2045(20)30314-4.</p>

<p>151&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hernández-Garduño E. Obesity 
is the comorbidity more strongly associated for Covid-19 in Mexico. A 
case-control study. Obes Res Clin Pract 2020; published online June. 
DOI:10.1016/j.orcp.2020.06.001.</p>

<p>152&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Govind R, Freitas DF de, 
Pritchard MR, Hayes RD, MacCabe JH. Clozapine treatment and risk of 
COVID-19. medRxiv 2020; : 2020.06.17.20133595.</p>

<p>153&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sisó-almirall A, Kostov B, 
Mas-heredia M, Vilanova- S. PROGNOSTIC FACTORS IN SPANISH COVID-19 
PATIENTS : A CASE SERIES FROM BARCELONA. 2020.</p>

<p>154&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gu T, Mack JA, Salvatore M, 
et al. COVID-19 outcomes, risk factors and associations by race: a 
comprehensive analysis using electronic health records data in Michigan 
Medicine. medRxiv 2020; : 2020.06.16.20133140.</p>

<p>155&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kibler M, Carmona A, 
Marchandot B, et al. Risk and severity of COVID-19 and ABO blood group 
in transcatheter aortic valve patients. medRxiv 2020; : 
2020.06.13.20130211.</p>

<p>156&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ikitimur H, Borku Uysal B, 
Cengiz M, et al. ‘“Determining Host Factors Contributing to Disease 
Severity in a Family Cluster of 29 Hospitalized SARS‐CoV‐2 Patients: 
Could Genetic Factors Be Relevant in the Clinical Course of COVID‐19?”’ J
 Med Virol 2020; : jmv.26106.</p>

<p>157&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sierpiński R, Pinkas J, 
Jankowski M, et al. Gender differences in the frequency of 
gastrointestinal symptoms and olfactory or taste disorders among 1,942 
non-hospitalized patients with COVID-19. Polish Arch Intern Med 2020. 
DOI:10.20452/pamw.15414.</p>

<p>158&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Zhou Y, He X, Zhang J, et al.
 Prolonged SARS-CoV-2 Viral Shedding in Patients with COVID-19 was 
Associated with Delayed Initiation of Arbidol Treatment: a retrospective
 cohort study. medRxiv 2020; : 2020.06.09.20076646.</p>

<p>159&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Crovetto F, Crispi F, Llurba 
E, Figueras F, Gomez-Roig MD, Gratacos E. SEROPREVALENCE AND CLINICAL 
SPECTRUM OF SARS-CoV-2 INFECTION IN THE FIRST VERSUS THIRD TRIMESTER OF 
PREGNANCY. medRxiv 2020; : 2020.06.17.20134098.</p>

<p>160&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Veras FP, Pontelli M, Silva 
C, et al. SARS-CoV-2 triggered neutrophil extracellular traps (NETs) 
mediate COVID-19 pathology. medRxiv 2020; : 2020.06.08.20125823.</p>

<p>161&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sterlin D, Mathian A, Miyara 
M, et al. IgA dominates the early neutralizing antibody response to 
SARS-CoV-2. medRxiv 2020; : 2020.06.10.20126532.</p>

<p>162&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rossi B, Nguyen LS, 
Zimmermann P, et al. Effect of tocilizumab in hospitalized patients with
 severe pneumonia COVID-19: a cohort study. medRxiv 2020; 1872: 
2020.06.06.20122341.</p>

<p>163&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Duan L, Zhang S, Guo M, et 
al. Epidemiological and clinical characteristics in patients with 
SARS-CoV-2 antibody negative probable COVID-19 in Wuhan. medRxiv 2020; :
 2020.06.18.20134619.</p>

<p>164&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Martin-Jimenez P, 
Munoz-Garcia MI, Seoane D, et al. Cognitive impairment is a common 
comorbidity in COVID-19 deceased patients. A hospital-based 
retrospective cohort study. medRxiv 2020; : 2020.06.08.20125872.</p>

<p>165&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elezkurtaj S, Greuel S, Ihlow
 J, et al. Causes of Death and Comorbidities in Patients with COVID-19. 
medRxiv 2020; : 2020.06.15.20131540.</p>

<p>166&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lenka J, Chhabria MS, Sharma 
N, et al. Clinical characteristics and outcomes of critically ill 
patients with COVID-19 in a tertiary community hospital in upstate New 
York. medRxiv 2020; : 2020.06.18.20135046.</p>

<p>167&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Olivares F, Munoz D, Fica A, 
et al. Covid-19 in Chile. The experience of a Regional reference Center.
 Preliminary report. medRxiv 2020; : 2020.06.14.20130898.</p>

<p>168&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Salton F, Confalonieri P, 
Santus P, et al. Prolonged low-dose methylprednisolone in patients with 
severe COVID-19 pneumonia. medRxiv 2020; : 2020.06.17.20134031.</p>

<p>169&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wei W, Ortwine JK, Mang NS, 
Joseph C, Hall BC, Prokesch BC. Limited Role for Antibiotics in 
COVID-19: Scarce Evidence of Bacterial Coinfection. medRxiv 2020; : 
2020.06.16.20133181.</p>

<p>170&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Zuo Y, Estes SK, Gandhi AA, 
et al. Prothrombotic antiphospholipid antibodies in COVID-19 Yu. medRxiv
 2020.</p>

<p>171&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Killerby ME, Link-Gelles R, 
Haight SC, et al. Characteristics Associated with Hospitalization Among 
Patients with COVID-19 — Metropolitan Atlanta, Georgia, March–April 
2020. MMWR Morb Mortal Wkly Rep 2020; 69: 790–4.</p>

<p>172&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hopkinson NS, Rossi NN, 
Moustafa JE-SSE, et al. Current tobacco smoking and risk from COVID-19 
results from a population symptom app in over 2.4 million people. 
medrxiv 2020; 44: 2020.05.18.20105288.</p>

<p>173&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Major home testing programme 
for coronavirus will track levels of infection in the community - 
GOV.UK. 
https://www.gov.uk/government/news/major-home-testing-programme-for-coronavirus-will-track-levels-of-infection-in-the-community
 (accessed May 22, 2020).</p>

<p>174&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; COVID-19 Infection Survey 
(CIS) - Office for National Statistics. 
https://www.ons.gov.uk/surveys/informationforhouseholdsandindividuals/householdandindividualsurveys/covid19infectionsurveycis
 (accessed June 30, 2020).</p>

<p>175&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Farsalinos K, Barbouni A, 
Poulas K, Polosa R, Caponnetto P, Niaura R. Current smoking, former 
smoking, and adverse outcome among hospitalized COVID-19 patients: a 
systematic review and meta-analysis. Ther Adv Chronic Dis 2020; 11: 
204062232093576.</p>

<p>176&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Polubriaginof F, Salmasian H,
 Albert DA, Vawdrey DK. Challenges with Collecting Smoking Status in 
Electronic Health Records. AMIA . Annu Symp proceedings AMIA Symp 2017; 
2017: 1392–400.</p>

<p>177&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Benowitz NL, Schultz KE, 
Haller CA, Wu AHB, Dains KM, Jacob P. Prevalence of smoking assessed 
biochemically in an urban public hospital: a rationale for routine 
cotinine screening. Am J Epidemiol 2009; 170: 885–91.</p>

<p>178&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Griffith G, Morris TT, 
Tudball M, et al. Collider bias undermines our understanding of COVID-19
 disease risk and severity. medRxiv 2020; : 2020.05.04.20090506.</p>

<p>179&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Murray E. Causation in 
smoking and COVID-19. Twitter. 2020. 
https://twitter.com/EpiEllie/status/1258607277357006849?s=20.</p>

<p>180&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bowyer RCE, Varsavsky T, 
Carole H. Geo-social gradients in predicted COVID-19 prevalence and 
severity in Great Britain : results from Affiliations : Corresponding 
authors : Understanding the geographical distribution of COVID-19 
through the general population is key to the provision of ade. 2020.</p>

<p>181&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Jackson SE, Brown J, Shahab 
L, Steptoe A, Fancourt D. COVID-19, smoking, and inequalities: a 
cross-sectional survey of adults in the UK. Submitted 2020.</p>

<p>182&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shahab L, Brose LS, West R. 
Novel delivery systems for nicotine replacement therapy as an aid to 
smoking cessation and for harm reduction: Rationale, and evidence for 
advantages over existing systems. CNS Drugs 2013; 27: 1007–19.</p>

<p>183&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stead LF, Buitrago D, 
Preciado N, Sanchez G, Hartmann-Boyce J, Lancaster T. Physician advice 
for smoking cessation. Cochrane Database Syst. Rev. 2013; 2017. 
DOI:10.1002/14651858.CD000165.pub4.</p>

<p></p></div> <a name="reviews"></a> <section class="xBL_RnPNHCChGTK3xf2tj_0"><div class="_38aJuJuFnnSi7syicbJR1Y_0"><h2>Open Peer Review</h2> <button type="button" class="full-btn blue">
    Review Article
</button></div> <div class="_1adS6QYnXSmhgIQ3VjYT2J_0"><h3 class="_2stjCAs9ND8AkVnqteokCZ_0">Awaiting Peer Review</h3> <p class="_3w1doBm5c0zCT0HZ0QmOHJ_0">
                No Reviews yet for this version.
                <a href="https://www.qeios.com/register/researcher">Sign Up as Researcher</a> to review it or <div class="v-popover" style="display: inline-block;"><div aria-describedby="popover_150jlp1jfa" class="trigger" style="display: inline-block;"><a role="button">Suggest for a Review <i class="fa fa-angle-down"></i></a> </div> </div></p></div> <section><h3 class="_3bueFN-ilTjyaDkJQqsbVF_0">Reviews to other version(s)</h3> <ul class="F8cTAoYj-UoX0PTy1nkjM_0"><li><div><div class="_14Rvbm0yZ3ys0Ku6srjUQy_0" style="padding: 0px;"><div><section class="_2sfQLp3e4EVxbl8n17w9Oz_0"><ul class="vQ9oh6hbHIFNvCuTkBMA9_0"><!----> <!----> <li><ul class="vQ9oh6hbHIFNvCuTkBMA9_0"><li data-reorder-data="{&quot;author_id&quot;:1937}"><div class="v-popover"><div aria-describedby="popover_mvtywizjm9" class="trigger" style="display: inline-block;"><div data-v-6fd402d6="" style="cursor: pointer;"><div data-v-6fd402d6="" class="v-popover"><div aria-describedby="popover_u3le4tyi5k" class="trigger" style="display: inline-block;"><div data-v-6fd402d6="" class="avatar-wrapper"><div data-v-6fd402d6="" style="display: inline-block;"><div data-v-6fd402d6="" class="avatar-placeholder" style="width: 40px; height: 40px; font-size: 14px; background-image: url(&quot;/images/avatar-placeholders/1.png&quot;);"><span data-v-6fd402d6="">PH</span></div></div> <div data-v-6fd402d6="" class="account-badge-container"><img data-v-6fd402d6="" src="member.svg"></div></div> </div> </div> <!----></div> </div> </div></li></ul></li></ul> <!----> <!----></section></div> <div class="_4B3sMsx6UQTJuv4kbAbCv_0"><p><b><a href="https://www.qeios.com/profile/1937" target="_blank" class="_1PCWzjgVAD9So9IYYm-Rvl_0">Peter Hajek</a></b><!----> published a <b><a href="https://www.qeios.com/read/80GO5O" target="_blank" class="_1PCWzjgVAD9So9IYYm-Rvl_0">Review</a></b></p> <time class="_1hWqjRdZGf2oU5m78bvT0O_0">April 23, 2020</time></div> <div><div class="v-popover"><div aria-describedby="popover_pe0i0emki5" class="trigger" style="display: inline-block;"><a class="I4q0qxXQ2tWXh0tktZQF5_0"><img src="dot_menu_002.svg" alt="Make action"></a> </div> </div></div> <!----> <!----> <!----></div> <div class="_1_WunZCsvbkYjN37LLf03J_0"><div class="_2OXTuAUzFQdX7t_9qL0vFq_0"><div class="_3xHVpiJsRdpfCVGMMfyQB_0"><div data-v-34cbeed1="" class="vue-star-rating vue-star-rating-inline"><div data-v-34cbeed1="" class="vue-star-rating"><span data-v-34cbeed1="" class="vue-star-rating-star" style="margin-right: 0px;"><svg data-v-21f5376e="" data-v-34cbeed1="" height="20" width="20" viewBox="0 0 29 29" class="vue-star-rating-star" step="1"><linearGradient data-v-21f5376e="" id="vyok43s" x1="0" x2="100%" y1="0" y2="0"><stop data-v-21f5376e="" offset="100%" stop-color="#3cbc87"></stop> <stop data-v-21f5376e="" offset="100%" stop-color="#e6eaf0"></stop></linearGradient> <filter data-v-21f5376e="" id="qrsear" height="130%" width="130%" filterUnits="userSpaceOnUse"><feGaussianBlur data-v-21f5376e="" stdDeviation="0" result="coloredBlur"></feGaussianBlur> <feMerge data-v-21f5376e=""><feMergeNode data-v-21f5376e="" in="coloredBlur"></feMergeNode> <feMergeNode data-v-21f5376e="" in="SourceGraphic"></feMergeNode></feMerge></filter> <polygon data-v-21f5376e="" points="18.090909090909093,10.01010101010101,12.030303030303031,29,27.181818181818183,16.87878787878788,9,16.87878787878788,24.15151515151515,29" fill="url(#vyok43s)" stroke="#fff" filter="url(#qrsear)"></polygon> <polygon data-v-21f5376e="" points="18.090909090909093,10.01010101010101,12.030303030303031,29,27.181818181818183,16.87878787878788,9,16.87878787878788,24.15151515151515,29" fill="url(#vyok43s)" stroke="#3cbc87" stroke-width="6" stroke-linejoin="round"></polygon> <polygon data-v-21f5376e="" points="18.090909090909093,10.01010101010101,12.030303030303031,29,27.181818181818183,16.87878787878788,9,16.87878787878788,24.15151515151515,29" fill="url(#vyok43s)"></polygon></svg></span><span data-v-34cbeed1="" class="vue-star-rating-star" style="margin-right: 0px;"><svg data-v-21f5376e="" data-v-34cbeed1="" height="20" width="20" viewBox="0 0 29 29" class="vue-star-rating-star" step="1"><linearGradient data-v-21f5376e="" id="cieuiu" x1="0" x2="100%" y1="0" y2="0"><stop data-v-21f5376e="" offset="100%" stop-color="#3cbc87"></stop> <stop data-v-21f5376e="" offset="100%" stop-color="#e6eaf0"></stop></linearGradient> <filter data-v-21f5376e="" id="fn54ep" height="130%" width="130%" filterUnits="userSpaceOnUse"><feGaussianBlur data-v-21f5376e="" stdDeviation="0" result="coloredBlur"></feGaussianBlur> <feMerge data-v-21f5376e=""><feMergeNode data-v-21f5376e="" in="coloredBlur"></feMergeNode> <feMergeNode data-v-21f5376e="" in="SourceGraphic"></feMergeNode></feMerge></filter> <polygon data-v-21f5376e="" points="18.090909090909093,10.01010101010101,12.030303030303031,29,27.181818181818183,16.87878787878788,9,16.87878787878788,24.15151515151515,29" fill="url(#cieuiu)" stroke="#fff" filter="url(#fn54ep)"></polygon> <polygon data-v-21f5376e="" points="18.090909090909093,10.01010101010101,12.030303030303031,29,27.181818181818183,16.87878787878788,9,16.87878787878788,24.15151515151515,29" fill="url(#cieuiu)" stroke="#3cbc87" stroke-width="6" stroke-linejoin="round"></polygon> <polygon data-v-21f5376e="" points="18.090909090909093,10.01010101010101,12.030303030303031,29,27.181818181818183,16.87878787878788,9,16.87878787878788,24.15151515151515,29" fill="url(#cieuiu)"></polygon></svg></span><span data-v-34cbeed1="" class="vue-star-rating-star" style="margin-right: 0px;"><svg data-v-21f5376e="" data-v-34cbeed1="" height="20" width="20" viewBox="0 0 29 29" class="vue-star-rating-star" step="1"><linearGradient data-v-21f5376e="" id="6it76v" x1="0" x2="100%" y1="0" y2="0"><stop data-v-21f5376e="" offset="100%" stop-color="#3cbc87"></stop> <stop data-v-21f5376e="" offset="100%" stop-color="#e6eaf0"></stop></linearGradient> <filter data-v-21f5376e="" id="1z5eo" height="130%" width="130%" filterUnits="userSpaceOnUse"><feGaussianBlur data-v-21f5376e="" stdDeviation="0" result="coloredBlur"></feGaussianBlur> <feMerge data-v-21f5376e=""><feMergeNode data-v-21f5376e="" in="coloredBlur"></feMergeNode> <feMergeNode data-v-21f5376e="" in="SourceGraphic"></feMergeNode></feMerge></filter> <polygon data-v-21f5376e="" points="18.090909090909093,10.01010101010101,12.030303030303031,29,27.181818181818183,16.87878787878788,9,16.87878787878788,24.15151515151515,29" fill="url(#6it76v)" stroke="#fff" filter="url(#1z5eo)"></polygon> <polygon data-v-21f5376e="" points="18.090909090909093,10.01010101010101,12.030303030303031,29,27.181818181818183,16.87878787878788,9,16.87878787878788,24.15151515151515,29" fill="url(#6it76v)" stroke="#3cbc87" stroke-width="6" stroke-linejoin="round"></polygon> <polygon data-v-21f5376e="" points="18.090909090909093,10.01010101010101,12.030303030303031,29,27.181818181818183,16.87878787878788,9,16.87878787878788,24.15151515151515,29" fill="url(#6it76v)"></polygon></svg></span><span data-v-34cbeed1="" class="vue-star-rating-star" style="margin-right: 0px;"><svg data-v-21f5376e="" data-v-34cbeed1="" height="20" width="20" viewBox="0 0 29 29" class="vue-star-rating-star" step="1"><linearGradient data-v-21f5376e="" id="p3hl4" x1="0" x2="100%" y1="0" y2="0"><stop data-v-21f5376e="" offset="100%" stop-color="#3cbc87"></stop> <stop data-v-21f5376e="" offset="100%" stop-color="#e6eaf0"></stop></linearGradient> <filter data-v-21f5376e="" id="nz4trg" height="130%" width="130%" filterUnits="userSpaceOnUse"><feGaussianBlur data-v-21f5376e="" stdDeviation="0" result="coloredBlur"></feGaussianBlur> <feMerge data-v-21f5376e=""><feMergeNode data-v-21f5376e="" in="coloredBlur"></feMergeNode> <feMergeNode data-v-21f5376e="" in="SourceGraphic"></feMergeNode></feMerge></filter> <polygon data-v-21f5376e="" points="18.090909090909093,10.01010101010101,12.030303030303031,29,27.181818181818183,16.87878787878788,9,16.87878787878788,24.15151515151515,29" fill="url(#p3hl4)" stroke="#fff" filter="url(#nz4trg)"></polygon> <polygon data-v-21f5376e="" points="18.090909090909093,10.01010101010101,12.030303030303031,29,27.181818181818183,16.87878787878788,9,16.87878787878788,24.15151515151515,29" fill="url(#p3hl4)" stroke="#3cbc87" stroke-width="6" stroke-linejoin="round"></polygon> <polygon data-v-21f5376e="" points="18.090909090909093,10.01010101010101,12.030303030303031,29,27.181818181818183,16.87878787878788,9,16.87878787878788,24.15151515151515,29" fill="url(#p3hl4)"></polygon></svg></span><span data-v-34cbeed1="" class="vue-star-rating-star" style="margin-right: 0px;"><svg data-v-21f5376e="" data-v-34cbeed1="" height="20" width="20" viewBox="0 0 29 29" class="vue-star-rating-star" step="1"><linearGradient data-v-21f5376e="" id="81lkqg" x1="0" x2="100%" y1="0" y2="0"><stop data-v-21f5376e="" offset="0%" stop-color="#3cbc87"></stop> <stop data-v-21f5376e="" offset="0%" stop-color="#e6eaf0"></stop></linearGradient> <filter data-v-21f5376e="" id="2vmbjp" height="130%" width="130%" filterUnits="userSpaceOnUse"><feGaussianBlur data-v-21f5376e="" stdDeviation="0" result="coloredBlur"></feGaussianBlur> <feMerge data-v-21f5376e=""><feMergeNode data-v-21f5376e="" in="coloredBlur"></feMergeNode> <feMergeNode data-v-21f5376e="" in="SourceGraphic"></feMergeNode></feMerge></filter> <polygon data-v-21f5376e="" points="18.090909090909093,10.01010101010101,12.030303030303031,29,27.181818181818183,16.87878787878788,9,16.87878787878788,24.15151515151515,29" fill="url(#81lkqg)" stroke="#fff" filter="url(#2vmbjp)" style="display: none;"></polygon> <polygon data-v-21f5376e="" points="18.090909090909093,10.01010101010101,12.030303030303031,29,27.181818181818183,16.87878787878788,9,16.87878787878788,24.15151515151515,29" fill="url(#81lkqg)" stroke="#e6eaf0" stroke-width="6" stroke-linejoin="round"></polygon> <polygon data-v-21f5376e="" points="18.090909090909093,10.01010101010101,12.030303030303031,29,27.181818181818183,16.87878787878788,9,16.87878787878788,24.15151515151515,29" fill="url(#81lkqg)"></polygon></svg></span> <!----></div></div></div> <div class="lN8SYbshGK7NHsGeIPqvL_0">Preprint v1</div></div> <a href="https://doi.org/10.32388/80GO5O">https://doi.org/10.32388/80GO5O</a></div> <section class="_1IrAplnFeWIqdU2Ut184y6_0"><div class="_2nlIqXCXJn2qU-ZIE_NfvG_0"><p>The
 living review is a great idea that could provide a useful contribution 
to a hot topic. On most outcomes though, smokers were merged with 
ex-smokers. (The conclusion that 'current and former smoking is 
associated with greater disease severity' implies this is true for both 
of these groups, rather than for the merged sample of ever-smokers).</p>

<p>The counterintuitive hypothesis that is making waves and that is in 
urgent need of further testing is that current smoking (rather than 
smoking in the past) may provide a degree of protection (Qeios 561, 574,
 581).&nbsp;</p>

<p>Can you show the results for smokers and for ex-smokers separately?</p></div> <p role="button" class="_2R_X_G-Iyk4x5SQ4x9l-PE_0" style="display: none;">See more</p></section> <a role="button" class="_2zkXP5q0wmeFiQiLh8T5r1_0">2 Comments</a> <div class="kin6cMQVcVBc1wvFQkgh8_0" style="display: none;"><div><ul class="_1WZuk8vh5YvBtI0uwqRho3_0"><!----> </ul> <!----> <!----></div> <!----></div></div></li></ul></section> <!----></section></div> <div class="side-col-right"><!----> <!----></div></div> <footer class="_6hD2Lz5ysj_rssfmiGg05_0"><div class="_314Eb6zQf680xrNXVtUcRC_0"><div class="iqAxatK_XnAn2tt5QYHck_0"><img src="Qeios_002.svg" height="28"> <ul class="vyEinM6KjO8O8hoxOZG7S_0"><li><a href="https://www.qeios.com/about#advisory-board">Advisory Board</a></li> <li><a href="https://www.qeios.com/archive">Archive</a></li> <li><a href="https://www.qeios.com/conduct-policy">Conduct Policy</a></li> <li><a href="https://www.qeios.com/how-it-works">How It Works</a></li> <li><a href="https://www.qeios.com/publishing-policy">Publishing Policy</a></li> <li><a href="https://www.qeios.com/terms">Terms</a></li> <li><a href="https://www.qeios.com/privacy">Privacy</a></li> <li><a href="mailto:info@qeios.com">Contact Us</a></li></ul> <a href="https://twitter.com/qeios" target="_blank" class="_3X2zHDsRrmCseC66623-JS_0">Follow at @qeios</a></div> <p class="_18zgZn_SR0R4tUnqtjMng2_0">
            © 2020 Qeios Ltd. All rights reserved. London (UK).&nbsp;&nbsp;|&nbsp;&nbsp;Qeios &nbsp;·&nbsp; ISSN 2632-3834&nbsp;&nbsp;|&nbsp;&nbsp;Indexed in <a href="https://scholar.google.com/" target="_blank">Google Scholar</a>&nbsp;&nbsp;|&nbsp;&nbsp;Archived in <a href="https://www.portico.org/" target="_blank">Portico</a> and <a href="https://www.bl.uk/" target="_blank">The British Library</a>&nbsp;&nbsp;|&nbsp;&nbsp;<a href="https://creativecommons.org/licenses/" target="_blank">CC&nbsp;BY</a>&nbsp;&nbsp;|&nbsp;&nbsp;<img src="open_access_logo_grey.svg" alt="Open Access" class="_3Nd1-epD81ePEy78BqbNjD_0"></p></div></footer></div></div>

    <!-- Scripts -->

    <script>window.GLOB = window.GLOB || {};GLOB.publication = {"id":695,"title":"The association of smoking status with SARS-CoV-2 infection, hospitalisation and mortality from COVID-19: A living rapid evidence review (version 5)","qeios_id":"UJR2AW.6","published_at":"2020-07-01 10:42:10","created_at":"2020-07-01 10:06:22","updated_at":"2020-07-29 12:13:34","abstract":"Background: SARS-CoV-2 is the causative agent of COVID-19, an emergent zoonotic disease which has reached pandemic levels and is designated a public health emergency of international concern. It is plausible that former or current smoking status is associated with infection, hospitalisation and\/or mortality from COVID-19.\n\nObjective: We aimed to estimate the association of smoking status with rates of i) infection, ii) hospitalisation, iii) disease severity, and iv) mortality from SARS-CoV-2\/COVID-19 disease.\n\nMethods: This is a living evidence review with frequent updates. We adopted recommended practice for rapid evidence reviews, which involved limiting the search to main databases and having one reviewer extract data and another verify. Published articles and pre-prints were identified via Ovid MEDLINE, medRxiv and expertise within the review team. We included observational or experimental studies with community-dwelling or hospitalised adults aged 16+ years who had received a test for SARS-CoV-2 infection or a diagnosis of COVID-19, providing that data on smoking status were reported. Studies were judged as \u2018good\u2019 quality if they: i) had low levels of missing data on smoking status (i.e. <20%) and used a reliable self-report measure that distinguished between current, former and never smoking status; AND ii) used biochemical verification of smoking status and reported results from adjusted analyses; OR reported data from a representative\/random sample. Studies were rated as \u2018fair\u2019 if they fulfilled criterion i) only and were otherwise rated as \u2018poor\u2019.\n\nResults: Version 5 with searches up to 23 June 2020 included 148 studies, 43 of which were conducted in China, 37 in the US, 15 in the UK, nine in Mexico, nine in Spain, eight in France, six in Italy, five across multiple international sites, two in Israel, and one each from 14 further countries. Thirty-two (21.6%) studies reported current, former and never smoking status. Twenty-six studies (17.6%) explicitly reported the proportion missing data on smoking status, which ranged from 0.08% to 96.4%. Notwithstanding recording uncertainties, compared with adult national prevalence estimates, recorded current and former smoking rates were generally lower than expected. In 12 \u2018fair\u2019 quality studies, current smokers were at reduced risk of testing positive for SARS-CoV-2 compared with never smokers (RR = 0.70, 95% CI = 0.55-0.88, p = .003, I2 = 90%). No significant difference was observed between former and never smokers (RR = 1.02, 95% CI = 0.92-1.12, p = .76, I2 = 72%). In seven \u2018fair\u2019 quality studies, there was no significant difference between current and never (RR = 1.06, 95% CI = 0.79-1.44, p = .63, I2 = 79%) or former and never smokers (RR = 1.20, 95% CI = 0.95-1.51, p = .10, I2 = 79%) in the risk of requiring admission to hospital with COVID-19 among those testing positive in the community. In six \u2018fair\u2019 quality studies, no significant difference in disease severity was observed between current and never smokers (RR = 1.22, 95% CI = 0.98-1.53, p = .08, I2 = 22%). Former smokers were at increased risk of greater disease severity compared with never smokers (RR = 1.58, 95% CI = 1.07-2.32, p = .02, I2 = 68%). In five \u2018fair\u2019 quality studies, current (RR = 1.70, 95% CI = 1.14-2.55, p = .01, I2 = 29%) and former smokers (RR = 2.00, 95% CI = 1.57-2.55, p < .0.001, I2 = 0%) were at increased risk of in-hospital death compared with never smokers.\n\nConclusions: Across 148 studies, there is substantial uncertainty about the associations of smoking with COVID-19 outcomes. The recorded smoking prevalence in the included studies was generally lower than overall adult national estimates. There was no evidence of reduced risk of admission to hospital for current compared with never smokers among those testing positive in the community. There was some evidence that current compared with never smoking is associated with reduced risk of testing positive in the community but also greater in-hospital mortality from COVID-19. There was some evidence that former compared with never smoking is associated with increased risk of greater disease severity and in-hospital mortality from COVID-19.\n\nImplications: Unrelated to COVID-19, smokers are at a greater risk of a range of serious health problems. Given uncertainty around the association of smoking with COVID-19 outcomes, smoking cessation remains a public health priority and high-quality smoking cessation advice including recommendations to use alternative nicotine products should form part of public health efforts during this pandemic. High quality, smoking-specific research is needed to resolve these mixed findings.","body":"<p><strong>Introduction<\/strong><\/p>\n\n<p>&nbsp;<\/p>\n\n<p>COVID-19 is a respiratory disease caused by the emerging SARS-CoV-2 virus. Large age and gender differences in case severity and mortality have been observed in the ongoing COVID-19 pandemic<!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-begin;\r\nmso-field-lock:yes'><\/span>ADDIN CSL_CITATION\r\n{&quot;citationItems&quot;:[{&quot;id&quot;:&quot;ITEM-1&quot;,&quot;itemData&quot;:{&quot;DOI&quot;:&quot;10.1056\/nejmoa2002032&quot;,&quot;ISSN&quot;:&quot;0028-4793&quot;,&quot;PMID&quot;:&quot;32109013&quot;,&quot;abstract&quot;:&quot;BACKGROUND\r\nSince December 2019, when coronavirus disease 2019 (Covid-19) emerged in Wuhan\r\ncity and rapidly spread throughout China, data have been needed on the clinical\r\ncharacteristics of the affected patients. METHODS We extracted data regarding\r\n1099 patients with laboratory-confirmed Covid-19 from 552 hospitals in 30\r\nprovinces, autonomous regions, and municipalities in China through January 29,\r\n2020. The primary composite end point was admission to an intensive care unit\r\n(ICU), the use of mechanical ventilation, or death. RESULTS The median age of\r\nthe patients was 47 years; 41.9% of the patients were female. The primary\r\ncomposite end point occurred in 67 patients (6.1%), including 5.0% who were\r\nadmitted to the ICU, 2.3% who underwent invasive mechanical ventilation, and\r\n1.4% who died. Only 1.9% of the patients had a history of direct contact with\r\nwildlife. Among nonresidents of Wuhan, 72.3% had contact with residents of\r\nWuhan, including 31.3% who had visited the city. The most common symptoms were\r\nfever (43.8% on admission and 88.7% during hospitalization) and cough (67.8%).\r\nDiarrhea was uncommon (3.8%). The median incubation period was 4 days\r\n(interquartile range, 2 to 7). On admission, ground-glass opacity was the most\r\ncommon radiologic finding on chest computed tomography (CT) (56.4%). No\r\nradiographic or CT abnormality was found in 157 of 877 patients (17.9%) with\r\nnonsevere disease and in 5 of 173 patients (2.9%) with severe disease.\r\nLymphocytopenia was present in 83.2% of the patients on admission. CONCLUSIONS\r\nDuring the first 2 months of the current outbreak, Covid-19 spread rapidly\r\nthroughout China and caused varying degrees of illness. Patients often\r\npresented without fever, and many did not have abnormal radiologic findings.\r\n(Funded by the National Health Commission of China and\r\nothers.).&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Guan&quot;,&quot;given&quot;:&quot;Wei-jie&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Ni&quot;,&quot;given&quot;:&quot;Zheng-yi&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Hu&quot;,&quot;given&quot;:&quot;Ya-hua\r\nYu&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Liang&quot;,&quot;given&quot;:&quot;Wen-hua&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Ou&quot;,&quot;given&quot;:&quot;Chun-quan&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;He&quot;,&quot;given&quot;:&quot;Jian-xing&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Liu&quot;,&quot;given&quot;:&quot;Lei&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Shan&quot;,&quot;given&quot;:&quot;Hong&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Lei&quot;,&quot;given&quot;:&quot;Chun-liang&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Hui&quot;,&quot;given&quot;:&quot;David\r\nS.C.&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Du&quot;,&quot;given&quot;:&quot;Bin&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Li&quot;,&quot;given&quot;:&quot;Lan-juan&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Zeng&quot;,&quot;given&quot;:&quot;Guang&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Yuen&quot;,&quot;given&quot;:&quot;Kwok-Yung&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Chen&quot;,&quot;given&quot;:&quot;Ru-chong&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Tang&quot;,&quot;given&quot;:&quot;Chun-li&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Wang&quot;,&quot;given&quot;:&quot;Tao&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Chen&quot;,&quot;given&quot;:&quot;Ping-yan&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Xiang&quot;,&quot;given&quot;:&quot;Jie&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Li&quot;,&quot;given&quot;:&quot;Shi-yue&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Wang&quot;,&quot;given&quot;:&quot;Jian-ming\r\nJin-lin&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Liang&quot;,&quot;given&quot;:&quot;Zi-jing&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Peng&quot;,&quot;given&quot;:&quot;Yi-xiang&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Wei&quot;,&quot;given&quot;:&quot;Li&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Liu&quot;,&quot;given&quot;:&quot;Yong&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Hu&quot;,&quot;given&quot;:&quot;Ya-hua\r\nYu&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Peng&quot;,&quot;given&quot;:&quot;Peng&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Wang&quot;,&quot;given&quot;:&quot;Jian-ming\r\nJin-lin&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Liu&quot;,&quot;given&quot;:&quot;Ji-yang&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Chen&quot;,&quot;given&quot;:&quot;Zhong&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Li&quot;,&quot;given&quot;:&quot;Gang&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Zheng&quot;,&quot;given&quot;:&quot;Zhi-jian&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Qiu&quot;,&quot;given&quot;:&quot;Shao-qin&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Luo&quot;,&quot;given&quot;:&quot;Jie&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Ye&quot;,&quot;given&quot;:&quot;Chang-jiang&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Zhu&quot;,&quot;given&quot;:&quot;Shao-yong&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Zhong&quot;,&quot;given&quot;:&quot;Nan-shan&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;New\r\nEngland Journal of\r\nMedicine&quot;,&quot;id&quot;:&quot;ITEM-1&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2020&quot;,&quot;2&quot;,&quot;28&quot;]]},&quot;page&quot;:&quot;NEJMoa2002032&quot;,&quot;publisher&quot;:&quot;Massachusetts\r\nMedical Society&quot;,&quot;title&quot;:&quot;Clinical Characteristics of\r\nCoronavirus Disease 2019 in\r\nChina&quot;,&quot;type&quot;:&quot;article-journal&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=a61eeaad-2951-4f3f-af24-9f306f24b3db&quot;]}],&quot;mendeley&quot;:{&quot;formattedCitation&quot;:&quot;&lt;sup&gt;1&lt;\/sup&gt;&quot;,&quot;plainTextFormattedCitation&quot;:&quot;1&quot;,&quot;previouslyFormattedCitation&quot;:&quot;&lt;sup&gt;1&lt;\/sup&gt;&quot;},&quot;properties&quot;:{&quot;noteIndex&quot;:0},&quot;schema&quot;:&quot;https:\/\/github.com\/citation-style-language\/schema\/raw\/master\/csl-citation.json&quot;}<span\r\nstyle='mso-element:field-separator'><\/span><\/span><![endif]--><sup>1<\/sup><!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-end'><\/span><\/span><![endif]-->; however, these differences are currently unexplained. SARS-CoV-2 enters epithelial cells through the ACE-2 receptor<!--[if supportFields]><span style='font-size:11.0pt;line-height:\r\n150%'><span style='mso-element:field-begin;mso-field-lock:yes'><\/span>ADDIN\r\nCSL_CITATION {&quot;citationItems&quot;:[{&quot;id&quot;:&quot;ITEM-1&quot;,&quot;itemData&quot;:{&quot;DOI&quot;:&quot;10.1016\/j.cell.2020.02.052&quot;,&quot;ISSN&quot;:&quot;00928674&quot;,&quot;abstract&quot;:&quot;Graphical\r\nAbstract Highlights d SARS-CoV-2 uses the SARS-CoV receptor ACE2 for host cell\r\nentry d The spike protein of SARS-CoV-2 is primed by TMPRSS2 d Antibodies\r\nagainst SARS-CoV spike may offer some protection against SARS-CoV-2 In Brief\r\nThe emerging SARS-coronavirus 2 (SARS-CoV-2) threatens public health. Hoffmann\r\nand coworkers show that SARS-CoV-2 infection depends on the host cell factors\r\nACE2 and TMPRSS2 and can be blocked by a clinically proven protease inhibitor.\r\nThese findings might help to establish options for prevention and treatment.\r\nSUMMARY The recent emergence of the novel, pathogenic SARS-coronavirus 2\r\n(SARS-CoV-2) in China and its rapid national and international spread pose a\r\nglobal health emergency. Cell entry of coronaviruses depends on binding of the\r\nviral spike (S) proteins to cellular receptors and on S protein priming by host\r\ncell proteases. Unravelling which cellular factors are used by SARS-CoV-2 for\r\nentry might provide insights into viral transmission and reveal therapeutic\r\ntargets. Here, we demonstrate that SARS-CoV-2 uses the SARS-CoV receptor ACE2\r\nfor entry and the serine protease TMPRSS2 for S protein priming. A TMPRSS2 inhibitor\r\napproved for clinical use blocked entry and might constitute a treatment\r\noption. Finally, we show that the sera from convalescent SARS patients\r\ncross-neutralized SARS-2-S-driven entry. Our results reveal important\r\ncom-monalities between SARS-CoV-2 and SARS-CoV infection and identify a\r\npotential target for antiviral\r\nintervention.&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Hoffmann&quot;,&quot;given&quot;:&quot;Markus&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Kleine-Weber&quot;,&quot;given&quot;:&quot;Hannah&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Schroeder&quot;,&quot;given&quot;:&quot;Simon&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Kr\u00fcger&quot;,&quot;given&quot;:&quot;Nadine&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Herrler&quot;,&quot;given&quot;:&quot;Tanja&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Erichsen&quot;,&quot;given&quot;:&quot;Sandra&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Schiergens&quot;,&quot;given&quot;:&quot;Tobias\r\nS.&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Herrler&quot;,&quot;given&quot;:&quot;Georg&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Wu&quot;,&quot;given&quot;:&quot;Nai-Huei&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Nitsche&quot;,&quot;given&quot;:&quot;Andreas&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;M\u00fcller&quot;,&quot;given&quot;:&quot;Marcel\r\nA.&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Drosten&quot;,&quot;given&quot;:&quot;Christian&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;P\u00f6hlmann&quot;,&quot;given&quot;:&quot;Stefan&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;Cell&quot;,&quot;id&quot;:&quot;ITEM-1&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2020&quot;,&quot;3&quot;,&quot;5&quot;]]},&quot;publisher&quot;:&quot;Elsevier\r\nBV&quot;,&quot;title&quot;:&quot;SARS-CoV-2 Cell Entry Depends on ACE2 and\r\nTMPRSS2 and Is Blocked by a Clinically Proven Protease\r\nInhibitor&quot;,&quot;type&quot;:&quot;article-journal&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=e3b7dacd-d8e1-384c-bc71-7ff32a02c88a&quot;]}],&quot;mendeley&quot;:{&quot;formattedCitation&quot;:&quot;&lt;sup&gt;2&lt;\/sup&gt;&quot;,&quot;plainTextFormattedCitation&quot;:&quot;2&quot;,&quot;previouslyFormattedCitation&quot;:&quot;&lt;sup&gt;2&lt;\/sup&gt;&quot;},&quot;properties&quot;:{&quot;noteIndex&quot;:0},&quot;schema&quot;:&quot;https:\/\/github.com\/citation-style-language\/schema\/raw\/master\/csl-citation.json&quot;}<span\r\nstyle='mso-element:field-separator'><\/span><\/span><![endif]--><sup>2<\/sup><!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-end'><\/span><\/span><![endif]-->. Some evidence suggests that gene expression and subsequent receptor levels are elevated in the airway and oral epithelium of current smokers<!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-begin;\r\nmso-field-lock:yes'><\/span>ADDIN CSL_CITATION\r\n{&quot;citationItems&quot;:[{&quot;id&quot;:&quot;ITEM-1&quot;,&quot;itemData&quot;:{&quot;DOI&quot;:&quot;10.3390\/JCM9030841&quot;,&quot;abstract&quot;:&quot;The\r\nepicenter of the original outbreak in China has high male smoking rates of\r\naround 50%, and early reported death rates have an emphasis on older males,\r\ntherefore the likelihood of smokers being overrepresented in fatalities is\r\nhigh. In Iran, China, Italy, and South Korea, female smoking rates are much lower\r\nthan males. Fewer females have contracted the virus. If this analysis is\r\ncorrect, then Indonesia would be expected to begin experiencing high rates of\r\nCovid-19 because its male smoking rate is over 60% (Tobacco Atlas). Smokers are\r\nvulnerable to respiratory viruses. Smoking can upregulate\r\nangiotensin-converting enzyme-2 (ACE2) receptor, the known receptor for both\r\nthe severe acute respiratory syndrome (SARS)-coronavirus (SARS-CoV) and the\r\nhuman respiratory coronavirus NL638. This could also be true for new electronic\r\nsmoking devices such as electronic cigarettes and\r\n&amp;ldquo;heat-not-burn&amp;rdquo; IQOS devices. ACE2 could be a novel\r\nadhesion molecule for SARS-CoV-2 causing Covid-19 and a potential therapeutic\r\ntarget for the prevention of fatal microbial infections, and therefore it\r\nshould be fast tracked and prioritized for research and investigation. Data on\r\nsmoking status should be collected on all identified cases of\r\nCovid-19.&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Brake&quot;,&quot;given&quot;:&quot;Samuel\r\nJames&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Barnsley&quot;,&quot;given&quot;:&quot;Kathryn&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Lu&quot;,&quot;given&quot;:&quot;Wenying&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;McAlinden&quot;,&quot;given&quot;:&quot;Kielan\r\nDarcy&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Eapen&quot;,&quot;given&quot;:&quot;Mathew\r\nSuji&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Sohal&quot;,&quot;given&quot;:&quot;Sukhwinder\r\nSingh&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;Journal\r\nof Clinical Medicine 2020, Vol. 9, Page\r\n841&quot;,&quot;id&quot;:&quot;ITEM-1&quot;,&quot;issue&quot;:&quot;3&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2020&quot;,&quot;3&quot;,&quot;20&quot;]]},&quot;page&quot;:&quot;841&quot;,&quot;publisher&quot;:&quot;Multidisciplinary\r\nDigital Publishing Institute&quot;,&quot;title&quot;:&quot;Smoking Upregulates\r\nAngiotensin-Converting Enzyme-2 Receptor: A Potential Adhesion Site for Novel\r\nCoronavirus SARS-CoV-2 (Covid-19)&quot;,&quot;type&quot;:&quot;article-journal&quot;,&quot;volume&quot;:&quot;9&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=53aaf724-04f3-3218-ae0a-339bfbe61c1d&quot;]},{&quot;id&quot;:&quot;ITEM-2&quot;,&quot;itemData&quot;:{&quot;DOI&quot;:&quot;10.20944\/PREPRINTS202002.0051.V3&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Cai&quot;,&quot;given&quot;:&quot;Guoshuai&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;id&quot;:&quot;ITEM-2&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2020&quot;,&quot;3&quot;,&quot;2&quot;]]},&quot;publisher&quot;:&quot;Preprints&quot;,&quot;title&quot;:&quot;Bulk\r\nand Single-Cell Transcriptomics Identify Tobacco-Use Disparity in Lung Gene\r\nExpression of ACE2, the Receptor of\r\n2019-nCov&quot;,&quot;type&quot;:&quot;article-journal&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=fb0b2e9a-cf7a-3a5d-920e-b940233ff20d&quot;]}],&quot;mendeley&quot;:{&quot;formattedCitation&quot;:&quot;&lt;sup&gt;3,4&lt;\/sup&gt;&quot;,&quot;plainTextFormattedCitation&quot;:&quot;3,4&quot;,&quot;previouslyFormattedCitation&quot;:&quot;&lt;sup&gt;3,4&lt;\/sup&gt;&quot;},&quot;properties&quot;:{&quot;noteIndex&quot;:0},&quot;schema&quot;:&quot;https:\/\/github.com\/citation-style-language\/schema\/raw\/master\/csl-citation.json&quot;}<span\r\nstyle='mso-element:field-separator'><\/span><\/span><![endif]--><sup>3,4<\/sup><!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-end'><\/span><\/span><![endif]-->, thus putting smokers at higher risk of contracting SARS-CoV-2. Other studies, however, suggest that nicotine downregulates the ACE-2 receptor<!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-begin;\r\nmso-field-lock:yes'><\/span>ADDIN CSL_CITATION\r\n{&quot;citationItems&quot;:[{&quot;id&quot;:&quot;ITEM-1&quot;,&quot;itemData&quot;:{&quot;DOI&quot;:&quot;10.1152\/ajpregu.00099.2018&quot;,&quot;ISSN&quot;:&quot;15221490&quot;,&quot;abstract&quot;:&quot;Cigarette\r\nsmoking is the single most important risk factor for the development of cardiovascular\r\nand pulmonary diseases (CVPD). Although cigarette smoking has been in constant\r\ndecline since the 1950s, the introduction of e-cigarettes or electronic\r\nnicotine delivery systems 10 yr ago has attracted former smokers as well as a\r\nnew generation of consumers. Nicotine is a highly addictive substance, and it\r\nis currently unclear whether e-cigarettes are \u201csafer\u201d than regular cigarettes\r\nor whether they have the potential to reverse the health benefits, notably on\r\nthe cardiopulmonary system, acquired with the decline of tobacco smoking. Of\r\ngreat concern, nicotine inhalation devices are becoming popular among young\r\nadults and youths, emphasizing the need for awareness and further study of the\r\npotential cardiopulmonary risks of nicotine and associated products. This\r\nreview focuses on the interaction between nicotine and the renin-angiotensin\r\nsystem (RAS), one of the most important regulatory systems on autonomic,\r\ncardiovascular, and pulmonary functions in both health and disease. The\r\nliterature presented in this review strongly suggests that nicotine alters the\r\nhomeostasis of the RAS by upregulating the detrimental angiotensin-converting\r\nenzyme (ACE)\/angiotensin (ANG)-II\/ANG II type 1 receptor axis and\r\ndown-regulating the compensatory ACE2\/ANG-(1\u20137)\/Mas receptor axis, contributing\r\nto the development of\r\nCVPD.&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Oakes&quot;,&quot;given&quot;:&quot;Joshua\r\nM.&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Fuchs&quot;,&quot;given&quot;:&quot;Robert\r\nM.&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Gardner&quot;,&quot;given&quot;:&quot;Jason\r\nD.&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Lazartigues&quot;,&quot;given&quot;:&quot;Eric&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Yue&quot;,&quot;given&quot;:&quot;Xinping&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;American\r\nJournal of Physiology - Regulatory Integrative and Comparative Physiology&quot;,&quot;id&quot;:&quot;ITEM-1&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2018&quot;,&quot;11&quot;,&quot;1&quot;]]},&quot;page&quot;:&quot;R895-R906&quot;,&quot;publisher&quot;:&quot;American\r\nPhysiological Society&quot;,&quot;title&quot;:&quot;Nicotine and the\r\nrenin-angiotensin\r\nsystem&quot;,&quot;type&quot;:&quot;article&quot;,&quot;volume&quot;:&quot;315&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=83ff7019-6877-3f36-8312-3fd9eaadecdf&quot;]}],&quot;mendeley&quot;:{&quot;formattedCitation&quot;:&quot;&lt;sup&gt;5&lt;\/sup&gt;&quot;,&quot;plainTextFormattedCitation&quot;:&quot;5&quot;,&quot;previouslyFormattedCitation&quot;:&quot;&lt;sup&gt;5&lt;\/sup&gt;&quot;},&quot;properties&quot;:{&quot;noteIndex&quot;:0},&quot;schema&quot;:&quot;https:\/\/github.com\/citation-style-language\/schema\/raw\/master\/csl-citation.json&quot;}<span\r\nstyle='mso-element:field-separator'><\/span><\/span><![endif]--><sup>5<\/sup><!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-end'><\/span><\/span><![endif]-->. These uncertainties notwithstanding, both former and current smoking is known to increase the risk of respiratory viral<!--[if supportFields]><span style='font-size:11.0pt;\r\nline-height:150%'><span style='mso-element:field-begin;mso-field-lock:yes'><\/span>ADDIN\r\nCSL_CITATION\r\n{&quot;citationItems&quot;:[{&quot;id&quot;:&quot;ITEM-1&quot;,&quot;itemData&quot;:{&quot;DOI&quot;:&quot;10.5694\/j.1326-5377.2010.tb03424.x&quot;,&quot;ISSN&quot;:&quot;0025-729X&quot;,&quot;abstract&quot;:&quot;Objective:\r\nTo describe the case characteristics and outcomes of patients hospitalised with\r\npandemic (H1N1) 2009 influenza infection during the first 2 months of the\r\nepidemic. Design, participants and setting: Prospective case series of 112\r\npatients admitted to seven hospitals in Melbourne with laboratory-confirmed\r\npandemic (H1N1) 2009 influenza between 1 May and 17 July 2009. Main outcome\r\nmeasures: Details of case characteristics, risk factors for severe disease,\r\ntreatment and clinical course. Results: Of 112 hospitalised patients, most\r\npresented with cough (88%) and\/or fever (82%), but several (4%) had neither\r\nsymptom. A quarter of female patients (15) were pregnant or in the post-partum\r\nperiod. Patients presenting with multifocal changes on chest x-ray had\r\nsignificantly longer hospital lengths of stay, and were more likely to require\r\nintensive care unit admission. Thirty patients required admission to an\r\nintensive care unit, and three died during their acute illness. The median\r\nlength of intensive care admission was 10.5 days (interquartile range, 5-16\r\ndays). Conclusions: This study highlights risk factors for severe disease,\r\nparticularly pregnancy. Clinical and public health planning for upcoming\r\ninfluenza seasons should take into account the spectrum and severity of\r\nclinical infection demonstrated in this report, and the need to concentrate\r\nresources effectively in high-risk patient\r\ngroups.&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Denholm&quot;,&quot;given&quot;:&quot;Justin\r\nT&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Gordon&quot;,&quot;given&quot;:&quot;Claire\r\nL&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Johnson&quot;,&quot;given&quot;:&quot;Paul\r\nD&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Hewagama&quot;,&quot;given&quot;:&quot;Saliya\r\nS&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Stuart&quot;,&quot;given&quot;:&quot;Rhonda\r\nL&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Aboltins&quot;,&quot;given&quot;:&quot;Craig&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Jeremiah&quot;,&quot;given&quot;:&quot;Cameron&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Knox&quot;,&quot;given&quot;:&quot;James&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Lane&quot;,&quot;given&quot;:&quot;Garry\r\nP&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Tramontana&quot;,&quot;given&quot;:&quot;Adrian\r\nR&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Slavin&quot;,&quot;given&quot;:&quot;Monica\r\nA&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Schulz&quot;,&quot;given&quot;:&quot;Thomas\r\nR&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Richards&quot;,&quot;given&quot;:&quot;Michael&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Birch&quot;,&quot;given&quot;:&quot;Chris\r\nJ&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Cheng&quot;,&quot;given&quot;:&quot;Allen\r\nC&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;Medical\r\nJournal of Australia&quot;,&quot;id&quot;:&quot;ITEM-1&quot;,&quot;issue&quot;:&quot;2&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2010&quot;,&quot;1&quot;,&quot;18&quot;]]},&quot;page&quot;:&quot;84-86&quot;,&quot;publisher&quot;:&quot;John\r\nWiley &amp; Sons, Ltd&quot;,&quot;title&quot;:&quot;Hospitalised adult patients\r\nwith pandemic (H1N1) 2009 influenza in Melbourne,\r\nAustralia&quot;,&quot;type&quot;:&quot;article-journal&quot;,&quot;volume&quot;:&quot;192&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=a732513d-08ab-3e86-a67e-f7bd31452b8e&quot;]},{&quot;id&quot;:&quot;ITEM-2&quot;,&quot;itemData&quot;:{&quot;DOI&quot;:&quot;10.1016\/j.vaccine.2016.09.011&quot;,&quot;ISSN&quot;:&quot;18732518&quot;,&quot;abstract&quot;:&quot;Background\r\nInfluenza is a common cause of severe respiratory illness, but risk factors for\r\nhospitalisation in low income settings with a high HIV prevalence are not well\r\ndescribed. We aimed to assess risk factors associated with influenza-associated\r\nsevere acute respiratory illness (SARI) hospitalisation in South Africa.\r\nMethods We conducted a case-population study using data on risk conditions in\r\npatients hospitalised with SARI and the national prevalence of these\r\nconditions. Data on hospitalised cases were from the national SARI surveillance\r\nprogram while data on the referent population were from the latest national\r\ncensus or health and demographic surveillance surveys. Findings From 2009 to\r\n2012, we identified 3646 (7.9%) of 46,031 enrolled cases of SARI that were\r\nassociated with influenza infection. Risk factors associated with\r\nhospitalisation included previous history of smoking [case-population ratio\r\n(CPR) 3.82, 95% confidence interval (CI) 3.5\u20134.16], HIV infection (CPR 3.61,\r\n95% CI 3.5\u20133.71), asthma (CPR 2.45, 95% CI 2.19\u20132.73), previous history of\r\nhospital admission in the past 12&nbsp;months (CPR 2.07, 95% CI 1.92\u20132.23), and\r\ntuberculosis (CPR 1.85, 95% CI 1.68\u20132.02). When stratified by age, there is\r\nincreased risk of hospitalisation in those <\/span><span style='font-size:11.0pt;\r\nline-height:150%;font-family:\"Cambria Math\",serif;mso-bidi-font-family:\"Cambria Math\"'>\u2a7d<\/span><span\r\nstyle='font-size:11.0pt;line-height:150%'>5&nbsp;years&nbsp;of age (CPR 3.07,\r\n95% CI 2.93\u20133.21) and among those 35&nbsp;years&nbsp;of age and above (CPR\r\n1.23, 95% CI 1.28\u20131.18). Male sex (CPR 0.85, 95% CI 0.82\u20130.88) and completion\r\nof pneumococcal conjugate vaccination schedule in children\r\n&lt;5&nbsp;years&nbsp;of age (CPR 0.74, 95% CI 0.71\u20130.77) were associated with\r\ndecreased risk of hospitalisation. Conclusion These results identify groups at\r\nhigh-risk for severe influenza who should be considered potential targets for\r\ninfluenza vaccination in South Africa and similar\r\nsettings.&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Abadom&quot;,&quot;given&quot;:&quot;Tochukwu\r\nRaphael&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Smith&quot;,&quot;given&quot;:&quot;Adrian\r\nD.&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Tempia&quot;,&quot;given&quot;:&quot;Stefano&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Madhi&quot;,&quot;given&quot;:&quot;Shabir\r\nA.&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Cohen&quot;,&quot;given&quot;:&quot;Cheryl&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Cohen&quot;,&quot;given&quot;:&quot;Adam\r\nL.&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;Vaccine&quot;,&quot;id&quot;:&quot;ITEM-2&quot;,&quot;issue&quot;:&quot;46&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2016&quot;,&quot;11&quot;,&quot;4&quot;]]},&quot;page&quot;:&quot;5649-5655&quot;,&quot;publisher&quot;:&quot;Elsevier\r\nLtd&quot;,&quot;title&quot;:&quot;Risk factors associated with hospitalisation\r\nfor influenza-associated severe acute respiratory illness in South Africa: A\r\ncase-population study&quot;,&quot;type&quot;:&quot;article-journal&quot;,&quot;volume&quot;:&quot;34&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=725f3781-0c7c-30d7-abd6-750268953fea&quot;]}],&quot;mendeley&quot;:{&quot;formattedCitation&quot;:&quot;&lt;sup&gt;6,7&lt;\/sup&gt;&quot;,&quot;plainTextFormattedCitation&quot;:&quot;6,7&quot;,&quot;previouslyFormattedCitation&quot;:&quot;&lt;sup&gt;6,7&lt;\/sup&gt;&quot;},&quot;properties&quot;:{&quot;noteIndex&quot;:0},&quot;schema&quot;:&quot;https:\/\/github.com\/citation-style-language\/schema\/raw\/master\/csl-citation.json&quot;}<span\r\nstyle='mso-element:field-separator'><\/span><\/span><![endif]--><sup>6,7<\/sup><!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-end'><\/span><\/span><![endif]--> and bacterial<!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-begin;\r\nmso-field-lock:yes'><\/span>ADDIN CSL_CITATION\r\n{&quot;citationItems&quot;:[{&quot;id&quot;:&quot;ITEM-1&quot;,&quot;itemData&quot;:{&quot;DOI&quot;:&quot;10.1378\/chest.116.2.375&quot;,&quot;ISSN&quot;:&quot;00123692&quot;,&quot;abstract&quot;:&quot;Study\r\nobjectives: To assess the population-attributable risk (PAR) of smoking and the\r\neffect of tobacco smoking on the development of community- acquired pneumonia\r\n(CAP) in adults. Design: A population-based case-control study. Information on\r\nhistory of smoking and other risk factors was obtained by a questionnaire\r\nadministered by interview. Setting: Mixed residential- industrial area having\r\n74,610 adult inhabitants in Barcelona, Spain. Participants: Two hundred five\r\nmale and female patients (age, 15 to 74 years old) with CAP diagnosed between 1993\r\nand 1995. They were matched to 475 control subjects randomly selected from the\r\nmunicipal census. Results: Smoking any type of tobacco had an odds ratio (OR)\r\nof CAP of 2.0 for ever smokers (95% confidence interval [CI], 1.24 to 3.24);\r\n1.88 for current smokers (95% CI, 1.11 to 3.19); and 2.14 for ex-smokers (95%\r\nCI, 1.26 to 3.65). A positive trend for increased risk of CAP was observed for\r\nan increase in the duration of the habit, the average number of cigarettes\r\nsmoked daily, and cumulative cigarette consumption. Former smokers had a 50%\r\nreduction in the OR 5 years after the cessation of smoking. The risk of CAP\r\nattributable to the consumption of any type of tobacco in this population was\r\n32.4% of cases (95% CI, 14.8 to 50.1%). In subjects without a history of COPD,\r\nthe PAR of tobacco was 23.0% (95% CI, 3.3 to 42.7%). Conclusion: This study\r\ngives better quantitative and qualitative evidence about the effects of tobacco\r\nsmoking on the occurrence of pneumonia in the adult\r\ncommunity.&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Almirall&quot;,&quot;given&quot;:&quot;Jordi&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Gonz\u00e1lez&quot;,&quot;given&quot;:&quot;Carlos\r\nA.&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Balanz\u00f3&quot;,&quot;given&quot;:&quot;Xavier&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Bol\u00edbar&quot;,&quot;given&quot;:&quot;Ignasi&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;Chest&quot;,&quot;id&quot;:&quot;ITEM-1&quot;,&quot;issue&quot;:&quot;2&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;1999&quot;,&quot;8&quot;,&quot;1&quot;]]},&quot;page&quot;:&quot;375-379&quot;,&quot;publisher&quot;:&quot;American\r\nCollege of Chest Physicians&quot;,&quot;title&quot;:&quot;Proportion of\r\ncommunity-acquired pneumonia cases attributable to tobacco\r\nsmoking&quot;,&quot;type&quot;:&quot;article-journal&quot;,&quot;volume&quot;:&quot;116&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=598c70e6-d8cf-3d88-8f36-d600ed4067a2&quot;]},{&quot;id&quot;:&quot;ITEM-2&quot;,&quot;itemData&quot;:{&quot;DOI&quot;:&quot;10.1016\/j.jinf.2013.05.004&quot;,&quot;ISSN&quot;:&quot;01634453&quot;,&quot;abstract&quot;:&quot;The\r\npredisposition of cigarette smokers for development of oral and respiratory\r\ninfections caused by microbial pathogens is well recognised, with those\r\ninfected with the human immunodeficiency virus (HIV) at particularly high risk.\r\nSmoking cigarettes has a suppressive effect on the protective functions of\r\nairway epithelium, alveolar macrophages, dendritic cells, natural killer (NK)\r\ncells and adaptive immune mechanisms, in the setting of chronic systemic\r\nactivation of neutrophils. Cigarette smoke also has a direct effect on\r\nmicrobial pathogens to promote the likelihood of infective disease,\r\nspecifically promotion of microbial virulence and antibiotic resistance. In\r\naddition to interactions between smoking and HIV infection, a number of\r\nspecific infections\/clinical syndromes have been associated epidemiologically\r\nwith cigarette smoking, including those of the upper and lower respiratory\r\ntract, gastrointestinal tract, central nervous and other organ systems. Smoking\r\ncessation benefits patients in many ways, including reduction of the risk of\r\ninfectious disease. \u00a9 2013 The British Infection\r\nAssociation.&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Feldman&quot;,&quot;given&quot;:&quot;Charles&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Anderson&quot;,&quot;given&quot;:&quot;Ronald&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;Journal\r\nof\r\nInfection&quot;,&quot;id&quot;:&quot;ITEM-2&quot;,&quot;issue&quot;:&quot;3&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2013&quot;,&quot;9&quot;,&quot;1&quot;]]},&quot;page&quot;:&quot;169-184&quot;,&quot;publisher&quot;:&quot;Elsevier&quot;,&quot;title&quot;:&quot;Cigarette\r\nsmoking and mechanisms of susceptibility to infections of the respiratory tract\r\nand other organ\r\nsystems&quot;,&quot;type&quot;:&quot;article&quot;,&quot;volume&quot;:&quot;67&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=cca87f97-7aab-4cfd-b582-d43336419974&quot;]}],&quot;mendeley&quot;:{&quot;formattedCitation&quot;:&quot;&lt;sup&gt;8,9&lt;\/sup&gt;&quot;,&quot;plainTextFormattedCitation&quot;:&quot;8,9&quot;,&quot;previouslyFormattedCitation&quot;:&quot;&lt;sup&gt;8,9&lt;\/sup&gt;&quot;},&quot;properties&quot;:{&quot;noteIndex&quot;:0},&quot;schema&quot;:&quot;https:\/\/github.com\/citation-style-language\/schema\/raw\/master\/csl-citation.json&quot;}<span\r\nstyle='mso-element:field-separator'><\/span><\/span><![endif]--><sup>8,9<\/sup><!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-end'><\/span><\/span><![endif]--> infections and is associated with worse outcomes once infected. Cigarette smoke reduces the respiratory immune defence through peri-bronchiolar inflammation and fibrosis, impaired mucociliary clearance and disruption of the respiratory epithelium<!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-begin;\r\nmso-field-lock:yes'><\/span>ADDIN CSL_CITATION\r\n{&quot;citationItems&quot;:[{&quot;id&quot;:&quot;ITEM-1&quot;,&quot;itemData&quot;:{&quot;DOI&quot;:&quot;10.1136\/thx.49.8.825&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Dye&quot;,&quot;given&quot;:&quot;Janice\r\nA&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Adler&quot;,&quot;given&quot;:&quot;Kenneth\r\nB&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;Thorax&quot;,&quot;id&quot;:&quot;ITEM-1&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;1994&quot;]]},&quot;page&quot;:&quot;825-834&quot;,&quot;title&quot;:&quot;Occasional\r\nreview Effects of cigarette smoke on epithelial cells of the respiratory tract&quot;,&quot;type&quot;:&quot;article-journal&quot;,&quot;volume&quot;:&quot;49&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=30f70d64-1b4d-3bad-9e59-932d6eeeee53&quot;]}],&quot;mendeley&quot;:{&quot;formattedCitation&quot;:&quot;&lt;sup&gt;10&lt;\/sup&gt;&quot;,&quot;plainTextFormattedCitation&quot;:&quot;10&quot;,&quot;previouslyFormattedCitation&quot;:&quot;&lt;sup&gt;10&lt;\/sup&gt;&quot;},&quot;properties&quot;:{&quot;noteIndex&quot;:0},&quot;schema&quot;:&quot;https:\/\/github.com\/citation-style-language\/schema\/raw\/master\/csl-citation.json&quot;}<span\r\nstyle='mso-element:field-separator'><\/span><\/span><![endif]--><sup>10<\/sup><!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-end'><\/span><\/span><![endif]-->. There is also reason to believe that behavioural factors (e.g. regular hand-to-mouth movements) involved in smoking may increase SARS-CoV-2 infection and transmission in current smokers. However, early data from the COVID-19 pandemic have not provided clear evidence for a negative impact of current or former smoking on SARS-CoV-2 infection or COVID-19 disease outcomes, such as hospitalisation or mortality<!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-begin;\r\nmso-field-lock:yes'><\/span>ADDIN CSL_CITATION\r\n{&quot;citationItems&quot;:[{&quot;id&quot;:&quot;ITEM-1&quot;,&quot;itemData&quot;:{&quot;DOI&quot;:&quot;10.18332\/tid\/119324&quot;,&quot;ISSN&quot;:&quot;1617-9625&quot;,&quot;PMID&quot;:&quot;32206052&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Vardavas&quot;,&quot;given&quot;:&quot;Constantine\r\nI&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Nikitara&quot;,&quot;given&quot;:&quot;Katerina&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;Tobacco\r\ninduced diseases&quot;,&quot;id&quot;:&quot;ITEM-1&quot;,&quot;issue&quot;:&quot;March&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2020&quot;]]},&quot;page&quot;:&quot;20&quot;,&quot;title&quot;:&quot;COVID-19\r\nand smoking: A systematic review of the evidence.&quot;,&quot;type&quot;:&quot;article-journal&quot;,&quot;volume&quot;:&quot;18&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=6cd5911b-58f4-4a63-b5a1-36e5ee9e20ee&quot;]}],&quot;mendeley&quot;:{&quot;formattedCitation&quot;:&quot;&lt;sup&gt;11&lt;\/sup&gt;&quot;,&quot;plainTextFormattedCitation&quot;:&quot;11&quot;,&quot;previouslyFormattedCitation&quot;:&quot;&lt;sup&gt;11&lt;\/sup&gt;&quot;},&quot;properties&quot;:{&quot;noteIndex&quot;:0},&quot;schema&quot;:&quot;https:\/\/github.com\/citation-style-language\/schema\/raw\/master\/csl-citation.json&quot;}<span\r\nstyle='mso-element:field-separator'><\/span><\/span><![endif]--><sup>11<\/sup><!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-end'><\/span><\/span><![endif]-->. It has also been hypothesised that nicotine might protect against a hyper-inflammatory response (or &ldquo;cytokine storm&rdquo;) to SARS-CoV-2 infection, which may lead to adverse outcomes in patients with COVID-19 disease<!--[if supportFields]><span style='font-size:11.0pt;\r\nline-height:150%'><span style='mso-element:field-begin;mso-field-lock:yes'><\/span>ADDIN\r\nCSL_CITATION\r\n{&quot;citationItems&quot;:[{&quot;id&quot;:&quot;ITEM-1&quot;,&quot;itemData&quot;:{&quot;DOI&quot;:&quot;10.1016\/j.toxrep.2020.04.012&quot;,&quot;ISSN&quot;:&quot;22147500&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Farsalinos&quot;,&quot;given&quot;:&quot;Konstantinos&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Niaura&quot;,&quot;given&quot;:&quot;Raymond&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Houezec&quot;,&quot;given&quot;:&quot;Jacques&quot;,&quot;non-dropping-particle&quot;:&quot;Le&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Barbouni&quot;,&quot;given&quot;:&quot;Anastasia&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Tsatsakis&quot;,&quot;given&quot;:&quot;Aristidis&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Kouretas&quot;,&quot;given&quot;:&quot;Dimitrios&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Vantarakis&quot;,&quot;given&quot;:&quot;Apostolos&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Poulas&quot;,&quot;given&quot;:&quot;Konstantinos&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;Toxicology\r\nReports&quot;,&quot;id&quot;:&quot;ITEM-1&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2020&quot;,&quot;4&quot;]]},&quot;title&quot;:&quot;Editorial:\r\nNicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic\r\nsystem&quot;,&quot;type&quot;:&quot;article-journal&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=84781c5d-c6a6-44a5-b5be-cd6c41e014af&quot;]}],&quot;mendeley&quot;:{&quot;formattedCitation&quot;:&quot;&lt;sup&gt;12&lt;\/sup&gt;&quot;,&quot;plainTextFormattedCitation&quot;:&quot;12&quot;,&quot;previouslyFormattedCitation&quot;:&quot;&lt;sup&gt;12&lt;\/sup&gt;&quot;},&quot;properties&quot;:{&quot;noteIndex&quot;:0},&quot;schema&quot;:&quot;https:\/\/github.com\/citation-style-language\/schema\/raw\/master\/csl-citation.json&quot;}<span\r\nstyle='mso-element:field-separator'><\/span><\/span><![endif]--><sup>12<\/sup><!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-end'><\/span><\/span><![endif]-->.<\/p>\n\n<p>&nbsp;<\/p>\n\n<p>There are several reviews that fall within the scope of smoking and COVID-19<!--[if supportFields]><span style='font-size:11.0pt;\r\nline-height:150%'><span style='mso-element:field-begin;mso-field-lock:yes'><\/span>ADDIN\r\nCSL_CITATION\r\n{&quot;citationItems&quot;:[{&quot;id&quot;:&quot;ITEM-1&quot;,&quot;itemData&quot;:{&quot;DOI&quot;:&quot;10.18332\/tid\/119324&quot;,&quot;ISSN&quot;:&quot;1617-9625&quot;,&quot;PMID&quot;:&quot;32206052&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Vardavas&quot;,&quot;given&quot;:&quot;Constantine\r\nI&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Nikitara&quot;,&quot;given&quot;:&quot;Katerina&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;Tobacco\r\ninduced diseases&quot;,&quot;id&quot;:&quot;ITEM-1&quot;,&quot;issue&quot;:&quot;March&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2020&quot;]]},&quot;page&quot;:&quot;20&quot;,&quot;title&quot;:&quot;COVID-19\r\nand smoking: A systematic review of the evidence.&quot;,&quot;type&quot;:&quot;article-journal&quot;,&quot;volume&quot;:&quot;18&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=6cd5911b-58f4-4a63-b5a1-36e5ee9e20ee&quot;]},{&quot;id&quot;:&quot;ITEM-2&quot;,&quot;itemData&quot;:{&quot;ISSN&quot;:&quot;2645-4904&quot;,&quot;PMID&quot;:&quot;32232218&quot;,&quot;abstract&quot;:&quot;Introduction\r\nIn the beginning of 2020, an unexpected outbreak due to a new corona virus made\r\nthe headlines all over the world. Exponential growth in the number of those\r\naffected makes this virus such a threat. The current meta-analysis aimed to\r\nestimate the prevalence of underlying disorders in hospitalized COVID-19\r\npatients. Methods A comprehensive systematic search was performed on PubMed,\r\nScopus, Web of science, and Google scholar, to find articles published until 15\r\nFebruary 2020. All relevant articles that reported clinical characteristics and\r\nepidemiological information of hospitalized COVID-19 patients were included in\r\nthe analysis. Results The data of 76993 patients presented in 10 articles were\r\nincluded in this study. According to the meta-analysis, the pooled prevalence\r\nof hypertension, cardiovascular disease, smoking history and diabetes in people\r\ninfected with SARS-CoV-2 were estimated as 16.37% (95%CI: 10.15%-23.65%),\r\n12.11% (95%CI 4.40%-22.75%), 7.63% (95%CI 3.83%-12.43%) and 7.87% (95%CI\r\n6.57%-9.28%), respectively. Conclusion According to the findings of the present\r\nstudy, hypertension, cardiovascular diseases, diabetes mellitus, smoking,\r\nchronic obstructive pulmonary disease (COPD), malignancy, and chronic kidney\r\ndisease were among the most prevalent underlying diseases among hospitalized\r\nCOVID-19 patients,\r\nrespectively.&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Emami&quot;,&quot;given&quot;:&quot;Amir&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Javanmardi&quot;,&quot;given&quot;:&quot;Fatemeh&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Pirbonyeh&quot;,&quot;given&quot;:&quot;Neda&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Akbari&quot;,&quot;given&quot;:&quot;Ali&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;Archives\r\nof academic emergency\r\nmedicine&quot;,&quot;id&quot;:&quot;ITEM-2&quot;,&quot;issue&quot;:&quot;1&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2020&quot;]]},&quot;page&quot;:&quot;e35&quot;,&quot;title&quot;:&quot;Prevalence\r\nof Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic\r\nReview and\r\nMeta-Analysis.&quot;,&quot;type&quot;:&quot;article-journal&quot;,&quot;volume&quot;:&quot;8&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=cf9d584a-2a53-4281-a445-3ad32ebce0ec&quot;]},{&quot;id&quot;:&quot;ITEM-3&quot;,&quot;itemData&quot;:{&quot;DOI&quot;:&quot;10.1101\/2020.03.25.20043745&quot;,&quot;abstract&quot;:&quot;Background:\r\nCoronavirus disease 2019 (COVID-19) is an evolving infectious disease that dramatically\r\nspread all over the world in the early part of 2020. No studies have yet\r\nsummarised the potential severity and mortality risks caused by COVID-19 in\r\npatients with chronic obstructive pulmonary disease (COPD), and we update\r\ninformation in smokers. Methods: We systematically searched electronic\r\ndatabases from inception to March 24, 2020. Data were extracted by two\r\nindependent authors in accordance with the Preferred Reporting Items for\r\nSystematic Reviews and Meta-analyses guidelines. Study quality was assessed\r\nusing a modified version of the Newcastle Ottawa Scale. We synthesised a\r\nnarrative from eligible studies and conducted a meta-analysis using a\r\nrandom-effects model to calculate pooled prevalence rates and 95% confidence\r\nintervals (95%CI). Results: In total, 123 abstracts were screened and 61\r\nfull-text manuscripts were reviewed. A total of 15 studies met the inclusion\r\ncriteria, which included a total of 2473 confirmed COVID-19 patients. All\r\nstudies were included in the meta-analysis. The crude case fatality rate of\r\nCOVID-19 was 6.4%. The pooled prevalence rates of COPD patients and smokers in\r\nCOVID-19 cases were 2% (95% CI, 1%-3%) and 9% (95% CI, 4%-14%) respectively.\r\nCOPD patients were at a higher risk of more severe disease (risk of severity =\r\n63%, (22\/35) compared to patients without COPD 33.4% (409\/1224) [calculated RR,\r\n1.88 (95% CI, 1.4-2.4)]. This was associated with higher mortality (60%). Our\r\nresults showed that 22% (31\/139) of current smokers and 46% (13\/28) of\r\nex-smokers had severe complications. The calculated RR showed that current\r\nsmokers were 1.45 times more likely [95% CI: 1.03-2.04] to have severe\r\ncomplications compared to former and never smokers. Current smokers also had a\r\nhigher mortality rate of 38.5%. Conclusion: Although COPD prevalence in\r\nCOVID-19 cases was low in current reports, COVID-19 infection was associated\r\nwith substantial severity and mortality rates in COPD. Compared to former and\r\nnever smokers, current smokers were at greater risk of severe complications and\r\nhigher mortality rate. Effective preventive measures are required to reduce COVID-19\r\nrisk in COPD patients and current smokers. ### Competing Interest Statement The\r\nauthors have declared no competing interest. ### Funding Statement None. ###\r\nAuthor Declarations All relevant ethical guidelines have been followed; any\r\nnecessary IRB and\/or ethics committee approvals\r\nh\u2026&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Alqahtani&quot;,&quot;given&quot;:&quot;Jaber\r\nS&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Oyelade&quot;,&quot;given&quot;:&quot;Tope&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Aldhahir&quot;,&quot;given&quot;:&quot;Abdulelah\r\nM&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Alghamdi&quot;,&quot;given&quot;:&quot;Saeed\r\nM&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Almehmadi&quot;,&quot;given&quot;:&quot;Mater&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Alqahtani&quot;,&quot;given&quot;:&quot;Abdullah\r\nS&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Quaderi&quot;,&quot;given&quot;:&quot;Shumonta&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Mandal&quot;,&quot;given&quot;:&quot;Swapna&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Hurst&quot;,&quot;given&quot;:&quot;John&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;medRxiv&quot;,&quot;id&quot;:&quot;ITEM-3&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2020&quot;,&quot;3&quot;,&quot;27&quot;]]},&quot;page&quot;:&quot;2020.03.25.20043745&quot;,&quot;publisher&quot;:&quot;Cold\r\nSpring Harbor Laboratory Press&quot;,&quot;title&quot;:&quot;Prevalence,\r\nSeverity and Mortality associated with COPD and Smoking in patients with\r\nCOVID-19: A Rapid Systematic Review and\r\nMeta-Analysis&quot;,&quot;type&quot;:&quot;article-journal&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=e3a4bb99-7696-46eb-9ff1-290b2555ae2e&quot;]},{&quot;id&quot;:&quot;ITEM-4&quot;,&quot;itemData&quot;:{&quot;DOI&quot;:&quot;10.14171\/j.2095-5944.sg.2014.02.004&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Patanavanich&quot;,&quot;given&quot;:&quot;Roengrudee&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Glantz&quot;,&quot;given&quot;:&quot;Stanton\r\nA.&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;medRxiv&quot;,&quot;id&quot;:&quot;ITEM-4&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2020&quot;]]},&quot;title&quot;:&quot;Smoking\r\nis Associated with COVID-19 Progression: A Meta-Analysis&quot;,&quot;type&quot;:&quot;article-journal&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=2c9de314-024a-470c-8c7c-0d528e6cbb3e&quot;]},{&quot;id&quot;:&quot;ITEM-5&quot;,&quot;itemData&quot;:{&quot;DOI&quot;:&quot;10.32388\/Z69O8A.8&quot;,&quot;ISSN&quot;:&quot;2632-3834&quot;,&quot;abstract&quot;:&quot;The\r\nstudy presents an analysis of the current smoking prevalence among hospitalized\r\npatients with COVID-19 in China, compared to the population smoking prevalence\r\nin China (52.1% in males and 2.7% in females). We identified 6 studies\r\nexamining the clinical characteristics of hospitalized COVID-19 patients that\r\npresented data on the smoking status. The expected number of smokers was\r\ncalculated using the formula Expected smokers = (males x 0.521) + (females x\r\n0.027). An unusually low prevalence of current smoking was observed among\r\nhospitalized COVID-19 patients (9.6%, 95%CI: 8.2-11.1%) compared to the\r\nexpected prevalence based on smoking prevalence in China (31.2%, 95%CI:\r\n29.0-33.4%; z-statistic: 19.16, P &lt; 0.0001). This preliminary analysis does\r\nnot support the argument that current smoking is a risk factor for\r\nhospitalization for COVID-19, and might suggest a protective role. The latter\r\ncould be linked to the downregulation of ACE2 expression that has been\r\npreviously known to be induced by smoking. No studies recording e-cigarette use\r\nstatus among hospitalized COVID-19 patients were identified. Thus, no\r\nrecommendation can be made for e-cigarette users. Keywords. SARS-CoV-2,\r\nCOVID-19, ACE2, expression, susceptibility, smoking, hospitalization,\r\nelectronic cigarette.&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Farsalinos&quot;,&quot;given&quot;:&quot;Konstantinos&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Barbouni&quot;,&quot;given&quot;:&quot;Anastasia&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Niaura&quot;,&quot;given&quot;:&quot;Raymond&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;Qeios&quot;,&quot;id&quot;:&quot;ITEM-5&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2020&quot;,&quot;3&quot;,&quot;25&quot;]]},&quot;publisher&quot;:&quot;Qeios\r\nLtd&quot;,&quot;title&quot;:&quot;Smoking, vaping and hospitalization for\r\nCOVID-19&quot;,&quot;type&quot;:&quot;article-journal&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=39efac61-9bf1-4437-b1a3-f83b732938fa&quot;]},{&quot;id&quot;:&quot;ITEM-6&quot;,&quot;itemData&quot;:{&quot;DOI&quot;:&quot;10.1093\/NTR\/NTAA059&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Berlin&quot;,&quot;given&quot;:&quot;Ivan&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Thomas&quot;,&quot;given&quot;:&quot;Daniel&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Faou&quot;,&quot;given&quot;:&quot;Anne-Laurence&quot;,&quot;non-dropping-particle&quot;:&quot;Le&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Cornuz&quot;,&quot;given&quot;:&quot;Jacques&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;Nicotine\r\n&amp; Tobacco\r\nResearch&quot;,&quot;id&quot;:&quot;ITEM-6&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;0&quot;]]},&quot;title&quot;:&quot;COVID-19\r\nand\r\nSmoking&quot;,&quot;type&quot;:&quot;article-journal&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=6e7dfd27-907e-3938-816b-c6e465dfa43e&quot;]}],&quot;mendeley&quot;:{&quot;formattedCitation&quot;:&quot;&lt;sup&gt;11,13\u201317&lt;\/sup&gt;&quot;,&quot;plainTextFormattedCitation&quot;:&quot;11,13\u201317&quot;,&quot;previouslyFormattedCitation&quot;:&quot;&lt;sup&gt;11,13\u201317&lt;\/sup&gt;&quot;},&quot;properties&quot;:{&quot;noteIndex&quot;:0},&quot;schema&quot;:&quot;https:\/\/github.com\/citation-style-language\/schema\/raw\/master\/csl-citation.json&quot;}<span\r\nstyle='mso-element:field-separator'><\/span><\/span><![endif]--><sup>11,13&ndash;17<\/sup><!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-end'><\/span><\/span><![endif]-->. We aimed to produce a rapid synthesis of available evidence pertaining to the rates of infection, hospitalisation, disease severity and mortality from SARS-CoV-2\/COVID-19 stratified by smoking status. Given the increasing availability of data on this topic, this is a living review with regular updates. As evidence accumulates, the review will be expanded to include studies reporting COVID-19 outcomes by alternative nicotine use (e.g., nicotine replacement therapy or e-cigarettes).<\/p>\n\n<p>&nbsp;<\/p>\n\n<p><strong>Methods<\/strong><\/p>\n\n<p>&nbsp;<\/p>\n\n<p><em>Study design<\/em><\/p>\n\n<p>This is a living evidence review which is updated as new evidence becomes available<!--[if supportFields]><span style='font-size:\r\n11.0pt;line-height:150%'><span style='mso-element:field-begin;mso-field-lock:\r\nyes'><\/span>ADDIN CSL_CITATION\r\n{&quot;citationItems&quot;:[{&quot;id&quot;:&quot;ITEM-1&quot;,&quot;itemData&quot;:{&quot;DOI&quot;:&quot;10.1371\/journal.pmed.1001603&quot;,&quot;ISSN&quot;:&quot;15491676&quot;,&quot;PMID&quot;:&quot;24558353&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Elliott&quot;,&quot;given&quot;:&quot;Julian\r\nH.&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Turner&quot;,&quot;given&quot;:&quot;Tari&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Clavisi&quot;,&quot;given&quot;:&quot;Ornella&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Thomas&quot;,&quot;given&quot;:&quot;James&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Higgins&quot;,&quot;given&quot;:&quot;Julian\r\nP.T.&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Mavergames&quot;,&quot;given&quot;:&quot;Chris&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Gruen&quot;,&quot;given&quot;:&quot;Russell\r\nL.&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;PLoS\r\nMedicine&quot;,&quot;id&quot;:&quot;ITEM-1&quot;,&quot;issue&quot;:&quot;2&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2014&quot;]]},&quot;publisher&quot;:&quot;Public\r\nLibrary of Science&quot;,&quot;title&quot;:&quot;Living Systematic Reviews: An\r\nEmerging Opportunity to Narrow the Evidence-Practice\r\nGap&quot;,&quot;type&quot;:&quot;article-journal&quot;,&quot;volume&quot;:&quot;11&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=3dc293ee-005f-3320-900f-3348b9141674&quot;]}],&quot;mendeley&quot;:{&quot;formattedCitation&quot;:&quot;&lt;sup&gt;18&lt;\/sup&gt;&quot;,&quot;plainTextFormattedCitation&quot;:&quot;18&quot;,&quot;previouslyFormattedCitation&quot;:&quot;&lt;sup&gt;18&lt;\/sup&gt;&quot;},&quot;properties&quot;:{&quot;noteIndex&quot;:0},&quot;schema&quot;:&quot;https:\/\/github.com\/citation-style-language\/schema\/raw\/master\/csl-citation.json&quot;}<span\r\nstyle='mso-element:field-separator'><\/span><\/span><![endif]--><sup>18<\/sup><!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-end'><\/span><\/span><![endif]-->. We adopted recommended practice for rapid evidence reviews, which involved limiting the search to main databases and having one reviewer extract the data and another verify<!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-begin;\r\nmso-field-lock:yes'><\/span>ADDIN CSL_CITATION\r\n{&quot;citationItems&quot;:[{&quot;id&quot;:&quot;ITEM-1&quot;,&quot;itemData&quot;:{&quot;DOI&quot;:&quot;10.1186\/s12916-015-0465-6&quot;,&quot;ISSN&quot;:&quot;17417015&quot;,&quot;PMID&quot;:&quot;26377409&quot;,&quot;abstract&quot;:&quot;Background:\r\nRapid reviews are a form of knowledge synthesis in which components of the\r\nsystematic review process are simplified or omitted to produce information in a\r\ntimely manner. Although numerous centers are conducting rapid reviews\r\ninternationally, few studies have examined the methodological characteristics\r\nof rapid reviews. We aimed to examine articles, books, and reports that\r\nevaluated, compared, used or described rapid reviews or methods through a\r\nscoping review. Methods: MEDLINE, EMBASE, the Cochrane Library, internet\r\nwebsites of rapid review producers, and reference lists were searched to\r\nidentify articles for inclusion. Two reviewers independently screened\r\nliterature search results and abstracted data from included studies.\r\nDescriptive analysis was conducted. Results: We included 100 articles plus one\r\ncompanion report that were published between 1997 and 2013. The studies were\r\ncategorized as 84 application papers, seven development papers, six impact\r\npapers, and four comparison papers (one was included in two categories). The\r\nrapid reviews were conducted between 1 and 12 months, predominantly in Europe\r\n(58 %) and North America (20 %). The included studies failed to report 6 % to\r\n73 % of the specific systematic review steps examined. Fifty unique rapid\r\nreview methods were identified; 16 methods occurred more than once. Streamlined\r\nmethods that were used in the 82 rapid reviews included limiting the literature\r\nsearch to published literature (24 %) or one database (2 %), limiting inclusion\r\ncriteria by date (68 %) or language (49 %), having one person screen and\r\nanother verify or screen excluded studies (6 %), having one person abstract\r\ndata and another verify (23 %), not conducting risk of bias\/quality appraisal\r\n(7 %) or having only one reviewer conduct the quality appraisal (7 %), and\r\npresenting results as a narrative summary (78 %). Four case studies were\r\nidentified that compared the results of rapid reviews to systematic reviews.\r\nThree studies found that the conclusions between rapid reviews and systematic\r\nreviews were congruent. Conclusions: Numerous rapid review approaches were\r\nidentified and few were used consistently in the literature. Poor quality of\r\nreporting was observed. A prospective study comparing the results from rapid\r\nreviews to those obtained through systematic reviews is\r\nwarranted.&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Tricco&quot;,&quot;given&quot;:&quot;Andrea\r\nC.&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Antony&quot;,&quot;given&quot;:&quot;Jesmin&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Zarin&quot;,&quot;given&quot;:&quot;Wasifa&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Strifler&quot;,&quot;given&quot;:&quot;Lisa&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Ghassemi&quot;,&quot;given&quot;:&quot;Marco&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Ivory&quot;,&quot;given&quot;:&quot;John&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Perrier&quot;,&quot;given&quot;:&quot;Laure&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Hutton&quot;,&quot;given&quot;:&quot;Brian&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Moher&quot;,&quot;given&quot;:&quot;David&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Straus&quot;,&quot;given&quot;:&quot;Sharon\r\nE.&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;BMC\r\nMedicine&quot;,&quot;id&quot;:&quot;ITEM-1&quot;,&quot;issue&quot;:&quot;1&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2015&quot;,&quot;9&quot;,&quot;16&quot;]]},&quot;page&quot;:&quot;224&quot;,&quot;publisher&quot;:&quot;BioMed\r\nCentral Ltd.&quot;,&quot;title&quot;:&quot;A scoping review of rapid review\r\nmethods&quot;,&quot;type&quot;:&quot;article-journal&quot;,&quot;volume&quot;:&quot;13&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=2131d12c-c3a6-39eb-ba40-3443060153d8&quot;]}],&quot;mendeley&quot;:{&quot;formattedCitation&quot;:&quot;&lt;sup&gt;19&lt;\/sup&gt;&quot;,&quot;plainTextFormattedCitation&quot;:&quot;19&quot;,&quot;previouslyFormattedCitation&quot;:&quot;&lt;sup&gt;19&lt;\/sup&gt;&quot;},&quot;properties&quot;:{&quot;noteIndex&quot;:0},&quot;schema&quot;:&quot;https:\/\/github.com\/citation-style-language\/schema\/raw\/master\/csl-citation.json&quot;}<span\r\nstyle='mso-element:field-separator'><\/span><\/span><![endif]--><sup>19<\/sup><!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-end'><\/span><\/span><![endif]-->.<\/p>\n\n<p>Eligibility criteria<\/p>\n\n<p>&nbsp;<\/p>\n\n<p>Studies were included if they:<\/p>\n\n<p>&nbsp;<\/p>\n\n<p>1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Were primary research studies using experimental (e.g. randomised controlled trial), quasi-experimental (e.g. pre- and post-test) or observational (e.g. case-control, retrospective cohort, prospective cohort) study designs;<\/p>\n\n<p>2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Included adults aged 16+ years;<\/p>\n\n<p>3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recorded as outcome i) results of a SARS-CoV-2 diagnostic test (including antibody assays), ii) clinical diagnosis of COVID-19, iii) hospitalisation with COVID-19, iv) severity of COVID-19 disease in those hospitalised or v) mortality from COVID-19;<\/p>\n\n<p>4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reported any of the outcomes of interest by self-reported or biochemically verified smoking status (e.g. current smoker, former smoker, never smoker);<\/p>\n\n<p>5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Were available in English;<\/p>\n\n<p>6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Were published in a peer-reviewed journal, as a pre-print or a public health report by reputable agents (e.g. governments, scientific societies).<\/p>\n\n<p>&nbsp;<\/p>\n\n<p><em>Search strategy<\/em><\/p>\n\n<p>&nbsp;<\/p>\n\n<p>The following terms were searched for in Ovid MEDLINE as free text or Medical Subject Headings:<\/p>\n\n<p>&nbsp;<\/p>\n\n<p>1. Tobacco Smoking\/ or Smoking Cessation\/ or Water Pipe Smoking\/ or Smoking\/ or Smoking Pipes\/ or Cigar Smoking\/ or Smoking Prevention\/ or Cigarette Smoking\/ or smoking.mp. or Pipe Smoking\/ or Smoking, Non-Tobacco Products\/ or Smoking Water Pipes\/<\/p>\n\n<p>2. Nicotine\/ or nicotine.mp. or Electronic Nicotine Delivery Systems\/ or Nicotine Chewing Gum\/<\/p>\n\n<p>3. vaping.mp. or Vaping\/<\/p>\n\n<p>4. 1 or 2 or 3<\/p>\n\n<p>5. Coronavirus\/ or Severe Acute Respiratory Syndrome\/ or Coronavirus Infections\/ or covid.mp.<\/p>\n\n<p>6. 4 and 5<\/p>\n\n<p>&nbsp;<\/p>\n\n<p>The following terms were searched for in titles, abstracts and full texts in medRxiv:<\/p>\n\n<p>&nbsp;<\/p>\n\n<p>covid smoking<\/p>\n\n<p>covid nicotine<\/p>\n\n<p>covid vaping<\/p>\n\n<p>&nbsp;<\/p>\n\n<p>Additional articles\/reports of interest were identified through mailing lists, Twitter, the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC), the Intensive Care National Audit &amp; Research Centre (ICNARC) and the US Centers for Disease Control and Prevention (CDC).<\/p>\n\n<p>&nbsp;<\/p>\n\n<p>Where updated versions of pre-prints or public health reports were available, old versions were superseded.<\/p>\n\n<p>&nbsp;<\/p>\n\n<p><em>Selection of studies<\/em><\/p>\n\n<p>&nbsp;<\/p>\n\n<p>One reviewer screened titles, abstracts and full texts against the inclusion criteria.<\/p>\n\n<p>&nbsp;<\/p>\n\n<p><em>Data extraction<\/em><\/p>\n\n<p>&nbsp;<\/p>\n\n<p>Data were extracted by one reviewer and verified by a second on i) author (year); ii) date published; iii) country; iv) study design; v) study setting; vi) sample size; vii) sex; viii) age; ix) smoking status (e.g. current, former, never, not stated, missing); x) SARS-CoV-2 infection; xi) diagnosis of COVID-19; xii) hospitalisation with COVID-19; xiii) disease severity in those hospitalised with COVID-19; and xiv) mortality.<\/p>\n\n<p>&nbsp;<\/p>\n\n<p><em>Quality appraisal<\/em><\/p>\n\n<p>&nbsp;<\/p>\n\n<p>In previous review versions, we used the National Institutes of Health&rsquo;s Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies to determine the quality of included studies<!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-begin;\r\nmso-field-lock:yes'><\/span>ADDIN CSL_CITATION\r\n{&quot;citationItems&quot;:[{&quot;id&quot;:&quot;ITEM-1&quot;,&quot;itemData&quot;:{&quot;URL&quot;:&quot;https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools&quot;,&quot;abstract&quot;:&quot;Tools\r\nand\r\nbackground&quot;,&quot;accessed&quot;:{&quot;date-parts&quot;:[[&quot;2020&quot;,&quot;4&quot;,&quot;24&quot;]]},&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;National\r\nHeart Lung and Blood\r\nInstitute&quot;,&quot;given&quot;:&quot;&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;Natonal\r\nInstitutes of\r\nHealth&quot;,&quot;id&quot;:&quot;ITEM-1&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2018&quot;]]},&quot;page&quot;:&quot;1-35&quot;,&quot;title&quot;:&quot;Study\r\nQuality Assessment\r\nTools&quot;,&quot;type&quot;:&quot;webpage&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=5a282c2e-c3d9-349a-8243-fd399ea1c45f&quot;]}],&quot;mendeley&quot;:{&quot;formattedCitation&quot;:&quot;&lt;sup&gt;20&lt;\/sup&gt;&quot;,&quot;plainTextFormattedCitation&quot;:&quot;20&quot;,&quot;previouslyFormattedCitation&quot;:&quot;&lt;sup&gt;20&lt;\/sup&gt;&quot;},&quot;properties&quot;:{&quot;noteIndex&quot;:0},&quot;schema&quot;:&quot;https:\/\/github.com\/citation-style-language\/schema\/raw\/master\/csl-citation.json&quot;}<span\r\nstyle='mso-element:field-separator'><\/span><\/span><![endif]--><sup>20<\/sup><!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-end'><\/span><\/span><![endif]-->. However, we decided against applying the entire tool in the current review version. The appraisal is challenging to apply when studying an emerging disease with unknown pathology. For example, it is not possible to determine what proportion of eligible participants\/patients are included in the studied populations when the total number of infections in a given region\/city is unknown. With a largely unknown disease process, it is also difficult to determine whether the time between the exposure and outcome is sufficient. We therefore focused on three of the 14 criteria to determine whether studies were of sufficient quality to warrant inclusion in meta-analysis. Studies were judged as &lsquo;good&rsquo; quality if they: i) had low levels of missing data on smoking status (i.e. &lt;20%) and used a reliable self-report measure that distinguished between current, former and never smoking status; AND ii) used biochemical verification of smoking status and reported results from adjusted analyses; OR reported data from a representative\/random sample. Studies were rated as &lsquo;fair&rsquo; if they fulfilled only criterion i) and were otherwise rated as &lsquo;poor&rsquo;. The quality appraisal was conducted by one reviewer and verified by a second.<\/p>\n\n<p>&nbsp;<\/p>\n\n<p><em>Evidence synthesis<\/em><\/p>\n\n<p>&nbsp;<\/p>\n\n<p>A narrative synthesis was conducted. Where possible, data were pooled in R v.3.6.3<!--[if supportFields]><sup><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-begin;\r\nmso-field-lock:yes'><\/span>ADDIN CSL_CITATION\r\n{&quot;citationItems&quot;:[{&quot;id&quot;:&quot;ITEM-1&quot;,&quot;itemData&quot;:{&quot;abstract&quot;:&quot;\u02c6&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;R\r\nCore\r\nTeam&quot;,&quot;given&quot;:&quot;&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;id&quot;:&quot;ITEM-1&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2013&quot;]]},&quot;page&quot;:&quot;1-12&quot;,&quot;title&quot;:&quot;The\r\nR Project for Statistical\r\nComputing&quot;,&quot;type&quot;:&quot;article&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=8bf7a025-ed1b-395b-91df-9b8eb1874134&quot;]}],&quot;mendeley&quot;:{&quot;formattedCitation&quot;:&quot;&lt;sup&gt;21&lt;\/sup&gt;&quot;,&quot;plainTextFormattedCitation&quot;:&quot;21&quot;,&quot;previouslyFormattedCitation&quot;:&quot;&lt;sup&gt;21&lt;\/sup&gt;&quot;},&quot;properties&quot;:{&quot;noteIndex&quot;:0},&quot;schema&quot;:&quot;https:\/\/github.com\/citation-style-language\/schema\/raw\/master\/csl-citation.json&quot;}<span\r\nstyle='mso-element:field-separator'><\/span><\/span><\/sup><![endif]--><sup>21<\/sup><!--[if supportFields]><sup><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-end'><\/span><\/span><\/sup><![endif]--> with the Mantel-Haenszel or inverse variance method using random or fixed effects, depending on heterogeneity, and presented as risk ratios (RRs)<!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-begin;\r\nmso-field-lock:yes'><\/span>ADDIN CSL_CITATION\r\n{&quot;citationItems&quot;:[{&quot;id&quot;:&quot;ITEM-1&quot;,&quot;itemData&quot;:{&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Higgins&quot;,&quot;given&quot;:&quot;J.\r\nP.\r\nT.&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Wells&quot;,&quot;given&quot;:&quot;G.\r\nA.&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;id&quot;:&quot;ITEM-1&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2011&quot;]]},&quot;title&quot;:&quot;Cochrane\r\nhandbook for systematic reviews of\r\ninterventions&quot;,&quot;type&quot;:&quot;book&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=d9b93d0d-5af9-4970-8c56-a5a7b82c6edf&quot;]}],&quot;mendeley&quot;:{&quot;formattedCitation&quot;:&quot;&lt;sup&gt;22&lt;\/sup&gt;&quot;,&quot;plainTextFormattedCitation&quot;:&quot;22&quot;,&quot;previouslyFormattedCitation&quot;:&quot;&lt;sup&gt;22&lt;\/sup&gt;&quot;},&quot;properties&quot;:{&quot;noteIndex&quot;:0},&quot;schema&quot;:&quot;https:\/\/github.com\/citation-style-language\/schema\/raw\/master\/csl-citation.json&quot;}<span\r\nstyle='mso-element:field-separator'><\/span><\/span><![endif]--><sup>22<\/sup><!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-end'><\/span><\/span><![endif]-->. Heterogeneity between study outcomes was assessed using the I2 statistic, suitable for smaller meta\u2010analyses<!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-begin;\r\nmso-field-lock:yes'><\/span>ADDIN CSL_CITATION {&quot;citationItems&quot;:[{&quot;id&quot;:&quot;ITEM-1&quot;,&quot;itemData&quot;:{&quot;DOI&quot;:&quot;10.1136\/bmj.327.7414.557&quot;,&quot;ISSN&quot;:&quot;09598146&quot;,&quot;PMID&quot;:&quot;12958120&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Higgins&quot;,&quot;given&quot;:&quot;Julian\r\nP.T.&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Thompson&quot;,&quot;given&quot;:&quot;Simon\r\nG.&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Deeks&quot;,&quot;given&quot;:&quot;Jonathan\r\nJ.&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Altman&quot;,&quot;given&quot;:&quot;Douglas\r\nG.&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;British\r\nMedical\r\nJournal&quot;,&quot;id&quot;:&quot;ITEM-1&quot;,&quot;issue&quot;:&quot;7414&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2003&quot;,&quot;9&quot;,&quot;6&quot;]]},&quot;page&quot;:&quot;557-560&quot;,&quot;publisher&quot;:&quot;BMJ\r\nPublishing Group&quot;,&quot;title&quot;:&quot;Measuring inconsistency in\r\nmeta-analyses&quot;,&quot;type&quot;:&quot;article&quot;,&quot;volume&quot;:&quot;327&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=f407d06d-dac2-37ac-b823-d8a8bd200263&quot;]}],&quot;mendeley&quot;:{&quot;formattedCitation&quot;:&quot;&lt;sup&gt;23&lt;\/sup&gt;&quot;,&quot;plainTextFormattedCitation&quot;:&quot;23&quot;,&quot;previouslyFormattedCitation&quot;:&quot;&lt;sup&gt;23&lt;\/sup&gt;&quot;},&quot;properties&quot;:{&quot;noteIndex&quot;:0},&quot;schema&quot;:&quot;https:\/\/github.com\/citation-style-language\/schema\/raw\/master\/csl-citation.json&quot;}<span\r\nstyle='mso-element:field-separator'><\/span><\/span><![endif]--><sup>23<\/sup><!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-end'><\/span><\/span><![endif]-->.<\/p>\n\n<p>To aid in the visualisation of smoking prevalence in the included studies, 95% bootstrap percentile confidence intervals were calculated for each study estimate. We performed 1,000 bootstrap replications, with the 2.5th and 97.5th percentiles of the empirical distribution forming the 95% bootstrap percentile confidence intervals<!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%;mso-bidi-font-family:Calibri;\r\nmso-bidi-theme-font:minor-latin'><span style='mso-element:field-begin;\r\nmso-field-lock:yes'><\/span>ADDIN CSL_CITATION\r\n{&quot;citationItems&quot;:[{&quot;id&quot;:&quot;ITEM-1&quot;,&quot;itemData&quot;:{&quot;DOI&quot;:&quot;10.1080\/01621459.1987.10478410&quot;,&quot;ISSN&quot;:&quot;1537274X&quot;,&quot;abstract&quot;:&quot;We\r\nconsider the problem of setting approximate confidence intervals for a single\r\nparameter \u03b8 in a multiparameter family. The standard approximate intervals\r\nbased on maximum likelihood theory, (Equation presented), can be quite\r\nmisleading. In practice, tricks based on transformations, bias corrections, and\r\nso forth, are often used to improve their accuracy. The bootstrap confidence\r\nintervals discussed in this article automatically incorporate such tricks\r\nwithout requiring the statistician to think them through for each new\r\napplication, at the price of a considerable increase in computational effort.\r\nThe new intervals incorporate an improvement over previously suggested methods,\r\nwhich results in second-order correctness in a wide variety of problems. In\r\naddition to parametric families, bootstrap intervals are also developed for\r\nnonparametric situations. \u00a9 1976 Taylor &amp; Francis Group,\r\nLLC.&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Efron&quot;,&quot;given&quot;:&quot;Bradley&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;Journal\r\nof the American Statistical\r\nAssociation&quot;,&quot;id&quot;:&quot;ITEM-1&quot;,&quot;issue&quot;:&quot;397&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;1987&quot;]]},&quot;page&quot;:&quot;171-185&quot;,&quot;title&quot;:&quot;Better\r\nbootstrap confidence\r\nintervals&quot;,&quot;type&quot;:&quot;article-journal&quot;,&quot;volume&quot;:&quot;82&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=5cf12cd2-0aca-36d7-b1ee-27d288f171f2&quot;]}],&quot;mendeley&quot;:{&quot;formattedCitation&quot;:&quot;&lt;sup&gt;24&lt;\/sup&gt;&quot;,&quot;plainTextFormattedCitation&quot;:&quot;24&quot;,&quot;previouslyFormattedCitation&quot;:&quot;&lt;sup&gt;24&lt;\/sup&gt;&quot;},&quot;properties&quot;:{&quot;noteIndex&quot;:0},&quot;schema&quot;:&quot;https:\/\/github.com\/citation-style-language\/schema\/raw\/master\/csl-citation.json&quot;}<span\r\nstyle='mso-element:field-separator'><\/span><\/span><![endif]--><sup>24<\/sup><!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%;mso-bidi-font-family:Calibri;\r\nmso-bidi-theme-font:minor-latin'><span style='mso-element:field-end'><\/span><\/span><![endif]-->. It should be noted that prevalence estimates in the included studies were not adjusted for age, sex, socioeconomic position, or region within countries.<\/p>\n\n<p>&nbsp;<\/p>\n\n<p><strong>Results<\/strong><\/p>\n\n<p>&nbsp;<\/p>\n\n<p>In the current review version (v5), a total of 636 new records were identified, with 148 studies included in a narrative synthesis and 23 studies included in meta-analyses (see Figure 1).<\/p>\n\n<p>&nbsp;<\/p>\n\n<figure class=\"image\"><img alt=\"\" src=\"https:\/\/qeios-uploads.s3.eu-west-1.amazonaws.com\/editor\/8vOhv67TaPUOGgK4Z9Tu1J7Gh9OMBmltUKeQCXW2.png\" \/>\n<figcaption>\n<p>Figure 1. PRISMA flow diagram of included studies.<\/p>\n<\/figcaption>\n<\/figure>\n\n<p>&nbsp;<\/p>\n\n<p><em>Study characteristics<\/em><\/p>\n\n<p>&nbsp;<\/p>\n\n<p>Characteristics of included studies are presented in Table 1. Forty-three studies were conducted in China, 37 in the US, 15 in the UK, nine in Mexico, nine in Spain, eight in France, six in Italy, five across multiple international sites, two in Israel, and one each from Brazil, Chile, Denmark, Finland, Germany, India, Iran, South Korea, Kuwait, Poland, Portugal, Saudi Arabia, Switzerland and Turkey (see Figure 2). One-hundred-and-five studies were conducted in hospital settings. Thirty-four studies included a community component in addition to hospitalised patients. Seven studies were conducted exclusively in the community, one in a quarantine centre and one did not state the study setting. Studies had a median of 326 (interquartile range = 106-1,122) participants.<\/p>\n\n<p>&nbsp;<\/p>\n\n<figure class=\"image\"><img alt=\"\" height=\"396\" src=\"https:\/\/qeios-uploads.s3.eu-west-1.amazonaws.com\/editor\/YcDJoVHRdoAwAV3ZMtDeRsyobjIaa9hgc3fY3BVE.png\" width=\"654\" \/>\n<figcaption>\n<p>Figure 2. Map of countries where included studies were conducted. Five studies were performed in multiple countries and are hence not included here.<\/p>\n<\/figcaption>\n<\/figure>\n\n<p>&nbsp;<\/p>\n\n<p><em>Smoking status<\/em><\/p>\n\n<p>&nbsp;<\/p>\n\n<p>Categorisation of smoking status was heterogeneous (see Table 1). Ninety-two studies collected data on smoking status through routine electronic health records, 35 studies used a bespoke case report form for COVID-19 and 21 studies did not state the source for information on smoking status. None of the studies verified smoking status biochemically. Notably, only 32 (21.6%) studies reported current, former and never smoking status, with a further 11 studies reporting current\/former and never smoking status. The remaining 105 studies reported current, current\/former or current and former smoking status but did not explicitly state whether remaining participants were never smokers or if data were missing on smoking status. Twenty-six studies explicitly reported the proportion with missing data on smoking status, which ranged from 0.08% to 96.4%.<\/p>\n\n<p>&nbsp;<\/p>\n\n<p><em>Use of alternative nicotine products<\/em><\/p>\n\n<p>&nbsp;<\/p>\n\n<p>Two studies recorded the use of alternative nicotine products in current and\/or former smokers but did not report COVID-19 outcomes stratified by nicotine use<!--[if supportFields]><span style='font-size:11.0pt;\r\nline-height:150%'><span style='mso-element:field-begin;mso-field-lock:yes'><\/span>ADDIN\r\nCSL_CITATION\r\n{&quot;citationItems&quot;:[{&quot;id&quot;:&quot;ITEM-1&quot;,&quot;itemData&quot;:{&quot;DOI&quot;:&quot;10.1101\/2020.06.10.20127514&quot;,&quot;abstract&quot;:&quot;Background:\r\nIdentification of prognostic factors in COVID-19 remains a global challenge.\r\nThe role of smoking is still controversial. Objective: To evaluate the rate of\r\ndaily smokers in patients with COVID-19. Methods: COVID-19 in-and outpatients\r\nfrom a large French university hospital were systematically interviewed for\r\ntheir smoking status, use of e-cigarette and nicotinic substitutes. The rates\r\nof daily smokers in in-and outpatients were compared to those in the 2019\r\nFrench general population, after standardization for sex and age. Results: The\r\ninpatient group was composed of 340 patients, median age 66 years: 203 men\r\n(59.7%) and 137 women (40.3%), median age for both 66 years, with a daily\r\nsmokers rate of 4.1 % CI95% [2.3-6.9] (5.4% of men, 2.2% of women). The\r\noutpatient group was composed of 139 patients, median age 44 years: 62 men\r\n(44.6%, median age 43 years), and 77 women (55.4%, median age 44 years). The\r\ndaily smoker rate was 6.1 % CI 95% [2.7-11.6] (5.1% of men, 6.8% of women). In\r\nthe 2019 French population, the daily smoker rate was 24.0% (27.5% of men,\r\n20.7% of women). Among inpatients, daily smokers represented 2.2% and 3.4% of\r\nthe 45 dead patients and of the 29 patients transferred to ICU, respectively.\r\nThe rate of daily smokers was significantly lower in COVID-19 patients, as\r\ncompared to that in the French general population after standardization by age\r\nand sex, with Standardized Incidence Ratios of 0.24 [0.12-0.48] for outpatients\r\nand 0.24 [0.14-0.40] for inpatients. Conclusion: Daily smokers rate in patients\r\nwith symptomatic COVID-19 is lower as compared to the general\r\npopulation&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Miyara&quot;,&quot;given&quot;:&quot;Makoto&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Tubach&quot;,&quot;given&quot;:&quot;Florence&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Martinez&quot;,&quot;given&quot;:&quot;Valerie&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Morelot-Panzini&quot;,&quot;given&quot;:&quot;Capucine&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Pernet&quot;,&quot;given&quot;:&quot;Julie&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Haroche&quot;,&quot;given&quot;:&quot;Julien&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Lebbah&quot;,&quot;given&quot;:&quot;Said&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Morawiec&quot;,&quot;given&quot;:&quot;Elise&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Gorochov&quot;,&quot;given&quot;:&quot;Guy&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Caumes&quot;,&quot;given&quot;:&quot;Eric&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Hausfater&quot;,&quot;given&quot;:&quot;Pierre&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Combes&quot;,&quot;given&quot;:&quot;Alain&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Similowski&quot;,&quot;given&quot;:&quot;Thomas&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Amoura&quot;,&quot;given&quot;:&quot;Zahir&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;medrxiv&quot;,&quot;id&quot;:&quot;ITEM-1&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2020&quot;,&quot;6&quot;,&quot;12&quot;]]},&quot;page&quot;:&quot;2020.06.10.20127514&quot;,&quot;publisher&quot;:&quot;Cold\r\nSpring Harbor Laboratory Press&quot;,&quot;title&quot;:&quot;Low rate of daily\r\nsmokers in patients with symptomatic\r\nCOVID-19&quot;,&quot;type&quot;:&quot;article-journal&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=3b2b5068-f9f6-3ad9-8056-4b78643363c7&quot;]},{&quot;id&quot;:&quot;ITEM-2&quot;,&quot;itemData&quot;:{&quot;DOI&quot;:&quot;10.1101\/2020.05.13.20100404&quot;,&quot;abstract&quot;:&quot;Limited\r\nevidence is available to guide treatment of coronavirus disease 2019 (COVID-19),\r\ncaused by the novel severe acute respiratory syndrome coronavirus 2\r\n(SARS-CoV-2). A hyperinflammatory state mediated by interleukin-6 (IL-6) has\r\nbeen proposed as a driver of severe disease. Use of the IL-6 receptor inhibitor\r\ntocilizumab for severe COVID-19 was first reported in China, where a case\r\nseries described marked improvements in inflammatory markers, fever, oxygen\r\nrequirement, and outcomes following its administration. Here, we provide the\r\nfirst description of a tocilizumab-treated cohort of patients with COVID-19 in\r\nthe United States. We describe 11 patients from a single academic medical\r\ncenter, nine (82%) of whom were critically ill requiring mechanical ventilation\r\nin an intensive care unit at the time of tocilizumab administration. C-reactive\r\nprotein levels decreased in all patients following treatment (median 211.6 pre-\r\nvs. 19.7 mg\/L 5 days post-tocilizumab [p=0.001]). When IL-6 levels were\r\nobtained before and after therapy, wide variation was seen in baseline levels;\r\npost-dose IL-6 concentrations were consistently increased. In contrast to prior\r\nreports, we did not observe significant clinical improvement in temperature or\r\noxygen requirements in most patients. Two patients were discharged (18%), five\r\nremained in critical condition in the intensive care unit (46%), one was weaned\r\noff the ventilator to room air (9%), and three died (27%). Our findings suggest\r\nthat tocilizumab should be used with caution in severe and critically ill\r\npatients and highlight the need for data from randomized controlled trials to\r\ndetermine its efficacy in the treatment of COVID-19.Competing Interest\r\nStatement JBP reports research support outside the submitted work from Gilead\r\nSciences and the World Health Organization, and non-financial support from\r\nAbbott Laboratories. CLG has received research support outside the submitted\r\nwork from Viiv Healthcare and Gilead Sciences. SSC reports research support\r\noutside of the submitted work from Biomarck Pharmaceuticals.Funding\r\nStatementThe authors report no designated funding for the project. CAR and CEM\r\nreceive training support from the University of North Carolina at Chapel Hill\r\nMedical Scientist Training Program. CAR additionally receives training support\r\nfrom the National Institutes of Health MD\/PhD Partnership Program.Author\r\nDeclarationsAll relevant ethical guidelines have been followed; any necessary\r\nIRB and\/or ethics committee\r\nap\u2026&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Rimland&quot;,&quot;given&quot;:&quot;Casey\r\nAllison&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Morgan&quot;,&quot;given&quot;:&quot;Camille\r\nE&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Bell&quot;,&quot;given&quot;:&quot;Griffin\r\nJ&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Kim&quot;,&quot;given&quot;:&quot;Min\r\nK&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Hedrick&quot;,&quot;given&quot;:&quot;Tanner&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Marx&quot;,&quot;given&quot;:&quot;Ashley&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Bramson&quot;,&quot;given&quot;:&quot;Brian&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Napravnik&quot;,&quot;given&quot;:&quot;Sonia&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Schmitz&quot;,&quot;given&quot;:&quot;John\r\nL&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Carson&quot;,&quot;given&quot;:&quot;Shannon\r\nS&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Fischer&quot;,&quot;given&quot;:&quot;William\r\nA&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Eron&quot;,&quot;given&quot;:&quot;Joseph\r\nJ&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Gay&quot;,&quot;given&quot;:&quot;Cynthia\r\nL&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Parr&quot;,&quot;given&quot;:&quot;Jonathan\r\nB&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;medRxiv&quot;,&quot;id&quot;:&quot;ITEM-2&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2020&quot;,&quot;5&quot;,&quot;19&quot;]]},&quot;page&quot;:&quot;2020.05.13.20100404&quot;,&quot;publisher&quot;:&quot;Cold\r\nSpring Harbor Laboratory Press&quot;,&quot;title&quot;:&quot;Clinical\r\ncharacteristics and early outcomes in patients with COVID-19 treated with\r\ntocilizumab at a United States academic\r\ncenter&quot;,&quot;type&quot;:&quot;article-journal&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=206b722d-673b-38af-ae84-1eb52b2f5501&quot;]}],&quot;mendeley&quot;:{&quot;formattedCitation&quot;:&quot;&lt;sup&gt;25,26&lt;\/sup&gt;&quot;,&quot;plainTextFormattedCitation&quot;:&quot;25,26&quot;,&quot;previouslyFormattedCitation&quot;:&quot;&lt;sup&gt;25,26&lt;\/sup&gt;&quot;},&quot;properties&quot;:{&quot;noteIndex&quot;:0},&quot;schema&quot;:&quot;https:\/\/github.com\/citation-style-language\/schema\/raw\/master\/csl-citation.json&quot;}<span\r\nstyle='mso-element:field-separator'><\/span><\/span><![endif]--><sup>25,26<\/sup>.<\/p>\n\n<p>&nbsp;<\/p>\n\n<p><em>Quality appraisal<\/em><\/p>\n\n<p>&nbsp;<\/p>\n\n<p>Twenty-eight studies were rated as &lsquo;fair&rsquo; quality due to having low levels of missing data and distinguishing between current, former and never smoking status (see Table 1). The remaining 120 studies were rated as &lsquo;poor&rsquo; quality.<\/p>\n\n<p>&nbsp;<\/p>\n\n<figure class=\"image\"><img alt=\"\" src=\"https:\/\/qeios-uploads.s3.eu-west-1.amazonaws.com\/editor\/jLCZuDSyrlenhIUYA5OuZN6RUAb3784T6xuXxt77.png\" \/>\n<figcaption>\n<p>&nbsp;<\/p>\n<\/figcaption>\n<\/figure>\n\n<figure class=\"image\"><img alt=\"\" src=\"https:\/\/qeios-uploads.s3.eu-west-1.amazonaws.com\/editor\/qqydUW2B4Oar2xsLIysat1gDWFDqknClqChLK9Yt.png\" \/>\n<figcaption>\n<p>&nbsp;<\/p>\n<\/figcaption>\n<\/figure>\n\n<figure class=\"image\"><img alt=\"\" src=\"https:\/\/qeios-uploads.s3.eu-west-1.amazonaws.com\/editor\/x3gd2Hbvv0maA3E1wsR6PbFLtt9nspWMnOvVakfb.png\" \/>\n<figcaption>\n<p>&nbsp;<\/p>\n<\/figcaption>\n<\/figure>\n\n<figure class=\"image\"><img alt=\"\" src=\"https:\/\/qeios-uploads.s3.eu-west-1.amazonaws.com\/editor\/R7nKVgMAxfMTOqrI1AZEJQZFZEOvTLPdA38fpzHi.png\" \/>\n<figcaption>\n<p>&nbsp;<\/p>\n<\/figcaption>\n<\/figure>\n\n<figure class=\"image\"><img alt=\"\" src=\"https:\/\/qeios-uploads.s3.eu-west-1.amazonaws.com\/editor\/9Dk1ER8fcMI2cX17rJS7z6yabw9YBkUokh8DQty0.png\" \/>\n<figcaption>\n<p>&nbsp;<\/p>\n<\/figcaption>\n<\/figure>\n\n<figure class=\"image\"><img alt=\"\" src=\"https:\/\/qeios-uploads.s3.eu-west-1.amazonaws.com\/editor\/KP3RbfeLtvx1EK6yZtebHQLyF17DDYJUN8nyusTD.png\" \/>\n<figcaption>\n<p>&nbsp;<\/p>\n<\/figcaption>\n<\/figure>\n\n<figure class=\"image\"><img alt=\"\" src=\"https:\/\/qeios-uploads.s3.eu-west-1.amazonaws.com\/editor\/rCAYt9d9gSXKmNJ6TCJiTQHd9Vm2QxAeNcax6PTD.png\" \/>\n<figcaption>\n<p>&nbsp;<\/p>\n<\/figcaption>\n<\/figure>\n\n<figure class=\"image\"><img alt=\"\" src=\"https:\/\/qeios-uploads.s3.eu-west-1.amazonaws.com\/editor\/4jX7SQZthyeo5tgReT4RJflttwZ7lWodbBe1Qcve.png\" \/>\n<figcaption>\n<p>&nbsp;<\/p>\n<\/figcaption>\n<\/figure>\n\n<figure class=\"image\"><img alt=\"\" src=\"https:\/\/qeios-uploads.s3.eu-west-1.amazonaws.com\/editor\/B8Y9Yncd9qs42i4fpX8LJd44EFYKMOCmW1yrpEKF.png\" \/>\n<figcaption>\n<p>&nbsp;<\/p>\n<\/figcaption>\n<\/figure>\n\n<p><em>Smoking prevalence by country<\/em><\/p>\n\n<p>&nbsp;<\/p>\n\n<p>Unadjusted smoking prevalence compared with overall estimates for national adult smoking prevalence split by country and study setting is presented in Figure 3a and 3b. Lower than expected current and former smoking prevalence was generally observed. Large variability in prevalence estimates was observed across studies conducted in the US.<\/p>\n\n<p>&nbsp;<\/p>\n\n<figure class=\"image\"><img alt=\"\" height=\"380\" src=\"https:\/\/qeios-uploads.s3.eu-west-1.amazonaws.com\/editor\/jR4PPcEyJyGc1x6p180xjJnzzRQv659yH6LsqwTq.png\" width=\"653\" \/>\n<figcaption>\n<p>Figure 3a. Weighted mean prevalence of current smoking in included studies with 95% bootstrap confidence intervals compared with national current smoking prevalence (solid red lines), split by country. Shape corresponds to study setting (community, community and hospital, hospital) and shape size corresponds to relative study sample size.<\/p>\n<\/figcaption>\n<\/figure>\n\n<p>&nbsp;<\/p>\n\n<figure class=\"image\"><img alt=\"\" height=\"379\" src=\"https:\/\/qeios-uploads.s3.eu-west-1.amazonaws.com\/editor\/jzowbJRImaprGAfOMni2WWAqb7bfmZZS6b0TOMB6.png\" width=\"647\" \/>\n<figcaption>\n<p>Figure 3b. Weighted mean prevalence of former smoking in included studies (where this was reported) with 95% bootstrap confidence intervals compared with national former smoking prevalence (solid red lines), split by country. Shape corresponds to study setting (community, community and hospital, hospital) and shape size corresponds to relative study sample size.<\/p>\n<\/figcaption>\n<\/figure>\n\n<p>&nbsp;<\/p>\n\n<p><em>SARS-CoV-2 infection by smoking status<\/em><\/p>\n\n<p>&nbsp;<\/p>\n\n<p>Twenty-five studies provided data on SARS-CoV-2 test results for people meeting local testing criteria by smoking status (see Table 2). Meta-analyses were performed for 12 &lsquo;fair&rsquo; quality studies (see Figure 4 and 5). Current smokers were at reduced risk of testing positive for SARS-CoV-2 compared with never smokers (RR = 0.70, 95% CI = 0.55-0.88, p = .003, I<sup>2<\/sup> = 90%). No significant difference was observed between former and never smokers (RR = 1.02, 95% CI = 0.92-1.12, p = .76, I<sup>2<\/sup> = 72%).<\/p>\n\n<p>&nbsp;<\/p>\n\n<p><em>Table 2<\/em>. SARS-CoV-2 infection by smoking status.<\/p>\n\n<figure class=\"image\"><img alt=\"\" src=\"https:\/\/qeios-uploads.s3.eu-west-1.amazonaws.com\/editor\/HuQMNbCMVtjA2VjM0Oq4SItZnCzcgNDnhH2VZ6uK.png\" \/>\n<figcaption>\n<p>&nbsp;<\/p>\n<\/figcaption>\n<\/figure>\n\n<p><em>&nbsp;<\/em><\/p>\n\n<figure class=\"image\"><img alt=\"\" src=\"https:\/\/qeios-uploads.s3.eu-west-1.amazonaws.com\/editor\/K8TF9uuUUDAk2XPcbgwVXofYpAjJwIPEqt9KNW55.png\" \/>\n<figcaption>\n<p>&nbsp;<\/p>\n<\/figcaption>\n<\/figure>\n\n<figure class=\"image\"><img alt=\"\" height=\"349\" src=\"https:\/\/qeios-uploads.s3.eu-west-1.amazonaws.com\/editor\/vXBXuDbiSImvRBFYiItlOixZAopxfWL4uDTnpaRd.png\" width=\"655\" \/>\n<figcaption>\n<p>Figure 4. Forest plot for risk of testing positive for SARS-CoV-2 in current vs. never smokers.<\/p>\n<\/figcaption>\n<\/figure>\n\n<p>&nbsp;<\/p>\n\n<figure class=\"image\"><img alt=\"\" height=\"357\" src=\"https:\/\/qeios-uploads.s3.eu-west-1.amazonaws.com\/editor\/KNe8bbiGnAPWSQtLJub1dXssx78W7xHNNyq6pDuT.png\" width=\"652\" \/>\n<figcaption>\n<p>Figure 5. Forest plot for risk of testing positive for SARS-CoV-2 in former vs. never smokers.<\/p>\n<\/figcaption>\n<\/figure>\n\n<p>&nbsp;<\/p>\n\n<p><em>Hospitalisation for COVID-19 by smoking status<\/em><\/p>\n\n<p>&nbsp;<\/p>\n\n<p>Twenty-one studies examined hospitalisation for COVID-19 disease stratified by smoking status (see Table 3). Meta-analyses were performed for seven &lsquo;fair&rsquo; quality studies (see Figure 6 and 7). There was no significant difference between current and never (RR = 1.06, 95% CI = 0.79-1.44, p = .63, I<sup>2<\/sup> = 79%) or former and never smokers (RR = 1.20, 95% CI = 0.95-1.51, p = .10, I<sup>2<\/sup> = 79%) in the risk of requiring admission to hospital with COVID-19.<\/p>\n\n<p>&nbsp;<\/p>\n\n<p><em>Table 3.<\/em> Hospitalisation for COVID-19 by smoking status.<\/p>\n\n<figure class=\"image\"><img alt=\"\" src=\"https:\/\/qeios-uploads.s3.eu-west-1.amazonaws.com\/editor\/qbcxovWb5A7GvK3yK7vvhD3ooAnuqQOZ5WZWl9QE.png\" \/>\n<figcaption>\n<p>&nbsp;<\/p>\n<\/figcaption>\n<\/figure>\n\n<figure class=\"image\"><img alt=\"\" src=\"https:\/\/qeios-uploads.s3.eu-west-1.amazonaws.com\/editor\/yaYyF8lvtFSPUDrwuEmpTjBsAhsxdXsxf08TjRoA.png\" \/>\n<figcaption>\n<p>&nbsp;<\/p>\n<\/figcaption>\n<\/figure>\n\n<p>&nbsp;<\/p>\n\n<figure class=\"image\"><img alt=\"\" height=\"209\" src=\"https:\/\/qeios-uploads.s3.eu-west-1.amazonaws.com\/editor\/VTSE0IcPE8FbpiKWKDI4CqJd4kQANkPH0NVSJ4ak.png\" width=\"639\" \/>\n<figcaption>\n<p>Figure 6. Forest plot for risk of hospitalisation in current vs. never smokers.<\/p>\n<\/figcaption>\n<\/figure>\n\n<figure class=\"image\"><img alt=\"\" height=\"212\" src=\"https:\/\/qeios-uploads.s3.eu-west-1.amazonaws.com\/editor\/WpGOy7JlScqcMPp9qthvgEtwxA0XwRrYTReUHuDl.png\" width=\"655\" \/>\n<figcaption>\n<p>Figure 7. Forest plot for risk of hospitalisation in former vs. never smokers.<\/p>\n<\/figcaption>\n<\/figure>\n\n<p>&nbsp;<\/p>\n\n<p><em>Disease severity by smoking status<\/em><\/p>\n\n<p>&nbsp;<\/p>\n\n<p>Forty studies reported disease severity in hospitalised patients stratified by smoking status (see Table 4). Severe (as opposed to non-severe) disease was broadly defined as requiring ITU admission, requiring oxygen as a hospital inpatient or in-hospital death. Meta-analyses were performed for six &lsquo;fair&rsquo; quality studies (see Figure 8 and 9). No significant difference was observed between current and never smokers (RR = 1.22, 95% CI = 0.98-1.53, &nbsp;p = .08, I<sup>2<\/sup> = 22%). Former smokers were at increased risk of greater disease severity compared with never smokers (RR = 1.58, 95% CI = 1.07-2.32, p = .02, I<sup>2<\/sup> = 68%).<\/p>\n\n<p>&nbsp;<\/p>\n\n<p><em>Table 4.<\/em> Disease severity by smoking status.<\/p>\n\n<figure class=\"image\"><img alt=\"\" src=\"https:\/\/qeios-uploads.s3.eu-west-1.amazonaws.com\/editor\/62EMyGUuQ71sld86Yag3hpX9CPLvMoaHU39CqgKx.png\" \/>\n<figcaption>\n<p>&nbsp;<\/p>\n<\/figcaption>\n<\/figure>\n\n<figure class=\"image\"><img alt=\"\" src=\"https:\/\/qeios-uploads.s3.eu-west-1.amazonaws.com\/editor\/C42GQtmlZcUZWKZA5GoVasLNOvJLFDKV5Lb5lIJT.png\" \/>\n<figcaption>\n<p>&nbsp;<\/p>\n<\/figcaption>\n<\/figure>\n\n<figure class=\"image\"><img alt=\"\" src=\"https:\/\/qeios-uploads.s3.eu-west-1.amazonaws.com\/editor\/Ti2tZhi2FRXruMXCXChXEHbdDPS0AGcHmKcRVXk5.png\" \/>\n<figcaption>\n<p>&nbsp;<\/p>\n<\/figcaption>\n<\/figure>\n\n<figure class=\"image\"><img alt=\"\" height=\"231\" src=\"https:\/\/qeios-uploads.s3.eu-west-1.amazonaws.com\/editor\/5aMUaBERffujL2950pxH0QIveK7sOvLEeJa6Mxvn.png\" width=\"645\" \/>\n<figcaption>\n<p>Figure 8. Forest plot for the risk of severe disease in current vs. never smokers.<\/p>\n<\/figcaption>\n<\/figure>\n\n<p>&nbsp;<\/p>\n\n<figure class=\"image\"><img alt=\"\" height=\"212\" src=\"https:\/\/qeios-uploads.s3.eu-west-1.amazonaws.com\/editor\/kPkVGuUpxScmgiDMoI7YeSjPo8ZG7r1Vd6hdlPR8.png\" width=\"642\" \/>\n<figcaption>\n<p>Figure 9. Forest plot for the risk of severe disease in former vs. never smokers.<\/p>\n<\/figcaption>\n<\/figure>\n\n<p>&nbsp;<\/p>\n\n<p><em>Mortality by smoking status<\/em><\/p>\n\n<p>&nbsp;<\/p>\n\n<p>Thirty studies reported mortality from COVID-19 by smoking status (see Table 5), with five &lsquo;fair&rsquo; quality studies included in meta-analyses (see Figure 10 and 11). Current (RR = 1.70, 95% CI = 1.14-2.55, p = .01, I<sup>2<\/sup> = 29%) and former (RR = 2.00, 95% CI = 1.57-2.55, p &lt; .0.001, I<sup>2<\/sup> = 0%) smokers were at increased risk of in-hospital mortality from COVID-19 compared with never smokers.<\/p>\n\n<p>&nbsp;<\/p>\n\n<p><em>Table 5<\/em>. Mortality by smoking status.<\/p>\n\n<figure class=\"image\"><img alt=\"\" src=\"https:\/\/qeios-uploads.s3.eu-west-1.amazonaws.com\/editor\/91E0nfxfs7eiAsFT9mQ476oA9RF2jqXB5bhz6dR8.png\" \/>\n<figcaption>\n<p>&nbsp;<\/p>\n<\/figcaption>\n<\/figure>\n\n<figure class=\"image\"><img alt=\"\" src=\"https:\/\/qeios-uploads.s3.eu-west-1.amazonaws.com\/editor\/UkbDtYuxD1nT1yh3fe4bxdH29VzrciEupRDZs7yj.png\" \/>\n<figcaption>\n<p>&nbsp;<\/p>\n<\/figcaption>\n<\/figure>\n\n<p>&nbsp;<\/p>\n\n<p>&nbsp;<\/p>\n\n<figure class=\"image\"><img alt=\"\" height=\"215\" src=\"https:\/\/qeios-uploads.s3.eu-west-1.amazonaws.com\/editor\/ZEOZEbM2R9PGT6iNGoXeygPjtesnwDPvafyo7eRr.png\" width=\"641\" \/>\n<figcaption>\n<p>Figure 10. Forest plot for the risk of mortality in current vs. never smokers.<\/p>\n<\/figcaption>\n<\/figure>\n\n<p>&nbsp;<\/p>\n\n<figure class=\"image\"><img alt=\"\" height=\"198\" src=\"https:\/\/qeios-uploads.s3.eu-west-1.amazonaws.com\/editor\/rJb7Qz5ooqFrEzGT2dNNI0hmjFsZq1EIzVXEXYgd.png\" width=\"643\" \/>\n<figcaption>\n<p>Figure 11. Forest plot for the risk of mortality in former vs. never smokers.<\/p>\n<\/figcaption>\n<\/figure>\n\n<p>&nbsp;<\/p>\n\n<p><strong>Discussion<\/strong><\/p>\n\n<p>&nbsp;<\/p>\n\n<p>This rapid review of 148 studies found substantial uncertainty arising from the recording of smoking status. Notwithstanding these uncertainties, compared with overall adult national prevalence estimates, recorded current and former smoking rates in most countries were lower than expected. From available data, there was insufficient evidence to conclude that current and\/or former smoking status is associated with hospitalisation. There was some evidence from &lsquo;fair&rsquo; quality studies that the risk of SARS-CoV-2 infection is reduced in current compared with never smokers. Conversely, former compared with never smokers were at increased risk of greater disease severity in those hospitalised for COVID-19. Both current and former smokers had increased risk of in-hospital mortality from COVID-19 compared with never smokers.<\/p>\n\n<p>&nbsp;<\/p>\n\n<p><em>Infection by smoking status<\/em><\/p>\n\n<p>&nbsp;<\/p>\n\n<p>In 12 &lsquo;fair&rsquo; quality studies, evidence suggests that current smokers in the community are less likely to test positive for SARS-CoV-2 compared with never smokers. It should be noted that criteria for accessing testing will vary during the course of the epidemic. It is possible that current and former smokers are more likely to receive a test due to increased prevalence of cough or altered sense of smell or taste<!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-begin;\r\nmso-field-lock:yes'><\/span>ADDIN CSL_CITATION\r\n{&quot;citationItems&quot;:[{&quot;id&quot;:&quot;ITEM-1&quot;,&quot;itemData&quot;:{&quot;DOI&quot;:&quot;10.1101\/2020.05.18.20105288&quot;,&quot;abstract&quot;:&quot;Background:\r\nThe association between current tobacco smoking, the risk of developing\r\nCOVID-19 and the severity of illness is an important information gap. Methods:\r\nUK users of the COVID Symptom Study app provided baseline data including\r\ndemographics, anthropometrics, smoking status and medical conditions, were\r\nasked to log symptoms daily from 24th March 2020 to 23rd April 2020.\r\nParticipants reporting that they did not feel physically normal were taken\r\nthrough a series of questions, including 14 potential COVID-19 symptoms and any\r\nhospital attendance. The main study outcome was the association between current\r\nsmoking and the development of classic symptoms of COVID-19 during the pandemic\r\ndefined as fever, new persistent cough and breathlessness. The number of\r\nconcurrent COVID-19 symptoms was used as a proxy for severity. In addition,\r\nassociation of subcutaneous adipose tissue expression of ACE2, both the\r\nreceptor for SARS-CoV-2 and a potential mediator of disease severity, with\r\nsmoking status was assessed in a subset of 541 twins from the TwinsUK cohort.\r\nResults: Data were available on 2,401,982 participants, mean(SD) age 43.6(15.1)\r\nyears, 63.3% female, overall smoking prevalence 11.0%. 834,437 (35%)\r\nparticipants reported being unwell and entered one or more symptoms. Current\r\nsmokers were more likely to develop symptoms suggesting a diagnosis of\r\nCOVID-19; classic symptoms adjusted OR[95%CI] 1.14[1.10 to 1.18]; &gt;5\r\nsymptoms 1.29[1.26 to 1.31]; &gt;10 symptoms 1.50[1.42 to 1.58]. Smoking was\r\nassociated with reduced ACE2 expression in adipose tissue (Beta(SE)=\r\n-0.395(0.149); p=7.01x10-3). Interpretation: These data are consistent with\r\nsmokers having an increased risk from\r\nCOVID-19.&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Hopkinson&quot;,&quot;given&quot;:&quot;Nicholas\r\nS&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Rossi&quot;,&quot;given&quot;:&quot;Niccol\u00f2\r\nNiccolo&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Moustafa&quot;,&quot;given&quot;:&quot;Julia\r\nEl-Sayed S El-sayed&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Laverty&quot;,&quot;given&quot;:&quot;Anthony\r\nA&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Quint&quot;,&quot;given&quot;:&quot;Jennifer\r\nK&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Freydin&quot;,&quot;given&quot;:&quot;Maxim\r\nB&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Visconti&quot;,&quot;given&quot;:&quot;Alessia&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Murray&quot;,&quot;given&quot;:&quot;Benjamin&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Modat&quot;,&quot;given&quot;:&quot;Marc&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Ourselin&quot;,&quot;given&quot;:&quot;Sebastien&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Small&quot;,&quot;given&quot;:&quot;Kerrin&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Davies&quot;,&quot;given&quot;:&quot;Richard&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Wolf&quot;,&quot;given&quot;:&quot;Jonathan&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Spector&quot;,&quot;given&quot;:&quot;Timothy\r\nD&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Steves&quot;,&quot;given&quot;:&quot;Claire\r\nJ&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Falchi&quot;,&quot;given&quot;:&quot;Mario&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Freidin&quot;,&quot;given&quot;:&quot;Maxim\r\nB&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Visconti&quot;,&quot;given&quot;:&quot;Alessia&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Murray&quot;,&quot;given&quot;:&quot;Benjamin&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Modat&quot;,&quot;given&quot;:&quot;Marc&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Ourselin&quot;,&quot;given&quot;:&quot;Sebastien&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Small&quot;,&quot;given&quot;:&quot;Kerrin&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Davies&quot;,&quot;given&quot;:&quot;Richard&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Wolf&quot;,&quot;given&quot;:&quot;Jonathan&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Spector&quot;,&quot;given&quot;:&quot;Timothy\r\nD&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Steves&quot;,&quot;given&quot;:&quot;J&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Falchi&quot;,&quot;given&quot;:&quot;Mario&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;medrxiv&quot;,&quot;id&quot;:&quot;ITEM-1&quot;,&quot;issue&quot;:&quot;0&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2020&quot;,&quot;5&quot;,&quot;21&quot;]]},&quot;page&quot;:&quot;2020.05.18.20105288&quot;,&quot;publisher&quot;:&quot;Cold\r\nSpring Harbor Laboratory Press&quot;,&quot;title&quot;:&quot;Current tobacco\r\nsmoking and risk from COVID-19 results from a population symptom app in over\r\n2.4 million\r\npeople&quot;,&quot;type&quot;:&quot;article-journal&quot;,&quot;volume&quot;:&quot;44&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=ec8abcf5-2732-4d9f-8c1b-9119301719fb&quot;]}],&quot;mendeley&quot;:{&quot;formattedCitation&quot;:&quot;&lt;sup&gt;172&lt;\/sup&gt;&quot;,&quot;plainTextFormattedCitation&quot;:&quot;172&quot;,&quot;previouslyFormattedCitation&quot;:&quot;&lt;sup&gt;172&lt;\/sup&gt;&quot;},&quot;properties&quot;:{&quot;noteIndex&quot;:0},&quot;schema&quot;:&quot;https:\/\/github.com\/citation-style-language\/schema\/raw\/master\/csl-citation.json&quot;}<span\r\nstyle='mso-element:field-separator'><\/span><\/span><![endif]--><sup>172<\/sup><!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-end'><\/span><\/span><![endif]-->, which are used as screening criteria. Infection positivity rates estimated among random samples will be more informative than currently available data. Smoking status is being collected in at least two large representative infection and antibody surveys in the UK<!--[if supportFields]><span style='font-size:11.0pt;\r\nline-height:150%'><span style='mso-element:field-begin;mso-field-lock:yes'><\/span>ADDIN\r\nCSL_CITATION {&quot;citationItems&quot;:[{&quot;id&quot;:&quot;ITEM-1&quot;,&quot;itemData&quot;:{&quot;URL&quot;:&quot;https:\/\/www.gov.uk\/government\/news\/major-home-testing-programme-for-coronavirus-will-track-levels-of-infection-in-the-community&quot;,&quot;accessed&quot;:{&quot;date-parts&quot;:[[&quot;2020&quot;,&quot;5&quot;,&quot;22&quot;]]},&quot;id&quot;:&quot;ITEM-1&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;0&quot;]]},&quot;title&quot;:&quot;Major\r\nhome testing programme for coronavirus will track levels of infection in the\r\ncommunity -\r\nGOV.UK&quot;,&quot;type&quot;:&quot;webpage&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=2d446ad9-dbe2-324c-92ee-d8b02bb11439&quot;]},{&quot;id&quot;:&quot;ITEM-2&quot;,&quot;itemData&quot;:{&quot;URL&quot;:&quot;https:\/\/www.ons.gov.uk\/surveys\/informationforhouseholdsandindividuals\/householdandindividualsurveys\/covid19infectionsurveycis&quot;,&quot;accessed&quot;:{&quot;date-parts&quot;:[[&quot;2020&quot;,&quot;6&quot;,&quot;30&quot;]]},&quot;id&quot;:&quot;ITEM-2&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;0&quot;]]},&quot;title&quot;:&quot;COVID-19\r\nInfection Survey (CIS) - Office for National\r\nStatistics&quot;,&quot;type&quot;:&quot;webpage&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=484b79b0-3a1f-3a77-891d-5c83e6d873b0&quot;]}],&quot;mendeley&quot;:{&quot;formattedCitation&quot;:&quot;&lt;sup&gt;173,174&lt;\/sup&gt;&quot;,&quot;plainTextFormattedCitation&quot;:&quot;173,174&quot;,&quot;previouslyFormattedCitation&quot;:&quot;&lt;sup&gt;173&lt;\/sup&gt;&quot;},&quot;properties&quot;:{&quot;noteIndex&quot;:0},&quot;schema&quot;:&quot;https:\/\/github.com\/citation-style-language\/schema\/raw\/master\/csl-citation.json&quot;}<span\r\nstyle='mso-element:field-separator'><\/span><\/span><![endif]--><sup>173,174<\/sup><!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-end'><\/span><\/span><![endif]-->.<\/p>\n\n<p>&nbsp;<\/p>\n\n<p><em>Hospitalisation and disease severity by smoking status<\/em><\/p>\n\n<p>&nbsp;<\/p>\n\n<p>As reported elsewhere<!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-begin;\r\nmso-field-lock:yes'><\/span>ADDIN CSL_CITATION\r\n{&quot;citationItems&quot;:[{&quot;id&quot;:&quot;ITEM-1&quot;,&quot;itemData&quot;:{&quot;DOI&quot;:&quot;10.1177\/2040622320935765&quot;,&quot;ISSN&quot;:&quot;2040-6223&quot;,&quot;abstract&quot;:&quot;Background:\r\nThe purpose of this study was to examine the prevalence and effects of current\r\nsmoking on adverse outcomes among hospitalized COVID-19 patients. Methods: A\r\nsystematic review of the literature (PubMed) identified 18 (from a total of\r\n1398) relevant studies. Pooled current smoking prevalence was compared with the\r\ngender-adjusted and gender and age-adjusted, population-based expected\r\nprevalence by calculating prevalence odds ratio (POR). The association between\r\ncurrent, compared with non-current and former, smoking and adverse outcome was\r\nexamined. A secondary analysis was performed by including 12 pre-publications\r\n(30 studies in total). All analyses were performed using random-effects\r\nmeta-analysis. Results: Among 6515 patients, the pooled prevalence of current\r\nsmoking was 6.8% [95% confidence interval (CI): 4.8\u20139.1%]. The gender-adjusted\r\nPOR was 0.20 (95% CI: 0.16\u20130.25, p &lt; 0.001), and the gender and age-adjusted\r\nPOR was 0.24 (95% CI: 0.19\u20130.30, p &lt; 0.001). Current smokers were more\r\nlikely to have an adverse outcome compared with non-current smokers [odds ratio\r\n(OR): 1.53, 95%CI: 1.06\u20132.20, p = 0.022] but less likely compared with former\r\nsmokers (OR: 0.42, 95% CI: 0.27\u20130.74, p = 0.003). When pre-publications were\r\nadded (n = 10,631), the gender-adjusted POR was 0.27 (95% CI: 0.19\u20130.38, p &lt;\r\n0.001) and the gender and age-adjusted POR was 0.34 (95% CI: 0.24\u20130.48, p &lt;\r\n0.001). Conclusion: This meta-analysis of retrospective observational case\r\nseries found an unexpectedly low prevalence of current smoking among\r\nhospitalized patients with COVID-19. Hospitalized current smokers had higher\r\nodds compared with non-current smokers but lower odds compared with former\r\nsmokers for an adverse outcome. Smoking cannot be considered a protective\r\nmeasure for COVID-19. However, the hypothesis that nicotine may have a\r\nprotective effect in COVID-19 that is partially masked by smoking-related\r\ntoxicity and by the abrupt cessation of nicotine intake when smokers are\r\nhospitalized should be explored in laboratory studies and clinical trials using\r\npharmaceutical nicotine\r\nproducts.&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Farsalinos&quot;,&quot;given&quot;:&quot;Konstantinos&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Barbouni&quot;,&quot;given&quot;:&quot;Anastasia&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Poulas&quot;,&quot;given&quot;:&quot;Konstantinos&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Polosa&quot;,&quot;given&quot;:&quot;Riccardo&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Caponnetto&quot;,&quot;given&quot;:&quot;Pasquale&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Niaura&quot;,&quot;given&quot;:&quot;Raymond&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;Therapeutic\r\nAdvances in Chronic\r\nDisease&quot;,&quot;id&quot;:&quot;ITEM-1&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2020&quot;,&quot;1&quot;,&quot;25&quot;]]},&quot;page&quot;:&quot;204062232093576&quot;,&quot;publisher&quot;:&quot;SAGE\r\nPublications Ltd&quot;,&quot;title&quot;:&quot;Current smoking, former smoking,\r\nand adverse outcome among hospitalized COVID-19 patients: a systematic review\r\nand meta-analysis&quot;,&quot;type&quot;:&quot;article-journal&quot;,&quot;volume&quot;:&quot;11&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=c7469e8f-b761-318a-9b73-9e83aedf196e&quot;]}],&quot;mendeley&quot;:{&quot;formattedCitation&quot;:&quot;&lt;sup&gt;175&lt;\/sup&gt;&quot;,&quot;plainTextFormattedCitation&quot;:&quot;175&quot;,&quot;previouslyFormattedCitation&quot;:&quot;&lt;sup&gt;174&lt;\/sup&gt;&quot;},&quot;properties&quot;:{&quot;noteIndex&quot;:0},&quot;schema&quot;:&quot;https:\/\/github.com\/citation-style-language\/schema\/raw\/master\/csl-citation.json&quot;}<span\r\nstyle='mso-element:field-separator'><\/span><\/span><![endif]--><sup>175<\/sup><!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-end'><\/span><\/span><![endif]-->, smoking prevalence among multiple hospital and community cohorts was consistently lower than national estimates. In a single study conducted in Korea and 15 studies of varying quality conducted in the UK, however, current and former smoking rates were more similar to expected national estimates.<\/p>\n\n<p>&nbsp;<\/p>\n\n<p>In seven &lsquo;fair&rsquo; quality studies across four countries, there was no evidence that current or former smokers are at lower risk of hospitalisation for COVID-19 compared with never smokers among those testing positive in the community. There was some evidence from six &lsquo;fair&rsquo; quality studies that former (but insufficient evidence that current) smokers are at increased risk of greater disease severity compared with never smokers.<\/p>\n\n<p>&nbsp;<\/p>\n\n<p><em>Mortality by smoking status<\/em><\/p>\n\n<p>&nbsp;<\/p>\n\n<p>In five &lsquo;fair&rsquo; quality studies, there was some evidence that current and former smokers are at increased risk of in-hospital mortality from COVID-19 compared with never smokers. It should, however, be noted that given lack of knowledge of the disease progression and long-term outcomes of COVID-19 disease, it is unclear whether studies conducted thus far in the pandemic have monitored patients for a sufficient time period to report complete survival outcomes or whether they are subject to early censoring.<\/p>\n\n<p>&nbsp;<\/p>\n\n<p><em>Issues complicating interpretation<\/em><\/p>\n\n<p>&nbsp;<\/p>\n\n<p>Interpretation of results from studies conducted during the first phase of the SARS-CoV-2 pandemic is complicated by several factors (see Figure 11). First, exposure to SARS-CoV-2 is heterogeneous with different subgroups at heightened risk of infection at different stages of the pandemic. This will likely introduce bias in studies assessing the rate of infection by smoking status conducted early on. Second, as mentioned above, current and former smokers may be more likely to meet local criteria for community testing due to increased prevalence of symptoms consistent with SARS-CoV-2 infection, such as cough, increased sputum production or altered sense of smell or taste<!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-begin;\r\nmso-field-lock:yes'><\/span>ADDIN CSL_CITATION\r\n{&quot;citationItems&quot;:[{&quot;id&quot;:&quot;ITEM-1&quot;,&quot;itemData&quot;:{&quot;DOI&quot;:&quot;10.1101\/2020.05.18.20105288&quot;,&quot;abstract&quot;:&quot;Background:\r\nThe association between current tobacco smoking, the risk of developing\r\nCOVID-19 and the severity of illness is an important information gap. Methods:\r\nUK users of the COVID Symptom Study app provided baseline data including\r\ndemographics, anthropometrics, smoking status and medical conditions, were\r\nasked to log symptoms daily from 24th March 2020 to 23rd April 2020.\r\nParticipants reporting that they did not feel physically normal were taken\r\nthrough a series of questions, including 14 potential COVID-19 symptoms and any\r\nhospital attendance. The main study outcome was the association between current\r\nsmoking and the development of classic symptoms of COVID-19 during the pandemic\r\ndefined as fever, new persistent cough and breathlessness. The number of\r\nconcurrent COVID-19 symptoms was used as a proxy for severity. In addition, association\r\nof subcutaneous adipose tissue expression of ACE2, both the receptor for\r\nSARS-CoV-2 and a potential mediator of disease severity, with smoking status\r\nwas assessed in a subset of 541 twins from the TwinsUK cohort. Results: Data\r\nwere available on 2,401,982 participants, mean(SD) age 43.6(15.1) years, 63.3%\r\nfemale, overall smoking prevalence 11.0%. 834,437 (35%) participants reported\r\nbeing unwell and entered one or more symptoms. Current smokers were more likely\r\nto develop symptoms suggesting a diagnosis of COVID-19; classic symptoms\r\nadjusted OR[95%CI] 1.14[1.10 to 1.18]; &gt;5 symptoms 1.29[1.26 to 1.31];\r\n&gt;10 symptoms 1.50[1.42 to 1.58]. Smoking was associated with reduced ACE2\r\nexpression in adipose tissue (Beta(SE)= -0.395(0.149); p=7.01x10-3). Interpretation:\r\nThese data are consistent with smokers having an increased risk from\r\nCOVID-19.&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Hopkinson&quot;,&quot;given&quot;:&quot;Nicholas\r\nS&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Rossi&quot;,&quot;given&quot;:&quot;Niccol\u00f2\r\nNiccolo&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Moustafa&quot;,&quot;given&quot;:&quot;Julia\r\nEl-Sayed S\r\nEl-sayed&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Laverty&quot;,&quot;given&quot;:&quot;Anthony\r\nA&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Quint&quot;,&quot;given&quot;:&quot;Jennifer\r\nK&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Freydin&quot;,&quot;given&quot;:&quot;Maxim\r\nB&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Visconti&quot;,&quot;given&quot;:&quot;Alessia&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Murray&quot;,&quot;given&quot;:&quot;Benjamin&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Modat&quot;,&quot;given&quot;:&quot;Marc&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Ourselin&quot;,&quot;given&quot;:&quot;Sebastien&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Small&quot;,&quot;given&quot;:&quot;Kerrin&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Davies&quot;,&quot;given&quot;:&quot;Richard&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Wolf&quot;,&quot;given&quot;:&quot;Jonathan&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Spector&quot;,&quot;given&quot;:&quot;Timothy\r\nD&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Steves&quot;,&quot;given&quot;:&quot;Claire\r\nJ&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Falchi&quot;,&quot;given&quot;:&quot;Mario&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Freidin&quot;,&quot;given&quot;:&quot;Maxim\r\nB&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Visconti&quot;,&quot;given&quot;:&quot;Alessia&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Murray&quot;,&quot;given&quot;:&quot;Benjamin&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Modat&quot;,&quot;given&quot;:&quot;Marc&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Ourselin&quot;,&quot;given&quot;:&quot;Sebastien&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Small&quot;,&quot;given&quot;:&quot;Kerrin&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Davies&quot;,&quot;given&quot;:&quot;Richard&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Wolf&quot;,&quot;given&quot;:&quot;Jonathan&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Spector&quot;,&quot;given&quot;:&quot;Timothy\r\nD&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Steves&quot;,&quot;given&quot;:&quot;J&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Falchi&quot;,&quot;given&quot;:&quot;Mario&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;medrxiv&quot;,&quot;id&quot;:&quot;ITEM-1&quot;,&quot;issue&quot;:&quot;0&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2020&quot;,&quot;5&quot;,&quot;21&quot;]]},&quot;page&quot;:&quot;2020.05.18.20105288&quot;,&quot;publisher&quot;:&quot;Cold\r\nSpring Harbor Laboratory Press&quot;,&quot;title&quot;:&quot;Current tobacco\r\nsmoking and risk from COVID-19 results from a population symptom app in over\r\n2.4 million\r\npeople&quot;,&quot;type&quot;:&quot;article-journal&quot;,&quot;volume&quot;:&quot;44&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=ec8abcf5-2732-4d9f-8c1b-9119301719fb&quot;]}],&quot;mendeley&quot;:{&quot;formattedCitation&quot;:&quot;&lt;sup&gt;172&lt;\/sup&gt;&quot;,&quot;plainTextFormattedCitation&quot;:&quot;172&quot;,&quot;previouslyFormattedCitation&quot;:&quot;&lt;sup&gt;172&lt;\/sup&gt;&quot;},&quot;properties&quot;:{&quot;noteIndex&quot;:0},&quot;schema&quot;:&quot;https:\/\/github.com\/citation-style-language\/schema\/raw\/master\/csl-citation.json&quot;}<span\r\nstyle='mso-element:field-separator'><\/span><\/span><![endif]--><sup>172<\/sup><!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-end'><\/span><\/span><![endif]-->. Third, testing for acute infection requires swabbing of the mucosal epithelium, which may be disrupted in current smokers, potentially altering the sensitivity of assays<!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-begin;\r\nmso-field-lock:yes'><\/span>ADDIN CSL_CITATION\r\n{&quot;citationItems&quot;:[{&quot;id&quot;:&quot;ITEM-1&quot;,&quot;itemData&quot;:{&quot;DOI&quot;:&quot;10.1016\/S1473-3099(20)30371-6&quot;,&quot;ISSN&quot;:&quot;14733099&quot;,&quot;abstract&quot;:&quot;Summary\r\nBackground There are few primary care studies of the COVID-19 pandemic. We\r\naimed to identify demographic and clinical risk factors for testing positive\r\nfor severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) within the\r\nOxford Royal College of General Practitioners (RCGP) Research and Surveillance\r\nCentre primary care network. Methods We analysed routinely collected,\r\npseudonymised data for patients in the RCGP Research and Surveillance Centre\r\nprimary care sentinel network who were tested for SARS-CoV-2 between Jan 28 and\r\nApril 4, 2020. We used multivariable logistic regression models with multiple\r\nimputation to identify risk factors for positive SARS-CoV-2 tests within this\r\nsurveillance network. Findings We identified 3802 SARS-CoV-2 test results, of\r\nwhich 587 were positive. In multivariable analysis, male sex was independently\r\nassociated with testing positive for SARS-CoV-2 (296 [18\u00b74%] of 1612 men vs 291\r\n[13\u00b73%] of 2190 women; adjusted odds ratio [OR] 1\u00b755, 95% CI 1\u00b727\u20131\u00b789). Adults\r\nwere at increased risk of testing positive for SARS-CoV-2 compared with\r\nchildren, and people aged 40\u201364 years were at greatest risk in the\r\nmultivariable model (243 [18\u00b75%] of 1316 adults aged 40\u201364 years vs 23 [4\u00b76%]\r\nof 499 children; adjusted OR 5\u00b736, 95% CI 3\u00b728\u20138\u00b776). Compared with white\r\npeople, the adjusted odds of a positive test were greater in black people (388\r\n[15\u00b75%] of 2497 white people vs 36 [62\u00b71%] of 58 black people; adjusted OR\r\n4\u00b775, 95% CI 2\u00b765\u20138\u00b751). People living in urban areas versus rural areas (476\r\n[26\u00b72%] of 1816 in urban areas vs 111 [5\u00b76%] of 1986 in rural areas; adjusted\r\nOR 4\u00b759, 95% CI 3\u00b757\u20135\u00b790) and in more deprived areas (197 [29\u00b75%] of 668 in\r\nmost deprived vs 143 [7\u00b77%] of 1855 in least deprived; adjusted OR 2\u00b703, 95% CI\r\n1\u00b751\u20132\u00b771) were more likely to test positive. People with chronic kidney\r\ndisease were more likely to test positive in the adjusted analysis (68 [32\u00b79%]\r\nof 207 with chronic kidney disease vs 519 [14\u00b74%] of 3595 without; adjusted OR\r\n1\u00b791, 95% CI 1\u00b731\u20132\u00b778), but there was no significant association with other\r\nchronic conditions in that analysis. We found increased odds of a positive test\r\namong people who are obese (142 [20\u00b79%] of 680 people with obesity vs 171\r\n[13\u00b72%] of 1296 normal-weight people; adjusted OR 1\u00b741, 95% CI 1\u00b704\u20131\u00b791).\r\nNotably, active smoking was linked with decreased odds of a positive test\r\nresult (47 [11\u00b74%] of 413 active smokers vs 201 [17\u00b79%] of 1125 non-smokers;\r\nadjusted OR 0\u00b749, 95% CI\r\n0\u00b734\u20130\u00b771).\u2026&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Lusignan&quot;,&quot;given&quot;:&quot;Simon&quot;,&quot;non-dropping-particle&quot;:&quot;de&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Dorward&quot;,&quot;given&quot;:&quot;Jienchi&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Correa&quot;,&quot;given&quot;:&quot;Ana&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Jones&quot;,&quot;given&quot;:&quot;Nicholas&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Akinyemi&quot;,&quot;given&quot;:&quot;Oluwafunmi&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Amirthalingam&quot;,&quot;given&quot;:&quot;Gayatri&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Andrews&quot;,&quot;given&quot;:&quot;Nick&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Byford&quot;,&quot;given&quot;:&quot;Rachel&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Dabrera&quot;,&quot;given&quot;:&quot;Gavin&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Elliot&quot;,&quot;given&quot;:&quot;Alex&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Ellis&quot;,&quot;given&quot;:&quot;Joanna&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Ferreira&quot;,&quot;given&quot;:&quot;Filipa&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Lopez\r\nBernal&quot;,&quot;given&quot;:&quot;Jamie&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Okusi&quot;,&quot;given&quot;:&quot;Cecilia&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Ramsay&quot;,&quot;given&quot;:&quot;Mary&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Sherlock&quot;,&quot;given&quot;:&quot;Julian&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Smith&quot;,&quot;given&quot;:&quot;Gillian&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Williams&quot;,&quot;given&quot;:&quot;John&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Howsam&quot;,&quot;given&quot;:&quot;Gary&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Zambon&quot;,&quot;given&quot;:&quot;Maria&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Joy&quot;,&quot;given&quot;:&quot;Mark&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Hobbs&quot;,&quot;given&quot;:&quot;F\r\nD Richard&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;The\r\nLancet Infectious\r\nDiseases&quot;,&quot;id&quot;:&quot;ITEM-1&quot;,&quot;issue&quot;:&quot;0&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2020&quot;,&quot;5&quot;]]},&quot;publisher&quot;:&quot;Elsevier&quot;,&quot;title&quot;:&quot;Risk\r\nfactors for SARS-CoV-2 among patients in the Oxford Royal College of General\r\nPractitioners Research and Surveillance Centre primary care network: a\r\ncross-sectional\r\nstudy&quot;,&quot;type&quot;:&quot;article-journal&quot;,&quot;volume&quot;:&quot;0&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=5b6ff295-7413-350a-979d-405ad2e40afb&quot;]}],&quot;mendeley&quot;:{&quot;formattedCitation&quot;:&quot;&lt;sup&gt;88&lt;\/sup&gt;&quot;,&quot;plainTextFormattedCitation&quot;:&quot;88&quot;,&quot;previouslyFormattedCitation&quot;:&quot;&lt;sup&gt;88&lt;\/sup&gt;&quot;},&quot;properties&quot;:{&quot;noteIndex&quot;:0},&quot;schema&quot;:&quot;https:\/\/github.com\/citation-style-language\/schema\/raw\/master\/csl-citation.json&quot;}<span\r\nstyle='mso-element:field-separator'><\/span><\/span><![endif]--><sup>88<\/sup><!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-end'><\/span><\/span><![endif]-->.<\/p>\n\n<p>&nbsp;<\/p>\n\n<p>Fourth, most included studies relied on electronic health records (EHRs) as the source of information on smoking status. Research shows large discrepancies between EHRs and actual behaviour<!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-begin;\r\nmso-field-lock:yes'><\/span>ADDIN CSL_CITATION\r\n{&quot;citationItems&quot;:[{&quot;id&quot;:&quot;ITEM-1&quot;,&quot;itemData&quot;:{&quot;ISSN&quot;:&quot;1942597X&quot;,&quot;abstract&quot;:&quot;Smoking\r\nis the leading cause of preventable death in the United States. Obtaining\r\npatients' smoking status is the first step in delivering smoking cessation\r\ncounseling. In this study, we assessed the quality of smoking status captured\r\nin an electronic health record from a large academic medical center. We\r\nanalyzed data from structured notes, finding that smoking status was documented\r\nin 98% of 64,451 hospital encounters in 2016. 32% hospital encounters had\r\ndiscrepant documentation, and 54.5% of patients had implausible changes (e.g.,\r\nchanges from \\&quot;current smoker\\&quot; to \\&quot;never smoker\\&quot;).\r\nOverall, only 2.9% of patients were documented as active smokers, but 36.4%\r\nwere documented as \\&quot;unknown\\&quot; or had discrepancies in their smoking\r\nstatus. These results suggest that patients that smoke are not appropriately\r\nidentified. Centralized documentation with clinically actionable smoking status\r\ncategories and implementation of patient-facing tools that allow patients to\r\ndirectly record their information could improve data quality of smoking\r\nstatus.&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Polubriaginof&quot;,&quot;given&quot;:&quot;Fernanda&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Salmasian&quot;,&quot;given&quot;:&quot;Hojjat&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Albert&quot;,&quot;given&quot;:&quot;David\r\nA.&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Vawdrey&quot;,&quot;given&quot;:&quot;David\r\nK.&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;AMIA\r\n... Annual Symposium proceedings. AMIA\r\nSymposium&quot;,&quot;id&quot;:&quot;ITEM-1&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2017&quot;]]},&quot;page&quot;:&quot;1392-1400&quot;,&quot;title&quot;:&quot;Challenges\r\nwith Collecting Smoking Status in Electronic Health Records&quot;,&quot;type&quot;:&quot;article-journal&quot;,&quot;volume&quot;:&quot;2017&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=b1080b3d-e227-45a0-8e15-8c1c10e50039&quot;]}],&quot;mendeley&quot;:{&quot;formattedCitation&quot;:&quot;&lt;sup&gt;176&lt;\/sup&gt;&quot;,&quot;plainTextFormattedCitation&quot;:&quot;176&quot;,&quot;previouslyFormattedCitation&quot;:&quot;&lt;sup&gt;175&lt;\/sup&gt;&quot;},&quot;properties&quot;:{&quot;noteIndex&quot;:0},&quot;schema&quot;:&quot;https:\/\/github.com\/citation-style-language\/schema\/raw\/master\/csl-citation.json&quot;}<span\r\nstyle='mso-element:field-separator'><\/span><\/span><![endif]--><sup>176<\/sup><!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-end'><\/span><\/span><![endif]-->. Known failings of EHRs include implausible longitudinal changes, such as former smokers being recorded as never smokers at subsequent hospital visits<!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-begin;\r\nmso-field-lock:yes'><\/span>ADDIN CSL_CITATION\r\n{&quot;citationItems&quot;:[{&quot;id&quot;:&quot;ITEM-1&quot;,&quot;itemData&quot;:{&quot;ISSN&quot;:&quot;1942597X&quot;,&quot;abstract&quot;:&quot;Smoking\r\nis the leading cause of preventable death in the United States. Obtaining patients'\r\nsmoking status is the first step in delivering smoking cessation counseling. In\r\nthis study, we assessed the quality of smoking status captured in an electronic\r\nhealth record from a large academic medical center. We analyzed data from\r\nstructured notes, finding that smoking status was documented in 98% of 64,451\r\nhospital encounters in 2016. 32% hospital encounters had discrepant\r\ndocumentation, and 54.5% of patients had implausible changes (e.g., changes\r\nfrom \\&quot;current smoker\\&quot; to \\&quot;never smoker\\&quot;). Overall, only\r\n2.9% of patients were documented as active smokers, but 36.4% were documented\r\nas \\&quot;unknown\\&quot; or had discrepancies in their smoking status. These\r\nresults suggest that patients that smoke are not appropriately identified.\r\nCentralized documentation with clinically actionable smoking status categories\r\nand implementation of patient-facing tools that allow patients to directly\r\nrecord their information could improve data quality of smoking\r\nstatus.&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Polubriaginof&quot;,&quot;given&quot;:&quot;Fernanda&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Salmasian&quot;,&quot;given&quot;:&quot;Hojjat&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Albert&quot;,&quot;given&quot;:&quot;David\r\nA.&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Vawdrey&quot;,&quot;given&quot;:&quot;David\r\nK.&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;AMIA\r\n... Annual Symposium proceedings. AMIA\r\nSymposium&quot;,&quot;id&quot;:&quot;ITEM-1&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2017&quot;]]},&quot;page&quot;:&quot;1392-1400&quot;,&quot;title&quot;:&quot;Challenges\r\nwith Collecting Smoking Status in Electronic Health\r\nRecords&quot;,&quot;type&quot;:&quot;article-journal&quot;,&quot;volume&quot;:&quot;2017&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=b1080b3d-e227-45a0-8e15-8c1c10e50039&quot;]}],&quot;mendeley&quot;:{&quot;formattedCitation&quot;:&quot;&lt;sup&gt;176&lt;\/sup&gt;&quot;,&quot;plainTextFormattedCitation&quot;:&quot;176&quot;,&quot;previouslyFormattedCitation&quot;:&quot;&lt;sup&gt;175&lt;\/sup&gt;&quot;},&quot;properties&quot;:{&quot;noteIndex&quot;:0},&quot;schema&quot;:&quot;https:\/\/github.com\/citation-style-language\/schema\/raw\/master\/csl-citation.json&quot;}<span\r\nstyle='mso-element:field-separator'><\/span><\/span><![endif]--><sup>176<\/sup><!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-end'><\/span><\/span><![endif]-->. Misreporting on the part of the patient (perhaps due to perceived stigmatisation) has also been observed, with biochemical measures showing higher rates of smoking compared with self-report in hospitalised patients in the US<!--[if supportFields]><sup><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-begin;\r\nmso-field-lock:yes'><\/span>ADDIN CSL_CITATION\r\n{&quot;citationItems&quot;:[{&quot;id&quot;:&quot;ITEM-1&quot;,&quot;itemData&quot;:{&quot;DOI&quot;:&quot;10.1093\/aje\/kwp215&quot;,&quot;ISSN&quot;:&quot;00029262&quot;,&quot;abstract&quot;:&quot;Cotinine,\r\na metabolite of nicotine, has been used to study tobacco smoke exposure in\r\npopulation studies, but the authors are unaware of its use to screen\r\nhospitalized patients. The authors measured serum cotinine levels in 948\r\npatients admitted to an urban public hospital in San Francisco, California,\r\nbetween September 2005 and July 2006. On the basis of cotinine levels, they\r\nclassified patients as active smokers (cotinine \u2265 14 ng\/mL), recent smokers or\r\nsignificantly exposed to secondhand smoke (SHS) (0.5-13.9 ng\/mL), lightly\r\nexposed to SHS (0.05-0.49 ng\/mL), or unexposed (&lt;0.05 ng\/mL). In contrast to\r\nthe 13% prevalence of smoking in the general population of San Francisco, 40%\r\nof patients were active smokers; 15% were recent smokers or heavily exposed to\r\nSHS; 25% had low-level exposure to SHS; and 20% were unexposed. Active smoking\r\nor heavy SHS exposure was particularly high among African Americans (77%), the\r\nuninsured (65%), self-reported alcohol drinkers (77%), and illicit drug users\r\n(90%). Of people who denied smoking, 32% were found to have had significant\r\nexposure. If serum cotinine measurement became part of routine screening at\r\nurban public hospitals, cotinine levels would be abnormal in many patients and\r\nwould provide objective evidence of tobacco smoke exposure, probably resulting\r\nin more intensive intervention to encourage patients to stop smoking and avoid\r\nSHS.&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Benowitz&quot;,&quot;given&quot;:&quot;Neal\r\nL.&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Schultz&quot;,&quot;given&quot;:&quot;Katherine\r\nE.&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Haller&quot;,&quot;given&quot;:&quot;Christine\r\nA.&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Wu&quot;,&quot;given&quot;:&quot;Alan\r\nH.B.&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Dains&quot;,&quot;given&quot;:&quot;Katherine\r\nM.&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Jacob&quot;,&quot;given&quot;:&quot;Peyton&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;American\r\nJournal of\r\nEpidemiology&quot;,&quot;id&quot;:&quot;ITEM-1&quot;,&quot;issue&quot;:&quot;7&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2009&quot;]]},&quot;page&quot;:&quot;885-891&quot;,&quot;title&quot;:&quot;Prevalence\r\nof smoking assessed biochemically in an urban public hospital: a rationale for\r\nroutine cotinine screening&quot;,&quot;type&quot;:&quot;article-journal&quot;,&quot;volume&quot;:&quot;170&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=52792d68-7c35-4ce4-9818-a8f27aa8f4c8&quot;]}],&quot;mendeley&quot;:{&quot;formattedCitation&quot;:&quot;&lt;sup&gt;177&lt;\/sup&gt;&quot;,&quot;plainTextFormattedCitation&quot;:&quot;177&quot;,&quot;previouslyFormattedCitation&quot;:&quot;&lt;sup&gt;176&lt;\/sup&gt;&quot;},&quot;properties&quot;:{&quot;noteIndex&quot;:0},&quot;schema&quot;:&quot;https:\/\/github.com\/citation-style-language\/schema\/raw\/master\/csl-citation.json&quot;}<span\r\nstyle='mso-element:field-separator'><\/span><\/span><\/sup><![endif]--><sup>177<\/sup><!--[if supportFields]><sup><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-end'><\/span><\/span><\/sup><![endif]-->. It is hence possible that under-reporting of current and former smoking status in hospitals occurred across the included studies. Fifth, individuals with severe COVID-19 symptoms may have stopped smoking immediately before admission to hospital and may therefore not have been recorded as current smokers (i.e. reverse causality).<\/p>\n\n<p>&nbsp;<\/p>\n\n<p>Sixth, smokers with COVID-19 may be less likely to receive a SARS-CoV-2 test or present to hospital due to lack of access to healthcare and may be more likely to die in the community from sudden complications (i.e. self-selection bias) and thus not be recorded. Seventh, if there is a protective effect of nicotine on COVID-19 disease outcomes, abrupt nicotine withdrawal upon hospitalisation may lead to worse outcomes<!--[if supportFields]><sup><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-begin;\r\nmso-field-lock:yes'><\/span>ADDIN CSL_CITATION\r\n{&quot;citationItems&quot;:[{&quot;id&quot;:&quot;ITEM-1&quot;,&quot;itemData&quot;:{&quot;DOI&quot;:&quot;10.1016\/j.toxrep.2020.04.012&quot;,&quot;ISSN&quot;:&quot;22147500&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Farsalinos&quot;,&quot;given&quot;:&quot;Konstantinos&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Niaura&quot;,&quot;given&quot;:&quot;Raymond&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Houezec&quot;,&quot;given&quot;:&quot;Jacques&quot;,&quot;non-dropping-particle&quot;:&quot;Le&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Barbouni&quot;,&quot;given&quot;:&quot;Anastasia&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Tsatsakis&quot;,&quot;given&quot;:&quot;Aristidis&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Kouretas&quot;,&quot;given&quot;:&quot;Dimitrios&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Vantarakis&quot;,&quot;given&quot;:&quot;Apostolos&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Poulas&quot;,&quot;given&quot;:&quot;Konstantinos&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;Toxicology\r\nReports&quot;,&quot;id&quot;:&quot;ITEM-1&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2020&quot;,&quot;4&quot;]]},&quot;title&quot;:&quot;Editorial:\r\nNicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic\r\nsystem&quot;,&quot;type&quot;:&quot;article-journal&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=84781c5d-c6a6-44a5-b5be-cd6c41e014af&quot;]}],&quot;mendeley&quot;:{&quot;formattedCitation&quot;:&quot;&lt;sup&gt;12&lt;\/sup&gt;&quot;,&quot;plainTextFormattedCitation&quot;:&quot;12&quot;,&quot;previouslyFormattedCitation&quot;:&quot;&lt;sup&gt;12&lt;\/sup&gt;&quot;},&quot;properties&quot;:{&quot;noteIndex&quot;:0},&quot;schema&quot;:&quot;https:\/\/github.com\/citation-style-language\/schema\/raw\/master\/csl-citation.json&quot;}<span\r\nstyle='mso-element:field-separator'><\/span><\/span><\/sup><![endif]--><sup>12<\/sup><!--[if supportFields]><sup><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-end'><\/span><\/span><\/sup><![endif]-->. Eight, during periods of heightened demand of limited healthcare resources, current and former smokers with extensive comorbidities may have reduced priority for intensive care admission, thus leading to higher in-hospital mortality.<\/p>\n\n<p>&nbsp;<\/p>\n\n<p>Another important issue is that the reason for hospitalisation varies by country and time in the pandemic. For example, early cases may have been hospitalised for isolation and quarantine reasons and not due to medical necessity. It is plausible that this may have skewed early data towards less severe cases. In addition, the observed association between former smoking and greater disease severity may be explained by collider bias<!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-begin;\r\nmso-field-lock:yes'><\/span>ADDIN CSL_CITATION {&quot;citationItems&quot;:[{&quot;id&quot;:&quot;ITEM-1&quot;,&quot;itemData&quot;:{&quot;DOI&quot;:&quot;10.1101\/2020.05.04.20090506&quot;,&quot;abstract&quot;:&quot;Observational\r\ndata on COVID-19 including hypothesised risk factors for infection and progression\r\nare accruing rapidly. Here, we highlight the challenge of interpreting\r\nobservational evidence from non-random samples of the population, which may be\r\naffected by collider bias. We illustrate these issues using data from the UK\r\nBiobank in which individuals tested for COVID-19 are highly selected for a wide\r\nrange of genetic, behavioural, cardiovascular, demographic, and anthropometric\r\ntraits. We discuss the sampling mechanisms that leave aetiological studies of\r\nCOVID-19 infection and progression particularly susceptible to collider bias.\r\nWe also describe several tools and strategies that could help mitigate the\r\neffects of collider bias in extant studies of COVID-19 and make available a web\r\napp for performing sensitivity analyses. While bias due to non-random sampling\r\nshould be explored in existing studies, the optimal way to mitigate the problem\r\nis to use appropriate sampling strategies at the study design stage.\\n\\n###\r\nCompeting Interest Statement\\n\\nThe authors have declared no competing\r\ninterest.\\n\\n### Funding Statement\\n\\nThis research has been conducted using\r\nthe UK Biobank Resource under Application Number 16729. The Medical Research\r\nCouncil (MRC) and the University of Bristol support the MRC Integrative\r\nEpidemiology Unit [MC\\\\_UU\\\\_12013\/1, MC\\\\_UU\\\\_12013\/9, MC\\\\_UU\\\\_00011\/1].\r\nNMD is supported by a Norwegian Research Council Grant number 295989. GH is\r\nsupported by the Wellcome Trust and Royal Society [208806\/Z\/17\/Z].\\n\\n###\r\nAuthor Declarations\\n\\nAll relevant ethical guidelines have been followed; any\r\nnecessary IRB and\/or ethics committee approvals have been obtained and details\r\nof the IRB\/oversight body are included in the manuscript.\\n\\nYes\\n\\nAll\r\nnecessary patient\/participant consent has been obtained and the appropriate\r\ninstitutional forms have been archived.\\n\\nYes\\n\\nI understand that all\r\nclinical trials and any other prospective interventional studies must be\r\nregistered with an ICMJE-approved registry, such as ClinicalTrials.gov. I\r\nconfirm that any such study reported in the manuscript has been registered and\r\nthe trial registration ID is provided (note: if posting a prospective study\r\nregistered retrospectively, please provide a statement in the trial ID field\r\nexplaining why the study was not registered in advance).\\n\\nYes\\n\\nI have\r\nfollowed all appropriate research reporting guidelines and uploaded the\r\nrelevant EQUATOR Network research reporting checklist(s) and other\r\npert\u2026&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Griffith&quot;,&quot;given&quot;:&quot;Gareth&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Morris&quot;,&quot;given&quot;:&quot;Tim\r\nT&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Tudball&quot;,&quot;given&quot;:&quot;Matt&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Herbert&quot;,&quot;given&quot;:&quot;Annie&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Mancano&quot;,&quot;given&quot;:&quot;Giulia&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Pike&quot;,&quot;given&quot;:&quot;Lindsey&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Sharp&quot;,&quot;given&quot;:&quot;Gemma\r\nC&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Palmer&quot;,&quot;given&quot;:&quot;Tom\r\nM&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Smith&quot;,&quot;given&quot;:&quot;George\r\nDavey&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Tilling&quot;,&quot;given&quot;:&quot;Kate&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Zuccolo&quot;,&quot;given&quot;:&quot;Luisa&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Davies&quot;,&quot;given&quot;:&quot;Neil\r\nM&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Hemani&quot;,&quot;given&quot;:&quot;Gibran&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;medRxiv&quot;,&quot;id&quot;:&quot;ITEM-1&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2020&quot;,&quot;5&quot;,&quot;20&quot;]]},&quot;page&quot;:&quot;2020.05.04.20090506&quot;,&quot;publisher&quot;:&quot;Cold\r\nSpring Harbor Laboratory Press&quot;,&quot;title&quot;:&quot;Collider bias\r\nundermines our understanding of COVID-19 disease risk and\r\nseverity&quot;,&quot;type&quot;:&quot;article-journal&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=583886f0-bc75-3836-a977-dab9f5685d77&quot;]}],&quot;mendeley&quot;:{&quot;formattedCitation&quot;:&quot;&lt;sup&gt;178&lt;\/sup&gt;&quot;,&quot;plainTextFormattedCitation&quot;:&quot;178&quot;,&quot;previouslyFormattedCitation&quot;:&quot;&lt;sup&gt;177&lt;\/sup&gt;&quot;},&quot;properties&quot;:{&quot;noteIndex&quot;:0},&quot;schema&quot;:&quot;https:\/\/github.com\/citation-style-language\/schema\/raw\/master\/csl-citation.json&quot;}<span\r\nstyle='mso-element:field-separator'><\/span><\/span><![endif]--><sup>178<\/sup><!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-end'><\/span><\/span><![endif]-->, where conditioning on a collider (e.g. testing or hospitalisation) by design or analysis may introduce a spurious association between current or former smoking (a potential cause of testing or hospitalisation) and SARS-CoV-2 infection\/adverse outcomes from COVID-19 (potentially exacerbated by smoking)<!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-begin;\r\nmso-field-lock:yes'><\/span>ADDIN CSL_CITATION\r\n{&quot;citationItems&quot;:[{&quot;id&quot;:&quot;ITEM-1&quot;,&quot;itemData&quot;:{&quot;URL&quot;:&quot;https:\/\/twitter.com\/EpiEllie\/status\/1258607277357006849?s=20&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Murray&quot;,&quot;given&quot;:&quot;E&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;Twitter&quot;,&quot;id&quot;:&quot;ITEM-1&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2020&quot;]]},&quot;title&quot;:&quot;Causation\r\nin smoking and COVID-19&quot;,&quot;type&quot;:&quot;webpage&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=b7a1d5b1-0683-4588-bfcc-17d22ddb3ad6&quot;]}],&quot;mendeley&quot;:{&quot;formattedCitation&quot;:&quot;&lt;sup&gt;179&lt;\/sup&gt;&quot;,&quot;plainTextFormattedCitation&quot;:&quot;179&quot;,&quot;previouslyFormattedCitation&quot;:&quot;&lt;sup&gt;178&lt;\/sup&gt;&quot;},&quot;properties&quot;:{&quot;noteIndex&quot;:0},&quot;schema&quot;:&quot;https:\/\/github.com\/citation-style-language\/schema\/raw\/master\/csl-citation.json&quot;}<span\r\nstyle='mso-element:field-separator'><\/span><\/span><![endif]--><sup>179<\/sup><!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-end'><\/span><\/span><![endif]-->.<\/p>\n\n<p>&nbsp;<\/p>\n\n<figure class=\"image\"><img alt=\"\" height=\"172\" src=\"https:\/\/qeios-uploads.s3.eu-west-1.amazonaws.com\/editor\/0DOMoKSZJgeS15o90DYAGRUmC50637Cr0MaLtC49.png\" width=\"646\" \/>\n<figcaption>\n<p>Figure 11. A schematic of some of the interpretation issues for the association of smoking and SARS-CoV-2\/COVID-19. * Indicates potential confounding with smoking status.<\/p>\n<\/figcaption>\n<\/figure>\n\n<p>&nbsp;<\/p>\n\n<p><em>Limitations<\/em><\/p>\n\n<p>&nbsp;<\/p>\n\n<p>This living rapid evidence review was limited by not having two independent reviewers extracting data, limiting the search to one electronic database and one pre-print server and by not including at least three large population surveys due to their reliance on self-reported suspected SARS-CoV-2 infection (which means they do not meet our eligibility criteria)<!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-begin;\r\nmso-field-lock:yes'><\/span>ADDIN CSL_CITATION\r\n{&quot;citationItems&quot;:[{&quot;id&quot;:&quot;ITEM-1&quot;,&quot;itemData&quot;:{&quot;ISBN&quot;:&quot;0000000205&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Bowyer&quot;,&quot;given&quot;:&quot;Ruth\r\nC E&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Varsavsky&quot;,&quot;given&quot;:&quot;Thomas&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Carole&quot;,&quot;given&quot;:&quot;H&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;id&quot;:&quot;ITEM-1&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2020&quot;]]},&quot;title&quot;:&quot;Geo-social\r\ngradients in predicted COVID-19 prevalence and severity in Great Britain :\r\nresults from Affiliations : Corresponding authors : Understanding the\r\ngeographical distribution of COVID-19 through the general population is key to\r\nthe provision of\r\nade&quot;,&quot;type&quot;:&quot;article-journal&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=4b05fb36-6ef6-49b0-b493-ddfb1ba189ed&quot;]},{&quot;id&quot;:&quot;ITEM-2&quot;,&quot;itemData&quot;:{&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Jackson&quot;,&quot;given&quot;:&quot;S\r\nE&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Brown&quot;,&quot;given&quot;:&quot;J&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Shahab&quot;,&quot;given&quot;:&quot;L&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Steptoe&quot;,&quot;given&quot;:&quot;A&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Fancourt&quot;,&quot;given&quot;:&quot;D&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;Submitted&quot;,&quot;id&quot;:&quot;ITEM-2&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2020&quot;]]},&quot;title&quot;:&quot;COVID-19,\r\nsmoking, and inequalities: a cross-sectional survey of adults in the\r\nUK&quot;,&quot;type&quot;:&quot;article-journal&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=d443be2f-2e70-46af-be35-2ba67e6873a7&quot;]},{&quot;id&quot;:&quot;ITEM-3&quot;,&quot;itemData&quot;:{&quot;DOI&quot;:&quot;10.1101\/2020.05.18.20105288&quot;,&quot;abstract&quot;:&quot;Background:\r\nThe association between current tobacco smoking, the risk of developing\r\nCOVID-19 and the severity of illness is an important information gap. Methods:\r\nUK users of the COVID Symptom Study app provided baseline data including\r\ndemographics, anthropometrics, smoking status and medical conditions, were\r\nasked to log symptoms daily from 24th March 2020 to 23rd April 2020.\r\nParticipants reporting that they did not feel physically normal were taken\r\nthrough a series of questions, including 14 potential COVID-19 symptoms and any\r\nhospital attendance. The main study outcome was the association between current\r\nsmoking and the development of classic symptoms of COVID-19 during the pandemic\r\ndefined as fever, new persistent cough and breathlessness. The number of\r\nconcurrent COVID-19 symptoms was used as a proxy for severity. In addition,\r\nassociation of subcutaneous adipose tissue expression of ACE2, both the\r\nreceptor for SARS-CoV-2 and a potential mediator of disease severity, with\r\nsmoking status was assessed in a subset of 541 twins from the TwinsUK cohort.\r\nResults: Data were available on 2,401,982 participants, mean(SD) age 43.6(15.1)\r\nyears, 63.3% female, overall smoking prevalence 11.0%. 834,437 (35%)\r\nparticipants reported being unwell and entered one or more symptoms. Current\r\nsmokers were more likely to develop symptoms suggesting a diagnosis of\r\nCOVID-19; classic symptoms adjusted OR[95%CI] 1.14[1.10 to 1.18]; &gt;5\r\nsymptoms 1.29[1.26 to 1.31]; &gt;10 symptoms 1.50[1.42 to 1.58]. Smoking was\r\nassociated with reduced ACE2 expression in adipose tissue (Beta(SE)=\r\n-0.395(0.149); p=7.01x10-3). Interpretation: These data are consistent with\r\nsmokers having an increased risk from\r\nCOVID-19.&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Hopkinson&quot;,&quot;given&quot;:&quot;Nicholas\r\nS&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Rossi&quot;,&quot;given&quot;:&quot;Niccol\u00f2\r\nNiccolo&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Moustafa&quot;,&quot;given&quot;:&quot;Julia\r\nEl-Sayed S El-sayed&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Laverty&quot;,&quot;given&quot;:&quot;Anthony\r\nA&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Quint&quot;,&quot;given&quot;:&quot;Jennifer\r\nK&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Freydin&quot;,&quot;given&quot;:&quot;Maxim\r\nB&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Visconti&quot;,&quot;given&quot;:&quot;Alessia&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Murray&quot;,&quot;given&quot;:&quot;Benjamin&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Modat&quot;,&quot;given&quot;:&quot;Marc&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Ourselin&quot;,&quot;given&quot;:&quot;Sebastien&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Small&quot;,&quot;given&quot;:&quot;Kerrin&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Davies&quot;,&quot;given&quot;:&quot;Richard&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Wolf&quot;,&quot;given&quot;:&quot;Jonathan&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Spector&quot;,&quot;given&quot;:&quot;Timothy\r\nD&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Steves&quot;,&quot;given&quot;:&quot;Claire\r\nJ&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Falchi&quot;,&quot;given&quot;:&quot;Mario&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Freidin&quot;,&quot;given&quot;:&quot;Maxim\r\nB&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Visconti&quot;,&quot;given&quot;:&quot;Alessia&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Murray&quot;,&quot;given&quot;:&quot;Benjamin&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Modat&quot;,&quot;given&quot;:&quot;Marc&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Ourselin&quot;,&quot;given&quot;:&quot;Sebastien&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Small&quot;,&quot;given&quot;:&quot;Kerrin&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Davies&quot;,&quot;given&quot;:&quot;Richard&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Wolf&quot;,&quot;given&quot;:&quot;Jonathan&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Spector&quot;,&quot;given&quot;:&quot;Timothy\r\nD&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Steves&quot;,&quot;given&quot;:&quot;J&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Falchi&quot;,&quot;given&quot;:&quot;Mario&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;medrxiv&quot;,&quot;id&quot;:&quot;ITEM-3&quot;,&quot;issue&quot;:&quot;0&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2020&quot;,&quot;5&quot;,&quot;21&quot;]]},&quot;page&quot;:&quot;2020.05.18.20105288&quot;,&quot;publisher&quot;:&quot;Cold\r\nSpring Harbor Laboratory Press&quot;,&quot;title&quot;:&quot;Current tobacco\r\nsmoking and risk from COVID-19 results from a population symptom app in over\r\n2.4 million\r\npeople&quot;,&quot;type&quot;:&quot;article-journal&quot;,&quot;volume&quot;:&quot;44&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=ec8abcf5-2732-4d9f-8c1b-9119301719fb&quot;]}],&quot;mendeley&quot;:{&quot;formattedCitation&quot;:&quot;&lt;sup&gt;172,180,181&lt;\/sup&gt;&quot;,&quot;plainTextFormattedCitation&quot;:&quot;172,180,181&quot;,&quot;previouslyFormattedCitation&quot;:&quot;&lt;sup&gt;172,179,180&lt;\/sup&gt;&quot;},&quot;properties&quot;:{&quot;noteIndex&quot;:0},&quot;schema&quot;:&quot;https:\/\/github.com\/citation-style-language\/schema\/raw\/master\/csl-citation.json&quot;}<span\r\nstyle='mso-element:field-separator'><\/span><\/span><![endif]--><sup>172,180,181<\/sup><!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-end'><\/span><\/span><![endif]-->. Population surveys &ndash; particularly with linked health data &ndash; will be included in future review versions to help mitigate some of the limitations of healthcare based observational studies. . The comparisons of current and former smoking prevalence in the included studies with national prevalence estimates did not adjust observed prevalence for the demographic profile of those tested\/admitted to hospital. Other reviews focused on this comparison have applied adjustment for sex, and continue to find lower than expected prevalence &ndash; notwithstanding the issues complicating interpretation described above<!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-begin;\r\nmso-field-lock:yes'><\/span>ADDIN CSL_CITATION\r\n{&quot;citationItems&quot;:[{&quot;id&quot;:&quot;ITEM-1&quot;,&quot;itemData&quot;:{&quot;DOI&quot;:&quot;10.32388\/Z69O8A.8&quot;,&quot;ISSN&quot;:&quot;2632-3834&quot;,&quot;abstract&quot;:&quot;The\r\nstudy presents an analysis of the current smoking prevalence among hospitalized\r\npatients with COVID-19 in China, compared to the population smoking prevalence\r\nin China (52.1% in males and 2.7% in females). We identified 6 studies\r\nexamining the clinical characteristics of hospitalized COVID-19 patients that\r\npresented data on the smoking status. The expected number of smokers was\r\ncalculated using the formula Expected smokers = (males x 0.521) + (females x\r\n0.027). An unusually low prevalence of current smoking was observed among\r\nhospitalized COVID-19 patients (9.6%, 95%CI: 8.2-11.1%) compared to the\r\nexpected prevalence based on smoking prevalence in China (31.2%, 95%CI:\r\n29.0-33.4%; z-statistic: 19.16, P &lt; 0.0001). This preliminary analysis does\r\nnot support the argument that current smoking is a risk factor for\r\nhospitalization for COVID-19, and might suggest a protective role. The latter\r\ncould be linked to the downregulation of ACE2 expression that has been\r\npreviously known to be induced by smoking. No studies recording e-cigarette use\r\nstatus among hospitalized COVID-19 patients were identified. Thus, no\r\nrecommendation can be made for e-cigarette users. Keywords. SARS-CoV-2,\r\nCOVID-19, ACE2, expression, susceptibility, smoking, hospitalization,\r\nelectronic\r\ncigarette.&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Farsalinos&quot;,&quot;given&quot;:&quot;Konstantinos&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Barbouni&quot;,&quot;given&quot;:&quot;Anastasia&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Niaura&quot;,&quot;given&quot;:&quot;Raymond&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;Qeios&quot;,&quot;id&quot;:&quot;ITEM-1&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2020&quot;,&quot;3&quot;,&quot;25&quot;]]},&quot;publisher&quot;:&quot;Qeios\r\nLtd&quot;,&quot;title&quot;:&quot;Smoking, vaping and hospitalization for\r\nCOVID-19&quot;,&quot;type&quot;:&quot;article-journal&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=39efac61-9bf1-4437-b1a3-f83b732938fa&quot;]}],&quot;mendeley&quot;:{&quot;formattedCitation&quot;:&quot;&lt;sup&gt;16&lt;\/sup&gt;&quot;,&quot;plainTextFormattedCitation&quot;:&quot;16&quot;,&quot;previouslyFormattedCitation&quot;:&quot;&lt;sup&gt;16&lt;\/sup&gt;&quot;},&quot;properties&quot;:{&quot;noteIndex&quot;:0},&quot;schema&quot;:&quot;https:\/\/github.com\/citation-style-language\/schema\/raw\/master\/csl-citation.json&quot;}<span\r\nstyle='mso-element:field-separator'><\/span><\/span><![endif]--><sup>16<\/sup><!--[if supportFields]><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-end'><\/span><\/span><![endif]-->.&nbsp; Future versions of the review will take a Bayesian approach to the comparisons to mitigate the issue of repeating multiple meta-analyses across different versions of this living review.<\/p>\n\n<p>&nbsp;<\/p>\n\n<p><em>Implications for research, policy and practice<\/em><\/p>\n\n<p>&nbsp;<\/p>\n\n<p>Further scientific research is needed to resolve the mixed findings summarised in our review. First, clinical trials of the posited therapeutic effect of nicotine could have important implications both for smokers and for improved understanding of how the SARS-CoV-2 virus causes disease in humans. Such trials should focus on medicinal nicotine (as smoked tobacco is a dirty delivery mechanism that could mask beneficial effects) and potentially differentiate between different modes of delivery (i.e. inhaled vs. ingested) since this can affect pharmacokinetics<!--[if supportFields]><sup><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-begin;\r\nmso-field-lock:yes'><\/span>ADDIN CSL_CITATION\r\n{&quot;citationItems&quot;:[{&quot;id&quot;:&quot;ITEM-1&quot;,&quot;itemData&quot;:{&quot;DOI&quot;:&quot;10.1007\/s40263-013-0116-4&quot;,&quot;ISSN&quot;:&quot;11727047&quot;,&quot;abstract&quot;:&quot;Nicotine\r\nreplacement therapy (NRT) has been used in the treatment of tobacco dependence\r\nfor over three decades. Whilst the choice of NRT was limited early on, in the\r\nlast ten years there has been substantial increase in the number of nicotine\r\ndelivery devices that have become available. This article briefly summarises\r\nexisting forms of NRT, evidence of their efficacy and use, and reviews the\r\nrationale for the development of novel products delivering nicotine via buccal,\r\ntransdermal or pulmonary routes (including nicotine mouth spray, nicotine\r\nfilms, advanced nicotine inhalers and electronic cigarettes). It presents\r\navailable evidence on the efficacy, tolerability and abuse potential of these\r\nproducts, with a focus on their advantages as well as disadvantages compared\r\nwith established forms of NRT for use as an aid to both smoking cessation as\r\nwell as harm reduction. \u00a9 2013 Springer International Publishing\r\nSwitzerland.&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Shahab&quot;,&quot;given&quot;:&quot;Lion&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Brose&quot;,&quot;given&quot;:&quot;Leonie\r\nS.&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;West&quot;,&quot;given&quot;:&quot;Robert&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;CNS\r\nDrugs&quot;,&quot;id&quot;:&quot;ITEM-1&quot;,&quot;issue&quot;:&quot;12&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2013&quot;,&quot;12&quot;,&quot;11&quot;]]},&quot;page&quot;:&quot;1007-1019&quot;,&quot;publisher&quot;:&quot;Springer&quot;,&quot;title&quot;:&quot;Novel\r\ndelivery systems for nicotine replacement therapy as an aid to smoking\r\ncessation and for harm reduction: Rationale, and evidence for advantages over\r\nexisting\r\nsystems&quot;,&quot;type&quot;:&quot;article-journal&quot;,&quot;volume&quot;:&quot;27&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=3b968134-d0ee-3669-a10d-687c996fd158&quot;]}],&quot;mendeley&quot;:{&quot;formattedCitation&quot;:&quot;&lt;sup&gt;182&lt;\/sup&gt;&quot;,&quot;plainTextFormattedCitation&quot;:&quot;182&quot;,&quot;previouslyFormattedCitation&quot;:&quot;&lt;sup&gt;181&lt;\/sup&gt;&quot;},&quot;properties&quot;:{&quot;noteIndex&quot;:0},&quot;schema&quot;:&quot;https:\/\/github.com\/citation-style-language\/schema\/raw\/master\/csl-citation.json&quot;}<span\r\nstyle='mso-element:field-separator'><\/span><\/span><\/sup><![endif]--><sup>182<\/sup><!--[if supportFields]><sup><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-end'><\/span><\/span><\/sup><![endif]--> and potential therapeutic effects. A second research priority would be a large, representative (randomly sampled) population survey with a validated assessment of smoking status which distinguishes between recent and long-term ex-smokers &ndash; ideally biochemically verified &ndash; and assesses seroprevalence and links to health records.<\/p>\n\n<p>&nbsp;<\/p>\n\n<p>In the meantime, public-facing messages about the possible protective effect of smoking or nicotine are premature. In our view, until there is further research, the quality of the evidence does not justify the huge risk associated with a message likely to reach millions of people that a lethal activity, such as smoking, may protect against COVID-19. It continues to be appropriate to recommend smoking cessation and emphasise the role of alternative nicotine products to support smokers to stop as part of public health efforts during COVID-19. At the very least, smoking cessation reduces acute risks from cardiovascular disease and could reduce demands on the healthcare system<!--[if supportFields]><sup><span style='font-size:\r\n11.0pt;line-height:150%'><span style='mso-element:field-begin;mso-field-lock:\r\nyes'><\/span>ADDIN CSL_CITATION\r\n{&quot;citationItems&quot;:[{&quot;id&quot;:&quot;ITEM-1&quot;,&quot;itemData&quot;:{&quot;DOI&quot;:&quot;10.1002\/14651858.CD000165.pub4&quot;,&quot;ISSN&quot;:&quot;1469493X&quot;,&quot;abstract&quot;:&quot;Background:\r\nHealthcare professionals frequently advise people to improve their health by\r\nstopping smoking. Such advice may be brief, or part of more intensive\r\ninterventions. Objectives: The aims of this review were to assess the\r\neffectiveness of advice from physicians in promoting smoking cessation; to\r\ncompare minimal interventions by physicians with more intensive interventions;\r\nto assess the effectiveness of various aids to advice in promoting smoking\r\ncessation, and to determine the effect of anti-smoking advice on\r\ndisease-specific and all-cause mortality. Search methods: We searched the\r\nCochrane Tobacco Addiction Group trials register in January 2013 for trials of\r\ninterventions involving physicians. We also searched Latin American databases\r\nthrough BVS (Virtual Library in Health) in February 2013. Selection criteria:\r\nRandomised trials of smoking cessation advice from a medical practitioner in\r\nwhich abstinence was assessed at least six months after advice was first\r\nprovided. Data collection and analysis: We extracted data in duplicate on the\r\nsetting in which advice was given, type of advice given (minimal or intensive),\r\nand whether aids to advice were used, the outcome measures, method of\r\nrandomisation and completeness of follow-up. The main outcome measure was\r\nabstinence from smoking after at least six months follow-up. We also considered\r\nthe effect of advice on mortality where long-term follow-up data were\r\navailable. We used the most rigorous definition of abstinence in each trial,\r\nand biochemically validated rates where available. People lost to follow-up\r\nwere counted as smokers. Effects were expressed as relative risks. Where\r\npossible, we performed meta-analysis using a Mantel-Haenszel fixed-effect\r\nmodel. Main results: We identified 42 trials, conducted between 1972 and 2012,\r\nincluding over 31,000 smokers. In some trials, participants were at risk of\r\nspecified diseases (chest disease, diabetes, ischaemic heart disease), but most\r\nwere from unselected populations. The most common setting for delivery of\r\nadvice was primary care. Other settings included hospital wards and outpatient\r\nclinics, and industrial clinics. Pooled data from 17 trials of brief advice\r\nversus no advice (or usual care) detected a significant increase in the rate of\r\nquitting (relative risk (RR) 1.66, 95% confidence interval (CI) 1.42 to 1.94).\r\nAmongst 11 trials where the intervention was judged to be more intensive the\r\nestimated effect was higher (RR 1.84, 95% CI 1.60 to 2.13) but\r\n\u2026&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Stead&quot;,&quot;given&quot;:&quot;Lindsay\r\nF.&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Buitrago&quot;,&quot;given&quot;:&quot;Diana&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Preciado&quot;,&quot;given&quot;:&quot;Nataly&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Sanchez&quot;,&quot;given&quot;:&quot;Guillermo&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Hartmann-Boyce&quot;,&quot;given&quot;:&quot;Jamie&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Lancaster&quot;,&quot;given&quot;:&quot;Tim&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;Cochrane\r\nDatabase of Systematic\r\nReviews&quot;,&quot;id&quot;:&quot;ITEM-1&quot;,&quot;issue&quot;:&quot;12&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2013&quot;,&quot;5&quot;,&quot;31&quot;]]},&quot;publisher&quot;:&quot;John\r\nWiley and Sons Ltd&quot;,&quot;title&quot;:&quot;Physician advice for smoking\r\ncessation&quot;,&quot;type&quot;:&quot;article&quot;,&quot;volume&quot;:&quot;2017&quot;},&quot;uris&quot;:[&quot;http:\/\/www.mendeley.com\/documents\/?uuid=9cd75678-7835-3c17-9d1a-cb9d5a0c83ce&quot;]}],&quot;mendeley&quot;:{&quot;formattedCitation&quot;:&quot;&lt;sup&gt;183&lt;\/sup&gt;&quot;,&quot;plainTextFormattedCitation&quot;:&quot;183&quot;,&quot;previouslyFormattedCitation&quot;:&quot;&lt;sup&gt;182&lt;\/sup&gt;&quot;},&quot;properties&quot;:{&quot;noteIndex&quot;:0},&quot;schema&quot;:&quot;https:\/\/github.com\/citation-style-language\/schema\/raw\/master\/csl-citation.json&quot;}<span\r\nstyle='mso-element:field-separator'><\/span><\/span><\/sup><![endif]--><sup>183<\/sup><!--[if supportFields]><sup><span\r\nstyle='font-size:11.0pt;line-height:150%'><span style='mso-element:field-end'><\/span><\/span><\/sup><![endif]-->. GPs and other healthcare providers can play a crucial role &ndash; brief, high-quality and free online training is available at National Centre for Smoking Cessation and Training.<\/p>\n\n<p>&nbsp;<\/p>\n\n<p><strong>Conclusion<\/strong><\/p>\n\n<p>&nbsp;<\/p>\n\n<p>Across 148 studies, there is substantial uncertainty arising from the recording of smoking status on whether current and\/or former smoking status is associated with SARS-CoV-2 infection, hospitalisation or mortality. There is some evidence that current smoking compared with never is associated with reduced risk of testing positive in the community but greater in-hospital mortality from COVID-19. There is some evidence that former compared with never smoking is associated with increased risk of greater disease severity and in-hospital mortality from COVID-19.<\/p>\n\n<p>&nbsp;<\/p>\n\n<p><strong>Acknowledgements<\/strong><\/p>\n\n<p>&nbsp;<\/p>\n\n<p>An original short review for the Royal College of Physicians was converted to an extended living review after a request by&nbsp;Martin Dockrell, Tobacco Control Lead,&nbsp;Public Health England. All scientific decisions were made by the authors independently of funders and external organisations. The authors would like to thank Rosemary Koper for her assistance in running the electronic searches and data extraction.<\/p>\n\n<p>&nbsp;<\/p>\n\n<p><strong>Declaration of conflicts of interest<\/strong><\/p>\n\n<p>&nbsp;<\/p>\n\n<p>DS and OP have no conflicts of interest to declare. LS has received a research grant and honoraria for a talk and travel expenses from manufacturers of smoking cessation medications (Pfizer and Johnson &amp; Johnson). JB has received unrestricted research funding to study smoking cessation from companies who manufacture smoking cessation medications. All authors declare no financial links with tobacco companies or e-cigarette manufacturers or their representatives.<\/p>\n\n<p>&nbsp;<\/p>\n\n<p><strong>Funding statement<\/strong><\/p>\n\n<p>&nbsp;<\/p>\n\n<p>DS is supported by a PhD studentship from the UK Biotechnology and Biological Sciences Research Council [BB\/M009513\/1]. OP receives salary support from Cancer Research UK (C1417\/A22962). JB, LS, &amp; OP are members of SPECTRUM, a UK Prevention Research Partnership Consortium (MR\/S037519\/1). UKPRP is an initiative funded by the UK Research and Innovation Councils, the Department of Health and Social Care (England) and the UK devolved administrations, and leading health research charities.<\/p>\n\n<p>&nbsp;<\/p>\n\n<p><strong>Data availability<\/strong><\/p>\n\n<p>&nbsp;<\/p>\n\n<p>Extracted data from included studies is available from a maintained Google Sheet document here:&nbsp;<a href=\"https:\/\/docs.google.com\/spreadsheets\/d\/1fuOcaN7K_f3msmt0aQAWwOWjgD4SsEt7iJ_0to1wotA\/edit?usp=sharing\" target=\"_blank\">link<\/a><\/p>\n\n<p>The code to reproduce&nbsp;the analysis and generate the plots and figures is available here:&nbsp;<a href=\"https:\/\/diddrog11.github.io\/\" target=\"_blank\">link<\/a><\/p>\n\n<p>&nbsp;<\/p>\n\n<p><strong>References<\/strong><\/p>\n\n<p><!--[if supportFields]><span\r\nstyle='font-size:11.0pt'><span style='mso-element:field-begin;mso-field-lock:\r\nyes'><\/span>ADDIN Mendeley Bibliography CSL_BIBLIOGRAPHY <span\r\nstyle='mso-element:field-separator'><\/span><\/span><![endif]-->1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Guan W, Ni Z, Hu YY, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; : NEJMoa2002032.<\/p>\n\n<p>2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020; published online March 5. DOI:10.1016\/j.cell.2020.02.052.<\/p>\n\n<p>3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brake SJ, Barnsley K, Lu W, McAlinden KD, Eapen MS, Sohal SS. Smoking Upregulates Angiotensin-Converting Enzyme-2 Receptor: A Potential Adhesion Site for Novel Coronavirus SARS-CoV-2 (Covid-19). J Clin Med 2020, Vol 9, Page 841 2020; 9: 841.<\/p>\n\n<p>4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cai G. Bulk and Single-Cell Transcriptomics Identify Tobacco-Use Disparity in Lung Gene Expression of ACE2, the Receptor of 2019-nCov. 2020; published online March 2. DOI:10.20944\/PREPRINTS202002.0051.V3.<\/p>\n\n<p>5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oakes JM, Fuchs RM, Gardner JD, Lazartigues E, Yue X. Nicotine and the renin-angiotensin system. Am. J. Physiol. - Regul. Integr. Comp. Physiol. 2018; 315: R895&ndash;906.<\/p>\n\n<p>6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Denholm JT, Gordon CL, Johnson PD, et al. Hospitalised adult patients with pandemic (H1N1) 2009 influenza in Melbourne, Australia. Med J Aust 2010; 192: 84&ndash;6.<\/p>\n\n<p>7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abadom TR, Smith AD, Tempia S, Madhi SA, Cohen C, Cohen AL. Risk factors associated with hospitalisation for influenza-associated severe acute respiratory illness in South Africa: A case-population study. Vaccine 2016; 34: 5649&ndash;55.<\/p>\n\n<p>8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Almirall J, Gonz&aacute;lez CA, Balanz&oacute; X, Bol&iacute;bar I. Proportion of community-acquired pneumonia cases attributable to tobacco smoking. Chest 1999; 116: 375&ndash;9.<\/p>\n\n<p>9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feldman C, Anderson R. Cigarette smoking and mechanisms of susceptibility to infections of the respiratory tract and other organ systems. J. Infect. 2013; 67: 169&ndash;84.<\/p>\n\n<p>10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dye JA, Adler KB. Occasional review Effects of cigarette smoke on epithelial cells of the respiratory tract. Thorax 1994; 49: 825&ndash;34.<\/p>\n\n<p>11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vardavas CI, Nikitara K. COVID-19 and smoking: A systematic review of the evidence. Tob Induc Dis 2020; 18: 20.<\/p>\n\n<p>12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Farsalinos K, Niaura R, Le Houezec J, et al. Editorial: Nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system. Toxicol Reports 2020; published online April. DOI:10.1016\/j.toxrep.2020.04.012.<\/p>\n\n<p>13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis. Arch Acad Emerg Med 2020; 8: e35.<\/p>\n\n<p>14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alqahtani JS, Oyelade T, Aldhahir AM, et al. Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis. medRxiv 2020; : 2020.03.25.20043745.<\/p>\n\n<p>15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patanavanich R, Glantz SA. Smoking is Associated with COVID-19 Progression: A Meta-Analysis. medRxiv 2020. DOI:10.14171\/j.2095-5944.sg.2014.02.004.<\/p>\n\n<p>16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Farsalinos K, Barbouni A, Niaura R. Smoking, vaping and hospitalization for COVID-19. Qeios 2020; published online March 25. DOI:10.32388\/Z69O8A.8.<\/p>\n\n<p>17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Berlin I, Thomas D, Le Faou A-L, Cornuz J. COVID-19 and Smoking. Nicotine Tob Res DOI:10.1093\/NTR\/NTAA059.<\/p>\n\n<p>18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elliott JH, Turner T, Clavisi O, et al. Living Systematic Reviews: An Emerging Opportunity to Narrow the Evidence-Practice Gap. PLoS Med 2014; 11. DOI:10.1371\/journal.pmed.1001603.<\/p>\n\n<p>19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tricco AC, Antony J, Zarin W, et al. A scoping review of rapid review methods. BMC Med 2015; 13: 224.<\/p>\n\n<p>20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; National Heart Lung and Blood Institute. Study Quality Assessment Tools. Natonal Institutes Heal. 2018; : 1&ndash;35.<\/p>\n\n<p>21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; R Core Team. The R Project for Statistical Computing. 2013; : 1&ndash;12.<\/p>\n\n<p>22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Higgins JPT, Wells GA. Cochrane handbook for systematic reviews of interventions. 2011.<\/p>\n\n<p>23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br. Med. J. 2003; 327: 557&ndash;60.<\/p>\n\n<p>24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Efron B. Better bootstrap confidence intervals. J Am Stat Assoc 1987; 82: 171&ndash;85.<\/p>\n\n<p>25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Miyara M, Tubach F, Martinez V, et al. Low rate of daily smokers in patients with symptomatic COVID-19. medrxiv 2020; : 2020.06.10.20127514.<\/p>\n\n<p>26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rimland CA, Morgan CE, Bell GJ, et al. Clinical characteristics and early outcomes in patients with COVID-19 treated with tocilizumab at a United States academic center. medRxiv 2020; : 2020.05.13.20100404.<\/p>\n\n<p>27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Guan W, Liang W, Zhao Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. Eur Respir J 2020; : 2000547.<\/p>\n\n<p>28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lian J, Jin X, Hao S, et al. Analysis of Epidemiological and Clinical Features in Older Patients With Coronavirus Disease 2019 (COVID-19) Outside Wuhan. Clin Infect Dis 2020; 2019: 1&ndash;8.<\/p>\n\n<p>29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Jin X, Lian JS, Hu JH, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut 2020; published online March 24. DOI:10.1136\/gutjnl-2020-320926.<\/p>\n\n<p>30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. Bmj 2020; 368: m1295.<\/p>\n\n<p>31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 0. DOI:10.1016\/s0140-6736(20)30566-3.<\/p>\n\n<p>32&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mo P, Xing Y, Xiao Y, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis 2020; published online March 16. DOI:10.1093\/cid\/ciaa270.<\/p>\n\n<p>33&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Zhang J, Dong X, Cao Y, et al. Clinical characteristics of 140 patients infected with SARS\u2010CoV\u20102 in Wuhan, China. Allergy 2020; : all.14238.<\/p>\n\n<p>34&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wan S, Xiang Y, Fang W, et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol 2020; : 1&ndash;10.<\/p>\n\n<p>35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liu W, Tao Z-W, Wang L, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J (Engl) 2020; 133: 1.<\/p>\n\n<p>36&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497&ndash;506.<\/p>\n\n<p>37&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Zhang X, Cai H, Hu J, et al. Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings. Int J Infect Dis 2020; 94: 81&ndash;7.<\/p>\n\n<p>38&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020; 2019. DOI:10.1001\/jamacardio.2020.1017.<\/p>\n\n<p>39&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liu R, Ming X, Zhu H, et al. Association of Cardiovascular Manifestations with In-hospital Outcomes in Patients with COVID-19: A Hospital Staff Data. medRxiv 2020; : 2020.02.29.20029348.<\/p>\n\n<p>40&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Xu HH, Hou K, Xu HH, et al. Acute Myocardial Injury of Patients with Coronavirus Disease 2019. medRxiv 2020; : 2020.03.05.20031591.<\/p>\n\n<p>41&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Li J, Li S, Cai Y, et al. Epidemiological and Clinical Characteristics of 17 Hospitalized Patients with 2019 Novel Coronavirus Infections Outside Wuhan, China. medRxiv 2020; : 2020.02.11.20022053.<\/p>\n\n<p>42&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rentsch CT, Kidwai-Khan F, Tate JP, et al. Covid-19 Testing, Hospital Admission, and Intensive Care Among 2,026,227 United States Veterans Aged 54-75 Years. medRxiv 2020; : 2020.04.09.20059964.<\/p>\n\n<p>43&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hu L, Chen S, Fu Y, et al. Risk Factors Associated with Clinical Outcomes in 323 COVID-19 Patients in Wuhan, China. medRxiv 2020; : 2020.03.25.20037721.<\/p>\n\n<p>44&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wang R, Pan M, Zhang X, et al. Epidemiological and clinical features of 125 Hospitalized Patients with COVID-19 in Fuyang, Anhui, China. Int J Infect Dis 2020; : 127065.<\/p>\n\n<p>45&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City. medRxiv 2020; : 2020.04.08.20057794.<\/p>\n\n<p>46&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chow N, Fleming-Dutra K, Gierke R, et al. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 &mdash; United States, February 12&ndash;March 28, 2020. Morb Mortal Wkly Rep 2020; 69: 382&ndash;6.<\/p>\n\n<p>47&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dong X, Cao Y, Lu X, et al. Eleven Faces of Coronavirus Disease 2019. Allergy 2020; : 1&ndash;11.<\/p>\n\n<p>48&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kim ES, Chin BS, Kang CK, et al. Clinical Course and Outcomes of Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Preliminary Report of the First 28 Patients from the Korean Cohort Study on COVID-19. J Korean Med Sci 2020; 35: e142.<\/p>\n\n<p>49&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: Findings of 487 cases outside Wuhan. Crit Care 2020; 24: 2&ndash;5.<\/p>\n\n<p>50&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020; 2600: 1&ndash;7.<\/p>\n\n<p>51&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Argenziano MG, Bruce SL, Slater CL, et al. Characterization and Clinical Course of 1000 Patients with COVID-19 in New York: retrospective case series. medRxiv 2020; : 2020.04.20.20072116.<\/p>\n\n<p>52&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Solis P, Carreno H. COVID-19 Fatality and Comorbidity Risk Factors among Diagnosed Patients in Mexico. 2020. DOI:10.1101\/2020.04.21.20074591.<\/p>\n\n<p>53&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 2020; 10022: 1&ndash;8.<\/p>\n\n<p>54&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fontanet A, Tondeur L, Madec Y, et al. Cluster of COVID-19 in northern France: A retrospective closed cohort study. medRxiv 2020; : 2020.04.18.20071134.<\/p>\n\n<p>55&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Zheng KI, Gao F, Wang X-B, et al. Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metabolism 2020; : 154244.<\/p>\n\n<p>56&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liao Y, Feng Y, Wang B, et al. Clinical Characteristics and Risk factors for developed COVID-19 patients transferring to designated hospital from Jianghan Fangcang shelter Hospital\u202f: a retrospective , Summary\u202f: 2020; : 1&ndash;16.<\/p>\n\n<p>57&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rodriguez-Cola M, Jimenez-Velasco I, Gutierrez-Henares F, et al. Clinical features of coronavirus disease 2019 (COVID-19) in a cohort of patients with disability due to spinal cord injury. 2020. DOI:10.1101\/2020.04.20.20072918.<\/p>\n\n<p>58&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Magagnoli J, Narendran S, Pereira F, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRxiv 2020; : 2020.04.16.20065920.<\/p>\n\n<p>59&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shi P, Ren G, Yang J, et al. Clinical characteristics of imported and second-generation COVID-19 cases outside Wuhan, China: A multicenter retrospective study. 2020. DOI:10.1101\/2020.04.19.20071472.<\/p>\n\n<p>60&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients. medRxiv 2020; : 2020.04.19.20068015.<\/p>\n\n<p>61&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Niedzweidz C, O&rsquo;Donnell CA, Jani BD, et al. Ethnic and socioeconomic differences in SARS-CoV-2 infection: prospective cohort study using UK Biobank. 2020. DOI:10.1101\/2020.04.22.20075663.<\/p>\n\n<p>62&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gold JAW, Wong KK, Szablewski CM, Patel PR, Rossow J, Silva J. Characteristics and Clinical Outcomes of Adult Patients Hospitalized with COVID-19 &mdash; Georgia , March 2020. 2020; 69. https:\/\/www.cdc.gov\/mmwr\/volumes\/69\/wr\/mm6918e1. htm?s_cid=mm6918e1_w.<\/p>\n\n<p>63&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yu T, Cai S, Zheng Z, et al. Association between clinical manifestations and prognosis in patients with COVID-19. Clin Ther 2020; xxx: 1&ndash;9.<\/p>\n\n<p>64&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Zheng Y, Xiong C, Liu Y, et al. Epidemiological and Clinical Characteristics Analysis of COVID-19 in the Surrounding Areas of Wuhan, Hubei Province in 2020. Pharmacol Res 2020; 157: 104821.<\/p>\n\n<p>65&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rica R de la, Borges M, Aranda M, et al. Low albumin levels are associated with poorer outcomes in a case series of COVID-19 patients in Spain: a retrospective cohort study. medRxiv 2020; : 1&ndash;35.<\/p>\n\n<p>66&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yin R, Yang Z, Wei Y, et al. Clinical characteristics of 106 patients with neurological diseases and co-morbid coronavirus disease 2019: a retrospective study. medRxiv 2020; : 2020.04.29.20085415.<\/p>\n\n<p>67&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gaibazzi N, Tuttolomondo D, Guidorossi A, et al. Smoking Prevalence is Low in Symptomatic Patients Admitted for COVID-19. medRxiv 2020; : 2020.05.05.20092015.<\/p>\n\n<p>68&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shi H, Zuo Y, Yalavarthi S, et al. Neutrophil calprotectin identifies severe pulmonary disease in COVID-19 Hui. medRxiv 2020; : 1&ndash;15.<\/p>\n\n<p>69&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cho ER, Jha P. Smoking and the risk of COVID-19 infection in the UK Biobank Prospective Study. 2020; : 10&ndash;3.<\/p>\n\n<p>70&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allenbach Y, Saadoun D, Maalouf G, et al. Multivariable prediction model of intensive care unit transfer and death: a French prospective cohort study of COVID-19 patients. medRxiv 2020; : 2020.05.04.20090118.<\/p>\n\n<p>71&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Robilotti E V, Babady NE, Ph D, et al. Determinants of Severity in Cancer Patients with COVID-19 Illness. medRxiv 2020; : 1&ndash;19.<\/p>\n\n<p>72&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Collaborative TO, Williamson E, Walker AJ, et al. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. medRxiv 2020; : 2020.05.06.20092999.<\/p>\n\n<p>73&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Borobia AM, Carcas AJ, Arnalich F, Alvarez-Sala R, Montserrat J, Quintana M. A cohort of patients with COVID-19 in a major teaching hospital in Europe. medRxiv 2020. DOI:10.1101\/2020.04.29.20080853.<\/p>\n\n<p>74&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Giacomelli A, Ridolfo AL, Milazzo L, et al. 30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: a prospective cohort study. medRxiv 2020; : 1&ndash;25.<\/p>\n\n<p>75&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shah SJ, Barish PN, Prasad PA, et al. illness\u202f: a comparison of patients with and without COVID-19. 2020.<\/p>\n\n<p>76&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bello-Chavolla OY, Bahena-Lopez JP, Antonio-Villa NE, et al. Predicting mortality attributable to SARS-CoV-2: A mechanistic score relating obesity and diabetes to COVID-19 outcomes in Mexico. medRxiv 2020; 52: 2020.04.20.20072223.<\/p>\n\n<p>77&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kolin DA, Kulm S, Elemento O. Clinical and Genetic Characteristics of Covid-19 Patients from UK Biobank. medRxiv 2020; : 2020.05.05.20075507.<\/p>\n\n<p>78&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lubetzky M, Aull M, Craig-Shapiro R, et al. Kidney Allograft Recipients Diagnosed with Coronavirus Disease-2019\u202f: A Single Center Report. medRxiv 2020; : 2020.04.30.20086462.<\/p>\n\n<p>79&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Goyal P, Choi JJ, Pinheiro LC, et al. Clinical Characteristics of Covid-19 in New York City. N Engl J Med 2020; published online April 17. DOI:10.1056\/nejmc2010419.<\/p>\n\n<p>80&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feng Y, Ling Y, Bai T, et al. COVID-19 with Different Severity: A Multi-center Study of Clinical Features. Am J Respir Crit Care Med 2020; : 1&ndash;53.<\/p>\n\n<p>81&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yao Q, Wang P, Wang X, et al. Retrospective study of risk factors for severe SARS-Cov-2 infections in hospitalized adult patients. Polish Arch Intern Med 2020. DOI:10.20452\/pamw.15312.<\/p>\n\n<p>82&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sami R, Soltaninejad F, Amra B, et al. A one-year hospital-based prospective CVOID-19 open-cohort in the Eastern Mediterranean region: The Khorshid COVID Cohort (KCC) study. medRxiv 2020; : 2020.05.11.20096727.<\/p>\n\n<p>83&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Almazeedi S, Youha S Al, Jamal MH, et al. Clinical Characteristics, Risk Factors and Outcomes Among the First Consecutive 1,096 Patients Diagnosed with COVID-19: The Kuwait Experience. medRxiv 2020; : 2020.05.09.20096495.<\/p>\n\n<p>84&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Carrillo-Vega MF, Salinas-Escudero G, Garcia-Pe&ntilde;a C, Gutierrez-Robledo LM, Parra-Rodriguez L, Fernanda M. Early estimation of the risk factors for hospitalisation and mortality by COVID-19 in Mexico. medRxiv 2020; : 2020.05.11.20098145.<\/p>\n\n<p>85&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yanover AC, Mizrahi B, Kalkstein N, Marcus K, Akiva P, Barer Y. What factors increase the risk of complications in SARS-CoV-2 positive patients\u202f? A cohort study in a nationwide Israeli health organization. 2020.<\/p>\n\n<p>86&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hamer M, Kivim&auml;ki M, Gale CR, Batty GD. Lifestyle Risk Factors for Cardiovascular Disease in Relation to COVID-19 Hospitalization\u202f: A Community-Based Cohort Study of 387 , 109 Adults in UK Division of Surgery and Interventional Sciences , Faculty Medical Sciences , University College London , L. 2020; : 1&ndash;11.<\/p>\n\n<p>87&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Regina J, Papadimitriou-Olivgeris M, Burger R, et al. Epidemiology, risk factors and clinical course of SARS-CoV-2 infected patients in a Swiss university hospital: an observational retrospective study. medRxiv 2020; : 2020.05.11.20097741.<\/p>\n\n<p>88&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; de Lusignan S, Dorward J, Correa A, et al. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. Lancet Infect Dis 2020; 0. DOI:10.1016\/S1473-3099(20)30371-6.<\/p>\n\n<p>89&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Targher G, Mantovani A, Wang X-B, et al. Patients with diabetes are at higher risk for severe illness from COVID-19. Diabetes Metab 2020; published online May 13. DOI:10.1016\/j.diabet.2020.05.001.<\/p>\n\n<p>90&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Valenti L, Bergna A, Pelusi S, et al. SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 Milan outbreak. medRxiv 2020; : 2020.05.11.20098442.<\/p>\n\n<p>91&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feuth T, Saaresranta T, Karlsson A, et al. Is sleep apnoea a risk factor for Covid-19? Findings from a retrospective cohort study. medRxiv 2020; : 2020.05.14.20098319.<\/p>\n\n<p>92&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ge H, Zhu M, Du J, et al. Cardiac Structural and Functional Characteristics in Patients with Coronavirus Disease 2019: A Serial Echocardiographic Study. medRxiv 2020; : 2020.05.12.20095885.<\/p>\n\n<p>93&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Parrotta E, Kister I, Charvet L, et al. COVID-19 OUTCOMES IN MS EARLY EXPERIENCE FROM NYU MULTIPLE SCLEROSIS COMPREHENSIVE CARE CENTER. medrxiv 2020; : 1&ndash;9.<\/p>\n\n<p>94&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shekhar R, Upadhyay S, Sheikh A, Atencio J, Kapuria D. Early experience with COVD-19 patients at tertiary care teaching hospital in southwestern United states. medrxiv 2020; : 1&ndash;15.<\/p>\n\n<p>95&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mejia-Vilet JM, Cordova-Sanchez BM, Fernandez-Camargo D, Mendez-Perez RA, Morales-Buenrostro LE, Hernandez-Gilsoul T. DERIVATION OF A SCORE TO PREDICT ADMISSION TO INTENSIVE CARE UNIT IN PATIENTS WITH COVID-19: THE ABC-GOALS SCORE. medRxiv 2020; : 2020.05.12.20099416.<\/p>\n\n<p>96&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chen C, Jiang J, Xu X, Hu Y, Hu Y, Zhao Y. Dynamic liver function indexes monitoring and clinical characteristics in three types of COVID-19 patients. medRxiv 2020; : 2020.05.13.20099614.<\/p>\n\n<p>97&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Li J, Chen Y, Chen S, et al. Derivation and validation of a prognostic model for predicting in-hospital mortality in patients admitted with COVID-19 in Wuhan China the PLANS (Platelet Lymphocyte Age Neutrophil Sex) model. medrxiv 2020; : 2020.05.13.20100370.<\/p>\n\n<p>98&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Palaiodimos L, Kokkinidis DG, Li W, et al. Severe obesity is associated with higher in-hospital mortality in a cohort of patients with COVID-19 in the Bronx, New York. Metabolism 2020; 108: 154262.<\/p>\n\n<p>99&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ip A, Berry DA, Hansen E, et al. Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients - An Observational Study. medRxiv 2020; : 2020.05.21.20109207.<\/p>\n\n<p>100&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heili-Frades S, Minguez P, Mahillo-Fernandez I, et al. COVID-19 Outcomes in 4712 consecutively confirmed SARS-CoV2 cases in the city of Madrid. medRxiv 2020; : 2020.05.22.20109850.<\/p>\n\n<p>101&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vaquero LM, Barrado MES, Escobar D, et al. C-Reactive protein and SOFA score as early predictors of critical care requirement in patients with COVID-19 pneumonia in Spain. medRxiv 2020; : 2020.05.22.20110429.<\/p>\n\n<p>102&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kim L, Garg S, O&rsquo;Halloran A, et al. Interim Analysis of Risk Factors for Severe Outcomes among a Cohort of Hospitalized Adults Identified through the U.S. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET). medRxiv 2020; : 2020.05.18.20103390.<\/p>\n\n<p>103&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wu MA, Fossali T, Pandolfi L, et al. COVID-19 the key role of pulmonary capillary leakage. An observational cohort study. medrxiv 2020; : 2020.05.17.20104877.<\/p>\n\n<p>104&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shi Q, Zhao K, Yu J, et al. Clinical characteristics of 101 COVID-19 nonsurvivors in Wuhan, China: a retrospective study. medRxiv 2020; : 2020.03.04.20031039.<\/p>\n\n<p>105&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kimmig LM, Wu D, Gold M, et al. IL6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections. medRxiv 2020; : 2020.05.15.20103531.<\/p>\n\n<p>106&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Al-Hindawi A, Sokhi J, Cuddihy J, et al. COVID-19 in London a Case Series Demonstrating Late Improvement in Survivors. medrxiv 2020; : 2020.05.16.20103853.<\/p>\n\n<p>107&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Basse C, Diakite S, Servois V, et al. Characteristics and outcome of SARS-CoV-2 infection in cancer patients. medRxiv 2020; : 2020.05.14.20101576.<\/p>\n\n<p>108&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Freites D, Leon L, Mucientes A, et al. Risk factors for hospital admission related to COVID-19 in inflammatory rheumatic diseases. medRxiv 2020; : 2020.05.14.20101584.<\/p>\n\n<p>109&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alshami AA, Alattas RA, Anan HF, et al. Silent Disease and Loss of Taste and Smell are Common Manifestations of SARS-COV-2 Infection in a Quarantine Facility: First report from Saudi Arabia. medRxiv 2020; : 2020.05.13.20100222.<\/p>\n\n<p>110&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Berumen J, Schmulson M, Alegre J, et al. Risk of infection and hospitalization by Covid-19 in Mexico: a case-control study. medRxiv 2020; : 2020.05.24.20104414.<\/p>\n\n<p>111&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2020; published online May 29. DOI:10.1136\/annrheumdis-2020-217871.<\/p>\n\n<p>112&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Li J, Long X, Zhu C, et al. Olfactory dysfunction in recovered COVID-19 patients. Mov Disord 2020; : mds.28172.<\/p>\n\n<p>113&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Batty GD, Deary I, Luciano M, Altschul D, Kivimaki M, Gale C. Psychosocial factors and hospitalisations for COVID-19: Prospective cohort study of the general population. medRxiv 2020; : 2020.05.29.20100735.<\/p>\n\n<p>114&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel A, Feldhamer I, Lahad A, Levin-Zamir D, Lavie G. Smoking and the risk of COVID-19 in a large observational population study. medRxiv 2020; : 2020.06.01.20118877.<\/p>\n\n<p>115&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Valle DM Del, Kim-schulze S, Hsin-hui H, et al. An inflammatory cytokine signature helps predict COVID-19 severity and death. medRxiv 2020; : 2020.05.28.20115758.<\/p>\n\n<p>116&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Zuo Y, Zuo M, Yalavarthi S, et al. Neutrophil extracellular traps and thrombosis in COVID-19. medRxiv 2020; : 2020.04.30.20086736.<\/p>\n\n<p>117&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chaudhry F, Bulka H, Rathnam AS, et al. COVID-19 in Multiple Sclerosis Patients and Risk Factors for Severe Infection. medRxiv 2020; : 2020.05.27.20114827.<\/p>\n\n<p>118&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Louis S, Dhawan A, Newey C, et al. Continuous Electroencephalography (cEEG) Characteristics and Acute Symptomatic Seizures in COVID-19 Patients. medRxiv 2020; : 2020.05.26.20114033.<\/p>\n\n<p>119&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Soto-Mota A, Garza BAM, Rodriguez EM, et al. THE LOW-HARM SCORE FOR PREDICTING MORTALITY IN PATIENTS DIAGNOSED WITH COVID-19: A MULTICENTRIC VALIDATION STUDY. medRxiv 2020; : 2020.05.26.20111120.<\/p>\n\n<p>120&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patel M, Gangemi A, Marron R, et al. Use of High Flow Nasal Therapy to Treat Moderate to Severe Hypoxemic Respiratory Failure in COVID-19. medRxiv 2020; : 2020.05.22.20109355.<\/p>\n\n<p>121&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Garibaldi BT, Fiksel J, Muschelli J, et al. Patient trajectories and risk factors for severe outcomes among persons hospitalized for COVID-19 in the Maryland\/DC region. medRxiv 2020; : 2020.05.24.20111864.<\/p>\n\n<p>122&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Docherty AB, Harrison EM, Green CA, et al. Features of 20&thinsp;133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ 2020; 369: m1985.<\/p>\n\n<p>123&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Boulware DR, Pullen MF, Bangdiwala AS, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med 2020; : NEJMoa2016638.<\/p>\n\n<p>124&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet 2020; 395: 1907&ndash;18.<\/p>\n\n<p>125&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rom&atilde;o VC, Oliveira-Ramos F, Cruz-Machado AR, et al. A COVID-19 outbreak in a rheumatology department upon the early days of the pandemic. medRxiv 2020; : 2020.06.05.20107011.<\/p>\n\n<p>126&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Giannouchos T, Sussman R, Mier JM, Poulas K, Farsalinos K. Characteristics and risk factors for COVID-19 diagnosis and adverse outcomes in Mexico: an analysis of 89,756 laboratory-confirmed COVID-19 cases. medRxiv 2020; : 2020.06.04.20122481.<\/p>\n\n<p>127&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ramlall V, Thangaraj P, Tatonetti NP, Shapira SD. Identification of Immune complement function as a determinant of adverse SARS-CoV-2 infection outcome. medRxiv 2020; : 2020.05.05.20092452.<\/p>\n\n<p>128&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wang B, Oekelen O Van, Mouhieddine T, et al. A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. medRxiv 2020; 1: 2020.06.04.20122846.<\/p>\n\n<p>129&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Perrone F, Piccirillo MC, Ascierto PA, et al. Department of Mental Health and Preventive Medicine, Universit&agrave; degli Studi della Campania Luigi Vanvitelli 1. 2020.<\/p>\n\n<p>130&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sharma AK, Ahmed A, Baig VN, et al. Characteristics and Outcomes of Hospitalized Young Adults with Mild to Moderate Covid-19 at a University Hospital in India. medRxiv 2020; : 2020.06.02.20106310.<\/p>\n\n<p>131&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; eugen-olsen&nbsp; jesper, Altintas I, Tingleff J, et al. Low levels of the prognostic biomarker suPAR are predictive of mild outcome in patients with symptoms of COVID-19 - a prospective cohort study. medRxiv 2020; : 2020.05.27.20114678.<\/p>\n\n<p>132&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Martinez-Portilla RJ, Sotiriadis A, Torres-Torres J, et al. Risk factors for mortality in pregnant women with SARS-CoV-2 infection. medRxiv 2020; : 2020.05.31.20107276.<\/p>\n\n<p>133&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Raisi-Estabragh Z, McCracken C, Bethell MS, et al. Greater risk of severe COVID-19 in non-White ethnicities is not explained by cardiometabolic, socioeconomic, or behavioural factors, or by 25(OH)-vitamin D status: study of 1,326 cases from the UK Biobank. medRxiv 2020; 25: 2020.06.01.20118943.<\/p>\n\n<p>134&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Luo H, Liu S, Wang Y, et al. Age differences in clinical features and outcomes in patients with COVID-19 Jiangsu China a retrospective multi-center cohort study. medrxiv 2020; : 1&ndash;16.<\/p>\n\n<p>135&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Houlihan C, Vora N, Byrne T, et al. SARS-CoV-2 virus and antibodies in front-line Health Care Workers in an acute hospital in London: preliminary results from a longitudinal study. medRxiv 2020; : 2020.06.08.20120584.<\/p>\n\n<p>136&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cen Y, Chen X, Shen Y, et al. Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019&mdash;a multi-centre observational study. Clin Microbiol Infect 2020; published online June. DOI:10.1016\/j.cmi.2020.05.041.<\/p>\n\n<p>137&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Klang E, Kassim G, Soffer S, Freeman R, Levin MA, Reich DL. Morbid Obesity as an Independent Risk Factor for COVID\u201019 Mortality in Hospitalized Patients Younger than 50. Obesity 2020; : 0&ndash;3.<\/p>\n\n<p>138&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Maraschini A, Corsi E, Salvatore MA, Donati S. Coronavirus and birth in Italy: results of a national population-based cohort study. medRxiv 2020; : 2020.06.11.20128652.<\/p>\n\n<p>139&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; WANG A-L, Zhong X, Hurd Y. Comorbidity and Sociodemographic determinants in COVID-19 Mortality in an US Urban Healthcare System. medRxiv 2020; : 2020.06.11.20128926.<\/p>\n\n<p>140&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; McQueenie R, Foster H, Jani BD, et al. Multimorbidity, Polypharmacy, and COVID-19 infection within the UK Biobank cohort. medRxiv 2020; : 2020.06.10.20127563.<\/p>\n\n<p>141&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Apea VJ, Wan YI, Dhairyawan R, et al. Ethnicity and outcomes in patients hospitalised with COVID-19 infection in East London: an observational cohort study. medRxiv 2020; : 2020.06.10.20127621.<\/p>\n\n<p>142&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Woolford SJ, D&rsquo;angelo S, Curtis EM, et al. COVID-19 and associations with frailty and multimorbidity: a prospective analysis of UK Biobank participants. medRxiv 2020; : 2020.06.09.20126292.<\/p>\n\n<p>143&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hultcrantz M, Richter J, Rosenbaum C, et al. COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers. medRxiv 2020; : 2020.06.09.20126516.<\/p>\n\n<p>144&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rajter JC, Sherman M, Fatteh N, Vogel F, Sacks J, Rajter J-J. ICON (Ivermectin in COvid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19. medRxiv 2020; : 2020.06.06.20124461.<\/p>\n\n<p>145&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lan F-Y, Suharlim C, Kales SN, Yang J. Association between SARS-CoV-2 infection, exposure risk and mental health among a cohort of essential retail workers in the United States. medRxiv 2020; : 2020.06.08.20125120.<\/p>\n\n<p>146&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russell B, Moss C, Papa S, et al. Factors affecting COVID-19 outcomes in cancer patients &minus; A first report from Guys Cancer Centre in London. medRxiv 2020; : 2020.05.12.20094219.<\/p>\n\n<p>147&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Zeng H, Zhang T, He X, et al. Impact of Chronic Comorbidities on Progression and Prognosis in Patients with COVID-19: A Retrospective Cohort Study in 1031 Hospitalized Cases in Wuhan, China. medRxiv 2020; : 2020.06.14.20125997.<\/p>\n\n<p>148&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Suleyman G, Fadel RA, Malette KM, et al. Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit. JAMA Netw open 2020; 3: e2012270.<\/p>\n\n<p>149&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chen L, Yu J, He W, et al. Risk factors for death in 1859 subjects with COVID-19. Leukemia 2020; : 1&ndash;11.<\/p>\n\n<p>150&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chiara Garassino M, Whisenant JG, Huang L-C, et al. Articles COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol 2045. DOI:10.1016\/S1470-2045(20)30314-4.<\/p>\n\n<p>151&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hern&aacute;ndez-Gardu&ntilde;o E. Obesity is the comorbidity more strongly associated for Covid-19 in Mexico. A case-control study. Obes Res Clin Pract 2020; published online June. DOI:10.1016\/j.orcp.2020.06.001.<\/p>\n\n<p>152&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Govind R, Freitas DF de, Pritchard MR, Hayes RD, MacCabe JH. Clozapine treatment and risk of COVID-19. medRxiv 2020; : 2020.06.17.20133595.<\/p>\n\n<p>153&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sis&oacute;-almirall A, Kostov B, Mas-heredia M, Vilanova- S. PROGNOSTIC FACTORS IN SPANISH COVID-19 PATIENTS\u202f: A CASE SERIES FROM BARCELONA. 2020.<\/p>\n\n<p>154&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gu T, Mack JA, Salvatore M, et al. COVID-19 outcomes, risk factors and associations by race: a comprehensive analysis using electronic health records data in Michigan Medicine. medRxiv 2020; : 2020.06.16.20133140.<\/p>\n\n<p>155&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kibler M, Carmona A, Marchandot B, et al. Risk and severity of COVID-19 and ABO blood group in transcatheter aortic valve patients. medRxiv 2020; : 2020.06.13.20130211.<\/p>\n\n<p>156&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ikitimur H, Borku Uysal B, Cengiz M, et al. &lsquo;&ldquo;Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS\u2010CoV\u20102 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID\u201019?&rdquo;&rsquo; J Med Virol 2020; : jmv.26106.<\/p>\n\n<p>157&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sierpi\u0144ski R, Pinkas J, Jankowski M, et al. Gender differences in the frequency of gastrointestinal symptoms and olfactory or taste disorders among 1,942 non-hospitalized patients with COVID-19. Polish Arch Intern Med 2020. DOI:10.20452\/pamw.15414.<\/p>\n\n<p>158&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Zhou Y, He X, Zhang J, et al. Prolonged SARS-CoV-2 Viral Shedding in Patients with COVID-19 was Associated with Delayed Initiation of Arbidol Treatment: a retrospective cohort study. medRxiv 2020; : 2020.06.09.20076646.<\/p>\n\n<p>159&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Crovetto F, Crispi F, Llurba E, Figueras F, Gomez-Roig MD, Gratacos E. SEROPREVALENCE AND CLINICAL SPECTRUM OF SARS-CoV-2 INFECTION IN THE FIRST VERSUS THIRD TRIMESTER OF PREGNANCY. medRxiv 2020; : 2020.06.17.20134098.<\/p>\n\n<p>160&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Veras FP, Pontelli M, Silva C, et al. SARS-CoV-2 triggered neutrophil extracellular traps (NETs) mediate COVID-19 pathology. medRxiv 2020; : 2020.06.08.20125823.<\/p>\n\n<p>161&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sterlin D, Mathian A, Miyara M, et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. medRxiv 2020; : 2020.06.10.20126532.<\/p>\n\n<p>162&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rossi B, Nguyen LS, Zimmermann P, et al. Effect of tocilizumab in hospitalized patients with severe pneumonia COVID-19: a cohort study. medRxiv 2020; 1872: 2020.06.06.20122341.<\/p>\n\n<p>163&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Duan L, Zhang S, Guo M, et al. Epidemiological and clinical characteristics in patients with SARS-CoV-2 antibody negative probable COVID-19 in Wuhan. medRxiv 2020; : 2020.06.18.20134619.<\/p>\n\n<p>164&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Martin-Jimenez P, Munoz-Garcia MI, Seoane D, et al. Cognitive impairment is a common comorbidity in COVID-19 deceased patients. A hospital-based retrospective cohort study. medRxiv 2020; : 2020.06.08.20125872.<\/p>\n\n<p>165&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elezkurtaj S, Greuel S, Ihlow J, et al. Causes of Death and Comorbidities in Patients with COVID-19. medRxiv 2020; : 2020.06.15.20131540.<\/p>\n\n<p>166&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lenka J, Chhabria MS, Sharma N, et al. Clinical characteristics and outcomes of critically ill patients with COVID-19 in a tertiary community hospital in upstate New York. medRxiv 2020; : 2020.06.18.20135046.<\/p>\n\n<p>167&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Olivares F, Munoz D, Fica A, et al. Covid-19 in Chile. The experience of a Regional reference Center. Preliminary report. medRxiv 2020; : 2020.06.14.20130898.<\/p>\n\n<p>168&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Salton F, Confalonieri P, Santus P, et al. Prolonged low-dose methylprednisolone in patients with severe COVID-19 pneumonia. medRxiv 2020; : 2020.06.17.20134031.<\/p>\n\n<p>169&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wei W, Ortwine JK, Mang NS, Joseph C, Hall BC, Prokesch BC. Limited Role for Antibiotics in COVID-19: Scarce Evidence of Bacterial Coinfection. medRxiv 2020; : 2020.06.16.20133181.<\/p>\n\n<p>170&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Zuo Y, Estes SK, Gandhi AA, et al. Prothrombotic antiphospholipid antibodies in COVID-19 Yu. medRxiv 2020.<\/p>\n\n<p>171&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Killerby ME, Link-Gelles R, Haight SC, et al. Characteristics Associated with Hospitalization Among Patients with COVID-19 &mdash; Metropolitan Atlanta, Georgia, March&ndash;April 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 790&ndash;4.<\/p>\n\n<p>172&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hopkinson NS, Rossi NN, Moustafa JE-SSE, et al. Current tobacco smoking and risk from COVID-19 results from a population symptom app in over 2.4 million people. medrxiv 2020; 44: 2020.05.18.20105288.<\/p>\n\n<p>173&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Major home testing programme for coronavirus will track levels of infection in the community - GOV.UK. https:\/\/www.gov.uk\/government\/news\/major-home-testing-programme-for-coronavirus-will-track-levels-of-infection-in-the-community (accessed May 22, 2020).<\/p>\n\n<p>174&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; COVID-19 Infection Survey (CIS) - Office for National Statistics. https:\/\/www.ons.gov.uk\/surveys\/informationforhouseholdsandindividuals\/householdandindividualsurveys\/covid19infectionsurveycis (accessed June 30, 2020).<\/p>\n\n<p>175&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Farsalinos K, Barbouni A, Poulas K, Polosa R, Caponnetto P, Niaura R. Current smoking, former smoking, and adverse outcome among hospitalized COVID-19 patients: a systematic review and meta-analysis. Ther Adv Chronic Dis 2020; 11: 204062232093576.<\/p>\n\n<p>176&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Polubriaginof F, Salmasian H, Albert DA, Vawdrey DK. Challenges with Collecting Smoking Status in Electronic Health Records. AMIA . Annu Symp proceedings AMIA Symp 2017; 2017: 1392&ndash;400.<\/p>\n\n<p>177&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Benowitz NL, Schultz KE, Haller CA, Wu AHB, Dains KM, Jacob P. Prevalence of smoking assessed biochemically in an urban public hospital: a rationale for routine cotinine screening. Am J Epidemiol 2009; 170: 885&ndash;91.<\/p>\n\n<p>178&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Griffith G, Morris TT, Tudball M, et al. Collider bias undermines our understanding of COVID-19 disease risk and severity. medRxiv 2020; : 2020.05.04.20090506.<\/p>\n\n<p>179&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Murray E. Causation in smoking and COVID-19. Twitter. 2020. https:\/\/twitter.com\/EpiEllie\/status\/1258607277357006849?s=20.<\/p>\n\n<p>180&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bowyer RCE, Varsavsky T, Carole H. Geo-social gradients in predicted COVID-19 prevalence and severity in Great Britain\u202f: results from Affiliations\u202f: Corresponding authors\u202f: Understanding the geographical distribution of COVID-19 through the general population is key to the provision of ade. 2020.<\/p>\n\n<p>181&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Jackson SE, Brown J, Shahab L, Steptoe A, Fancourt D. COVID-19, smoking, and inequalities: a cross-sectional survey of adults in the UK. Submitted 2020.<\/p>\n\n<p>182&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shahab L, Brose LS, West R. Novel delivery systems for nicotine replacement therapy as an aid to smoking cessation and for harm reduction: Rationale, and evidence for advantages over existing systems. CNS Drugs 2013; 27: 1007&ndash;19.<\/p>\n\n<p>183&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stead LF, Buitrago D, Preciado N, Sanchez G, Hartmann-Boyce J, Lancaster T. Physician advice for smoking cessation. Cochrane Database Syst. Rev. 2013; 2017. DOI:10.1002\/14651858.CD000165.pub4.<\/p>\n\n<p><!--[if supportFields]><span style='font-size:11.0pt;font-family:\"Calibri\",sans-serif;\r\nmso-fareast-font-family:Calibri;mso-ansi-language:EN-GB;mso-fareast-language:\r\nEN-GB;mso-bidi-language:AR-SA'><span style='mso-element:field-end'><\/span><\/span><![endif]--><\/p>","views_count":1234,"preview_image_url":null,"downloads_count":80,"is_high_quality":false,"is_preprint":true,"version_history_id":103363,"version_number":6,"declarations":{"coi":"The author(s) declared that no potential competing interests exist.","funding":"The author(s) received no specific funding for this work."},"presentation_authors":[{"id":2134,"first_name":"David","last_name":"Simons","is_researcher":true,"research_field_id":null,"research_institution_id":24964,"biography":null,"avatar_path":null,"deactivated_at":null,"last_login_at":"2020-07-17 13:15:53","dismissed_newsletter_proposal":false,"referrer_id":null,"promotion_ends_at":"2020-07-30 09:53:41","orcid_id":"0000-0001-9655-1656","is_gold":false,"labarchives_uid":null,"accepts_authoring_request_emails":true,"is_admin":true,"full_name":"David Simons","auth_is_following":false,"avatar_url":null,"is_profile_visitable":true,"profile_url":"https:\/\/www.qeios.com\/profile\/2134","follow_endpoint":"https:\/\/www.qeios.com\/follow\/user\/2134","unfollow_endpoint":"https:\/\/www.qeios.com\/unfollow\/user\/2134","pivot":{"authorable_id":695,"user_id":2134,"authorable_type":"App\\Models\\Article","created_at":"2020-07-01 10:06:22","updated_at":"2020-07-01 10:06:22","sort_index":0},"research_field":null,"research_institution":{"id":24964,"name":"Royal Veterinary College, RVC","email_domain":"rvc.ac.uk","country_name":"United Kingdom","city_name":"London","website":"https:\/\/www.rvc.ac.uk\/"}},{"id":1766,"first_name":"Lion","last_name":"Shahab","is_researcher":true,"research_field_id":null,"research_institution_id":7929,"biography":null,"avatar_path":null,"deactivated_at":null,"last_login_at":"2020-05-11 17:16:26","dismissed_newsletter_proposal":false,"referrer_id":null,"promotion_ends_at":"2020-01-30 10:33:27","orcid_id":"0000-0003-4033-442X","is_gold":false,"labarchives_uid":null,"accepts_authoring_request_emails":true,"is_admin":false,"full_name":"Lion Shahab","auth_is_following":false,"avatar_url":null,"is_profile_visitable":true,"profile_url":"https:\/\/www.qeios.com\/profile\/1766","follow_endpoint":"https:\/\/www.qeios.com\/follow\/user\/1766","unfollow_endpoint":"https:\/\/www.qeios.com\/unfollow\/user\/1766","pivot":{"authorable_id":695,"user_id":1766,"authorable_type":"App\\Models\\Article","created_at":"2020-07-01 10:06:22","updated_at":"2020-07-01 10:06:22","sort_index":1},"research_field":null,"research_institution":{"id":7929,"name":"University College London, University of London","email_domain":"ucl.ac.uk","country_name":"United Kingdom","city_name":null,"website":"http:\/\/www.ucl.ac.uk\/"}},{"id":1767,"first_name":"Jamie","last_name":"Brown","is_researcher":true,"research_field_id":16,"research_institution_id":7929,"biography":null,"avatar_path":null,"deactivated_at":null,"last_login_at":"2020-06-12 16:57:54","dismissed_newsletter_proposal":true,"referrer_id":null,"promotion_ends_at":"2020-01-30 10:36:31","orcid_id":"0000-0002-2797-5428","is_gold":false,"labarchives_uid":null,"accepts_authoring_request_emails":true,"is_admin":false,"full_name":"Jamie Brown","auth_is_following":false,"avatar_url":null,"is_profile_visitable":true,"profile_url":"https:\/\/www.qeios.com\/profile\/1767","follow_endpoint":"https:\/\/www.qeios.com\/follow\/user\/1767","unfollow_endpoint":"https:\/\/www.qeios.com\/unfollow\/user\/1767","pivot":{"authorable_id":695,"user_id":1767,"authorable_type":"App\\Models\\Article","created_at":"2020-07-01 10:06:22","updated_at":"2020-07-01 10:06:22","sort_index":2},"research_field":{"id":16,"name":"Psychology and Cognitive Sciences","enabled":1},"research_institution":{"id":7929,"name":"University College London, University of London","email_domain":"ucl.ac.uk","country_name":"United Kingdom","city_name":null,"website":"http:\/\/www.ucl.ac.uk\/"}},{"id":2135,"first_name":"Olga","last_name":"Perski","is_researcher":true,"research_field_id":null,"research_institution_id":7929,"biography":null,"avatar_path":null,"deactivated_at":null,"last_login_at":"2020-07-29 08:17:49","dismissed_newsletter_proposal":false,"referrer_id":2134,"promotion_ends_at":"2020-07-30 12:27:48","orcid_id":"0000-0003-3285-3174","is_gold":false,"labarchives_uid":null,"accepts_authoring_request_emails":true,"is_admin":false,"full_name":"Olga Perski","auth_is_following":false,"avatar_url":null,"is_profile_visitable":true,"profile_url":"https:\/\/www.qeios.com\/profile\/2135","follow_endpoint":"https:\/\/www.qeios.com\/follow\/user\/2135","unfollow_endpoint":"https:\/\/www.qeios.com\/unfollow\/user\/2135","pivot":{"authorable_id":695,"user_id":2135,"authorable_type":"App\\Models\\Article","created_at":"2020-07-01 10:06:22","updated_at":"2020-07-01 10:06:22","sort_index":3},"research_field":null,"research_institution":{"id":7929,"name":"University College London, University of London","email_domain":"ucl.ac.uk","country_name":"United Kingdom","city_name":null,"website":"http:\/\/www.ucl.ac.uk\/"}}],"publication_type":"article","version_label":"Preprint v6","can_be_preprint":true,"is_versionable":true,"is_reviewable":true,"read_url":"https:\/\/www.qeios.com\/read\/UJR2AW.6","doi_url":"https:\/\/doi.org\/10.32388\/UJR2AW.6","doi":"10.32388\/UJR2AW.6","edit_url":"https:\/\/www.qeios.com\/compose\/edit\/UJR2AW.6","vacant_authors":[],"tags":[{"id":242,"name":"COVID-19","topic_url":"https:\/\/www.qeios.com\/topic\/articles\/COVID-19","published_count":51,"auth_is_following":false,"followers_count":2,"icon_url":"https:\/\/www.qeios.com\/images\/icons\/tags\/article_tag.svg","follow_endpoint":"https:\/\/www.qeios.com\/follow\/article-tag\/242","unfollow_endpoint":"https:\/\/www.qeios.com\/unfollow\/article-tag\/242","readable_type":"Article Tag","pivot":{"article_id":695,"article_tag_id":242}},{"id":261,"name":"hospitalisation","topic_url":"https:\/\/www.qeios.com\/topic\/articles\/hospitalisation","published_count":6,"auth_is_following":false,"followers_count":0,"icon_url":"https:\/\/www.qeios.com\/images\/icons\/tags\/article_tag.svg","follow_endpoint":"https:\/\/www.qeios.com\/follow\/article-tag\/261","unfollow_endpoint":"https:\/\/www.qeios.com\/unfollow\/article-tag\/261","readable_type":"Article Tag","pivot":{"article_id":695,"article_tag_id":261}},{"id":262,"name":"infection","topic_url":"https:\/\/www.qeios.com\/topic\/articles\/infection","published_count":6,"auth_is_following":false,"followers_count":0,"icon_url":"https:\/\/www.qeios.com\/images\/icons\/tags\/article_tag.svg","follow_endpoint":"https:\/\/www.qeios.com\/follow\/article-tag\/262","unfollow_endpoint":"https:\/\/www.qeios.com\/unfollow\/article-tag\/262","readable_type":"Article Tag","pivot":{"article_id":695,"article_tag_id":262}},{"id":263,"name":"mortality","topic_url":"https:\/\/www.qeios.com\/topic\/articles\/mortality","published_count":6,"auth_is_following":false,"followers_count":0,"icon_url":"https:\/\/www.qeios.com\/images\/icons\/tags\/article_tag.svg","follow_endpoint":"https:\/\/www.qeios.com\/follow\/article-tag\/263","unfollow_endpoint":"https:\/\/www.qeios.com\/unfollow\/article-tag\/263","readable_type":"Article Tag","pivot":{"article_id":695,"article_tag_id":263}},{"id":243,"name":"SARS-CoV-2","topic_url":"https:\/\/www.qeios.com\/topic\/articles\/SARS-CoV-2","published_count":39,"auth_is_following":false,"followers_count":1,"icon_url":"https:\/\/www.qeios.com\/images\/icons\/tags\/article_tag.svg","follow_endpoint":"https:\/\/www.qeios.com\/follow\/article-tag\/243","unfollow_endpoint":"https:\/\/www.qeios.com\/unfollow\/article-tag\/243","readable_type":"Article Tag","pivot":{"article_id":695,"article_tag_id":243}},{"id":255,"name":"smoking","topic_url":"https:\/\/www.qeios.com\/topic\/articles\/smoking","published_count":10,"auth_is_following":false,"followers_count":0,"icon_url":"https:\/\/www.qeios.com\/images\/icons\/tags\/article_tag.svg","follow_endpoint":"https:\/\/www.qeios.com\/follow\/article-tag\/255","unfollow_endpoint":"https:\/\/www.qeios.com\/unfollow\/article-tag\/255","readable_type":"Article Tag","pivot":{"article_id":695,"article_tag_id":255}},{"id":264,"name":"tobacco","topic_url":"https:\/\/www.qeios.com\/topic\/articles\/tobacco","published_count":6,"auth_is_following":false,"followers_count":0,"icon_url":"https:\/\/www.qeios.com\/images\/icons\/tags\/article_tag.svg","follow_endpoint":"https:\/\/www.qeios.com\/follow\/article-tag\/264","unfollow_endpoint":"https:\/\/www.qeios.com\/unfollow\/article-tag\/264","readable_type":"Article Tag","pivot":{"article_id":695,"article_tag_id":264}}],"used_definitions":[],"ancillary_files":[],"auth_is_bookmarker":false,"auth_is_admin":false,"auth_can_publish":false,"auth_can_delete":false,"auth_can_quit":false,"auth_can_modify_authorship":false,"auth_can_give_administration":false,"auth_can_add_tags":false,"auth_can_remove_tags":false,"auth_can_create_new_version":false,"all_versions_views_count":20556,"all_versions_downloads_count":988,"ratings_count":0,"average_rating":null,"published_reviews_count":0,"all_versions_ratings_count":1,"all_versions_average_rating":4,"all_versions_published_reviews_count":1};</script><script>window.GLOB = window.GLOB || {};GLOB.authUser = null;GLOB.userTimezone = 'UTC';GLOB.serverTimezone = 'UTC';</script><script>window.GLOB = window.GLOB || {};GLOB.authUser = null;GLOB.userTimezone = 'UTC';GLOB.serverTimezone = 'UTC';</script>
    <script src="app.js"></script>
    
    <!-- In order to show math formulas that need MathJax to be rendered (because they are created with MathJax) -->
    <script type="text/x-mathjax-config;executed=true">MathJax.Hub.Config({ messageStyle: 'none' });</script>
    <script src="MathJax.js"></script>

    <script src="laroute.js"></script>
    <script src="ckeditor.js"></script>
    <script src="jquery.js"></script>

    
        <!-- Altmetric Embed -->
    <script type="text/javascript" src="embed.js"></script>

        <script src="article.js"></script>

    
    

<script type="text/javascript" src="ujr2aw.6"></script><div class="altmetric-embed altmetric-popover altmetric-right" data-uuid="530e6be9-0983-94e8-0d4b-d918441d34fd" id="_altmetric_popover_el_530e6be9-0983-94e8-0d4b-d918441d34fd" style="margin: 0px; display: none;"><div class="altmetric_container" id="_altmetric_container"><div class="altmetric_arrow altmetric-right"></div><div id="_altmetric_popover_inner" class="altmetric-embed altmetric-popover-inner altmetric-floating altmetric-right" data-uuid="530e6be9-0983-94e8-0d4b-d918441d34fd"><div class="altmetric-embed altmetric-popover-content altmetric-floating"><div>    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_self" href="https://www.altmetric.com/details.php?domain=www.qeios.com&amp;citation_id=85037253&amp;tab=twitter">
          Tweeted by <b>29</b>
      </a>
    </div>

    <div style="margin-top: 10px; text-align: center;">
        <a class="altmetric_details" target="_self" href="https://www.altmetric.com/details.php?domain=www.qeios.com&amp;citation_id=85037253">
            See more details
        </a>
    </div>
</div></div></div></div></div></body></html>